•xŽR‘åŠwˆãŠw•”—Õ°•ªŽq•a‘ÔŒŸ¸Šw

Œ¤‹†‹ÆÑ

2022”N

Œ´’˜

  1. Seiji Kubo, Hideki Niimi, Isao Kitajima. Rapid detection of blood and semen mRNA markers by reverse transcriptionrecombinase polymerase amplification. Forensic Science International:Genetics. 2022 Jan; 58: 102665. doi: 10.1016/j.fsigen.2022.102665.
  2. Seiji Kubo, Hideki Niimi, Isao Kitajima. Rapid and direct detection of male DNA by recombinase polymerase amplification assay. Forensic Science International:Genetics. 2022 Apr; 102704. doi: 10.1016/j.fsigen.2022.102704.
  3. Ozawa T, Tani H, Anraku Y, Kita S, Igarashi E, Saga Y, Inasaki N, Kawasuji H, Yamada H, Sasaki S, Somekawa M, Sasaki J, Hayakawa Y, Yamamoto Y, Morinaga Y, Kurosawa N, Isobe M, Fukuhara H, Maenaka K, Hashiguchi T, Kishi H, Kitajima I, Saito S, Niimi H. Novel super-neutralizing antibody UT28K is capable of protecting against infection from a wide variety of SARS-CoV-2 variants. mAbs. 2022 May; 14(1):2072455.
  4. Yoji Uejima, Eisuke Suganuma, Takuma Ohnish, Haruka Takei, Mihoko Furuichi, Satoshi Sato, Yutaka Kawano, Isao Kitajima, Hideki Niimi. Prospective Study of the Detection of Bacterial Pathogens in Pediatric Clinical Specimens Using the Melting Temperature Mapping Method. Microbiology Spectrum. 2022 Jun; 10(3): 1-11. doi: 10.1128/spectrum.
  5. Hitoshi Kawasuji, Yoshitomo Morinaga, Hideki Tani, Yumiko Saga, Makito Kaneda, Yushi Murai, Akitoshi Ueno, Yuki Miyajima, Yasutaka Fukui, Kentaro Nagaoka, Chikako Ono, Yoshiharu Matsuura, Hideki Niimi, Yoshihiro Yamamoto. Effectiveness of the third dose of BNT162b2 vaccine on neutralizing Omicron variant in the Japanese population. Journal of Infection and Chemotherapy. 2022 Jun; 28(9): 1273-1278. doi: 10.1016/j.jiac.
  6. Kentaro Nagaoka, Hitoshi Kawasuji, Yusuke Takegoshi, Yushi Murai, Makito Kaneda, Akitoshi Ueno, Yuki Miyajima, Hideki Niimi, Yoshitomo Morinaga, Yoshihiro Yamamoto. Effect of Casirivimab/Imdevimab Treatment on Serum Type I Interferon Levels in SARS-CoV-2 Infection. Viruses. 2022 Jun 27; 14(7): 1399. doi: 10.3390/v14071399.
  7. Seiji Kubo, Hideki Niimi, Isao Kitajima. Loop-mediated isothermal amplification assay for fluorescence analysis and lateral flow detection of male DNA. Analytical Biochemistry. 2022 Dec; 115029.

Ç—á•ñ

  1. Yoji Uejima, Eisuke Suganuma, Yukiko Taga, Isao Kitajima, Hideki Niimi. Risk of acute kidney injury in pediatric patient with severe acute respiratory syndrome coronavirus 2 infection. Pediatrics International. 2022 Jan; 64(1): e15176. doi:10.1111/ped.
  2. Yoji Uejima, Eisuke Suganuma, Kaede Matsunaga, Isao Kitajima, Hideki Niimi. COVID]19]associated multisystem inflammatory syndrome and Kawasaki disease. Pediatrics International. 2022 Sep; 15349. doi: 10.1111/ped.
  3. Yoji Uejima, Tsutomu Oh-Ishi, Isao Kitajima, Hideki Niimi. Purulent lymphadenitis due to Halomonas hamiltonii: a case report. International Journal of Infectious Diseases. 2022 Oct; 10.032. doi: 10.1016/j.ijid. Epub.

Šw‰ï•ñ

  1. mˆäŒ©‰pŽ÷. SARS-CoV-2 variants and the development of super-neutralizing antibody. KSCC Satellite Meeting; 2022 Jun 26-30; Seoul. (Invited lecture)
  2. mˆäŒ©‰pŽ÷. Š´õLjâ“`ŽqŒŸ¸–@‚ÌŠJ”­‚ÆVŒ^ƒRƒƒiƒEƒCƒ‹ƒXŠ´õǂւ̑Ήž. ‘æ44‰ñŽ­Ž™“‡Œ§ˆãŽt‰ï—Õ°ŒŸ¸¸“xŠÇ—’²¸Œ¤C‰ï; 2022 Mar 19; Ž­Ž™“‡.iµ‘Òu‰‰j
  3. mˆäŒ©‰pŽ÷.u‹Û”v‚ðŠ´õÇ‚ÌV‹KƒoƒCƒIƒ}[ƒJ[‚Æ‚·‚éV‚½‚È‹N‰Š‹Ûv‘¬“¯’èE’è—ÊŒŸ¸–@FTm mapping–@. “ú–{–òŠw‰ï‘æ142”N‰ï; 2022 Mar 25-28; –¼ŒÃ‰®.iµ‘Òu‰‰j
  4. mˆäŒ©‰pŽ÷. Š´õÇ‚ÌV‹KƒoƒCƒIƒ}[ƒJ[‚Æ‚µ‚Ä‚Ìu‹Û”v‚Ì—L—p«‚ɂ‚¢‚Ä. ‘æ32‰ñ“ú–{—Õ°ŒŸ¸ê–åˆã‰ït‹G‘å‰ï; 2022 May 20-21; Ž­Ž™“‡.iµ‘Òu‰‰j
  5. mˆäŒ©‰pŽ÷. ƒVƒ“ƒ|ƒWƒEƒ€3 –ƉuŽ¡—Êw[k ‘æ“ñ•”u•xŽR‘åˆãH˜AŒg‘̧‚É‚æ‚éRSARS-CoV-2 ƒX[ƒp[’†˜aR‘Ì‚Ììov. ‘æ19‰ñ“ú–{–ƉuŽ¡—Êw‰ïŠwpW‰ï; 2022 May 22; “Œ‹ž.
  6. mˆäŒ©‰pŽ÷. VŒ^ƒRƒƒiƒEƒCƒ‹ƒX’†˜aR‘ÌìoƒvƒƒWƒFƒNƒg‚ɂ‚¢‚Ä. ƒtƒH[ƒ‰ƒ€•xŽRu‘n–òv55thŒ¤‹†‰ï; 2022 May 26; •xŽRiµ‘Òu‰‰j
  7. mˆäŒ©‰pŽ÷. ˆãH˜AŒg‘̧‚É‚æ‚éRSARS CoV-2 ƒX[ƒp[’†˜aR‘Ì‚ÌŠJ”­‚¨‚æ‚Ñ‘n–ò. ‘æ46‰ñ–k—¤—Õ°•a—W’k‰ï; 2022 Sep 3; ‹à‘ò.
  8. mˆäŒ©‰pŽ÷. •xŽR‘åˆãH˜AŒg‘̧‚É‚æ‚é RSARS CoV-2 ƒX[ƒp[’†˜aR‘Ì‚Ììo. ‘æ62‰ñ“ú–{—Õ°‰»Šw‰ï”NŽŸŠwpW‰ï; 2022 Sep 30-Oct 2; •xŽR.
  9. mˆäŒ©‰pŽ÷. ‘åŠw•a‰@‚©‚猩‚½ˆã—ÂƃCƒmƒx[ƒVƒ‡ƒ“. ‘æ92‰ñ“ú–{Š´õÇŠw‰ï¼“ú–{’n•û‰ïŠwpW‰ï; 2022 Nov 3-5; ’·è.
  10. mˆäŒ©‰pŽ÷. ˆã–ò•i»‘¢•iŽ¿ŠÇ—‚É‚¨‚¯‚év‘¬–³‹ÛŒŸ¸–@‚ÌŠJ”­. ƒtƒH[ƒ‰ƒ€•xŽRu‘n–òv‘æ56‰ñŒ¤‹†‰ï; 2022 Nov 8; •xŽR.

ƒy[ƒW‚Ì擪‚Ö–ß‚é

2021”N

Œ´’˜

  1. Kamihara Yusuke, Kikuchi Shohei, Wada Akinori, Murakami Jun, Sugie Nana, Niimi Hideki, Nakashima Akitoshi, Sato Tsutomu. Successful preoperative replacement of prothrombin with prothrombin complex concentrate for Prothrombin Himi. The Japanese journal of clinical hematology. 2021; 62(9): 1412-3. doi: 10.11406/rinketsu.62.1412.
  2. Uejima Yoji, Niimi Hideki, Kato Reiko, Furuichi Mihoko, Sato Satoshi, Kitajima Isao, Kawano Yutaka, Oh-Ishi Tsutomu, Kawashima Hiroshi, Suganuma Eisuke. Infected simple renal cyst due to Streptococcus pneumoniae rapidly diagnosed by the melting temperature mapping method: a case report. BMC pediatrics. 2021 Jan 5; 21(1): 265. doi: 10.1186/s12887-021-02736-7.
  3. Nukui Takamasa, Matsui Atsushi, Niimi Hideki, Sugimoto Tomoyuki, Hayashi Tomohiro, Dougu Nobuhiro, Konishi Hirofumi, Yamamoto Mamoru, Anada Ryoko, Matsuda Noriyuki, Kitajima Isao, Nakatsuji Yuji. Increased cerebrospinal fluid adenosine 5'-triphosphate in patients with amyotrophic lateral sclerosis. BMC neurology. 2021 Jan 30; 21(1): 2288-4. doi: 10.1186/s12883-021-02288-4.
  4. Noriko Yoneda, Satoshi Yoneda, Sayaka Tsuda, Mika Ito, Arihiro Shiozaki, Hideki Niimi, Taketoshi Yoshida, Akitoshi Nakashima, Shigeru Saito. Pre-eclampsia Complicated With Maternal Renal Dysfunction Is Associated With Poor Neurological Development at 3 Years Old in Children Born Before 34 Weeks of Gestation. Frontiers in Pediatrics. 2021 Apr; 9: 624323. doi: 10.3389/fped.2021.624323.
  5. Yoji Uejima, Hideki Niimi, Reiko Kato, Mihoko Furuichi, Satoshi Sato, Isao Kitajima, Yutaka Kawano, Tsutomu Oh-Ishi, Hiroshi Kawashima, Eisuke Suganuma. Infected simple renal cyst due to Streptococcus pneumoniae rapidly diagnosed by the melting temperature mapping method: a case report. BMC Pediatrics. 2021 Jun; 21(1): 265. doi: 10.1186/s12887-021-02736-7.
  6. Takamasa Nukui, Atsushi Matsui, Hideki Niimi, Tomohiro Hayashi, Nobuhiro Dougu, Hirofumi Konishi, Mamoru Yamamoto, Ryoko Anada, Noriyuki Matsuda, Isao Kitajima, Yuji Nakatsuji. Increased Cerebrospinal Fluid Adenosine 5'-triphosphate in Patients with Amyotrophic Lateral Sclerosis. BMC Neurology. 2021 Jun; 21(1): 255. doi: 10.1186/s12883-021-02288-4.
  7. Shinsuke Ikeda, Katsufumi Uchiyama, Mitsutoshi Moriya, Keizo Sakurai, Shin Nihonyanagi, Hideki Niimi, Masashi Takaso. Disseminated nocardiosis complicated by multiple abscesses of the brain and lower limbs diagnosed by the melting temperature mapping method: A case report. Journal of Orthopaedic Science. 2021 Aug; 109(3): 140-3. doi: 10.1016/j.jos.2021.07.013.
  8. Kawasuji Hitoshi, Morinaga Yoshitomo, Tani Hideki, Saga Yumiko, Kaneda Makito, Murai Yushi, Ueno Akitoshi, Miyajima Yuki, Fukui Yasutaka, Nagaoka Kentaro, Ono Chikako, Matsuura Yoshiharu, Niimi Hideki, Yamamoto Yoshihiro. Age-Dependent Reduction in Neutralization against Alpha and Beta Variants of BNT162b2 SARS-CoV-2 Vaccine-Induced Immunity. Microbiology spectrum. 2021 Dec 22; 9(3): 561-21. doi: 10.1128/Spectrum.00561-21.
  9. Hitoshi Kawasuji, Yoshitomo Morinaga, Hideki Tani, Yumiko Saga, Makito Kaneda, Yushi Murai, Akitoshi Ueno, Yuki Miyajima, Yasutaka Fukui, Kentaro Nagaoka, Chikako Ono, Yoshiharu Matsuura, Hideki Niimi, Yoshihiro Yamamoto. Age-Dependent Reduction in Neutralization against Alpha and Beta Variants of BNT162b2 SARS-CoV-2 Vaccine-Induced Immunity. Microbiology Spectrum. 2021 Dec 22; 9(3): 561-21. doi: 10.1128/spectrum.00561-21.

Šw‰ï•ñ

  1. mˆäŒ©‰pŽ÷DVŒ^ƒRƒƒiƒEƒCƒ‹ƒXŒŸ¸‚ÉŠÖ‚µ‚ÄuPCRŒŸ¸ RŒ´ŒŸ¸ R‘ÌŒŸ¸ƒŒƒrƒ…[D“ú–{ˆâ“`Žqf—Êw‰ï ˆâ“`Žqf’fEŒŸ¸‹Zp„iƒtƒH[ƒ‰ƒ€ ŒöŠJƒVƒ“ƒ|ƒWƒEƒ€2020G2021 Jan 27-Feb 17;iµ‘Òu‰‰j
  2. mˆäŒ©‰pŽ÷D•xŽR‘åˆãH˜AŒg‘̧‚É‚æ‚éRSARS-CoV-2ƒX[ƒp[’†˜aR‘Ì‚ÌìoD‘æ12‰ñ“ú–{RNAiŒ¤‹†‰ïG2021 Aug 26-27;iµ‘Òu‰‰j
  3. mˆäŒ©‰pŽ÷DŠ´õLjâ“`ŽqŒŸ¸–@‚ÌŠJ”­‚ÆVŒ^ƒRƒƒiƒEƒCƒ‹ƒXŠ´õǂւ̑ΉžD—ߘa3”N“x“ú—Õ‹Z’†•”Œ—Žx•”ˆãŠwŒŸ¸Šw‰ïG2021 Sep 19
  4. mˆäŒ©‰pŽ÷DVŒ^ƒRƒƒiƒEƒCƒ‹ƒX‚Ì‘½Ží‚̕ψي”‚ð–hŒä‚Å‚«‚éƒqƒgEƒX[ƒp[’†˜aR‘Ì‚ÌìoDŽYŠwŠ¯˜AŒgƒVƒ“ƒ|ƒWƒEƒ€2021•xŽRG2021 Oct 1;iµ‘Òu‰‰j
  5. mˆäŒ©‰pŽ÷DSARS-CoV-2•ÏˆÙŠ”‚Ì—¬s‚Æ ƒX[ƒp[’†˜aR‘Ì‚ÌìoD“ú–{ˆã—ÃŒŸ¸‰ÈŠw‰ï‘æ53‰ñ‘å‰ïG2021 Oct10
  6. mˆäŒ©‰pŽ÷DRSARS-CoV-2ƒX[ƒp[’†˜aR‘ÌD“ú–{l—Þˆâ“`Šw‰ï‘æ66‰ñ‘å‰ï ‘æ28‰ñ“ú–{ˆâ“`Žqf—Êw‰ï‘å‰ï‡“¯ŠJÃ;2021 Oct 14
  7. mˆäŒ©‰pŽ÷D‹³ˆçƒZƒbƒVƒ‡ƒ“uŠ´õÇ‚ÌŽ‹“_‚©‚ç‚̈â“`ŽqŠÖ˜AŒŸ¸vD“ú–{l—Þˆâ“`Šw‰ï‘æ66‰ñ‘å‰ï ‘æ28‰ñ“ú–{ˆâ“`Žqf—Êw‰ï‘å‰ï ‡“¯ŠJÃ;2021 Oct 14
  8. mˆäŒ©‰pŽ÷D‹³ˆçu‰‰ Š´õÇf’fuTm mapping–@vD‘æ70‰ñ“ú–{Š´õÇŠw‰ï“Œ“ú–{’n•û‰ïŠwpW‰ï ‘æ68‰ñ“ú–{‰»Šw—Ö@Šw‰ï“Œ“ú–{Žx•”‘‰ï ‡“¯Šw‰ïG2021 Oct 28

‚»‚Ì‘¼

  1. ŒÜ\—’“oC‚ŒK–ƒˆßŽqC–쑺ŒbŽqC¼“c’¼“¿CmˆäŒ©‰pŽ÷DMelting Temperature mapping–@‚É‚Ä‹H—L‚È‹N‰Š‹Û‚𓯒肵“¾‚½ƒŠƒ“ƒp߉Š‚Ì‚QÇ—áD¬Ž™‰ÈD2021 Feb; 62(1): 93-98.
  2. “àŽRŸ•¶CŸNˆäŒc‘¢CmˆäŒ©‰pŽ÷C’r“cM‰îC•Ÿ“‡Œ’‰îCX’JŒõrC‚•½®LC‚‘Š»ŽmDœEŠÖߊ´õÇŽ¡—Âɂ¨‚¯‚é˜b‘è(‚ ‚é‚¢‚̓gƒsƒbƒNƒX) lHŠÖߎüˆÍŠ´õ‚É‚¨‚¯‚éf’f‚Ìi•à V‹KƒoƒCƒIƒ}[ƒJ[MPO‚ÆTmmapping–@. ŠÖ“Œ®Œ`ЊQŠO‰ÈŠw‰ïŽGŽD2021 Mar; 52(—ÕŽž†): 57.
  3. ú匴Ž‹IC‰ê—ˆŒhmC—é–ØL“¹C’·”ö”ü‹ICmˆäŒ©‰pŽ÷C¼–{“NÆCŽOŠ›œA”ÉDqˆÏˆõ‰ï•ñr’°ŠÇŠ´õÇf—Â̌»ó‚ɂ‚¢‚ẴAƒ“ƒP[ƒg’²¸DŠ´õÇŠwŽGŽD2021 Mar; 95: 117-121.

ƒy[ƒW‚Ì擪‚Ö–ß‚é

2020”N

Œ´’˜

  1. Higashi Y, Niimi H, Sakamaki I, Yamamoto Y, Kitajima I. Rapid Identification of Candida Species in Candidemia Directly from Blood Samples Using Imperfect Match Probes. Scientific Reports. 2019 Dec; 10(1). doi: 10.1038/s41598-020-62276-5.i2019”N–¢ŒfÚ•ªj
  2. Nukui T, Matsui A, Niimi H, Yamamoto M, Matsuda N, Piao JL, Noguchi K, Kitajima I, Nakatsuji Y. Cerebrospinal fluid ATP as a potential biomarker in patients with mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke like episodes (MELAS). Mitochondrion. 2019 Dec; 19(50): 145-148i2019”N–¢ŒfÚ•ªj
  3. Matsui A, Niimi H, Uchiho Y, Kawabe S, Noda H, Kitajima I. A Rapid ATP Bioluminescence-based Test for Detecting Levofloxacin Resistance Starting from Positive Blood Culture Bottles. Scientific Reports. 2019 Oct. doi: 10.1038/s41598-019-49358-9.i2019”N–¢ŒfÚ•ªj
  4. Kawasuji H, Kaya H, Kawamura T, Ueno A, Miyajima Y, Tsuda T, Taniguchi H, Nakamura M, Wada A, Sakamaki I, Niimi H, Yamamoto Y. Bacteremia caused by Slackia exigua: A report of two cases and literature review. Journal of Infection and Chemotherapy. 2019 Jul. doi: 10.1016/j.jiac.2019.06.00i2019”N–¢ŒfÚ•ªj
  5. mˆäŒ©‰pŽ÷DATP”­ŒõŒv‘ª‚É‚æ‚év‘¬‚È–òÜŠ´Žó«ŽŽŒ±–@‚ÌŠJ”­D“ú–{—Õ°ŒŸ¸ˆãŠw‰ïŽu—Õ°•a—vD20191200; 67(12): 1231-1237.i2019”N–¢ŒfÚ•ªj
  6. 㓇—m“ñC”ó“n‚¦‚è‚©CŸN’J_ŽuC“ì•”—²—ºC²“¡’qC›À‰h‰îC‚–ì’‰«C“¡‰iŽüˆê˜YCrˆäFCmˆäŒ©‰pŽ÷C–k“‡ŒMC‘åΕ×Cì–ì–LDv‘¬f’f‚Æ‘Šú‚©‚ç‚ÌŽ¡—Éî“ü‚É‚æ‚è‹~–½‚Å‚«‚½NP«‘–Œ‰Š‹ÛŠ´õÇD“ú–{¬Ž™‰ÈŠw‰ïŽGŽD2019 Jan; 123(1): 53-60.i2019”N–¢ŒfÚ•ªj

Ç—á•ñ

  1. Sato S, Aoyama T, Uejima Y, Furuichi M, Suganuma E, Takano T, Ikeda M, Mizoguchi M, Okugawa S, Moriya K, Niimi H,Kitajima I, Kawashima H, Kawano Y.. Pyogenic liver abscess due to hypervirulent Klebsiella pneumoniae in a 14-year-old boy. J Infect Chemother. 2019 Feb; 137-140. doi: 10.1016/j.jiac.2018. 07.00i. 2019”N–¢ŒfÚ•ª

Šw‰ï•ñ

  1. mˆäŒ©‰pŽ÷C“ŒËŽkC‹{˜W‰›CÖ“¡Ž CŽR–{‘P—TC–k“‡ŒMDV‚½‚È‹N‰Š‹Ûv‘¬“¯’èE’è—Ê‹Zp‚ðŠî”Õ‚Æ‚µCu‹Û”v‚ðŠ´õÇ‚ÌdÇ“x‚⎡—ÃŒø‰Ê”»’è‚ÌV‹KƒoƒCƒIƒ}[ƒJ[‚Æ‚·‚錟¸ƒVƒXƒeƒ€‚ÌŠJ”­D‘æ31‰ñ“ú–{—Õ°”÷¶•¨Šw‰ï‘‰ïEŠwpW‰ïG2020 Jan 31- Feb 2G‹à‘òDiµ‘Òu‰‰j
  2. mˆäŒ©‰pŽ÷C¼ˆä“ÄC–k“‡ŒMDATPŒuŒõ”­ŒõŒŸo–@‚ðŠî”Õ‚Æ‚µ‚½V‚½‚Èv‘¬–òÜŠ´Žó«ŽŽŒ±–@D‘æ31‰ñ“ú–{—Õ°”÷¶•¨Šw‰ï‘‰ïEŠwpW‰ïG2020 Jan 31- Feb 2G‹à‘òD
  3. mˆäŒ©‰pŽ÷C“ŒËŽkC‹{˜W‰›CÖ“¡Ž CŽR–{‘P—TC–k“‡ŒMDV‹KƒoƒCƒIƒ}[ƒJ[‚Æ‚µ‚Ä‚Ìu‹Û”v‚̈â“`ŽqŒŸ¸D‘æ27‰ñ“ú–{ˆâ“`Žqf—Êw‰ï‘å‰ïG2020 Sep 10-12iƒIƒ“ƒ‰ƒCƒ“jiµ‘Òu‰‰j
  4. mˆäŒ©‰pŽ÷Cã–ì’q_C–k“‡ŒMDATPŒuŒõ”­ŒõŒŸo–@‚ðŠî”Õ‚Æ‚·‚éV‚½‚Èv‘¬–òÜŠ´Žó«ŽŽŒ±–@‚ÌŠJ”­D‘æ60‰ñ“ú–{—Õ°‰»Šw‰ï”NŽŸŠwpW‰ïG2020 Oct 30-Nov 2iƒIƒ“ƒ‰ƒCƒ“j
  5. mˆäŒ©‰pŽ÷Cã–ì’q_C–k“‡ŒMDƒJƒ“ƒWƒ_ŒŒÇ‚É‚¨‚¯‚é‹N‰Š‹Ûv‘¬“¯’茟¸–@iIM Q-probe–@j‚ÌŠJ”­D‘æ60‰ñ“ú–{—Õ°‰»Šw‰ï”NŽŸŠwpW‰ïG2020 Oct 30-Nov 2iƒIƒ“ƒ‰ƒCƒ“j
  6. mˆäŒ©‰pŽ÷CFactor X heterozygous mutation in a patient with potential risk of bleeding: A case report. “ú–{l—Þˆâ“`Šw‰ï‘æ65‰ñ‘å‰ïG2020 Nov 18-20iƒIƒ“ƒ‰ƒCƒ“j
  7. mˆäŒ©‰pŽ÷C¼ˆä“ÄC‰Í–ì–ƒ—C¬“ˆ–]ŽÀC–k“‡ŒMD”sŒŒÇ‹^‚¢Š³ŽÒ‚É‚¨‚¯‚éXN‚ÌD’†‹…ŠÖ˜Aƒpƒ‰ƒ[ƒ^[‚Ì—L—p«‚ÌŒŸ“¢D‘æ67‰ñ“ú–{—Õ°ŒŸ¸ˆãŠw‰ïŠwp‘‰ïG2020 Nov 20-22GŠâŽèiƒIƒ“ƒ‰ƒCƒ“j
  8. Niimi H, Higashi Y, Ueno T, Mori M, Yamamoto Y, Saito S, Kitajima I. Novel Rapid Identification and Quantification Method of Bacteria in a Septic Blood Sample Can Produce an Effective Biomarker for Monitoring Patient Care. WASPaLM 2019; 2019 Sep 19-21G¼ˆÀC’†‘D(2019”N–¢ŒfÚ•ª)
  9. Niimi H, Higashi Y, Ueno T, Mori M, Yamamoto Y, Saito S, Kitajima I. Novel Rapid Identification and Quantification Method of Bacteria in a Septic Blood Sample Can Produce an Effective Biomarker for Monitoring Patient Care. EUROMEDLAB 2019; 2019 May 19-23Gƒoƒ‹ƒZƒƒiCƒXƒyƒCƒ“D(2019”N–¢ŒfÚ•ª)
  10. mˆäŒ©‰pŽ÷DATPŒuŒõ”­ŒõŒŸo–@‚ðŠî”Õ‚Æ‚µ‚ÄŒŒ‰t”|—{ŒŸ‘Ì‚©‚çƒXƒ^[ƒg‚·‚éV‚½‚Èv‘¬–òÜŠ´Žó«ŽŽŒ±–@D‘æ66‰ñ“ú–{—Õ°ŒŸ¸ˆãŠw‰ïŠwpW‰ïG2019 Nov 21-24G‰ªŽRD(2019”N–¢ŒfÚ•ª)
  11. mˆäŒ©‰pŽ÷DQ probe–@‚É‚æ‚é ƒvƒƒeƒCƒ“S“¿“‡ŠÈˆÕƒXƒNƒŠ[ƒjƒ“ƒOŒŸ¸–@ ‚Ì\’z‚Æ—Õ°“I—L—p«‚ÌŒŸ“¢D“ú–{l—Þˆâ“`Šw‰ï‘æ64‰ñ‘å‰ïG2019 Nov 6-9G’·èD(2019”N–¢ŒfÚ•ª)
  12. mˆäŒ©‰pŽ÷D‹N‰Š‹Ûv‘¬“¯’è–@(Tm mapping–@)C‹N‰Š‹Û’è—ÊŒŸ¸–@C‚¨‚æ‚Ñv‘¬–òÜŠ´Žó«ŽŽŒ±–@‚ÌŠJ”­D“ú—Õ‹Z’†•”Žx•”¶•¨‰»Šw•ªÍ•”–å^õF‘ÌEˆâ“`Žq•”–匤C‰ïG2019 Nov 9-10G•xŽRD(2019”N–¢ŒfÚ•ª)
  13. mˆäŒ©‰pŽ÷DV‹KATP‘ª’è‹Zp‚É‚æ‚év‘¬‚È–òÜŠ´Žó«ŽŽŒ±–@D‘æ93‰ñ“ú–{Š´õÇŠw‰ï‘‰ïEŠwpu‰‰‰ïG2019 Apr 4-6G–¼ŒÃ‰®D(2019”N–¢ŒfÚ•ª)
  14. mˆäŒ©‰pŽ÷D•sŠ®‘Sˆê’v”z—ñ‚Ìüó’·½ƒvƒ[ƒu‚ð—p‚¢‚½V‚½‚ÈTm mapping–@D‘æ93‰ñ“ú–{Š´õÇŠw‰ï‘‰ïEŠwpu‰‰‰ïG2019 Apr 4-6G–¼ŒÃ‰®D(2019”N–¢ŒfÚ•ª)
  15. mˆäŒ©‰pŽ÷DV‚½‚È‹N‰Š‹Ûv‘¬“¯’èE’è—Ê‹Zp‚ðŠî”Õ‚Æ‚µC‹Û”‚ð”sŒŒÇ‚ÌV‹KƒoƒCƒIƒ}[ƒJ[‚Æ‚·‚錟¸ƒVƒXƒeƒ€‚ÌŠJ”­D‘æ93‰ñ“ú–{Š´õÇŠw‰ï‘‰ïEŠwpu‰‰‰ïG2019 Apr 4-6G–¼ŒÃ‰®D(2019”N–¢ŒfÚ•ª)
  16. mˆäŒ©‰pŽ÷DŠ´õÇ‚É‚¨‚¯‚éV‚½‚Èv‘¬ŒŸ¸‹Zp‚Æ ˆã–ò•i»‘¢•iŽ¿ŠÇ—–@‚ÌŠJ”­Dƒrƒ^ƒ~ƒ“BŒ¤‹†‰ï•½¬30”N“xƒVƒ“ƒ|ƒWƒEƒ€G2019 Mar 8G•xŽRD(2019”N–¢ŒfÚ•ª)

‚»‚Ì‘¼

  1. mˆäŒ©‰pŽ÷Dq“ÁWrŠ´õLjã—Â̖¢—ˆ‚ð‘ñ‚­V‚½‚ÈŒŸ¸D—Õ°‰»ŠwD2020 Oct 1; 49(4): 250-250.
  2. ¼ˆä“ÄCmˆäŒ©‰pŽ÷DATP”­ŒõŒv‘ª‚É‚æ‚év‘¬‚È–òÜŠ´Žó«ŽŽŒ±–@D—Õ°‰»ŠwD2020 Oct 1; 49(4): 258-264.
  3. mˆäŒ©‰pŽ÷D“û‚ª‚ñ‚̈â“`Žqf’f `“û‚ª‚ñ‚͈â“`‚·‚é?D•xŽR‘åŠw•‘®•a‰@ “û‚ª‚ñæ’[Ž¡—ÃE“û–[ÄŒšƒZƒ“ƒ^[Žs–¯ŒöŠJuÀG2020 Jul 23G•xŽRiƒIƒ“ƒ‰ƒCƒ“jDiµ‘Òu‰‰j
  4. mˆäŒ©‰pŽ÷DŽ¨•@ˆôA‰Èê–åˆã‚É•K—v‚È—Õ°ŒŸ¸Šw -Š´õLjâ“`ŽqŒŸ¸‚ð’†S‚É-D‘æ107‰ñ•xŽRŒ§Ž¨•@ˆôA‰È—Õ°Œ¤‹†‰ïG2020 Sep 17G•xŽRDiµ‘Òu‰‰j
  5. mˆäŒ©‰pŽ÷DŠ´õÇ‹N‰Š‹Û‚Ìv‘¬“¯’èE’è—ÊE Š´Žó«ŽŽŒ±–@‚ÌŠJ”­D•xŽR‘åŠwPME—{¬ƒvƒƒOƒ‰ƒ€2020 ‘æ20‰ñŒöŠJƒZƒ~ƒi[G2020 Nov 27G•xŽRiƒIƒ“ƒ‰ƒCƒ“jDiµ‘Òu‰‰j
  6. mˆäŒ©‰pŽ÷D—Õ°‚ÆŒ¤‹† [‚æ‚è—Ç‚«ˆã—Âð„i‚·‚邽‚ß‚Ì—¼—Ö[D‰Šú—Õ°Œ¤CˆãƒXƒLƒ‹ƒAƒbƒvƒZƒ~ƒi[2020G2020 Dec 5G•xŽRiƒIƒ“ƒ‰ƒCƒ“jDiµ‘Òu‰‰j

ƒy[ƒW‚Ì擪‚Ö–ß‚é

2019”N

Œ´’˜

  1. Kawasuji H, Kaya H, Kawamura T, Ueno A, Miyajima Y, Tsuda T, Taniguchi H, Nakamura M, Wada A, Sakamaki I, Niimi H, Yamamoto Y. Bacteremia caused by Slackia exigua: A report of two cases and literature review. Journal of Infection and Chemotherapy. 2019 Jul; 1-5. doi: 10.1016/j.jiac.2019.06.00.
  2. Matsui A, Niimi H, Uchiho Y, Kawabe S, Noda H, Kitajima I. A Rapid ATP Bioluminescence-based Test for Detecting Levofloxacin Resistance Starting from Positive Blood Culture Bottles. Scientific Reports. 2019 Oct; 1-9. doi: 10.1038/s41598-019-49358-9. (Epub ahead of print)
  3. Matsui A, Niimi H, Uchiho Y, Kawabe S, Noda H, Kitajima I. Cerebrospinal fluid ATP as a potential biomarker in patients with mitochondrial myopathy, encephalopathy, lactic acidosis, and stroke like episodes (MELAS). Scientific Reports. 2019 Oct; 1-9. doi: 10.1016/j.mito.2019.11.001.

Ç—á•ñ

  1. 㓇—m“ñC”ó“n‚¦‚è‚©CŸN’J_ŽuC“ì•”—²—ºC²“¡’qC›À‰h‰îC‚–ì’‰«C“¡‰iŽüˆê˜YCrˆäFCmˆäŒ©‰pŽ÷C–k“‡ŒMC‘åΕ×Cì–ì–LDv‘¬f’f‚Æ‘Šú‚©‚ç‚ÌŽ¡—Éî“ü‚É‚æ‚è‹~–½‚Å‚«‚½NP«‘–Œ‰Š‹ÛŠ´õÇD“ú–{¬Ž™‰ÈŠw‰ïŽGŽD2019 Jan; 123(1): 53-60.
  2. Satoshi Sato, Tomohiro Aoyama, Yoji Uejima, Mihoko Furuichi, Eisuke Suganuma, Tadamasa Takano, Mahoko Ikeda, Miyuki Mizog uchi, Shu Okugawa, Kyoji Moriya, Hideki Niimi, Isao Kitajima, Hiroshi Kawashima, Yutaka Kawano. Pyogenic liver abscess due to hypervirulent Klebsiella pneumoniae in a 14-year-old boy. Journal of Infection and Chemotherapy. 2019 Feb; 25(2): 137-140. doi: 10.1016/j.jiac.2018.07.006.

Šw‰ï•ñ

  1. mˆäŒ©‰pŽ÷DNovel Rapid Identification and Quantification Method of Bacteria in a Septic Blood Sample Can Produce an Effective Biomarker for Monitoring Patient Care EUROMEDLAB 2019; 2019 May 19-23; Barcelonaiƒ|ƒXƒ^[jD
  2. mˆäŒ©‰pŽ÷DNovel Rapid Identification and Quantification Method of Bacteria in a Septic Blood Sample Can Produce an Effective Biomarker for Monitoring Patient Care WASPaLM 2019; 2019 Sep 19-21; Xianiƒ|ƒXƒ^[jD
  3. mˆäŒ©‰pŽ÷DŠ´õÇ‚É‚¨‚¯‚éV‚½‚Èv‘¬ŒŸ¸‹Zp‚Æ ˆã–ò•i»‘¢•iŽ¿ŠÇ—–@‚ÌŠJ”­ ƒrƒ^ƒ~ƒ“BŒ¤‹†‰ï•½¬30”N“xƒVƒ“ƒ|ƒWƒEƒ€G2019 Mar 8; Toyamai. ƒVƒ“ƒ|ƒWƒEƒ€Eƒ[ƒNƒVƒ‡ƒbƒv ƒpƒlƒ‹jD
  4. mˆäŒ©‰pŽ÷DV‚½‚È‹N‰Š‹Ûv‘¬“¯’èE’è—Ê‹Zp‚ðŠî”Õ‚Æ‚µC‹Û”‚ð”sŒŒÇ‚ÌV‹KƒoƒCƒIƒ}[ƒJ[‚Æ‚·‚錟¸ƒVƒXƒeƒ€‚ÌŠJ”­ ‘æ93‰ñ“ú–{Š´õÇŠw‰ï‘‰ïEŠwpu‰‰‰ïG2019 Apr 4-6; Nagoya. iƒVƒ“ƒ|ƒWƒEƒ€Eƒ[ƒNƒVƒ‡ƒbƒvƒpƒlƒ‹jD
  5. mˆäŒ©‰pŽ÷D•sŠ®‘Sˆê’v”z—ñ‚Ìüó’·½ƒvƒ[ƒu‚ð—p‚¢‚½V‚½‚ÈTm mapping–@ ‘æ93‰ñ“ú–{Š´õÇŠw‰ï‘‰ïEŠwpu‰‰‰ïG2019 Apr 4-6; Nagoya.
  6. mˆäŒ©‰pŽ÷DV‹KATP‘ª’è‹Zp‚É‚æ‚év‘¬‚È–òÜŠ´Žó«ŽŽŒ±–@ ‘æ93‰ñ“ú–{Š´õÇŠw‰ï‘‰ïEŠwpu‰‰‰ïG2019Apr 4-6; Nagoya.
  7. mˆäŒ©‰pŽ÷DQ probe–@‚É‚æ‚é ƒvƒƒeƒCƒ“S“¿“‡ŠÈˆÕƒXƒNƒŠ[ƒjƒ“ƒOŒŸ¸–@ ‚Ì\’z‚Æ—Õ°“I—L—p«‚ÌŒŸ“¢ “ú–{l—Þˆâ“`Šw‰ï‘æ64‰ñ‘å‰ïG2019 Nov 6-9; Nagasaki.
  8. mˆäŒ©‰pŽ÷D‹N‰Š‹Ûv‘¬“¯’è–@(Tm mapping–@), ‹N‰Š‹Û’è—ÊŒŸ¸–@, ‚¨‚æ‚Ñv‘¬–òÜŠ´Žó«ŽŽŒ±–@‚ÌŠJ”­ “ú—Õ‹Z’†•”Žx•”¶•¨‰»Šw•ªÍ•”–å^õF‘ÌEˆâ“`Žq•”–匤C‰ï; 2019 Nov 9-10; Toyamaiµ‘Òu‰‰j
  9. mˆäŒ©‰pŽ÷DATPŒuŒõ”­ŒõŒŸo–@‚ðŠî”Õ‚Æ‚µ‚ÄŒŒ‰t”|—{ŒŸ‘Ì‚©‚çƒXƒ^[ƒg‚·‚éV‚½‚Èv‘¬–òÜŠ´Žó«ŽŽŒ±–@ ‘æ66‰ñ“ú–{—Õ°ŒŸ¸ˆãŠw‰ïŠwpW‰ï; 2019 Nov 21-24; Okayama.

‚»‚Ì‘¼

  1. mˆäŒ©‰pŽ÷DƒgƒsƒbƒNƒXGIRUD‚ªŽ¦´‚·‚éˆâ“`Žqf’f‘̧‚Ì–¢—ˆ‚Ì‚©‚½‚¿D—Õ°‰»ŠwD2019 Apr; 48(2): 153-153.
  2. mˆäŒ©‰pŽ÷DATP”­ŒõŒv‘ª‚É‚æ‚év‘¬‚È–òÜŠ´Žó«ŽŽŒ±–@‚ÌŠJ”­D—Õ°•a—D2019 Dec; 67(12): 1231-1237.

ƒy[ƒW‚Ì擪‚Ö–ß‚é

2018”N

’˜‘

  1. –k“‡ŒMDt‚Æ“§Í ƒxƒbƒhƒTƒCƒhŒŸ¸Ž–“TD“Œ‹žF“Œ‹žˆãŠwŽÐG2018DƒtƒBƒuƒŠƒmƒQƒ“A‰Â—n«ƒtƒBƒuƒŠƒ“A‰Â—n«ƒtƒBƒuƒŠƒ“ƒ‚ƒmƒ}[•¡‡‘ÌAƒtƒBƒuƒŠƒ“^ƒtƒBƒuƒŠƒmƒQƒ“•ª‰ðŽY•¨AD ƒ_ƒCƒ}[Gp. 216-9D

Œ´’˜

  1. Yoneda N, Yoneda S, Niimi H, Ito M, Fukuta K, Ueno T, Ito MK, Shiozaki A, Kigawa M, Kitajima I, Saito S. Sludge reflects intra-amniotic inflammation with or without microorganisms. Am J Reprod Immunol. 2018 Feb; 79(2). DOI:10.1111/aji.12807.
  2. Ihara H, Kiuchi S, Ishige T, Nishimura M, Matsushita K, Satoh M, Nomura F, Yamashita M, Kitajima I, Tsugawa N, Okano T, Hirota K, Miura M, Totani M, Hashizume N. Surveillance evaluation of the standardization of assay values for serum total 25-hydroxyvitamin D concentration in Japan. Ann Clin Biochem. 2018 Nov; 55(6): 647-56. DOI: 10.1177/0004563218765570.
  3. Yoneda S, Yoneda N, Shiozaki A, Yoshino O, Ueno T, Niimi H, Kitajima I, Tamura K, Kawasaki Y, Makimoto M, Yoshida T, Saito S. 1:17OHP-C in patients with spontaneous preterm labor and intact membranes: is there an effect according to the presence of intra-amniotic inflammation?. Am J Reprod Immunol. 2018 Apr 30: e12867. DOI: 10.1111/aji.12867.
  4. Torai R, Makino T, Mizawa M, Hayashi M, Furukawa F, Niimi H, Shimizu T. Recurrent deep vein thrombosis with a protein S Tokushima mutation. Br J Dermatol. 2018 Jan; 178(1): e7-8. DOI: 10.1111/bjd.15700.
  5. Kawaguchi Y, Kitajima I, Nakano M, Yasuda T, Seki S, Suzuki K, Yahara Y, Makino H, Ujihara Y, Ueno T, Kimura T. Increase of the serum FGF-23 in ossification of the posterior longitudinal ligament. Global Spine J. 2018 Sep. DOI:10.1177/2192568218801015.
  6. ‹{˜W‰›CmˆäŒ©‰pŽ÷Cã–ì’q_C–ö‘òGˆê˜YC–k“‡ŒMC—Ñ“ÄŽuDTm mapping –@‚É‚æ‚é׋۫Šá“à‰Š‹N‰Š‹Û‚Ìv‘¬“¯’è–@D“ú–{Šá‰ÈŠw‰ïŽGŽD2018G128(8)F580-5D
  7. Sato S, Aoyama T, Uejima Y, Furuichi M, Suganuma E, Takano T, Ikeda M, Mizoguchi M, Okugawa S, Moriya K, Niimi H,Kitajima I, Kawashima H, Kawano Y. Pyogenic liver abscess due to hypervirulent Klebsiella pneumoniae in a 14-year-old boy. J Infect Chemother. 2018 Aug; 18: 30212-5. DOI: 10.1016/j.jiac.2018. 07.00.

Ç—á•ñ

  1. Arita K, Niimi H, Yamagishi N, Ueno T, Kitajima I, Sugiyama T. Factor X heterozygous mutation in a patient with potential risk of bleeding. Medicene (IF=1.803). 2018 Jun; 97(23): e10950. DOI: 10.1097/MD.

‘à

  1. mˆäŒ©‰pŽ÷DMelting Temperature (Tm) mappnig –@DV‚½‚È”sŒŒÇ‹N‰Š‹Ûv‘¬“¯’è–@D“ú–{—Õ°ŒŸ¸ˆãŠw‰ïŽD2018G66(3)F267-74D
  2. ŸÍŒ´”ŽC–Ø“àKŽqC¼‘ºŠîC–쑺•¶•vCŽR‰º•ôC–k“‡ŒMC’Ã쮎qC‰ª–ì“oŽu•vCœA“cWˆêCŽO‰Y‰ëˆêCŒË’J½”VC‹´‹l’¼FCˆÉ“¡ºŽOC“o•×C’·‘º—mˆêC΋´‚Ý‚Ç‚èC‘Oì^lC–ؖF˜aC‘å‹´z“ñC‘å“cDŽŸDŽ©“®•ªÍ–@‚É‚æ‚錌´‘25 ƒqƒhƒƒLƒVƒrƒ^ƒ~ƒ“D ‘ª’è’l‚Ì•W€‰»‚ÉŠÖ‚·‚錻󒲸D—Õ°‰»ŠwD2018G47F413-23D

Šw‰ï•ñ

  1. Niimi H, Higashi Y, Ueno T, Mori M, Yamamoto Y, Saito S, Kitajima I. Novel rapid quantification method of bacteria in a septic blood sample can produce an effective biomarker for monitoring patient care. 70th AACC Annual Scientific Meeting & Clinical Lab Expo; 2018 Aug 1; Chicago.i“Á•Êu‰‰AƒVƒ“ƒ|ƒWƒEƒ€j
  2. –k“‡ŒMDƒgƒƒ“ƒrƒ“§Œä‹@\‚É‚¨‚¯‚é—Õ°ŒŸ¸‚Ìd—v«D‘æ58‰ñ“ú–{—Õ°‰»Šw‰ï”NŽŸŠwpW‰ïƒTƒeƒ‰ƒCƒgƒVƒ“ƒ|ƒWƒEƒ€G2018 Aug 25G–¼ŒÃ‰®Diˆê”ʉ‰‘èj
  3. ŠÖŒûŒh•¶C™]˜a–ÎCX“c–¢Câ–{ƒŽqCã–ì’q_CŽðŠªˆê•½CŽR–{‘P—TC–k“‡ŒMD‹¹…”|—{‚ðŒ_‹@‚Éf’f‚³‚ꂽƒŒƒWƒIƒlƒ‰Ç‚Ì1 —áD‘æ29‰ñ“ú–{—Õ°”÷¶•¨Šw‰ï‘‰ïG2018 Feb 9GŠò•ŒD
  4. ™]“ÞXCã–ì’q_CmˆäŒ©‰pŽ÷C–k“‡ŒMDƒ|ƒŠ[ƒvØœpŒã‚ÉŽ~ŒŒ¢“ï‚𗈂µ‚½æ“V«‘æX ˆöŽqŒ‡–RǃwƒeƒÚ‡‘Ì‚Ì1 —áD‘æ57‰ñ“ú–{—Õ°ŒŸ¸ˆãŠw‰ï“ŒŠC–k—¤Žx•”‘‰ïD‘æ336‰ñ“ú–{—Õ°‰»Šw‰ï“ŒŠC–k—¤Žx•”—á‰ï˜A‡‘å‰ïG2018 Mar 11G‹à‘òD
  5. ‹g“c”¹‘¾CˆÀ‘º•qC“¹–ì~ŽqC’†oË‘ãC²’|ˆÉ’ÃŽqC•yŽR—²‰îC‘å’ÎW–çC“‡‹žŽqC–k“‡ŒMD‘æ57‰ñ“ú–{—Õ°ŒŸ¸ˆãŠw‰ï“ŒŠC–k—¤Žx•”‘‰ïD‘æ336‰ñ“ú–{—Õ°‰»Šw‰ï“ŒŠC–k—¤Žx•”—á‰ï˜A‡‘å‰ïG2018 Mar 11G‹à‘òD
  6. âV“¡»ŽqC™]“ÞXC•yŽR—²‰îCŒ´“cŒ’‰ECã–ì’q_CmˆäŒ©‰pŽ÷C–k“‡ŒMDQProbe–@‚É‚æ‚éƒvƒƒeƒCƒ““¿“‡ƒXƒNƒŠ[ƒjƒ“ƒOŒŸ¸–@ŠJ”­‚Æ‚»‚Ì—Õ°‰ž—pD‘æ40‰ñ“ú–{ŒŒðŽ~ŒŒŠw‰ïŠwpW‰ïG2018 Jun 30GŽD–yD
  7. ™]“ÞXCâV“¡»ŽqCã–ì’qCmˆäŒ©‰pŽ÷C–k“‡ŒMDæ“V«ŒŒ‰t‹ÃŒÅˆÙíǂɑ΂·‚év‘¬EŠÈ•ÖEˆÀ‰¿‚Ȉâ“`Žq•ÏˆÙƒXƒNƒŠ[ƒjƒ“ƒO–@‚ÌŒŸ“¢D‘æ40‰ñ“ú–{ŒŒðŽ~ŒŒŠw‰ïŠwpW‰ïG2018 Jun 30GŽD–yD
  8. mˆäŒ©‰pŽ÷C™]˜a–ÎC¼ˆä“ÄCã–ì’q_C“à•Û—TˆêCΊÛ^ŽqC–ì“c‰pC–k“‡ŒMD”sŒŒÇ‹N‰Š‹Û‚ÌV‚½‚ÈATP‘ª’è‹Zp‚ðŠî”Õ‚Æ‚µ‚½v‘¬‚È–òÜŠ´Žó«ŽŽŒ±–@‚ÌŠJ”­D‘æ30‰ñ—Õ°”÷¶•¨v‘¬f’fŒ¤‹†‰ïG2018 Jun 30G“V—D
  9. ΊÛ^ŽqC“à•Û—TˆêC–ì“c‰p”VC™]˜aC¼ˆä“ÄCã–ì’q_CmˆäŒ©‰pŽ÷C–k“‡ŒMD”sŒŒÇ‹N‰Š‹Û‚ÌATP ‘ª’è‚É‚æ‚év‘¬–òÜŠ´Žó«ŽŽŒ±–@‚ÌŠ´“xŒŸ“¢D‘æ30‰ñ—Õ°”÷¶•¨v‘¬f’fŒ¤‹†G2018 Jun 30G“V—D
  10. ŠÖª“¹˜aCŽOŒ´OCΖ؊wCœAìTˆê˜YC–k“‡ŒMDŠwŽm•Ò“üŠw§“x‚É‚¨‚¯‚éIRiInstitutional Researchj‚ðŠˆ—p‚µ‚½ˆÓŽuŒˆ’èŽx‰‡D‘æ50‰ñ“ú–{ˆãŠw‹³ˆçŠw‰ï‘å‰ïG2018 Aug 3G“Œ‹žD
  11. Ζ؊wCŽOŒ´OCœAìTˆê˜YCŠÖª“¹˜aC–k“‡ŒMDARCS ƒ‚ƒfƒ‹‚ÉŠî‚¢‚½Žö‹ÆƒAƒ“ƒP[ƒg‚Ì•ª—Þ‚Æ–ž‘«“x‚Æ‚Ì”äŠrŒŸ“¢‚ð—p‚¢‚½Žö‹Æ‰ü‘P•ûô‚ÌŒŸ“¢D‘æ50‰ñ“ú–{ˆãŠw‹³ˆçŠw‰ï‘å‰ïG2018 Aug 3G“Œ‹žD
  12. ŽOŒ´OCΖ؊wCœAìTˆê˜YCŠÖª“¹˜aC–k“‡ŒMDMoodle3 ‚ÆŒg‘Ñ’[––‚ð—p‚¢‚½­l”‹³Eˆõ‚É‚æ‚éTBL‚ÌŽÀ‘HD‘æ50‰ñ“ú–{ˆãŠw‹³ˆçŠw‰ï‘å‰ïG2018 Aug 3G“Œ‹žD
  13. ŽOŒ´OCΖ؊wCœAìTˆê˜YCŠÖª“¹˜aC–k“‡ŒMDˆãŠw¶“¯Žm‚ňê˜A‚Ìf—Âð—ûK‚·‚éŠwKƒRƒ“ƒeƒ“ƒc쬂̎Ž‚ÝD‘æ50‰ñ“ú–{ˆãŠw‹³ˆçŠw‰ï‘å‰ïG2018 Aug 3G“Œ‹žD
  14. ŠÖª“¹˜aCŽOŒ´OCΖ؊wCœAìTˆê˜YC–k“‡ŒMDŠwŽm•Ò“üŠw§“x‚ÉŠÖ‚·‚éIRiInstitutional Researchj‚ðŠˆ—p‚µ‚½ˆÓŽuŒˆ’èŽx‰‡D‘æ50‰ñ“ú–{ˆãŠw‹³ˆçŠw‰ï‘å‰ïG2018 Aug 3G“Œ‹žD
  15. âV“¡»ŽqC™]“ÞXCã–ì’q_CŒ´“cŒ’‰ECmˆäŒ©‰pŽ÷C–k“‡ŒMDQProb –@‚É‚æ‚éƒvƒƒeƒCƒ“S “¿“‡ŠÈˆÕƒXƒNƒŠ[ƒjƒ“ƒOŒŸ¸–@‚Ì\’z‚Æ—Õ°ŒŸ“¢D‘æ58‰ñ“ú–{—Õ°‰»Šw‰ï”NŽŸŠwpW‰ïG2018 Aug 24G–¼ŒÃ‰®D
  16. ™]“ÞXCâV“¡»ŽqCã–ì’q_CmˆäŒ©‰pŽ÷C–k“‡ŒMDæ“V«ŒŒ‰t‹ÃŒÅˆÙíǂɑ΂·‚éCHIPS –@“±“ü‚É‚æ‚錟¸Œø—¦‰»D‘æ58‰ñ“ú–{—Õ°‰»Šw‰ï”NŽŸŠwpW‰ïG2018 Aug 24G–¼ŒÃ‰®D
  17. ‹g“c‘CŒ´“cŒ’‰EC–k“‡ŒMCâV“¡Ÿ•FDRCPC S•s‘Sˆ«‰»‚ÅЉ‚ꂽ65 Î’j«D‘æ26‰ñ–k—¤—Õ°•a—W’k‰ïƒZƒ~ƒi[G2018 Sep 1G•xŽRD
  18. ‘å’ÎW–çCˆÀ‘º•qC“¹–ì~ŽqC’†oËŽqC²’|ˆÉ’ÃŽqC•yŽR—²‰îC‹g“c”¹‘¾CŽR–{—R‰Á—¢Cã–ì’q_C–k“‡ŒMD—AŒŒŒãŒŒ‰t»Ü‚̃oƒbƒO‰ñŽû‚ð—p‚¢‚½“K³Žg—pŒüã‚ÌŽæ‚è‘g‚ÝD‘æ26‰ñ–k—¤—Õ°•a—W’k‰ïƒZƒ~ƒi[G2018 Sep 1G•xŽRD
  19. X“c–¢C™]˜a–ÎCŠÖŒûŒh•¶Câ–{ƒŽqCã–ì’q_C–k“‡ŒMCì‹ØmŽjCŽðŠªˆê•½CŽR–{‘P—TD‹CŠÇ“à‹zˆø•¨‚̃Oƒ‰ƒ€õFŠŒ©‚©‚çRŽ_‹Û‚ð‹^‚¢AV¶Ž™æ“V«Œ‹Šj‚Æf’f‚³‚ꂽ1Ç—áD‘æ26‰ñ–k—¤—Õ°•a—W’k‰ïƒZƒ~ƒi[G2018 Sep 1G•xŽRD
  20. ™]˜a–ÎC¼ˆä“ÄCã–ì’q_CmˆäŒ©‰pŽ÷C–k“‡ŒMD”sŒŒÇ‹N‰Š‹Û‚ÌV‚½‚ÈATP ‘ª’è‹Zp‚ðŠî”Õ‚Æ‚µ‚½v‘¬‚È–òÜŠ´Žó«ŽŽŒ±–@‚ÌŠJ”­D‘æ26‰ñ–k—¤—Õ°•a—W’k‰ïƒZƒ~ƒi[G2018 Sep 1G•xŽRD
  21. ‘å’ÎW–çCã–ì’q_CmˆäŒ©‰pŽ÷C–k“‡ŒMD•sŠ®‘Sˆê’v”z—ñ‚Ìüã’·½ƒvƒ[ƒu‚ð—p‚¢‚½‰ü—ÇTm mapping –@D‘æ26‰ñ–k—¤—Õ°•a—W’k‰ïƒZƒ~ƒi[G2018 Sep 1G•xŽRD
  22. mˆäŒ©‰pŽ÷C“ŒËŽkC‹{˜W‰›Cã–ì’q_CâV“¡Ž CŽR–{‘P—TC–k“‡ŒMD‹Û”‚ð”sŒŒÇ‚ÌV‚½‚ȃoƒCƒIƒ}[ƒJ[‚Æ‚·‚é‹N‰Š‹Ûv‘¬“¯’èE’è—ÊŒŸ¸–@D‘æ26‰ñ–k—¤—Õ°•a—W’k‰ïƒZƒ~ƒi[G2018 Sep 1G•xŽRD
  23. ‰–è^‹|C¬£—¢•äC“àŽRŒ«ŽqCŠp“c”ü—éC‰¡“cˆ»Cã–ì’q_CŒ´“cŒ’‰ECH‰ª’¼C–k“‡ŒMD“àŒz“®–¬‹‘剼«“®–¬áŽ‚ɑ΂µŽ¡—ÃŒø‰Ê”»’è‚Éèò“®–¬ƒGƒR[‚ª—LŒø‚¾‚Á‚½1 —áD‘æ26‰ñ–k—¤—Õ°•a—W’k‰ïƒZƒ~ƒi[G2018 Sep 1G•xŽRD
  24. ™]“ÞXCâV“¡»ŽqC•yŽR—²‰îCã–ì’qCŒ´“cŒ’‰ECmˆäŒ©‰pŽ÷C–k“‡ŒMDƒvƒƒeƒCƒ“S “¿“‡•ÏˆÙŒŸo‚É‚¨‚¯‚éƒvƒƒeƒCƒ“S ”䊈«”»’èŠî€‚ÌŒŸØD“ú–{—Õ°ŒŸ¸Ž©“®‰»Šw‰ï‘æ50‰ñ‘å‰ïG2018 Oct 13G_ŒËD
  25. âV“¡»ŽqCŒ´“cŒ’‰ECã–ì’q_CmˆäŒ©‰pŽ÷C–k“‡ŒMDQProb –@‚É‚æ‚éƒvƒƒeƒCƒ“S “¿“‡ŠÈˆÕƒXƒNƒŠ[ƒjƒ“ƒO–@‚Ì\’z‚Æ—Õ°“I—L—p«‚ÌŒŸ“¢D‘æ65‰ñ“ú–{—Õ°ŒŸ¸ˆãŠw‰ïŠwpW‰ïG2018 Nov 16G“Œ‹ž
  26. mˆäŒ©‰pŽ÷C“ŒËŽkCã–ì’q_CŽR–{‘P—TC–k“‡ŒMD‹Û”‚ð”sŒŒÇ‚ÌV‹KƒoƒCƒIƒ}[ƒJ[‚Æ‚·‚é‹N‰Š‹Ûv‘¬“¯’èE’è—ÊŒŸ¸–@‚ÌŠJ”­D‘æ65‰ñ“ú–{—Õ°ŒŸ¸ˆãŠw‰ïŠwpW‰ïG2018 Nov 16G“Œ‹žD
  27. ™]˜a–ÎCmˆäŒ©‰pŽ÷Cã–ì’qC–k“‡ŒMDV‚½‚ÈATP ‘ª’è‹Zp‚ðŠî”Õ‚Æ‚µ‚½Av‘¬‚È–òÜŠ´Žó«ŽŽŒ±–@‚ÌŠJ”­D‘æ65‰ñ“ú–{—Õ°ŒŸ¸ˆãŠw‰ïŠwpW‰ïG2018 Nov 16G“Œ‹žD
  28. ‘å’ÎW–çCmˆäŒ©‰pŽ÷Cã–ì’q_C–k“‡ŒMD•sŠ®‘Sˆê’v”z—ñ‚Ìüó’·½ƒvƒ[ƒu‚ð—p‚¢‚½‰ü—ÇTm mapping –@D‘æ65‰ñ“ú–{—Õ°ŒŸ¸ˆãŠw‰ïŠwpW‰ïG2018 Nov 16G“Œ‹žD
  29. •xŽR—²‰îCˆÀ‘º•qC‘å’ÎW–çC‹g“c”¹‘¾C’†oË‘ãC²’|ˆÉ’ÃŽqC“¹–ì~ŽqCã–ì’q_C–k“‡ŒMD“–‰@‚É‚¨‚¯‚é—AŒŒƒ`[ƒ€ˆã—Âɂæ‚éˆÀ‘S‚Å“K³‚È—AŒŒ—Ö@‚Ö‚ÌŽæ‚è‘g‚ÝD‘æ65‰ñ“ú–{—Õ°ŒŸ¸ˆãŠw‰ïŠwpW‰ïG2018 Nov 16G“Œ‹žD
  30. ™]“ÞXCÝ“cK‘¾˜YCã–ì’q_CmˆäŒ©‰pŽ÷C–k“‡ŒMDpŒãŽ~ŒŒ¢“ï‚𗈂µ‚½æ“V«‘æXˆöŽqŒ‡–RǃwƒeƒÚ‡Œ^‚Ì1—áD‘æ65‰ñ“ú–{—Õ°ŒŸ¸ˆãŠw‰ïŠwpW‰ïG2018 Nov 16G“Œ‹žD
  31. Œ´“cŒ’‰ECâV“¡»ŽqC‚™@FC•c“SŒRCã–ì’q_C–k“‡ŒMDRH-PAT‚Ì’ZŠ‚ÌŽ•ž‚ð–ÚŽw‚µ‚½‘SŽ©“®ŒŒŠÇ“à”ç‹@”\ŒŸ¸‹@Ší‚ÌŠJ”­D‘æ65‰ñ“ú–{—Õ°ŒŸ¸ˆãŠw‰ïŠwpW‰ïG2018 Nov 16G“Œ‹žD
  32. Œ´“cŒ’‰EC™]“ÞXCâV“¡»ŽqCmˆäŒ©‰pŽ÷Cã–ì’q_C–k“‡ŒMD‘²‘O—Õ°ŽÀK‚É‚¨‚¯‚éƒvƒƒeƒCƒ“S•ÏˆÙƒXƒNƒŠ[ƒjƒ“ƒOŒŸ¸‚ð—˜—p‚µ‚½ˆâ“`ˆãŠw‹³ˆç‚ÌŽŽ‚ÝD‘æ65‰ñ“ú–{—Õ°ŒŸ¸ˆãŠw‰ïŠwpW‰ïG2018 Nov 16G“Œ‹žD
  33. mˆäŒ©‰pŽ÷C“ŒËŽkCŽR–{‘P—TC–k“‡ŒMD‹Û”‚ð”sŒŒÇ‚ÌV‹KƒoƒCƒIƒ}[ƒJ[‚Æ‚·‚é‹N‰Š‹Ûv‘¬ŒŸ¸–@D‘æ88‰ñ“ú–{Š´õÇŠw‰ï¼“ú–{’n•û‰ïŠwpW‰ïG2018 Nov 17GŽ­Ž™“‡D
  34. mˆäŒ©‰pŽ÷CŽR–{‘P—TC–k“‡ŒMD”sŒŒÇ‹N‰Š‹Û‚ÌV‚½‚ÈATP ‘ª’è‹Zp‚É‚æ‚év‘¬‚È–òÜŠ´Žó«ŽŽŒ±–@‚ÌŠJ”­D‘æ88‰ñ“ú–{Š´õÇŠw‰ï¼“ú–{’n•û‰ïŠwpW‰ïG2018 Nov 17GŽ­Ž™“‡D
  35. mˆäŒ©‰pŽ÷C–k“‡ŒMCˆÀˆäŽ¡D‹Û”‚ðƒoƒCƒIƒ}[ƒJ[‚Æ‚·‚éAV‹K‹N‰Š‹Ûv‘¬“¯’èE’è—ʃVƒXƒeƒ€DAMEDŽYŠw˜AŒgˆã—ÃCƒmƒx[ƒVƒ‡ƒ“‘noƒvƒƒOƒ‰ƒ€iACT-M/MSjD‘æ1‰ñ¬‰Ê”­•\‰ïiBioJapan2018jG2018 Oct 12G‰¡•lD
  36. mˆäŒ©‰pŽ÷DŠ´õÇ‚É‚¨‚¯‚éV‚½‚Èv‘¬ŒŸ¸‹Zp‚ÌŠJ”­D“ú–{Ô\ŽšŽÐ ‘æ31‰ñŠwpu‰‰‰ïi’†‰›ŒŒ‰tŒ¤‹†ŠŽåÃjG2018 Aug 28G“Œ‹žD
  37. mˆäŒ©‰pŽ÷C“ŒËŽkCŽðŠªˆê•½CŽá™‰ë_CŽR–{‘P—TC–k“‡ŒMD‹Û”‚ð”sŒŒÇ‚ÌV‹KƒoƒCƒIƒ}[ƒJ[‚Æ‚·‚é‹N‰Š‹Ûv‘¬“¯’èE’è—ÊŒŸ¸–@‚ÌŠJ”­D‘æ25‰ñ“ú–{ˆâ“`Žqf—Êw‰ï‘å‰ïG2018 Jul 13GˆÉ¨D
  38. mˆäŒ©‰pŽ÷CŽR–{‘P—TC–k“‡ŒMD”sŒŒÇ‹N‰Š‹Û‚ÌV‚½‚ÈATP‘ª’è‹Zp‚ðŠî”Õ‚Æ‚µ‚½Av‘¬‚È–òÜŠ´Žó«ŽŽŒ±–@‚ÌŠJ”­D‘æ92‰ñ“ú–{Š´õÇŠw‰ïŠwpu‰‰‰ïG2018 Jun 2G‰ªŽRD
  39. mˆäŒ©‰pŽ÷C“ŒËŽkCŽR–{‘P—TC–k“‡ŒMD‹Û”‚ð”sŒŒÇ‚ÌV‹KƒoƒCƒIƒ}[ƒJ[‚Æ‚·‚é‹N‰Š‹Ûv‘¬“¯’èE’è—ÊŒŸ¸–@D‘æ92‰ñ“ú–{Š´õÇŠw‰ïŠwpu‰‰‰ïG2018 Jun 2G‰ªŽRD

“Á‹–

  1. “ŒËŽkCmˆäŒ©‰pŽ÷C–k“‡ŒMCinventorsG•xŽR‘åŠwCassigneeD•sŠ®‘S‚ȃ}ƒbƒ`ƒvƒ[ƒu‚ð—p‚¢‚½ƒJƒ“ƒWƒ_‹Û‚Ìv‘¬“¯’è–@D‘“à“ÁŠè2018-061350D‘Û“Á‹–oŠèPCT-TU32-118D2018 Mar 28D
  2. mˆäŒ©‰pŽ÷C‘å’ÎŒ«–çC–k“‡ŒMCinventorsG•xŽR‘åŠwCassigneeD‰ü—ÇTmƒ}ƒbƒsƒ“ƒO–@D‘Û“Á‹–oŠèPTC/JP2018/23382D2018 Jun 20D
  3. mˆäŒ©‰pŽ÷C™]˜a–ÎC–k“‡ŒMCinventorsG•xŽR‘åŠwCassigneeDŒŒ‰tŒŸ‘Ì‚Ì‘Oˆ—•û–@D‘Û“Á‹–oŠèPTC/JP2018/23388D2018 Jun 20D
  4. mˆäŒ©‰pŽ÷C–k“‡ŒMC‹{˜W‰›C“ŒËŽkCinventorsG•xŽR‘åŠwEŽOˆä‰»ŠwiŠ”jCassigneeDŒŸ‘Ì’†‚Ì׋۔‚Ì’è—Ê•û–@D‘Û“Á‹–oŠèPCT/JP2018/023597D2018 Mar 28D

‚»‚Ì‘¼

  1. –k“‡ŒMDReverse Clinicopathological ConferenceiRCPCj“ü–åD‘æ26‰ñ–k—¤—Õ°•a—W’k‰ïG2018 Sep 1G•xŽRD
  2. –k“‡ŒMDŒŒŠÇŒnŽ¾Š³–¢•a‚ðŒŸo‚Å‚«‚é‘SŽ©“®ŒŒŠÇ“à”ç‹@”\ŒŸ¸ƒfƒoƒCƒX‚ÌŠJ”­D‘æ39‰ñ˜aŠ¿ˆã–ò‘‡Œ¤‹†Š“Á•ÊƒZƒ~ƒi[G2018 Oct 2G•xŽRD
  3. mˆäŒ©‰pŽ÷DŠ´õÇ‚É‚¨‚¯‚éV‚½‚Èv‘¬ŒŸ¸‹Zp‚ÌŠJ”­D•½¬29 ”N“xƒtƒ@[ƒ}EƒƒfƒCƒJƒ‹ƒGƒ“ƒWƒjƒAiPMEj—{¬ƒvƒƒOƒ‰ƒ€‚ƶ–½—Z‡‰ÈŠw‹³ˆç•”‚Ì‹¤ÃƒVƒ“ƒ|ƒWƒEƒ€G2018 Feb 13G•xŽRD
  4. –k“‡ŒMD—Õ°ŒŸ¸¸“xŠÇ—–@‰ü³‚Æ‘Û‰»‚ւ̑ΉžD•xŽRŒ§—Õ°ŒŸ¸¸“xŠÇ—’²¸Œ‹‰Ê•ñ‘D2018 Jan 30D
  5. –k“‡ŒMD’nˆæˆã—чŽx‰‡ŠwuÀ‚Ì–ðŠ„‚ÆŠú‘ÒD•½¬29 ”N“x’nˆæˆã—чŽx‰‡ŠwuÀŠˆ“®•ñ‘D2018 MayD
  6. –k“‡ŒMD–{•¨‚ðŒ©‹É‚ß‚éŠáDƒ‚ƒ_ƒ“ƒƒfƒCƒA750 †‹L”O•MWD2018F80D
  7. –k“‡ŒMD•xŽR‘åŠw‚ƈãŠw•”‚ÌV‚µ‚¢‹³ˆç•ûji3 ƒ|ƒŠƒV[j‚̉ü’ù”ÅD•xŽR‘åŠwˆãŠw•”Œã‰‡‰ï‰ï•ñ53D2018F2D
  8. –k“‡ŒMD‹³—{‹³ˆçŒ³”ND•xŽR‘åŠwˆãŠw•”Œã‰‡‰ï‰ï•ñ54D2018F2D
  9. –k“‡ŒMD–{ŠwˆãŠw‹³ˆç‰ü‘P‚Ì‚½‚߈ãŠw‹³ˆç•ª–ì•Ê•]‰¿‚ðŽóR‚µ‚ÄŽv‚¤‚±‚ÆD“¯‘‹‰ïˆõ‚ÌŠF—l‚Ö‚Ì‚¨Šè‚¢D•xŽR‘åŠwˆãŠw•”“¯‘‹‰ï•ñ27D2018F9-10D
  10. –k“‡ŒMDŠª“ªŒ¾D•½¬29 “x‘Šú‰îŒì‘ÌŒ±ŽÀK•ñ‘D2018F1D
  11. mˆäŒ©‰pŽ÷Dˆâ“`Žqf—Õ”‚ɂ‚¢‚ÄD•xŽR‘åŠwˆãŠw•”“¯‘‹‰ï•ñ27D2018F16D

ƒy[ƒW‚Ì擪‚Ö–ß‚é

2017”N

’˜‘

  1. –k“‡ŒMC•ì´Ct“ú‰ëlC–k‘º ¹•ÒD—Õ°ŒŸ¸ƒf[ƒ^ƒuƒbƒNLAB DATA2017-2018D“Œ‹žFˆãŠw‘‰@G2017 JunDƒvƒƒgƒƒ“ƒrƒ“Aƒvƒƒgƒƒ“ƒrƒ“ƒtƒ‰ƒOƒƒ“ƒgiPF1+2jC‘æVˆöŽqA‘æVIIˆöŽqA‘æVIIIˆöŽqAvon Willebrand ˆöŽqAvon Willenrand ˆöŽqƒ}ƒ‹ƒ`ƒ}[‰ðÍAVWF Ø’fy‘fiADAMTS13jC‘æIXˆöŽqA‘æXˆöŽqA‘æXIˆöŽqA‘æXIIˆöŽqA‘æXIIIˆöŽqGp.368-92D
  2. –k“‡ŒMC•ì´Ct“ú‰ëlC–k‘º ¹•ÒD—Õ°ŒŸ¸ƒf[ƒ^ƒuƒbƒNLAB DATA2017-2018D“Œ‹žFˆãŠw‘‰@G2017 JunD‹ÃŒÅˆöŽqƒCƒ“ƒqƒrƒ^[’è«iƒNƒƒXƒ~ƒLƒVƒ“ƒOŽŽŒ±jA‘æVIIIˆöŽqƒCƒ“ƒqƒrƒ^[A‘æIXˆöŽqƒCƒ“ƒqƒrƒ^[A‘gDˆöŽqi‘gDƒgƒƒ“ƒ{ƒvƒ‰ƒXƒ`ƒ“jA‘‘gDˆöŽqŒo˜HƒCƒ“ƒqƒrƒ^[i‘TFPIjAƒAƒ“ƒ`ƒgƒƒ“ƒrƒ“iATjCƒgƒƒ“ƒrƒ“E ƒAƒ“ƒ`ƒgƒƒ“ƒrƒ“•¡‡‘ÌiTATjGp.392-6D
  3. –k“‡ŒMC•ì´Ct“ú‰ëlC–k‘º ¹•ÒD—Õ°ŒŸ¸ƒf[ƒ^ƒuƒbƒNLAB DATA2017-2018D“Œ‹žFˆãŠw‘‰@G2017 JunDƒvƒƒeƒCƒ“CAƒvƒƒeƒCƒ“SA‘gDƒvƒ‰ƒXƒ~ƒmƒQƒ“ƒAƒNƒ`ƒx[ƒ^it-PAjCƒvƒ‰ƒXƒ~ƒmƒQƒ“ƒAƒNƒ`ƒx[ƒ^ƒCƒ“ƒqƒrƒ^[1iPAI-1jCt-PAEPAI-1 •¡‡‘ÌAƒvƒ‰ƒXƒ~ƒmƒQƒ“Aƒ¿2-ƒvƒ‰ƒXƒ~ƒ“ƒCƒ“ƒqƒrƒ^[Aƒvƒ‰ƒXƒ~ƒ“Eƒ¿2-ƒvƒ‰ƒXƒ~ƒ“ƒCƒ“ƒqƒrƒ^[•¡‡‘ÌiPIC ƒeƒXƒgjGp. 397-404D
  4. –k“‡ŒMC‚‹vŽj–›ŠÄCD—Õ°ŒŸ¸ƒf[ƒ^ƒuƒbƒNLAB DATA ƒRƒ“ƒpƒNƒg”ÅD‘æ9”ÅD“Œ‹žFˆãŠw‘‰@G2017 OctDŒŒ‰tE‹ÃŒÅEü—nGp. 148-55D

Œ´’˜

  1. Ichinose A; Japanese Collaborative Research Group on AH13. Autoimmune acquired factor XIII deficiency due to anti-factor XIII/13 antibodies: A summary of 93 patients. Blood Rev. 2017 Jan; 31(1): 37-45. DOI: 10.1016/j.blre.2016.08.002.
  2. Kawaguchi Y, Nakano M, Yasuda T, Seki S, Suzuki K, Yahara Y, Makino H, Kitajima I, Kimura T. Serum biomarkers in patients with ossification of the posterior longitudinal ligament (OPLL): Inflammation in OPLL. PLoS One. 2017 May 3; 12(5): e0174881. DOI: 10.1371/journal.pone.0174881.
  3. Higashi Y, Nakamura S, Niimi H, Ueno T, Matsumoto K, Kawago K, Sakamaki I, Kitajima I, Yamamoto Y. Spondylodiscitis due to Parvimonas micra diagnosed by the melting temperature mapping method: a case report. BMC Infect Dis. 2017 Aug 23;17(1): 584. DOI: 10.1186/s12879-017-2690-4.
  4. ˆê£”’’éC‘y‰F—˜³‘PC‹´ŒûÆlC–î•y —TC¬ìEKC–k“‡ŒMC’©‘q‰pôC‰ª–{DŽiC‰ÆŽq³—TCŽR–{WŽmC]Œû –LDGuidance on Diagnosis and Management of Autoimmune Hemorrhaphilia FXIII/13iAHFXIII/13jD“úŒŒðŽ~ŒŒ‰ïŽD2017G28(3)F393-420D

‘à

  1. –k“‡ŒMDƒvƒƒeƒCƒ“S ˆÙ킪ŠÖ—^‚·‚éÖ¬ŒŒðǂɑ΂·‚錟¸–@‚Ìi•àD•xŽRŽsˆãŽt‰ï‰ï•ñD2017 JunG554F18-21D
  2. mˆäŒ©‰pŽ÷DMelting Temperature (Tm) mapping –@FŒŸ‘ÌÌŽæŒã3 ŽžŠÔˆÈ“à‚Å”sŒŒÇ‹N‰Š‹Ûv‘¬“¯’è–@D—Õ°‰»ŠwD2017 JulG46(1)F47-54D
  3. mˆäŒ©‰pŽ÷DŠ´õÇŒŸ¸‚ÌV‚½‚È’ª—¬D—Õ°‰»ŠwD2017 JulG46(3)F190D
  4. mˆäŒ©‰pŽ÷D”]ƒŠƒLƒbƒhƒoƒCƒIƒvƒV[D”]_ŒoŽ¾Š³‚ÌV‚½‚ÈŒŸ¸‚Æ‚µ‚Ẳ”\«D—Õ°‰»ŠwD2017 JulG46(3)F252D

Šw‰ï•ñ

  1. Niimi H, Kitajima I. Tm Mapping. A novel testing method for rapid bacterial identification without blood culture. Singapore international infectious disease conference; 2017 Aug 25; Singapore.
  2. mˆäŒ©‰pŽ÷DTm mapping –@ŠT—v‚¨‚æ‚Ñ•¡”‹@ŠÖ‚ÌŽŽŒ±Œ‹‰ÊD“ú–{—Õ°”÷¶•¨Šw‰ïƒXƒ|ƒ“ƒT[ƒhƒZƒbƒVƒ‡ƒ“G2017 Jan 21G’·èD
  3. ã–ì’q_C•xŽR—²‰îC–ìŽè—Ç„CmˆäŒ©‰pŽ÷C–k“‡ŒMDƒvƒƒeƒCƒ“S “¿“‡ƒXƒNƒŠ[ƒjƒ“ƒOŠÈˆÕˆâ“`ŽqŒŸ¸–@‚ÌŠJ”­D‘æ17‰ñTTM ƒtƒH[ƒ‰ƒ€G2017 Mar 4G“Œ‹žD
  4. ‰¡“cˆ»C‘åŠp—F‹IC”öì’q”üCŠp“c”ü—éC’·“c‘ñÆCŠÖªTˆêC–k“‡ŒMD“û–[’´‰¹”gŒŸ¸‚Å‚Ì‚Ý„‘ª‚µ“¾‚½üˆÛŽî“à‚É”­¶‚µ‚½“û‚ª‚ñ‚̈ê—áD‘æ56‰ñ“ú–{—Õ°ŒŸ¸ˆãŠw‰ï“ŒŠC–k—¤Žx•”‘‰ïE‘æ334‰ñ“ú–{—Õ°‰»Šw‰ï“ŒŠCE–k—¤Žx•”—á‰ï˜A‡‘å‰ïG2017 Mar 12G–¼ŒÃ‰®D
  5. ìŒû‘PŽ¡CˆÀ“c„•qCŠÖ¯“ñC—é–؉ê‘ãCûŒ´NlC–q–ìhŽmC–k“‡ŒMC–Ø‘º—FŒúDŒãcx‘Ñœ‰»Ç‚É‚¨‚¯‚é‚Š´“xCRP ‚̈Ӌ`D‘æ31‰ñ“ú–{Ò’ÅÒ‘•aŠw‰ïG2017 Apr 13GŽD–yD
  6. ŽŒ´N—T*Cã–ì’q_CìŒû‘PŽ¡C–k“‡ŒMDŒãcx‘Ñœ‰»Ç•a‘ÔŒ`¬‚É‚¨‚¯‚鉊ǂ̊֗^D‘æ28‰ñ“ú–{—Õ°‰»Šw‰ï“ŒŠC–k—¤Žx•”‘‰ïE‘æ36‰ñ“ú–{—Õ°ŒŸ¸ˆãŠw‰ï“ŒŠC–k—¤Žx•”—á‰ï˜A‡‘å‰ïG2017 Aug 5G’ÃD
  7. ŽOŒ´OCΖ؊wCŠÖª“¹˜aC“c‘ºŒ’‘¾˜YCŽR“c“OCœAìTˆê˜YC–k“‡ŒMDMoodle ‚ð—˜—p‚µ‚½—Õ°ŽÀKŠw¶‚ÌŒoŒ±CŽÀŽ{ƒf[ƒ^ŽûW‚ÆŠˆ—pD‘æ49‰ñ“ú–{ˆãŠw‹³ˆçŠw‰ï‘å‰ïG2017 Aug 18GŽD–yD
  8. Ζ؊wCŽOŒ´OCŠÖª“¹˜aCœAìTˆê˜YCŽR“c“OC“c‘ºŒ«‘¾˜YC–k“‡ŒMDŒø‰Ê“I‚È—Õ°ŽÀK‘OƒJƒŠƒLƒ…ƒ‰ƒ€ŽÀŽ{‚ÌŽŽ‚ÝD‘æ49‰ñ“ú–{ˆãŠw‹³ˆçŠw‰ï‘å‰ïG2017 Aug 19GŽD–yD
  9. ŽOŒ´OCΖ؊wCŠÖª“¹˜aC“c‘ºŒ’‘¾˜YCŽR“c“OCœAìTˆê˜YC–k“‡ŒMD•xŽR‘åŠwˆãŠw•”ˆãŠw‰È‚É‚¨‚¯‚鎎Œ±¬Ñ‚ÉŠÖ‚·‚錟“¢D‘æ49‰ñ“ú–{ˆãŠw‹³ˆçŠw‰ï‘å‰ïG2017 Aug 19GŽD–yD
  10. ŽR“c“OC“c‘ºŒ«‘¾˜YC‹g–ìŠwC••”^—ŽqCŽá™‰ë_C–kŒ[ˆê˜YC‹g“cŽ÷ˆê˜YCŽOŒ´OCΖ؊wCŠÖª“¹˜aC•õ‘º³ŽÀCœAìTˆê˜YC–k“‡ŒMD•xŽR‘åŠw‚É‚¨‚¯‚é’nˆæ˜gE“Á•Ê˜gŠw¶‚Ö‚ÌŽæ‚è‘g‚ÝD‘æ49‰ñ“ú–{ˆãŠw‹³ˆçŠw‰ï‘å‰ïG2017 Aug 19GŽD–yD
  11. ‰¡“cˆ»CŒÃ“c”¹‘¾Cã–ì’q_C–k“‡ŒMDÌŒŒŽ©“®Žó•t‹@“±“ü‚É‚æ‚éŽó•t‘Ò‚¿ŽžŠÔ‰ü‘PŒø‰Ê‚ƉۑèD‘æ42‰ñ–k—¤—Õ°•a—W’k‰ïG2017 Sep 2G‹à‘òD
  12. •õ‘º—FŽ÷*C×ì’qOCâV“¡»ŽqCŽRŠÝ“ÞXCã–ì’q_CmˆäŒ©‰pŽ÷C–k“‡ŒMDƒvƒƒeƒCƒ“S “¿“‡ƒXƒNƒŠ[ƒjƒ“ƒOŠÈˆÕˆâ“`ŽqŒŸ¸–@‚ÌŠJ”­D‘æ42‰ñ–k—¤—Õ°•a—W’k‰ïG2017 Sep 2G‹à‘òD
  13. ×ì’qO*C•õ‘º—FŽ÷CâV“¡»ŽqCŽRŠÝ“ÞXCã–ì’q_CmˆäŒ©‰pŽ÷C–k“‡ŒMDŒ’íŽá”N¬l‚É‚¨‚¯‚éƒvƒƒeƒCƒ“S“¿“‡ƒXƒNƒŠ[ƒjƒ“ƒOŒŸ¸‚Ì—L—p«‚ÉŠÖ‚·‚錟“¢D‘æ42‰ñ–k—¤—Õ°•a—W’k‰ïG2017 Sep 2G‹à‘òD
  14. “àŽRŒ«ŽqC¬£—¢ŒbC‰–ú±^‹|C¬àVˆ»‰ÀCœA–ìŒbˆêCŽs“c•™ŽqC–k“‡ŒMD• •”‘å“®–¬ŒŒ—¬”gŒ`‚ªf’f‚É—L—p‚Å‚ ‚Á‚½‘å“®–¬‹|—£’fÇ‚Ì1 —áD‘æ42‰ñ–k—¤—Õ°•a—W’k‰ïG2017 Sep 2G‹à‘òD
  15. ‘å’ÎW–çCŽŒ´N—TCã–ì’q_C–k“‡ŒMD”Ä—pŽ©“®•ªÍ‘•’u‚ð—p‚¢‚½IL2R ‘ª’莎–òƒiƒmƒsƒARIL2R‚ÌŠî‘b“IŒŸ“¢D“ú–{—Õ°ŒŸ¸Ž©“®‰»Šw‰ï‘æ49‰ñ‘å‰ïG2017 Sep 21G‰¡•lD
  16. mˆäŒ©‰pŽ÷Cã–ì’q_C–k“‡ŒMD‹Û”‚ðV‹KƒoƒCƒIƒ}[ƒJ[‚Æ‚·‚év‘¬ŒŸ¸ƒVƒXƒeƒ€‚ÌŠJ”­D‘æ57‰ñ“ú–{—Õ°‰»Šw”NŽŸŠwpW‰ïG2017 Oct 7GŽD–yD
  17. ŽŒ´N—TCã–ì’q_CìŒû‘PŽ¡C–k“‡ŒMDŒãcx‘Ñœ‰»ÇOPLL ‚É‚¨‚¯‚錌’†FGF-23 ‚’l‚̈Ӌ`D‘æ57‰ñ“ú–{—Õ°‰»Šw”NŽŸŠwpW‰ïG2017 Oct 8GŽD–yD
  18. “¹–ì~ŽqCˆÀ‘º•qC•xŽR—²‰îC’†oË‘ãC²’|ˆÉ’ÃŽqC‹g“c”¹‘¾C‘å’ÎW–çC“‡‹žŽqC‘ºãƒC˜a“c‹Å–@C–k“‡ŒMD¬Ž™‚̻ܕªŠ„‚ɑ΂·‚é“–‰@‚ÌŽæ‚è‘g‚ÝD‘æ35‰ñ“ú–{—AŒŒE×–EŽ¡—Êw‰ï–k—¤Žx•”—á‰ïG2017 Nov 11G•ŸˆäD
  19. ‹g“c”¹‘¾C“¹–ì~ŽqCˆÀ‘º•qC•xŽR—²‰îC’†oË‘ãC²’|ˆÉ’ÃŽqC‘å’ÎW–çC“‡‹žŽqC‘ºãƒC˜a“c‹Å–@C–k“‡ŒMD‹Ù‹}—AŒŒ‚ª•K—v‚ÈŠ³ŽÒ‚Å—AŒŒ‚É‹ê—¶‚µ‚½2 Ç—áD‘æ35‰ñ“ú–{—AŒŒE×–EŽ¡—Êw‰ï–k—¤Žx•”—á‰ïG2017 Nov 11G•ŸˆäD
  20. mˆäŒ©‰pŽ÷D‹Û”‚ð”sŒŒÇ‚ÌV‹KƒoƒCƒIƒ}[ƒJ[‚Æ‚·‚év‘¬‚Ȉâ“`ŽqŒŸ¸ƒVƒXƒeƒ€‚ÌŠJ”­D‘æ64‰ñ“ú–{—Õ°ŒŸ¸ˆãŠw‰ïŠwpW‰ïG2017 Nov 17G‹ž“sD
  21. ‘å’ÎW–çC“¹–ì~ŽqC²’|ˆÉ’ÃŽqC’†oË‘ãC•xŽR—²‰îC‹g“c ”¹Cã–ì’q_CˆÀ‘º•qC–k“‡ŒMDˆÙŒ^—AŒŒŒã‚ÌŒŒ‰tŒ^ŒŸ¸‚ÉŠÖ‚·‚錟“¢D‘æ64‰ñ“ú–{—Õ°ŒŸ¸Šw‰ïŠwpW‰ïG2017 Nov 17G‹ž“sD
  22. ŽŒ´N—T*Cã–ì’q_CìŒû‘PŽ¡C–k“‡ŒMDŒãcx‘Ñœ‰»ÇiOPLLj‚É‚¨‚¯‚éƒoƒCƒIƒ}[ƒJ[‚ÌŒŸ“¢D‘æ64‰ñ“ú–{—Õ°ŒŸ¸Šw‰ïŠwpW‰ïG2017 Nov 18G‹ž“sD
  23. âV“¡»Žq*C•xŽR—²‰îCã–ì’q_CâV“¡ Ž C–k“‡ŒMDƒvƒƒeƒCƒ“S “¿“‡ƒXƒNƒŠ[ƒjƒ“ƒOŠÈˆÕˆâ“`ŽqŒŸ¸–@ŠJ”­‚Æ•sˆçÇŠO—ˆŠ³ŽÒ‚ÌŒŒð«‘fˆöƒXƒNƒŠ[ƒjƒ“ƒO‚Ì—L—p«D‘æ64‰ñ“ú–{—Õ°ŒŸ¸Šw‰ïŠwpW‰ïG2017 Nov 18G‹ž“sD
  24. ‹g“c ‘*C–k“‡ŒMD‰Šú—Õ°Œ¤C‚É‚¨‚¯‚錟¸‚ÉŠÖ‚·‚錤CŽÀ‘Ô‚ÆŒŸ¸‚Ìd—v«‚ªÄ”FŽ¯‚³‚ꂽǗá‘ÌŒ±D‘æ64‰ñ“ú–{—Õ°ŒŸ¸Šw‰ïŠwpW‰ïG2017 Nov 19G‹ž“sD
  25. ™]˜a–ÎCŠÖŒûŒh•¶CŽRŠÝ“ÞXCX“c”üCâ–{ƒŽqCã–ì’q_C–k“‡ŒMDLegionella pheumophila ‚̈â“`ŽqŒ^”»•Ê–@‚Å‚ ‚éSequence-Based TypingiSBTj–@‚̉@“à“±“ü‚ÉŒü‚¯‚½ŒŸ“¢D‘æ35‰ñ“ú–{õF‘̈â“`ŽqŒŸ¸Šw‰ï‘‰ïEŠwpW‰ïG2017 Nov 25G“V—D

“Á‹–

  1. mˆäŒ©‰pŽ÷C–k“‡ŒMC™]˜a–ÎCã–ì’q_CinventorsG•xŽR‘åŠw’·CassigneeDŒŒ‰t’†‚Ì‹N‰Š‹Û‚ðATP ‘ª’è‚·‚邽‚ß‚ÌŒŒ‰tŒŸ‘Ì‚Ì‘Oˆ—•û–@D“ÁŠè2017-219547D2017 Nov 15D
  2. mˆäŒ©‰pŽ÷C‘å’ÎW–çC–k“‡ŒMCinventorsG•xŽR‘åŠw’·CassigneeD‰ü—ÇTm ƒ}ƒbƒsƒ“ƒO–@D“ÁŠè2017-244461D2017Dec 20D
  3. mˆäŒ©‰pŽ÷C–k“‡ŒMC‹{˜W‰›C“ŒËŽkCinventorsG•xŽR‘åŠw’·CassigneeDŠ´õÇŠ³ŽÒŒŸ‘Ì’†‚Ì׋۔‚ð16Sribosomal RNA ˆâ“`ŽqƒRƒs[”‚Åv‘¬E³Šm‚É’è—Ê‚·‚錟¸‹ZpD“ÁŠè2017-246333D2017 Dec 22D
  4. mˆäŒ©‰pŽ÷C–k“‡ŒMC‹{˜W‰›C“ŒËŽkCinventorsG•xŽR‘åŠw’·CassigneeDŠ´õÇŠ³ŽÒŒŸ‘Ì’†‚Ì׋۔‚ðv‘¬‚©‚³Šm‚É’è—Ê‚·‚錟¸‹ZpD“ÁŠè2017-246724D2017 Dec 24D

‚»‚Ì‘¼

  1. ã–ì’q_C•xŽR—²‰îC–ìŽè—Ç„CmˆäŒ©‰pŽ÷C–k“‡ŒMDƒvƒƒeƒCƒ“S “¿“‡ƒXƒNƒŠ[ƒjƒ“ƒOŠÈˆÕˆâ“`ŽqŒŸ¸–@‚ÌŠJ”­D‘æ17‰ñTTMƒtƒH[ƒ‰ƒ€G2017 Mar 4G“Œ‹žD
  2. –k“‡ŒMDŒŒ‰t‹ÃŒÅŠw‚©‚ç‚Ý‚½DOAC ‚Ì–ò—Šw“I“Á’¥DShiga Stroke Expert MeetingG2017 Mar 9G‘’ÃD
  3. –k“‡ŒMDŒŒðÇ–¢•a‚Ìv‘¬ŠÈ•Ö‚Ȉâ“`ŽqŒŸ¸–@ŠJ”­D•½¬28 ”N“x•xŽR‘åŠw–¢•aƒvƒƒWƒFƒNƒgi’»•ñ‰ïG2017 Mar 17G•xŽRD
  4. –k“‡ŒMD•xŽR‘åŠw•‘®•a‰@ŒŸ¸•”‚Ì‚“xæiˆã—Âւ̎æ‚è‘g‚ÝD–kŠC“¹ŽOˆä‰»ŠwŠwpƒZƒ~ƒi[2017G2017 Sep 4G»ìD
  5. –k“‡ŒMDR‹ÃŒÅ—Ö@‚ÌV‚µ‚¢ƒXƒe[ƒWEŒŒðŽ~ŒŒŠw‚©‚ç‚Ý‚½ƒgƒƒ“ƒrƒ“‘jŠQ–ò‚Ì—L—p«DŠ™‘qR‹ÃŒÅ—Ö@ƒZƒ~ƒi[G2017 Oct 26GŠ™‘qD
  6. –k“‡ŒMDƒgƒƒ“ƒrƒ“‘jŠQ–ò‚Ì—L—p«DOSAKA Network Meeting 2017G2017 Nov 11G‘åãD
  7. –k“‡ŒMDŒŒ‰t‹ÃŒÅŠw‚©‚王‚½Xa ‘jŠQ–ò‚Ì—L—p«D”èŽsŠ¡‰HŒSˆãŽt‰ïŠwpu‰‰‰ïG2017 Nov 29G”èD
  8. –k“‡ŒMDDTI ‚ÌRŒŒ¬”Âì—pŒŸ“¢D2017Dadigatoran ŒŒ‰tŠwƒAƒhƒoƒCƒUƒŠ[ƒ{[ƒh‰ï‹cG2017 Dec 17G“Œ‹žD
  9. Œ´“cŒ’‰EDŒŸ¸à–¾‚ÌŽÀÛC‰‹‰ƒŒƒxƒ‹D•½¬28 ”N“xŒŸ¸à–¾E‘Š’k‚ª‚Å‚«‚é—Õ°ŒŸ¸‹Zpˆç¬uK‰ïG2017 Jan 29G•xŽRD
  10. –k“‡ŒMD•xŽR‘åŠwˆãŠw•”‘n—§40 Žü”N‹L”OŽ®“T•ñD•xŽR‘åŠwˆãŠw•”Œã‰‡‰ï‰ï•ñD2017G51F1D
  11. –k“‡ŒMD•a—‘gDŒŸ¸‚Ì•W€‰»‚Ƹ“xŠÇ—‚ÉŒü‚¯‚½Žæ‚è‘g‚ÝD—Õ°ŒŸ¸¸“xŠÇ—’²¸Œ‹‰Ê•ñ‘D2017G29F1D

ƒy[ƒW‚Ì擪‚Ö–ß‚é

2016”N

’˜‘

  1. –k“‡ŒMDVEŒŒðŽ~ŒŒŒŒŠÇŠwCŒŸ¸‚Æf—ÃDˆê£”’’éCŠÛŽRª˜YC‘º“c–ž•ÒD‹ž“sF‹à–FŽÐG2015DDOACs‚ƋÌŌŸ¸Gp.139-47Di2015 ”N–¢ŒfÚ•ªj
  2. –k“‡ŒMDƒXƒ^ƒ“ƒ_[ƒhŒŸ¸ŒŒ‰tŠwD‘æ3 ”ÅD“ú–{ŒŸ¸ŒŒ‰tŠw‰ï•ÒD“Œ‹žFˆãŽ•–òo”ÅŠ”Ž®‰ïŽÐG2016DŒŒŠÇ‚̈ÙíGp.345-52D
  3. –k“‡ŒMDŒŒðÇðÇUPTODATEDˆãŠw‚Ì‚ ‚ä‚ÝD2016 MayG257(7)F739-88D
  4. mˆäŒ©‰pŽ÷D”sŒŒÇ‚Ì‹N‰Š‹Û‚Ìv‘¬ŒŸoE“¯’èDŒŸ¸‚Æ‹ZpD2016 MayG44(5)F366-9D
  5. mˆäŒ©‰pŽ÷D”sŒŒÇ‹N‰Š‹Û‚ÌV‚½‚Èv‘¬“¯’è–@DƒoƒCƒIƒTƒCƒGƒ“ƒX‚ƃCƒ“ƒ_ƒXƒgƒŠ[D2016 SepG74(5)F422-4

Œ´’˜

  1. Yoneda N, Yoneda S, Niimi H, Ueno T, Hayashi S, Ito M, Shiozaki A, Urushiyama D, Hata K, Suda W, Hattori M, Kigawa M,Kitajima I, Saito S. Polymicrobial Amniotic Fluid Infection with Mycoplasma/Ureaplasma and Other Bacteria Induces Severe Intra-Amniotic Inflammation Associated with Poor Perinatal Prognosis in Preterm Labor. Am J Reprod Immunol. 2016 Feb; 75(2): 112-25. doi: 10.1111/aji.12456. PubMed PMID: 26668114.
  2. Yoneda S, Shiozaki A, Yoneda N, Ito M, Shima T, Fukuda K, Ueno T, Niimi H, Kitajima I, Kigawa M, Saito S. Antibiotic Therapy Increases the Risk of Preterm Birth in Preterm Labor without Intra-Amniotic Microbes, but may Prolong the Gestation Period in Preterm Labor with Microbes, Evaluated by Rapid and High-Sensitive PCR System. Am J Reprod Immunol. 2016 Apr; 75(4): 440-50. doi: 10.1111/aji.12484. PubMed PMID: 26777387.
  3. Kobayashi S, Hida Y, Ishizaki H, Inoue E, Tanaka-Okamoto M, Yamasaki M, Miyazaki T, Fukaya M, Kitajima I, Takai Y,Watanabe M, Ohtsuka T, Manabe T. The active zone protein CAST regulates synaptic vesicle recycling and quantal size in the mouse hippocampus. Eur J Neurosci. 2016 Sep; 44(5): 2272-84. doi: 10.1111/ejn.13331.
  4. Mochida S, Hida Y, Tanifuji S, Hagiwara A, Hamada S, Abe M, Huan M1, Kitajima I, Sakimura K, Ohtsuka T. SAD-B Phosphorylation of CAST Controls Active Zone Vesicle Recycling for Synaptic Depression. Cell Rep. 2016; 16: 1-13. doi:10.1016/j.celrep.2016.08.020.

Ç—á•ñ

  1. ‹à’J—Y•½C‚¼˜aOC‰º]–LCmˆäŒ©‰pŽ÷C–k“‡ŒMCŒIŽRŸDæ“V«ƒAƒ“ƒ`ƒgƒƒ“ƒrƒ“‡VŒ‡‘¹Ç‚É‚æ‚é”]Ö¬“´ŒŒðǂ𕹔­‚µ‚½‘½”­«d‰»ÇD—Õ°_ŒoD2016G56F248-54D

‘à

  1. ˆê£”’’éC˜a“c‰p•vC‘y‰F—˜³‘PC‹´ŒûÆlC–î•y —TC–k“‡ŒMC’©‘q‰pôC‰ª–{DŽiC‰ÆŽq³—TCŽR–{WŽmC]Œû–LDŽ©ŒÈ–Ɖu«oŒŒ•aFXIII/13 f—ÃKƒCƒhDGuidance on diagnostic criteria for autoimmune emorrhaphillia FXIII/13(AHFFXIII/13)D“úŒŒðŽ~ŒŒ‰ïŽD2015G26(6)F653-68Di2015 ”N–¢ŒfÚ•ªj
  2. –k“‡ŒMD‰ŠÇ‚ÆXaDXa-NexiaD2016G4F10-1D
  3. –k“‡ŒMDDOAC ‚ɑ΂·‚é‹ÃŒÅŒŸ¸UP-TO DATED“úŒŒðŽ~ŒŒ‰ïŽD2016G27(4)F481-8D
  4. –k“‡ŒMD’¼ÚŒoŒû‹ÃŒÅˆöŽq‘jŠQ–òiDOACj‚Ì–ò—ì—p‚Æ—Õ°ŒŸ¸D—Õ°•a—D2016G64(8)F972-9D
  5. ¼–{—S”VC–k“‡ŒMD—Õ°ŒŸ¸—̈æ‚É‚¨‚¯‚éƒOƒ[ƒoƒ‹‰»‚Ì„iD—Õ°•a—D2016G64(8)F895-7.

Šw‰ï•ñ

  1. Ueno T, Niimi H, Yoneda N, Yoneda S, Mori M, Saito S, Kitajima I. Eukaryote-Made Taq Polymerase Enables Reliable Detection of Pathogens in Amniotic Fluid of Preterm Labor Cases-Development of a Novel Nested-PCR-Based Assay for Detecting Mycoplasma, Ureaplasma, other Bacteria and Fungi in Amniotic Fluid Samples. The 32nd World Congress of Biomedical laboratory Scinece; 2016 Sep 1; Kobe.
  2. Sugie K, Ueno T, Niimi H, Hayashi S, Mori M, Yamamoto Y, Saito S, Kitajima I. Melting Temperature (Tm) Mapping Method -A Novel Method for Rapid Identification of Unknown Pathogenic Microorganisms within Three Hours of Sample Collection. The 32nd World Congress of Biomedical laboratory Scinece; 2016 Sep 1; Kobe.
  3. –k“‡ŒMD‹ÃŒÅü—nŒn‚ÉŠÖ‚·‚éŋ߂̘b‘èD‘æ28‰ñEducation Seminar in CardiologyF“ú–{ˆãŽt‰ï¶ŠU‹³ˆçG2016 Jan 26G“Œ‹žD
  4. –k“‡ŒMDRVWF Ž©ŒÈR‘ÌŒŸo‚Ì‚½‚߂̃Cƒ€ƒmƒNƒƒ}ƒg–@‚ÉŠÖ‚·‚錤‹†DŒú¶˜J“­‰ÈŠwŒ¤‹†ˆÏ‘õ”ïi“«Ž¾Š³ŽÀ—p‰»Œ¤‹†Ž–‹Æjˆê£”Ç‹†”­•\‰ïG2016 Feb 11G“Œ‹žD
  5. –k“‡ŒMDDOAC ‚ɑ΂·‚錌‰t‹ÃŒÅŒŸ¸‚ÌŽg‚¢•ûiƒI[ƒo[ƒrƒ…[jD‘æ10‰ñ“ú–{ŒŒðŽ~ŒŒŠw‰ïŠwp•W€‰»ˆÏˆõ‰ïƒVƒ“ƒ|ƒWƒEƒ€G2016 Feb 20G“Œ‹žD
  6. –k“‡ŒMDŒŒŠÇ•a•Ï‚Ì–¢•aó‘Ô‚ðf’f‚·‚錌ŠÇ“à”ç‹@”\ŒŸ¸–@‚ÌŠJ”­D•½¬27 ”N“xŠw’·Ù—ÊŒo”“¯Œ¤‹†•ñ‰ïG2016 Mar 3G•xŽRD
  7. –k“‡ŒMD’¼Úƒgƒƒ“ƒrƒ“‘jŠQ–ò‚̉”\«‚ð’T‚éDƒvƒ‰ƒUƒLƒTƒXƒyƒVƒƒƒ‹ƒCƒ“ƒ^ƒrƒ…[G2016 Mar 7D
  8. –k“‡ŒMDŒŒðŽ~ŒŒŠw‚©‚ç‚Ý‚½ƒgƒƒ“ƒrƒ“‘jŠQ–ò‚Ì—L—p«D‘æ4‰ñStroke Expert Meeting in ç—tG2016 Mar 10Gç—tD
  9. –k“‡ŒMDŒoŒûR‹ÃŒÅ–òDOAC ‚Ì–ò—ì—p‚Æ—Õ°ŒŸ¸D’·èRoche seminarG2016 Jun 3G’·èD
  10. –k“‡ŒMD‹ÃŒŒŠw“IŽ‹“_‚©‚ç‚ÌDVT ‚Ì•a‘ÔDR‹ÃŒÅ–ò‚Ì“K³Žg—p‚ðl‚¦‚é‰ïG2016 Jun 22G•xŽRD
  11. –k“‡ŒMDNOAC^DOAC ‚Ì–ò—ì—p‚ÆŒŒ‰t‹ÃŒÅŒŸ¸D²‰êŒ§ŒŒ‰t‹ÃŒÅŒŸ¸ƒZƒ~ƒi[“úˆã§Šw‹³ˆç§“x”F’èuÀG2016 Jun 24G²‰êD
  12. –k“‡ŒMDŒŒðŽ~ŒŒŠw‚©‚ç‚Ý‚½ƒgƒƒ“ƒrƒ“‘jŠQ–ò—L—p«DSTROKE Meeting 2016G2016 Jul 1G–¼ŒÃ‰®D
  13. –k“‡ŒMD’¼ÚŒoŒûR‹ÃŒÅ–òiDOACsj‚Ì–ò—ì—p‚ƋÌŌŸ¸‚ւ̉e‹¿D‘æ6‰ñŒŒ‰tŒŸ¸‹@Ší‹ZpƒZƒ~ƒi[G2016 Sep 22G‰¡•lD
  14. –k“‡ŒMDƒgƒƒ“ƒrƒ“‚ð„‚éDOAC ‚Ì–ò—ì—p‚ÆŒŒ‰t‹ÃŒÅŒŸ¸‚Ìŋ߂̘b‘èDVŠƒŒ§‹ÃŒÅü—nŒ¤‹†‰ïG2016 Nov 19GVŠƒD
  15. –k“‡ŒMDŒŒ‰t‹ÃŒÅŒŸ¸UPDATED•½¬28”N“ú–{‰q¯ŒŸ¸‹ZŽt‰ï’†Žl‘ˆãŠwŒŸ¸Šw‰ïG2016 Nov 26G‚’mD
  16. –k“‡ŒMDŒŒðŽ~ŒŒŠw‚©‚ç‚Ý‚½ƒgƒƒ“ƒrƒ“‘jŠQ–ò‚Ì—L—p«Dã‰zNetwork MeetingG2016 Dec 7Gã‰zD
  17. –k“‡ŒMDƒ_ƒrƒKƒgƒ‰ƒ“’†˜aÜ‚ÌŒø‰Ê‚ÆŒŸØDƒ_ƒrƒKƒgƒ‰ƒ“ŒŒ‰tŠwƒAƒhƒoƒCƒU[ƒ{[ƒh‰ï‹cG2016 Dec 17G“Œ‹žD
  18. ‰ª•”‘f“TC‹g“ciŽqCâ–{ƒŽqC–k“‡ŒMC¬’rç‰ÁCâV“¡ Ž C“ñŠK“°•q—YDƒnƒCƒp[ƒhƒ‰ƒCƒqƒgŠ£‘‡—r–Œ‚̉è–E‹Û‚ɑ΂·‚éŽE‹ÛŒø‰ÊFR¶•¨Ž¿‚Æ‚Ì”äŠrD‘æ15‰ñ“ú–{Ķˆã—Êw‰ï‘‰ïG2016 MarG‘åãD
  19. •xŽR—²‰îC–ìŽè—Ç„C–k“‡ŒMDV‹KƒvƒƒeƒCƒ“S‘ª’莎–ò‚É‚æ‚éƒvƒƒeƒCƒ“S”䊈«‚Ì—Õ°“I—L—p«‚ÌŒŸ“¢D‘æ55‰ñ“ú–{—Õ°ŒŸ¸ˆãŠw‰ï“ŒŠC–k—¤Žx•”‘‰ïC‘æ332‰ñ“ú–{—Õ°‰»Šw‰ï“ŒŠC–k—¤Žx•”—á‰ï˜A‡‘å‰ïG2016 Mar 6G•l¼D
  20. “àŽRŒ«ŽqCŽRŠÝ“ÞXC‰–ú±^‹|C¬àVˆ»‰ÀCŽs“c•™ŽqC¼”ö’C˜NC–F‘º’¼Ž÷C–k“‡ŒMD‘ÙŽ™Šú‚æ‚èSƒGƒR[’ÇÕ‚É‚æ‚è‘ŠúŽ¡—ªŽÀŽ{‚Å‚«‚½‰E–[“àŒŒŠÇŽî‚̈ê—áD‘æ55‰ñ“ú–{—Õ°ŒŸ¸ˆãŠw‰ï“ŒŠC–k—¤Žx•”‘‰ïC‘æ332‰ñ“ú–{—Õ°‰»Šw‰ï“ŒŠC–k—¤Žx•”—á‰ï˜A‡‘å‰ïG2016 Mar 6G•l¼D
  21. “¹–ì~ŽqCˆÀ‘º•qC•xŽR—²‰îC’†oË‘ãC²’|ˆÉ’ÃŽqC“‡‹žŽqCÝ“cK‘¾˜YC˜a“c‹Å–@C‘ºãƒC–k“‡ŒMDABOŒŒ‰tŒ^ˆŸŒ^‚É‚¨‚¯‚éˆâ“`Žq‰ðÍ‚ÌŽÀÑ‚Æ—L—p«‚ɂ‚¢‚ÄD‘æ64‰ñ“ú–{—AŒŒ×–EŽ¡—Êw‰ïG2016 Apr 28G‹ž“sD
  22. ²’|ˆÉ’ÃŽqCˆÀ‘º•qC•xŽR—²‰îC’†oË‘ãC“¹–ì~ŽqC“‡‹žŽqCÝ“cK‘¾˜YC˜a“c‹Å–@C‘ºãƒC–k“‡ŒMDpŒã‚É“Á”­«ŒŒ¬”ÂŒ¸­«Ž‡”Á•aiITPj‚ð”­Ç‚µ‚½1Ç—áD‘æ64‰ñ“ú–{—AŒŒ×–EŽ¡—Êw‰ïG2016 Apr 28G‹ž“sD
  23. ŽOŒ´OCΖ؊wCœAìTˆê˜YCŠÖª“¹˜aC–k“‡ŒMD•xŽR‘åŠwˆãŠw‹³ˆçƒZƒ“ƒ^[‚É‚¨‚¯‚鋳ˆçŽx‰‡CICT‚ÌŠˆ—p‚ÌŽæ‚è‘g‚ÝD‘æ48‰ñ“ú–{ˆãŠw‹³ˆçŠw‰ï‘å‰ïG2016 Jul 29G‘åãD
  24. •xŽR—²‰îC–ìŽè—Ç„C–k“‡ŒMDƒvƒƒeƒCƒ“SŠˆ«”ä‚ÆDƒ_ƒCƒ}[’l‚ÌŠÖ˜A«‚ɂ‚¢‚Ä‚ÌŒŸ“¢D‘æ27‰ñ“ú–{—Õ°‰»Šw‰ï“ŒŠC–k—¤Žx•”‘‰ïC‘æ35‰ñ“ú–{—Õ°ŒŸ¸Šw‰ï“ŒŠC–k—¤Žx•”—á‰ï˜A‡‘å‰ïG2016 Jul 30G‹à‘òD
  25. ŠÖŒûŒh•¶CX“c”üCâ–{ƒŽqC–ìŽè—Ç„C–k“‡ŒMD”÷¶•¨ŒŸ¸‚É‚¨‚¯‚鎿—Ê•ªÍ‘•’uMADI-TOF-MS“±“ü‚É‚¢‚é—L—p«‚ÌŒŸ“¢D‘æ27‰ñ“ú–{—Õ°‰»Šw‰ï“ŒŠC–k—¤Žx•”‘‰ïC‘æ35‰ñ“ú–{—Õ°ŒŸ¸Šw‰ï“ŒŠC–k—¤Žx•”—á‰ï˜A‡‘å‰ïG2016 Jul 30G‹à‘òD
  26. •xŽR—²‰îC–ìŽè—Ç„C–k“‡ŒMDV‹KƒvƒƒeƒCƒ“S‘ª’è–@‚É‚æ‚éƒvƒƒeƒCƒ“S”䊈«‚Ì—Õ°“I—L—p«‚ÌŒŸ“¢D‘æ63‰ñ“ú–{—Õ°ŒŸ¸ˆãŠw‰ïŠwpW‰ïG2016 Sep 1G_ŒËD
  27. ‹g“c”¹‘¾Cã–ì—R”üCX“c”üC•ÐÀ»ŽqC’J‚Ý‚ËŽqC×’JFŽqCŒKŒ´‘ì”üC–ìŽè—Ç„C’Þ_”VC¼“c’¼“¿C’†’Ø‹v‘ãC–쑺ŒbŽqC–k“‡ŒMD”jÓÔŒŒ‹…‚𔺂Á‚½‹Ô‰è‹…•nŒŒ‚Ì1—áD‘æ41‰ñ–k—¤—Õ°•a—W’k‰ïG2016 Sep 10G•Ÿˆä
  28. ã–ì’q_C•xŽR—²‰îC–ìŽè—Ç„CmˆäŒ©‰pŽ÷C–k“‡ŒMDˆâ“`ŽqŒŸ¸‚Ìd—v«‚ªŠm”F‚³‚ꂽƒvƒƒeƒCƒ“S“¿“‡‚Ì2Ç—áD‘æ41‰ñ–k—¤—Õ°•a—W’k‰ïG2016 Sep 10G•ŸˆäD
  29. ˆàŒ´”ŽCœA“cWˆêCŽOŒ´‰ëˆêC–k“‡ŒMCŽR‰º•ôC–쑺•¶•vC¼–{ŠîC‹´‹l’¼FCŒË’J½”VDŽ©“®•ªÍ‹@‚É‚æ‚錌´25-ƒqƒhƒƒLƒVƒrƒ^ƒ~ƒ“D‘ª’è’l‚Ì•W€‰»FSRM972a‚ðZ³‚É—p‚¢‚½‘ª’èD‘æ56‰ñ“ú–{—Õ°‰»Šw”NŽŸŠwpW‰ïG2016 Dec 2GŒF–{D
  30. ã–ì’q_C•xŽR—²‰îCmˆäŒ©‰pŽ÷C–k“‡ŒMD”䊈«‘ª’è‚ÅŒŸo‚³‚ê‚È‚©‚Á‚½ƒvƒƒeƒCƒ“S“¿“‡‚ƊȈՈâ“`ŽqŒŸ¸–@\’z‚ÌŽŽ‚ÝD‘æ56‰ñ“ú–{—Õ°‰»Šw”NŽŸŠwpW‰ïG2016 Dec 2GŒF–{D
  31. mˆäŒ©‰pŽ÷D”sŒŒÇ‹N‰Š‹Ûv‘¬“¯’è–@iTmmapping–@j‚ÌŠJ”­D‘æ56‰ñ“ú–{—Õ°‰»Šw‰ï”NŽŸŠwpW‰ïG2016 Dec 3GŒF–{D

‚»‚Ì‘¼

  1. –k“‡ŒMDV”C‚Ì‚²ˆ¥ŽAD•xŽR‘åŠwˆãŠw•”Œã‰‡‰ï‰ï•ñD2016G49-2D
  2. –k“‡ŒMD’nˆæˆã—ÃŽx‰‡ŠwuÀ•Âu‚É‚ ‚½‚Á‚Ä ‹OÕ‚Æ‚»‚ÌŒ÷ÑD•½¬27 ”N“x•xŽR‘åŠwˆãŠw–òŠwŒ¤‹†•”iˆãŠwj’nˆæˆã—ÃŽx‰‡ŠwuÀŠˆ“®•ñ‘D2016G3D
  3. –k“‡ŒMDvon Willebrand ˆöŽqR‘ÌÇ—á‚Ì’²¸‚ÆŽÀŒ±‚ÌŽÀŽ{DŒú¶˜J“­‰ÈŠwŒ¤‹†•â•‹à“«Ž¾Š³“™­ôŒ¤‹†Ž–‹ÆDŽ©ŒÈ–Ɖu«oŒŒ«ÇŽ¡—ÂÌu‹Ï‚Ä‚ñ‰»v‚Ì‚½‚ß‚ÌŽÀ‘Ô’²¸‚Æu‘‡“Ivf—ÃŽwj‚Ì쬂Ɋւ·‚錤‹†•½¬27 ”N“xŒ¤‹†•ñ‘D2016G35-6D
  4. –k“‡ŒMDˆãŠw’·A”C‚Ì‚²ˆ¥ŽAD•xŽR‘åŠwˆãŠw•”“¯‘‹‰ï‰ï•ñD2016G25F4-5D
  5. ¬—Ñ—mˆêC–k“‡ŒMC]“ª³lC–x’†”É•vD’´‚—ŽÐ‰ï‚ðŒ}‚¦‚½‚킪‘‚É“K‚µ‚½R‹ÃŒÅ—Ö@DMedical TribuneD2016G49(11)F8-9D
  6. –k“‡ŒMDˆã—ẪOƒ[ƒoƒ‹‰»‚ɑΉž‚µ‚½ŒŸ¸î•ñ‹¤—L‰»‚Æ‹¤—pŠî€”͈ÍD—Õ°ŒŸ¸¸“xŠÇ—’²¸•ñ‘D2016G28F1D
  7. Niimi H, Kitajima I. PCR primer set for bacterial DNA amplification, kit for detecting and/or identifying bacterial species, and methpd for detecting and/or identifying bacterial species. Application No.14853073.6-1404.PCT/JP2014076864. 2016 Nov 5.(European patent)

ƒy[ƒW‚Ì擪‚Ö–ß‚é

2015”N

’˜‘

  1. –k“‡ŒM. —Õ°ŒŸ¸ƒf[ƒ^ƒuƒbƒN2015-2016. •ì´, t“ú³‰ë, –k‘º¹•Ò. “Œ‹ž:ˆãŠw‘‰@;2015. ƒvƒƒgƒƒ“ƒrƒ“, ƒvƒƒgƒƒ“ƒrƒ“ƒtƒ‰ƒOƒƒ“ƒgiPF1+2j, ‘æVˆöŽq, ‘æVIIˆöŽq, ‘æVIIIˆöŽq, von Willebrand ˆöŽq, von WillenrandˆöŽqƒ}ƒ‹ƒ`ƒ}[‰ðÍ, VWF Ø’fy‘fiADAMTS13j, ‘æIXˆöŽq, ‘æXˆöŽq, ‘æXIˆöŽq, ‘æXIIˆöŽq, ‘æXIIIˆöŽq;p.378-91.
  2. –k“‡ŒM. —Õ°ŒŸ¸ƒf[ƒ^ƒuƒbƒN2015-2016. •ì´Ct“ú³‰ë,–k‘º ¹•Ò. “Œ‹ž:ˆãŠw‘‰@;2015. ‹ÃŒÅˆöŽqƒCƒ“ƒqƒrƒ^[’è«iƒNƒƒXƒ~ƒLƒVƒ“ƒOŽŽŒ±j,‘æVIIIˆöŽqƒCƒ“ƒqƒrƒ^[, ‘æIXˆöŽqƒCƒ“ƒqƒrƒ^[, ‘gDˆöŽqi‘gDƒgƒƒ“ƒ{ƒvƒ‰ƒXƒ`ƒ“j, ‘‘gDˆöŽqŒo˜HƒCƒ“ƒqƒrƒ^[i‘TFPIj. ƒAƒ“ƒ`ƒgƒƒ“ƒrƒ“iATj, ƒgƒƒ“ƒrƒ“EƒAƒ“ƒ`ƒgƒƒ“ƒrƒ“•¡‡‘ÌiTATj;p.391-5.
  3. –k“‡ŒM. —Õ°ŒŸ¸ƒf[ƒ^ƒuƒbƒN2015-2016. •ì´, t“ú³‰ë, –k‘º¹•Ò. “Œ‹ž:ˆãŠw‘‰@;2015. ƒgƒƒ“ƒ{ƒ‚ƒWƒ…ƒŠƒ“, ƒvƒƒeƒCƒ“C, ƒvƒƒeƒCƒ“S, ‘gDƒvƒ‰ƒXƒ~ƒmƒQƒ“ƒAƒNƒ`ƒx[ƒ^it-PAj, ƒvƒ‰ƒXƒ~ƒmƒQƒ“ƒAƒNƒ`ƒx[ƒ^ƒCƒ“ƒqƒrƒ^[1iPAI-1j, t-PAEPAI-1 •¡‡‘Ì, ƒvƒ‰ƒXƒ~ƒmƒQƒ“, α2|ƒvƒ‰ƒXƒ~ƒ“ƒCƒ“ƒqƒrƒ^[, ƒvƒ‰ƒXƒ~ƒ“Eα2|ƒvƒ‰ƒXƒ~ƒ“ƒCƒ“ƒqƒrƒ^[•¡‡‘ÌiPIC ƒeƒXƒgj;p.395-403.
  4. –k“‡ŒM. “ìŽR“°ˆãŠw‘厫“T. ‘æ20”Å. “Œ‹ž:“ìŽR“°;2015. ƒAƒ“ƒrƒIƒeƒ“ƒVƒ“1•ÏŠ·y‘f‘ª’è;p.82.
  5. –k“‡ŒM. “ìŽR“°ˆãŠw‘厫“T. ‘æ20”Å. “Œ‹ž:“ìŽR“°;2015. ƒAƒ“ƒ`ƒvƒ‰ƒXƒ~ƒ“ŒŸ¸;p.85.
  6. –k“‡ŒM. “ìŽR“°ˆãŠw‘厫“T. ‘æ20”Å. “Œ‹ž:“ìŽR“°;2015. ƒGƒ‰ƒXƒ^[ƒ[1‘ª’è;p.252.
  7. –k“‡ŒM. “ìŽR“°ˆãŠw‘厫“T. ‘æ20”Å. “Œ‹ž:“ìŽR“°;2015. ‹ÃŒÅˆöŽq‘ª’è, ‹ÃŒÅˆöŽqƒCƒ“ƒqƒrƒ^[‘ª’è;p.558.
  8. –k“‡ŒM. “ìŽR“°ˆãŠw‘厫“T. ‘æ20”Å. “Œ‹ž:“ìŽR“°;2015. ŒŒ¬”‹@”\ŒŸ¸;p.696.
  9. –k“‡ŒM. “ìŽR“°ˆãŠw‘厫“T. ‘æ20”Å. “Œ‹ž:“ìŽR“°;2015. C1ƒCƒ“ƒAƒNƒ`ƒx[ƒ^[;p.1187.
  10. –k“‡ŒM. “ìŽR“°ˆãŠw‘厫“T. ‘æ20”Å. “Œ‹ž:“ìŽR“°;2015. ‘gDƒvƒ‰ƒXƒ~ƒmƒQƒ“ƒAƒNƒ`ƒx[ƒ^;p.1482.
  11. –k“‡ŒM. “ìŽR“°ˆãŠw‘厫“T. ‘æ20”Å. “Œ‹ž:“ìŽR“°;2015. ‘æVIIIˆöŽq—lRŒ´’è—Ê;p.1522.
  12. –k“‡ŒM. “ìŽR“°ˆãŠw‘厫“T. ‘æ20”Å. “Œ‹ž:“ìŽR“°;2015. D-ƒ_ƒCƒ}[;p.1676.
  13. –k“‡ŒM. “ìŽR“°ˆãŠw‘厫“T. ‘æ20”Å. “Œ‹ž:“ìŽR“°;2015. ƒgƒƒ“ƒrƒ“EƒAƒ“ƒ`ƒgƒƒ“ƒrƒ“•¡‡‘Ì‘ª’è;p.1792-3.
  14. –k“‡ŒM. “ìŽR“°ˆãŠw‘厫“T. ‘æ20”Å. “Œ‹ž:“ìŽR“°;2015. ƒtƒHƒ“ƒEƒCƒ‹ƒuƒ‰ƒ“ƒhˆöŽq’è—Ê;p.2125.
  15. –k“‡ŒM. “ìŽR“°ˆãŠw‘厫“T. ‘æ20”Å. “Œ‹ž:“ìŽR“°;2015. ƒtƒBƒuƒŠƒmƒQƒ“EƒtƒBƒuƒŠƒ“•ª‰ðŽY•¨‘ª’è;p.2114-5.
  16. –k“‡ŒM. “ìŽR“°ˆãŠw‘厫“T. ‘æ20”Å. “Œ‹ž:“ìŽR“°;2015. ƒvƒ‰ƒXƒ~ƒmƒQƒ“‘ª’è;p.2171.
  17. –k“‡ŒM. “ìŽR“°ˆãŠw‘厫“T. ‘æ20”Å. “Œ‹ž:“ìŽR“°;2015. ƒvƒƒgƒƒ“ƒrƒ“ƒtƒ‰ƒOƒƒ“ƒg1+2 ‘ª’è;p.2200.
  18. ˆÀ‘º•q, “n•Ó–¾Ž¡. –Ú‚Å‚Ý‚é—Õ°‰h—{ŠwUPDATED‘æ2”ÅDˆãŽ•–òo”Å•ÒD“Œ‹ž:ˆãŽ•–òo”Å;2015DŠÌŽ¾Š³i2j|—Õ°ŒŸ¸Ef’f, ŠÌŽ¾Š³‚Ì•ª—Þ;p.26-33.

Œ´’˜

  1. Ichinose A, Souri M, Osaki T, Matsushita T, Urano T, Ieko M, Tamai Y, Ito T, Kawamae K, Yamamoto M, Madoiwa S, Kurosawa H, Ogawa Y, Yatomi Y, Hanafusa N, Kawasugi K, Ishida F, Kitajima I, Asakura H, Hosono N, Mouri H, Kobayashi T, Wada H, Miyata S, Kashiwagi H, Ikeda M, Yukawa M, Higasa S, Hato T, Okamoto K, Okamura T, Uchiba M, Hashiguchi T, Maruyama I. On AH13 Hemorrhagic Acquired Coagulopathies. Inhibitors of Factor XIII/13 in older patients. Semin Thromb Hemost. 2014 Sep;40(6):704-11. DOI:10.1055/s-0034-1390151.PMID:25215637i2014 ”N–¢ŒfÚ•ªj
  2. Ihara H, Hirota K, Miura M, Kitajima I, Yamashita M, Nomura F, Nishumura M, Kamioka K, Onda K, Sunahara S, Suzuki T, Itabashi M, Ishibashi M, Ito S, Ohashi K, Ohta Y, Nobori T, Fujishiro K, Maekawa M, Miyano H, Ando T, Nishumura K, Tsugawa N, Okano T. National Institute of standards and technology SRM 972 as a reference material for serum total 25-hydroxyvitamin D measurements. Int J Anal Bio-Sci. 2014 Mar 31;2(1):1-6.2014 ”N–¢ŒfÚ•ªj
  3. Nakamura M, Nishikawa M, Komuro I, Kitajima I, Uetsuka Y, Yamagami T, Minamiguchi H, Yoshimatsu R, Tanabe K, Matsuoka N, Kanmuri K, Ogawa H. Apixaban for the Treatment of Japanese Subjects With Acute Venous Thromboembolism (AMPLIFY-J Study). Circ J. 2015;79(6):1230-6. DOI:10.1253/circj.CJ-15-0195.PMID:25912695
  4. Ueno T, Niimi H, Yoneda N, Yoneda S, Mori M, Tabata H, Minami H, Saito S, Kitajima I. Eukaryote-Made Thermostable DNA Polymerase Enables Rapid PCR-Based Detection of Mycoplasma, Ureaplasma and Other Bacteria in the Amniotic Fluid of Preterm Labor Cases. PLoS One. 2015 Jun 4;10(6):e0129032. DOI:10.1371/journal.pone.0129032.PMID:26042418
  5. Niimi H, Ueno T, Hayashi S, Abe A, Tsurue T, Mori M, Tabata H, Minami H, Goto M, Akiyama M, Yamamoto Y, Saito S, Kitajima I. Melting Temperature Mapping Method: A Novel Method for Rapid Identification of Unknown Pathogenic Microorganisms within Three Hours of Sample Collection. Sci Rep. 2015 Jul 28;5:12543. DOI:10.1038/srep12543.PMID:26218169
  6. Tajiri K, Kawai K, Minemura M, Yasumura S, Hosokawa A, Kawabe H, Tomizawa G, Sugiyama T. Neutrophil/lymphocyte ratio as a prognostic indicator of hepatic arterial infusion chemotherapy with arterial cisplatin plus continuous 5-fluorouracil. Hepatol Res. 2015 Jul;45(7):755-63.PMID:25196816

‘à

  1. –k“‡ŒM. NOACs‚ɑ΂·‚郂ƒjƒ^ƒŠƒ“ƒO‚Ì—L—p«. Int Rev Thromb. 2015 Mar;10(1):22-7.
  2. –k“‡ŒM. NOAC‚É‚¨‚¯‚郂ƒjƒ^ƒŠƒ“ƒO‚Ì•K—v«. “ú–{ˆãŽ–V•ñD2015 Apr;4748:61-2.
  3. mˆäŒ©‰pŽ÷. ŒŒ‰tŒŸ‘Ì‚©‚ç‚Ì‹N‰Š‹Û‚Ì’¼ÚŒŸoE“¯’è•û–@‚ÌŠJ”­i‰ðàE“ÁWj. ‰»Šw—Ö@‚̗̈æ. 2015 Apr;31(Suppl.1):1089-97.
  4. –k“‡ŒM. ‚Ž‰ŒŒÇ‚Æ‚±‚Þ‚ç•Ô‚è. ˆã•ñ‚Æ‚â‚Ü. 2015 Apr;1620:22-3.
  5. –k“‡ŒM. ŒoŒûR‹ÃŒÅ–òŽg—pã‚ÌŠî‘b’mŽ¯. ”]‚ÆzŠÂ. 2015 May;20(2):117-21.
  6. –k“‡ŒM, –Ø‘º˜a”ü, ‘–쌒Œá, ‚‹´®•F, ŽO“c‘ºG—Y. S–[ד®‚ÌR‹ÃŒÅ—Ö@up-to-date. ˆãŠwƒWƒƒ[ƒiƒ‹. 2015 Aug;51(8):1954-65.
  7. ˜a“c‰p•v, –k“‡ŒM. “KØ‚ÈR‹ÃŒÅ—Ö@^ƒ‚ƒjƒ^[–@‚ÆŠó­oŒŒ«Ž¾Š³. “úŒŒðŽ~ŒŒ‰ïŽ. 2015 Nov;26(4):480-1.

Šw‰ï•ñ

  1. Kitajima I. Pharmacological characteristic of Novel oral anticoagulants. The 79th Annual Meeting of the Japanese Circulation Society; 2015 Apr 24; Osaka.
  2. Nishida K, Sakamoto T, Nakatani Y, Kataoka N, Wada O, Mizumaki K, Kitajima I, Inoue H. Chromogenic anti-factor Xa assay and routin coagulation tests in patients with atrial fibrillation treated with apixaban and rivaroxaban. The 79th Annual Meeting of the Japanese Circulation Society; 2015 Apr 24; Osaka.
  3. Tajiri K, Kawai K, Minemura M, Yasumura S, Takahara T, Sugiyama T. Neutrophil/lymphocyte ratio does not predict the recurrence after curative treatment with radiofrequency ablation for small hepatocellular carcinoma. The 6th Asia-Pacific Primary Liver Cancer Expert Meeting(APPLE); 2015 Jul 3-5; Osaka.
  4. –k“‡ŒM. _Œo¸_’x‘Ø‚ð’æ‚·‚éATRX ÇŒóŒQ‚̃‚ƒfƒ‹“®•¨ì¬‚É‚æ‚é•a‘Ô‰ðÍ.ˆ¤•Q‘åŠw_ŒoƒZƒ~ƒi[;2015 Jan 28;¼ŽR.
  5. –k“‡ŒM. ŒŒðÇf’f‚ÆŽ¡—ÂÌi•à.¼ŽR’ߗˉïu‰‰‰ï;2015 Jan 28;¼ŽR.
  6. “àŽRŒ«Žq, –k“‡ŒM, ¬‘òˆ»‰À, Žs“c•™Žq, –q–{—D”ü, ‹g“cär, •Ä“c“N, Ä“¡Ž .“–‰@‚É‚¨‚¯‚é‘ÙŽ™f’f‚³‚ꂽ18ƒgƒŠƒ\ƒ~[‚̇•¹SŠïŒ`‚Æ—\Œã.‘æ21‰ñ“ú–{‘ÙŽ™S‘Ÿ•aŠw‰ïŠwpW‰ï;2015 Feb 13;“Œ‹ž.
  7. –k“‡ŒM.ŒŒðŽ~ŒŒŠw‚©‚ç‚Ý‚½ƒgƒƒ“ƒrƒ“‘jŠQ–ò‚Ì—L—p«.BRAIN Prorection Core Member Meeting in Owari;2015 Feb 23;–¼ŒÃ‰®.
  8. Ý“cK‘¾˜Y, ‘ºãƒ, ˜a“c‹Å–@, ‹{‰€‘ì‹X, ˆÀ‘º•q, ™ŽR•q˜Y.RƒŠƒ“Ž‰Ž¿R‘ÌÇŒóŒQ‡•¹SLEŠ³ŽÒ‚ɶ‚¶‚½‹}«œ‘«”’ŒŒ•a‚ɑ΂·‚铯Ží‘¢ŒŒŠ²×–EˆÚA.‘æ37‰ñ“ú–{‘¢ŒŒ×–EˆÚAŠw‰ï‘‰ï;2015 Mar 5-7;_ŒË.
  9. “‡‹žŽq, ˆÀ‘º•q.“–‰@‚É‚¨‚¯‚é5”NŠÔ‚ÌŽ©ŒÈŒŒ’™ŒŒó‹µ‚Æ’™ŒŒ‘OŒã‚ÌHb•Ï“®‚ÌŒŸ“¢.‘æ28‰ñ“ú–{Ž©ŒÈŒŒ—AŒŒŠw‰ïŠwp‘‰ï;2015 Mar 6-7;“Œ‹ž.
  10. ‰¡“cˆ», ‘åŠp—F‹I, Šp“c”ü—é, ’·“c‘ñÆ, ’Ë“cˆê”Ž, –k“‡ŒM. “û–[’´‰¹”gŒŸ¸‚Å‚Ì‚Ý„‘ª‚µ“¾‚½“û–[“à“]ˆÚ‚̈ê—á.‘æ54‰ñ“ú–{—Õ°ŒŸ¸ˆãŠw‰ï“ŒŠCE–k—¤Žx•”‘‰ï, ‘æ329‰ñ“ú–{—Õ°‰»Šw‰ï“ŒŠCE–k—¤Žx•”—á‰ï˜A‡‘å‰ï;2015 Mar 8;–¼ŒÃ‰®.
  11. ã–ì’q_, mˆäŒ©‰pŽ÷, •Ä“c“¿Žq, •Ä“c“N, X³”V, ‘½—t“c—_, “ì _, âV“¡Ž , –k“‡ŒM. eukaryote-made Taq polymerase‚ð—p‚¢‚½v‘¬E³Šm‚ÈŽq‹{“àŠ´õÇ‹N‰Š‹ÛŒŸo–@‚Ì\’z.‘æ54‰ñ“ú–{—Õ°ŒŸ¸ˆãŠw‰ï“ŒŠCE–k—¤Žx•”‘‰ï, ‘æ329‰ñ“ú–{—Õ°‰»Šw‰ï“ŒŠCE–k—¤Žx•”—á‰ï˜A‡‘å‰ï;2015 Mar 8;–¼ŒÃ‰®.
  12. “cK˜al, ‰Í‡Œ’Œá, •õ‘º³ŽÀ, ˆÀ‘º•q, ‚Œ´Æ”ü, ™ŽR•q˜Y.“«• …ŠÇ—‚É‚¨‚¯‚éƒgƒ‹ƒoƒvƒ^ƒ“‚Ì—L—p«‚Æ‚»‚ÌŒø‰Ê—\‘ª‚ɂ‚¢‚Ä.‘æ51‰ñ“ú–{ŠÌ‘ŸŠw‰ï‘‰ï;2015 May 21-22;ŒF–{.
  13. ‰Í‡Œ’Œá, “cK˜al, ˆÀ‘º•q, •õ‘º³ŽÀ, ‚Œ´Æ”ü, ™ŽR•q˜Y.DAA‘Ï«•ÏˆÙ‚ð—L‚·‚éHCVƒEƒCƒ‹ƒX‚ÆIL-28B‚¨‚æ‚ÑIP-10‚ÌŠÖ˜A.‘æ51‰ñ“ú–{ŠÌ‘ŸŠw‰ï‘‰ï;2015 May 21-22;ŒF–{.
  14. –k“‡ŒM.ŒŒ‰t‹ÃŒÅŒŸ¸‚Ìŋ߂̘b‘è‚ÆŒŸ¸‹ZpŠJ”­.•½¬26”N“x“ú—§ƒnƒCƒeƒNƒmƒƒW[ƒYŠwpu‰‰‰ï;2015 Mar 25;‚Ђ½‚¿‚È‚©.
  15. ‰–ú±^‹|, ‘åŠp—F‹I, ŽRŠÝ“ÞX, ¬£—¢Œb, “àŽRŒ«Žq, Šp“c”ü—é, ‰¡“cˆ», •½ˆä’‰M, Žs“c•™Žq, ˆä㔎, –F‘º’¼Ž÷, –k“‡ŒM.ƒtƒ@ƒ|Žl’¥ÇC•œpŒã‚Ì”DPoŽY—á‚É‚¨‚¯‚éSƒGƒR[}ŠŒ©‚ɂ‚¢‚Ä.‘æ26‰ñ“ú–{SƒGƒR[}Šw‰ï;2015 Mar 27;–k‹ãB.
  16. ˆÀ‘º•q, “‡‹žŽq, “¹–ì~Žq.“K³‚ňÀ‘S‚ÈŽ©ŒÈŒŒ—AŒŒ„i‚ÉŒü‚¯‚Ă̈ãŽtAŠÅŒìŽtA—Õ°ŒŸ¸‹ZŽt‚Ì‹¦—̧͑.‘æ63‰ñ“ú–{—AŒŒE×–EŽ¡—Êw‰ï‘‰ï(ƒVƒ“ƒ|ƒWƒEƒ€);2015 May 28-30;“Œ‹ž.
  17. “‡‹žŽq, ˆÀ‘º•q.ƒ`[ƒ€ˆã—ÂƂµ‚Ä‚ÌPBM|ŠÅŒìŽt‚Ì–ðŠ„‚ÆŠˆ“®|.‘æ63‰ñ“ú–{—AŒŒE×–EŽ¡—Êw‰ï‘‰ï(ƒVƒ“ƒ|ƒWƒEƒ€);2015 May 28-30;“Œ‹ž.
  18. ˆÀ‘º•q.ƒAƒ‹ƒuƒ~ƒ“Ž¡—ẪGƒrƒfƒ“ƒX‰ðÍ‚ÆŽg—pŽwjô’è‚ɂ‚¢‚Ä.‘æ63‰ñ“ú–{—AŒŒE×–EŽ¡—Êw‰ï‘‰ï(ƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[);2015 May 28-30;“Œ‹ž.
  19. •xŽR—²‰î, ˆÀ‘º•q, ²’|ˆÉ’ÃŽq, ’†oË‘ã, “¹–ì~Žq, “‡‹žŽq.“–‰@‚É‚¨‚¯‚éƒtƒBƒuƒŠƒmƒQƒ“»Ü‚ÌŽg—pó‹µ.‘æ63‰ñ“ú–{—AŒŒE×–EŽ¡—Êw‰ï‘‰ï;2015 May 28-30;“Œ‹ž.
  20. mˆäŒ©‰pŽ÷, ŽR–{‘P—T, ã–ì’q_, âV“¡Ž , –k“‡ŒM.Tm mapping –@iŠ´õÇ‹N‰Š‹Ûv‘¬“¯’è–@j‚̉@“àŽŽŒ±‰^—pŒ‹‰Ê‚ƳŠm«‚Ì•]‰¿.‘æ89‰ñ“ú–{Š´õÇŠw‰ïŠwpu‰‰‰ï;2015 Apr 16;‹ž“s.
  21. –k“‡ŒM.ƒƒ‹ƒtƒ@ƒŠƒ“‚ÆNOAC, NOAC ŠÔ‚É‚¨‚¯‚é–ò—ì—p‚Ì‘Šˆá‚Æ“Á’¥.‘æ37‰ñ“ú–{ŒŒðŽ~ŒŒŠw‰ïŠwpW‰ïƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[;2015 May 22;b•{.
  22. –k“‡ŒM.ŒŒðŽ~ŒŒŠw‚©‚ç‚Ý‚½ƒgƒƒ“ƒrƒ“‘jŠQ–ò‚Ì—L—p«.•l–kR‹ÃŒÅ–ò•×‹­‰ï;2015 Jun 9;•l¼.
  23. –k“‡ŒM.RCPC ŒŸ¸’l‚Ì“Ç‚Ý•û.Œ¤CƒZƒ“ƒ^[ƒCƒuƒjƒ“ƒOƒZƒ~ƒi[;2015 Jun 16;•xŽR.
  24. –k“‡ŒM.‚Š´“xv‘¬‹Nˆö‹Û“¯’è‚ÆNF-κB Šˆ«‰»’è—ʉðÍ–@‚É‚æ‚é”sŒŒÇŒŸ¸ƒVƒXƒeƒ€ŠJ”­.“Œ–k‘åŠw–òŠwŒ¤‹†‰È–òŠwƒZƒ~ƒi[;2015 Jun 29;å‘ä.
  25. mˆäŒ©‰pŽ÷.Tm mapping –@:ŒŒ‰tŒŸ‘Ì‚©‚ç‚Ì‹N‰Š‹Û‚Ì’¼ÚŒŸoE“¯’è•û–@‚ÌŠJ”­.‘æ27‰ñ—Õ°”÷¶•¨v‘¬f’fŒ¤‹†‰ï‘‰ï;2015 Jul 4;‹à‘ò.
  26. “cK˜al, ‰Í‡Œ’Œá, •õ‘º³ŽÀ, ˆÀ‘º•q, ‚Œ´Æ”ü, ™ŽR•q˜Y.‰”­ŠÌ×–EŠà‚ɑ΂·‚郉ƒWƒI”gĎܗÖ@Œã‚Ì’·Šú¶‘¶‚ÉŠÖ‚í‚éˆöŽq‚ÌŒŸ“¢.‘æ51‰ñ“ú–{ŠÌŠàŒ¤‹†‰ï;2015 Jul 23-24;‹ž“s.
  27. –k“‡ŒM.ŒŒðŽ~ŒŒŠw‚©‚ç‚Ý‚½NOAC‚̈Ⴂ.–L’†ŒŒðŽ¡—ÃNetwork Meeting;2015 Jul 25;–L’†.
  28. –k“‡ŒM.ŒŒðÇ‚É‚¨‚¯‚é‹ÃŒÅEü—nƒ}[ƒJ[‚Ì—Õ°“I‰ž—p.ƒVƒXƒƒbƒNƒXƒZƒ~ƒi[in ‚³‚¢‚½‚Ü;2015 Aug 29;‚³‚¢‚½‚Ü.
  29. ã–ì’q_, mˆäŒ©‰pŽ÷, •Ä“c“¿Žq, •Ä“c“N, X³”V, ‘½—t“c—_, “ì—m, âV“¡Ž , –k“‡ŒM.eukaryote-made Taq polymerase‚ð—p‚¢‚½v‘¬‚ųŠm‚ÈŽq‹{Š´õÇ‹N‰Š‹Û‚ÌŒŸo‚ÆØ”—‘ŽY‚É‹y‚Ú‚·‰e‹¿.‘æ40‰ñ–k—¤—Õ°•a—W’k‰ï;2015 Sep 12;‹à‘ò.
  30. ŽRŠÝ“ÞX, “àŽRŒ«Žq, ‹{”ö¬–¾, ˆÉŒ\ˆê˜Y, ¬àVˆ»‰À, œA–ìŒbˆê, Žs“c•™Žq, –k“‡ŒM.SŽG‰¹¸¸–Ú“I‚ÌSƒGƒR[‚Å”­Œ©‚³‚ꂽ¶Š¥“®–¬”x“®–¬‹NŽnÇiBland-White-Garland ÇŒóŒQj‚Ì1—á.‘æ40‰ñ–k—¤—Õ°•a—W’k‰ï;2015 Sep 12;‹à‘ò.
  31. ŽŒ´N—T, ŠÖŒûŒh•¶, X“c”ü, â–{ƒŽq, –ìŽè—Ç„, ŽR–{‘P—T, –k“‡ŒM.•xŽR‘åŠw•‘®•a‰@‚É‚¨‚¯‚錌‰t”|—{‚Ì“úí‹Æ–±ŽžŠÔŠO’ño󋵂Ƃ»‚̑ΉžŒø‰Ê‚ÌlŽ@.‘æ40‰ñ–k—¤—Õ°•a—W’k‰ï;2015 Sep 12;‹à‘ò.
  32. •xŽR—²‰î*, –ìŽè—Ç„, –k“‡ŒM.ƒRƒAƒvƒŒƒXƒ^2000 ‚ð—p‚¢‚½ƒvƒƒeƒCƒ“S‘ª’莎–ò‚ÌŒŸ“¢.“ú–{—Õ°ŒŸ¸Ž©“®‰»Šw‰ï‘æ47‰ñ‘å‰ï;2015 Oct 9;‰¡•l.
  33. –k“‡ŒM.ŒuŒõ‘ŠŠÖ•ªŒõ–@‚É‚æ‚é“]ŽÊˆöŽqNF-κB‚̃nƒCƒXƒ‹[ƒvƒbƒg’è—Ê–@ŠJ”­‚Æ‚»‚Ì—Õ°‰ž—p.Ž­Ž™“‡‘åŠwŒŒŠÇ‘ãŽÓ•a‘ÔƒZƒ~ƒi[;2015 Oct 13;Ž­Ž™“‡.
  34. mˆäŒ©‰pŽ÷.Melting Temperature (Tm) mapping –@:ŒŸ‘ÌÌŽæŒã3ŽžŠÔˆÈ“à‚Å‚Ì”sŒŒÇ‹N‰Š‹Ûv‘¬“¯’è–@.‘æ58‰ñ“ú–{Š´õÇŠw‰ï’†“ú–{’n•û‰ïŠwpW‰ï;2015 Oct 16;“Þ—Ç.
  35. “‡‹žŽq.—AŒŒ‚ÉŠÖ‚í‚éŠÅŒìŽt‚Ì–ðŠ„‚ÆŠˆ“®iƒZƒ~ƒi[j.‘æ22‰ñ“ú–{—AŒŒE×–EŽ¡—Êw‰ïH‹GƒVƒ“ƒ|ƒWƒEƒ€;2015 Oct 23;Œyˆä‘ò.
  36. ã–ì’q_, mˆäŒ©‰pŽ÷, –k“‡ŒM.eukayote-made Taq polymerase ‚ð—p‚¢‚½v‘¬E‚Š´“xE³Šm‚ÈŽq‹{“àŠ´õÇ‹N‰Š‹ÛŒŸo–@‚Ì\’z.‘æ55‰ñ—Õ°‰»Šw”NŽŸŠwpW‰ï;2015 Oct 30;‘åã.
  37. ˆÀ‘º•q, “‡‹žŽq, “¹–ì~Žq, •xŽR—²‰î, ’†oË‘ã, ²’|ˆÉ’ÃŽq, –k“‡ŒM.“–‰@‚É‚¨‚¯‚鎩ŒÈŒŒ—AŒŒ‚ÌŒ»ó‚Ɖۑè.‘æ33‰ñ“ú–{—AŒŒE×–EŽ¡—Êw‰ï–k—¤Žx•”—á‰ï(ƒVƒ“ƒ|ƒWƒEƒ€);2015 Nov 7;•xŽR.
  38. “‡‹žŽq, ˆÀ‘º•q, “¹–ì~Žq, •xŽR—²‰î, ’†oË‘ã, ²’|ˆÉ’ÃŽq, –k“‡ŒM.Ž©ŒÈŒŒ—AŒŒ‚É‚¨‚¯‚éŠÅŒìŽt‚Ì–ðŠ„‚¨‚æ‚Ñ–â‘è“_.‘æ33‰ñ“ú–{—AŒŒE×–EŽ¡—Êw‰ï–k—¤Žx•”—á‰ï(ƒVƒ“ƒ|ƒWƒEƒ€);2015 Nov 7;•xŽR.
  39. ²’|ˆÉ’ÃŽq, ˆÀ‘º•q, •xŽR—²‰î, ’†oË‘ã, “¹–ì~Žq, “‡‹žŽq, –k“‡ŒM.“–‰@‚É‚¨‚¯‚鎩ŒÈR‘Ì•Û—LŠ³ŽÒ‚ւ̑Ήž.‘æ33‰ñ“ú–{—AŒŒE×–EŽ¡—Êw‰ï–k—¤Žx•”—á‰ï;2015 Nov 7;•xŽR.
  40. •xŽR—²‰î*, ˆÀ‘º•q, ²’|ˆÉ’ÃŽq, ’†oË‘ã, “¹–ì~Žq, “‡‹žŽq, –k“‡ŒM.—AŒŒŒã‚Ɍċz•s‘S‚ªoŒ»‚µ, TACO‚ª‹^‚í‚ꂽǗá.‘æ33‰ñ“ú–{—AŒŒE×–EŽ¡—Êw‰ï–k—¤Žx•”—á‰ï;2015 Nov 7;•xŽR.
  41. “¹–ì~Žq, ˆÀ‘º•q, •xŽR—²‰î, ’†oË‘ã, ²’|ˆÉ’ÃŽq, “‡‹žŽq, –k“‡ŒM.“–‰@‚É‚¨‚¯‚鑽ŒŒ¬”ÂŒŒŸ÷iPRPj—Ö@‚ɑ΂·‚é“–•”‚Å‚Ì‹Zp‹¦—Í.‘æ33‰ñ“ú–{—AŒŒE×–EŽ¡—Êw‰ï–k—¤Žx•”—á‰ï;2015 Nov 7;•xŽR.
  42. ’·“cI•½, “cK˜al, ‰Í‡Œ’Œá, ‹{‰€‘ì‹X, •õ‘º³ŽÀ, ˆÀ‘º•q, ‚Œ´Æ”ü, ŽO—ÖdŽ¡, ™ŽR•q˜Y.‰©át‚ª‘J‰„‚µ‚½–ò•¨«ŠÌáŠQ‚Ì1—á.“ú–{Á‰»Ší•aŠw‰ï–k—¤Žx•”‘æ121‰ñ—á‰ï;2015 Nov 8;‹à‘ò.
  43. –k“‡ŒM.ŒŒ‰t‹ÃŒÅŠw‚©‚ç‚Ý‚½Xa‘jŠQ–ò‚Ì—L—p«.R‹ÃŒÅ–ò‚Ì“K³Žg—p‚ðl‚¦‚é‰ï;2015 Nov 18;•xŽR.
  44. –k“‡ŒM.”ñƒrƒ^ƒ~ƒ“KŒoŒûR‹ÃŒÅ–òiNOACj‚Ì–ò—ì—p‚Æ—Õ°ŒŸ¸.—Õ°ŒŸ¸ˆãŠwCatch upƒZƒ~ƒi[, ‘æ62‰ñ“ú–{—Õ°ŒŸ¸ˆãŠw‰ïŠwpW‰ï;2015 Nov 20;Šò•Œ.
  45. ã–ì’q_, mˆäŒ©‰pŽ÷, •Ä“c“¿Žq, •Ä“c“N, X³”V, ‘½—t“c—_, “ì—m, âV“¡Ž , –k“‡ŒM.eukaryote-made Taq polymerase ‚ð—p‚¢‚½v‘¬‚ųŠm‚ÈŽq‹{“àŠ´õÇ‹N‰Š‹Û‚ÌŒŸo‚ÆØ”—‘ŽY‚É‹y‚Ú‚·‰e‹¿.‘æ62‰ñ“ú–{—Õ°ŒŸ¸ˆãŠw‰ïŠwpW‰ï;2015 Nov 20;Šò•Œ.
  46. –ìŽè—Ç„, ŽO‘º‘וF, –‰Í@‘, ŽR–{‘P—T, –k“‡ŒM.“–‰@‚É‚¨‚¯‚éMRSA ‚Ì•ª—£ó‹µ‚Æ–òÜŠ´Žó«‚Ì„ˆÚ.‘æ62‰ñ“ú–{—Õ°ŒŸ¸ˆãŠw‰ïŠwpW‰ï;2015 Nov 20;Šò•Œ.
  47. •õ‘º³ŽÀ, “cK˜al, ‰Í‡Œ’Œá, “‡“c´‘¾˜Y, ‚–ØG–¾, ˆÀ‘º•q, ‚Œ´Æ”ü, ™ŽR•q˜Y.B Œ^–«ŠÌ‰Š‚ɑ΂·‚éPeg-IFNα2a “Š—^Ç—á‚ÌŒŸ“¢.‘æ41‰ñ“ú–{ŠÌ‘ŸŠw‰ï¼•”‰ï;2015 Dec 3-4;–¼ŒÃ‰®.
  48. “cK˜al, ‰Í‡Œ’Œá, •õ‘º³ŽÀ, ˆÀ‘º•q, ‚Œ´Æ”ü, ™ŽR•q˜Y.Elastography‚ð—p‚¢‚½ŠÌüˆÛ‰»•]‰¿‚Ì—L—p«‚ÌŒŸ“¢.‘æ41‰ñ“ú–{ŠÌ‘ŸŠw‰ï¼•”‰ï;2015 Dec 3-4;–¼ŒÃ‰®.
  49. –k“‡ŒM.ŒŒ‰t‹ÃŒÅŠw‚©‚ç‚Ý‚½ŒoŒûR‹ÃŒÅ–ò‚Ì–ò—ì—p.CVMW2015 SŒŒŠÇ‘ãŽÓ, ‘æ23‰ñ“ú–{ŒŒŠÇ¶•¨ˆãŠw‰ïŠwpW‰ï, ‘æ19‰ñ“ú–{SŒŒŠÇ“à•ª”åŠwp‘‰ï, ‘æ32‰ñ‘ÛS‘ŸŒ¤‹†‰ï“ú–{•”‰ï, ‘æ37‰ñS‹Ø¶ŒŸŒ¤‹†‰ï˜A‡ƒZƒ~ƒi[;2015 Dec 11;_ŒË.

‚»‚Ì‘¼

  1. –k“‡ŒM. RVWFŽ©ŒÈR‘ÌŒŸo‚Ì‚½‚߂̃Cƒ€ƒmƒNƒƒ}ƒg–@‚É—p‚¢‚éRŒ´‚Æ“ÁˆÙR‘Ì‚ÌŒŸõ.Œú¶˜J“­‰ÈŠwŒ¤‹†“«Ž¾Š³“™ŽÀ—p‰»Œ¤‹†Ž–‹Æ”ljï‹ciˆê£”Çj;2015 Jan 25;“Œ‹ž.
  2. mˆäŒ©‰pŽ÷. ˆâ“`ŽqŒŸ¸ƒrƒWƒlƒX ŒŸ¸‹Zp‚ÌŒ»ó‚Æ–â‘è“_. —Õ°‰»Šw. 2015 Jan;44(1):76
  3. ˆÀ‘º•q. ƒAƒ‹ƒuƒ~ƒ“Ž¡—ẪGƒrƒfƒ“ƒX‰ðÍ‚ÆŽg—pŽwjô’è‚ɂ‚¢‚Ä. ‘æ18‰ñ•Ÿ‰ªŒ§—AŒŒ‡“¯ˆÏˆõ‰ï;2015 Jan 30;•Ÿ‰ª.
  4. ¼ˆäËŽq,‚‘qˆêŒb,–ìŒûŽõŒb,–k“‡ŒM. ‘åŠw¶‚É‚¨‚¯‚é–ƒ]E•—]R‘̉¿‚Ì„ˆÚ. Šw‰€‚Ì—Õ°Œ¤‹†. 2015 Mar;14:1-4.
  5. –q–ì–΋`,¼‰º³,•Ä‘º—YŽm,ˆÀ‘º•q,‹I–ìCˆê,‰Í–ì•O,“c’†’©Žu,¼–{‰ë‘¥,˜eâ–¾”ü,“ú–{—AŒŒE×–EŽ¡—Êw‰ïƒKƒCƒhƒ‰ƒCƒ“ˆÏˆõ‰ïƒAƒ‹ƒuƒ~ƒ“»Ü‚ÌŽg—pŽwjô’è‚ÉŠÖ‚·‚éƒ^ƒXƒNƒtƒH[ƒX. ‰ÈŠw“Iª‹’‚ÉŠî‚¢‚½ƒAƒ‹ƒuƒ~ƒ“»Ü‚ÌŽg—pƒKƒCƒhƒ‰ƒCƒ“i2015”N6ŒŽ1“ú‘æ1”Åj. “ú–{—AŒŒ×–EŽ¡—Êw‰ïŽ. 2015 Jun;61(3):Šª––3-22.
  6. ¼‰º³,¼–{‰ë‘¥,‹{“c–ÎŽ÷,‰H“¡‚–¾,‹I–ìCˆê,ˆÀ‘º•q,‰ªèm. ‰ÈŠw“Iª‹’‚ÉŠî‚­—AŒŒƒKƒCƒhƒ‰ƒCƒ“‚Ìô’è“™‚ÉŠÖ‚·‚錤‹† •½¬26”N“x‘Š‡E•ª’SŒ¤‹†•ñ‘ Œú¶˜J“­‰ÈŠwŒ¤‹†”ï•â•‹àˆã–ò•iEˆã—Ë@Ší“™ƒŒƒMƒ…ƒ‰ƒgƒŠ[ƒTƒCƒGƒ“ƒX‘‡Œ¤‹†Ž–‹Æ. –¼ŒÃ‰®:¼‰º³;2015. p.78
  7. ˆÀ‘º•q. ƒAƒ‹ƒuƒ~ƒ“Ž¡—ẪGƒrƒfƒ“ƒX‰ðÍ‚ÆŽg—pŽwjô’è‚ɂ‚¢‚Ä. ‘æ18‰ñ•Ÿ‰ªŒ§—AŒŒ‡“¯ˆÏˆõ‰ï•ñ‘. 2015 Mar:23-44.
  8. ˆÀ‘º•q. —AŒŒ—Ö@‚Ìl‚¦•û‚Æ“à‰È‚Ì—AŒŒ. ‘æ14‰ñŠw‰ï”F’èEŽ©ŒÈŒŒ—AŒŒŠÅŒìŽt§“x‡“¯Œ¤C‰ï;2015 Mar 6;“Œ‹ž.
  9. ˆÀ‘º•q. —AŒŒ‚ð‚ß‚®‚éŋ߂̘b‘è. ϶‰ï•xŽR•a‰@—AŒŒ—Ö@Œ¤C‰ï;2015 Mar 17;•xŽR.
  10. ˆÀ‘º•q. ƒAƒ‹ƒuƒ~ƒ“Ž¡—ẪGƒrƒfƒ“ƒX‰ðÍ‚ÆŽg—pŽwjô’è‚ɂ‚¢‚Ä. ŒŒŸ÷•ª‰æ»ÜƒtƒH[ƒ‰ƒ€;2015 Mar 26;–¼ŒÃ‰®.
  11. –k“‡ŒM. f—ÃŽQ‰ÁŒ^—Õ°ŽÀKŽÀŽ{ƒKƒCƒhƒ‰ƒCƒ“f—ÃŽQ‰ÁŒ^—Õ°ŽÀK‚É‚¨‚¯‚éˆã—ÈÀ‘S. ‘æ1‰ñ•xŽR‘åŠw•‘®•a‰@ˆã—ÈÀ‘SuK‰ï;2015 Apr 23;•xŽR.
  12. ˆÀ‘º•q. ƒCƒ“ƒ^[ƒtƒFƒƒ“ƒtƒŠ[‚ÌCŒ^ŠÌ‰ŠŽ¡—à ŠÔ‹ß‚É”—‚Á‚½HCV‚Ì–o–Å. ‘æ29‰ñŠÌŽõ‰ïu‰‰‰ï;2015 Apr 25;•xŽR.
  13. ˆÀ‘º•q. ƒAƒ‹ƒuƒ~ƒ“Ž¡—ẪGƒrƒfƒ“ƒX‰ðÍ‚ÆŽg—pŽwjô’è‚ɂ‚¢‚Ä. ‘æ1‰ñ‹}«Šú—A‰tŠÇ—Œ¤‹†‰ï;2015 Aug 1;“Œ‹ž.
  14. mˆäŒ©‰pŽ÷. CHIPS –@iˆâ“`Žq•ÏˆÙƒXƒNƒŠ[ƒjƒ“ƒO–@j‚͈â“`ŽqŒŸ¸‚ÌŠÈ•Ö‰»E’áƒRƒXƒg‰»‚ɖ𗧂Â. —Õ°‰»Šw. 2015 Oct;44(4):326.
  15. –k“‡ŒM. R-CPC ‰‹‰ƒŒƒxƒ‹. •½¬26”N“xŒŸ¸à–¾E‘Š’k‚ª‚Å‚«‚é—Õ°ŒŸ¸‹ZŽtˆç¬uK‰ï;2015 Mar 15;•xŽR.
  16. Œ´“cŒ’‰E. ŒŸ¸à–¾‚ÌŽÀÛA‰‹‰ƒŒƒxƒ‹. •½¬26”N“xŒŸ¸à–¾E‘Š’k‚ª‚Å‚«‚é—Õ°ŒŸ¸‹ZŽtˆç¬uK‰ï;2015 Mar 15;•xŽR.
  17. –k“‡ŒM. R-CPCq‰‹‰ƒŒƒxƒ‹r. •½¬27”N“xŒŸ¸à–¾E‘Š’k‚ª‚Å‚«‚é—Õ°ŒŸ¸‹ZŽtˆç¬uK‰ï;2015 Oct 25;•xŽR.
  18. Œ´“cŒ’‰E. ŒŸ¸à–¾‚ÌŽÀÛq‰‹‰ƒŒƒxƒ‹r. •½¬27”N“xŒŸ¸à–¾E‘Š’k‚ª‚Å‚«‚é—Õ°ŒŸ¸‹ZŽtˆç¬uK‰ï;2015 Oct 25;•xŽR.
  19. –k“‡ŒM. —Õ°ŒŸ¸¸“xŠÇ—‚Ìd—v«‚ðÄŠm”F‚µ‚Ü‚µ‚傤. —Õ°ŒŸ¸¸“xŠÇ—’²¸•ñ‘. 2015;27:1.

ƒy[ƒW‚Ì擪‚Ö–ß‚é

2014”N

’˜‘

  1. –k“‡ŒM. ƒXƒ^ƒ“ƒ_[ƒhŒŸ¸ŒŒ‰tŠw‘æ3”Å. “ú–{ŒŸ¸ŒŒ‰tŠw‰ï•Ò. “Œ‹ž:ˆãŽ•–òo”Å;2014. ŒŒŠÇ‚̈Ùí;p.345-9.
  2. mˆäŒ©‰pŽ÷ŠÄC. ?‚ª!‚É‚È‚éˆâ“`ŽqŒŸ¸Vol.2 ˆâ“`Žq. Sysmex. 2014 10.

Œ´’˜

  1. Hirono K, Sekine M, Shiba N, Hayashi S, Nakaoka H, Ibuki K, Saito K, Watanabe K, Ozawa S, Higuma T, Yoshimura N, Kitajima I. Ichida F. N-terminal pro-brain natriuretic peptide as a predictor of reoperation in children with surgically corrected tetralogy of fallot. Circulation Jurnal. 2014;78(3):693-700.PMID:24334564
  2. Shirahata A, Takahashi H, Kitajima I, Tsuji H, Eguchi Y, Matsushita T, Kajiki M, Honda G, Sataka Y. Recombinant soluble human thrombomodulin (thrombomojurin Alfa) in the treatment of neonatal disseminated intravascular coagulation. European Journal of Pediatrics. 2014;173(3):303-11.PMID:24005342
  3. Shirahata A, Mimuro J, Takahashi, H, Tsuji H, Kitajima I, Matsushita T, Eguchi Y, MD, Kitamura N8, Honda G, Sakata Y:Post-Marketing Surveillance of Recombinant Human Soluble Thrombomodulin (Thrombomodulin Alfa) in Pediatric Patients with Disseminated Intravascular Coagulation. Clinical and Applied Thrombosis/Hemostasis. 2014;20(5):465-72.PMID:24563247
  4. Asakura H, Takahashi H, Matsushita T, Ninomya H, Honda G, Mimuro J, Eguchi Y, Kitajima I, Sakata Y. Post-maketing surveillance of thrombomodulin alfa, a novel drug for treatment of disseminated intravascular coagulation treatment- Safety and efficacy in 1,032 patients assosiated with hematologic makignancy. Thromb Res. 2014;133:364-70.PMID:24440141
  5. Mastusita T, Watanabe J, Honda G, Mimuro J, Tsuji H, Eguchi Y, Kitajima I, Sakata Y. Thrombomodulin alfa treatment in patients with acute promyelocytic leukemia and disseminated intravascular coagulation: a retrospective analysis of a open label multicenter postmarketing surveillance study cohort. Thromb Res. 2014;133(5):772-81.PMID:24636871
  6. Eguchi Y, Gando S, Ishikura H, Saitoh D, Mimuro J, Takahashi H, Kitajima I, Tshuji H, Matsushita T, Tsujita R, Nagao O, Sakata Y. Post-marketing surveillance data of the thrombomodulin alfa: sub-analysis in patients with sepsis-induced disseminated intravascular coagulation. J Intensive Care. 2014 Apr 30;2(1):30.PMID:25520842
  7. Takiwaki M, Tomoda F, Koike T, Taki T, Inoue H, Kigawa M, Kitajima I, Uji Y. Increased level of small dense low-density lipoprotein cholesterol associated with hemorheological abnormalities in untreated early stage essential hypertensive. Hypertens Res. 2014 Nov;37(11):1008-13.PMID:24990092

‘à

  1. –k“‡ŒM. V‹KŒoŒûR‹ÃŒÅ–ò(NOAC)‚̃‚ƒjƒ^[–@. ˆã–òƒWƒƒ[ƒiƒ‹. 2014;50(2):97-102.
  2. –k“‡ŒM. V‹KŒoŒûR‹ÃŒÅ–ò‚Ì–ò—Šw“I“Á’¥.zŠÂŠí“à‰È.2014;75(5):542-8.
  3. –k“‡ŒM, ‹´ŒûÆl, X‰º‰p—¢Žq. V‹KŒoŒûR‹ÃŒÅ–òNOAC‚̃‚ƒjƒ^ƒŠƒ“ƒOŒŸ¸‚̉”\«‚Æ‚»‚Ì•W€‰»‚ÉŒü‚¯‚Ä. “ú–{ŒŒðŽ~ŒŒŠw‰ïŽ. 2014;25(4):552-3.
  4. –k“‡ŒM. S–[ד®Š³ŽÒ‚É‚¨‚¯‚錌‰t‹ÃŒÅ˜´i‚̃ƒJƒjƒYƒ€‚ÆŒoŒûR‹ÃŒÅ–ò‚ÌŒŒðŽ~ŒŒŠw“IlŽ@. “ú–{S“dŠw‰ïŽ. 2014;34(4):S4-3-10.
  5. z–K•”Í, ‘Oì^l, ¬ŽÄŒ«—m, ”nꮎu, ”ÑÀ—RŽk, ˆäŒ´Œ«Ž¡, ŒÃì‘׎i, “c’†–õl, ŒÃŽsŒ«Œá, ˜a“c—²Žu, ‹g“c”Ž, ’£‘ÖG˜Y, “nç³’¼Ž÷, –k“‡ŒM. —Õ°ŒŸ¸‚̃KƒCƒhƒ‰ƒCƒ“JSLM2012‚ÌŠˆ—p|‰ü’ù‚̃|ƒCƒ“ƒg‚ðˆê“—¼’f|. —Õ°•a—. 2014;62(7):702-9.
  6. –îâ³O, ‘–쌤Œá, –k“‡ŒM, •½–ìÆ”V, ‰r“cáÁŽ¡, R‹ÃŒÅ—Ö@‚É”º‚¤“ªŠW“àoŒŒ, Cardio-Coagulation, 2014;1(3):6-14.

Šw‰ï•ñ

  1. Niimi H, Ueno T, Kitajima I. The Melting Temperature (TM) Mapping Method: A Novel Method That Enables Rapid Identification of Unknown Pathogenic Microorganisms within Three Hours of Patient Sample Collection. The 9th International Conference of Clinical Laboratory Automation and Robotics; 2014 Apr 19; Yokohama.
  2. Niimi H, Ueno T, Hayashi S, Abe A, Tsurue T, Mori M, Tabata H, Minami H, Goto M, Saito S Kitajima I. The Melting Temperature (Tm) Mapping Method: A Novel Method That Enables Rapid Identification of Unknown Pathogenic Bacteria In Sepsis Within Three Hours of Whole Blood Collection. ECCMID 2014; 2014 May 10-13; Barcelona.
  3. Niimi H, Kitajima I. The Tm mapping method. A noel rapid, easy, and cost-effective method that identifies unknown pathogenic microorganisms within 3 hours of patients sample collection. Microbiology and Infectious Diseases Asia Congress; 2014 Jun 10-11; Singapore.
  4. mˆäŒ©‰pŽ÷. Tm mapping–@Š³ŽÒŒŸ‘ÌÌŽæŒã3ŽžŠÔˆÈ“à‚Å‚Ì‹N‰Š‹Ûv‘¬“¯’è–@D‘æ25‰ñ“ú–{—Õ°”÷¶•¨Šw‰ï‘‰ï; 2014 Feb 1; –¼ŒÃ‰®.
  5. –k“‡ŒM. Novel Oral Anticoagulant(NOAC)‚ɑ΂·‚é‹ÃŒÅEü—nŒŸ¸•W€‰»‚Ì“®ŒüD‘æ8‰ñ“ú–{ŒŒðŽ~ŒŒŠw‰ïŠwp•W€‰»ˆÏˆõ‰ïƒVƒ“ƒ|ƒWƒEƒ€;2014 Feb 22;“Œ‹ž.
  6. mˆäŒ©‰pŽ÷. V‹Kˆâ“`Žq•ÏˆÙƒXƒNƒŠ[ƒjƒ“ƒO–@‚Ì”­–¾‚ƈâ“`Žqf’f‚ւ̉ž—pD‘æ68‰ñ•xŽRŒ§ˆãŠw‰ï;2014 Feb 22;•xŽR.
  7. –k“‡ŒM. ŒŒðŽ~ŒŒ§Œä‚ÌŽå–ðƒgƒƒ“ƒrƒ“‚ð„‚éŋ߂̘b‘è. ‘æ43‰ñV“sŽsŒŒðŽ~ŒŒŒ¤‹†‰ï;2014 Mar 7;“Œ‹ž.
  8. –k“‡ŒM. ŒŒðŽ~ŒŒŠw‚©‚ç‚Ý‚½ƒgƒƒ“ƒrƒ“‘jŠQ–ò‚Ì—L—p«Dƒvƒ‰ƒUƒLƒT”­”„3Žü”N‹L”Ou‰‰ in ç—t;2014 Apr 15;ç—t.
  9. –k“‡ŒM. ƒgƒƒ“ƒrƒ“ì—p‚Ì‘½–Ê«‚ƃgƒƒ“ƒrƒ“‘jŠQ–ò‚Ì—L—p«. S–[ד®Š³ŽÒ‚³‚ñ‚Ì”]‚ðŒì‚錤‹†‰ï;2014 Apr 19;_ŒË.
  10. –k“‡ŒM. ’¼Úƒgƒƒ“ƒrƒ“‘jŠQ–ò‚Ì–ò—ì—p‚Æ—L—p«. R‹ÃŒÅ—Ö@VŽž‘ã ‘æ2‰ñŒŒðÇðŠwpW‰ï;2014 May 23;‰¡•l.
  11. mˆäŒ©‰pŽ÷. Tm mapping–@:Š³ŽÒŒŸ‘ÌÌŽæŒã3ŽžŠÔˆÈ“à‚Å‚ÌŠ´õÇ‹N‰Š‹Ûv‘¬“¯’è–@. ‘æ79‰ñ“ú–{ƒCƒ“ƒ^[ƒtƒFƒƒ“EƒTƒCƒgƒJƒCƒ“Šw‰ïŠwpW‰ï;2014 Jun 19;ŽD–y.
  12. –k“‡ŒM. V‹KŒoŒûR‹ÃŒÅ–ò‚̈À‘S«‚Æ—LŒø«‚̃‚ƒjƒ^ƒŠƒ“ƒO. ‘æ4‰ñŒŒðŽ~ŒŒŒŸ¸Œ¤‹†‰ï in Tokyo; 2014 Jun 28;“Œ‹ž.
  13. –k“‡ŒM. ŒŒðŽ~ŒŒŠw‚©‚ç‚Ý‚½ƒgƒƒ“ƒrƒ“‘jŠQ–ò‚Ì—L—p«. Core Member Meeting;2014 Jul 24;L“‡.
  14. –k“‡ŒM. Novel Oral Anticoagulant (NOAC)‚̃‚ƒjƒ^ƒŠƒ“ƒOŒŸ¸‚ÌŒ»ó‚Æ‚»‚̉”\«. ‘æ15‰ñ“ú–{ŒŸ¸ŒŒ‰tŠw‰ïŠwpW‰ï;2014 Jul 20;å‘ä.
  15. –k“‡ŒM. ŒŒðŽ~ŒŒ§Œä‚ÌŽå–ðƒgƒƒ“ƒrƒ“‚ð„‚é˜b‘è|‹ÃŒŒ•ªŽqƒ}[ƒJ[‚ð’†S‚É|;2014 Sep 27;•xŽR.
  16. –k“‡ŒM. R‹ÃŒÅ—Ö@‚É‚¨‚¯‚铪ŠW“àoŒŒ. Toyama Network Meeting;2014 Nov 26;•xŽR.
  17. –k“‡ŒM. ŒŒ‰t‹ÃŒÅŠw‚©‚ç‚Ý‚½V‹KŒoŒûR‹ÃŒÅ–ò‚Ì–ò—Šw“I“Á’¥. ‘æ35‰ñ“ú–{—Õ°–ò—Šw‰ïŠwp‘‰ï;2014 Dec 4;¼ŽR.
  18. mˆäŒ©‰pŽ÷. ŒŒ‰t’†‚Ì‹Û”‚ð”sŒŒÇdÇ“x‚⎡—ÃŒø‰Ê‚ÌV‚½‚ÈŽw•W‚Æ‚·‚錟¸‹Zp‚ÌŠJ”­. ‘æ61‰ñ“ú–{—Õ°ŒŸ¸ˆãŠw‰ïŠwpW‰ïŠwp„iƒvƒƒWƒFƒNƒg1;2014 Nov 25;•Ÿ‰ªD
  19. X“c–¢, ŠÖŒûŒh•¶, â–{ƒŽq, –ìŽè—Ç„, –‰Í@‘, ŽR–{‘P—T. “–‰@‚É‚¨‚¯‚é‰ß‹Ž10”NŠÔ‚ÌPseudomonas aeruginosa‚Ì•ª—£ó‹µ‚¨‚æ‚Ñ–òÜŠ´Žó«‚Ì„ˆÚ. ‘æ25‰ñ“ú–{—Õ°”÷¶•¨Šw‰ï‘‰ï;2014 Feb 1-2;–¼ŒÃ‰®.
  20. ŽÂŒ´Š°–¾, —é–سN, ‰““c_Ži, –k“‡ŒMDˆãH‚ª˜AŒg‚·‚鉻ŠwEƒoƒCƒIƒZƒ“ƒT‚ÌŠJ”­‚Æ—Õ°ŒŸ¸‚̉ۑè‰ðŒˆ‚ւ̉ž—pD2014 •xŽR‘åŠwŠwpŒð—¬‰ï;2014 Mar 10;•xŽRD 21) ŽR‰º•ô*D”Ä—p‹@‚É‚æ‚éCK-MB mass –@‚É—L—p«DÎ쌧ˆãŠwŒŸ¸Šw‰ïƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[;2014 Mar 23;‹à‘òD
  21. ã–ì’q_, mˆäŒ©‰pŽ÷, X³”V, ‘½—t“c—_, “ì—m, âV“¡Ž , –k“‡ŒMDEukaryote-made Taq polymerase ‚ð—p‚¢‚½v‘¬‚ųŠm‚ÈŽq‹{“àŠ´õÇ–@‚Ì\’zD‘æ53‰ñ“ú–{—Õ°ŒŸ¸ˆãŠw‰ï“ŒŠCE–k—¤Žx•”‘‰ï ‘æ328‰ñ“ú–{—Õ°‰»Šw‰ï“ŒŠCE–k—¤Žx•”—á‰ï;2014 Mar 9;•ŸˆäD
  22. ‰¡“cˆ»*, ì“Y—F‹I, –ìŽè—Ç„, –k“‡ŒMD’¼Úƒgƒƒ“ƒrƒ“‘jŠQ–òƒ_ƒrƒKƒgƒ‰ƒ“ƒ‚ƒjƒ^ƒŠƒ“ƒOŒŸ¸‚ÉŠÖ‚·‚錟“¢D‘æ53‰ñ“ú–{—Õ°ŒŸ¸ˆãŠw‰ï“ŒŠCE–k—¤Žx•”‘‰ï ‘æ328‰ñ“ú–{—Õ°‰»Šw‰ï“ŒŠCE–k—¤Žx•”—á‰ï;2014 Mar;•ŸˆäD
  23. Žß‰i´Žu, Œ´“cŒ’‰E, •ž•”’[Ž÷, ‹v•Û“c—º•½, –k“‡ŒM, ŽRèŒõÍD‰“Šu‹•ŒŒƒvƒŒƒRƒ“ƒfƒVƒ‡ƒiƒ‹‚É‚æ‚錌ð—\–hŒø‰ÊD“ú–{–ƒŒ‰ÈŠw‰ï‘æ61‰ñŠwpW‰ï;2014 May 16;‰¡•lD
  24. ŽR‰º•ô*, ‘å’ÎW–ç, –ìŽè—Ç„, –k“‡ŒMDƒ‰ƒeƒbƒNƒX‹ÃW”ä‘÷–@‚É‚æ‚éV‹KCK-MB’`”’‘ª’莎–ò‚ÌŠî‘b“IŒŸ“¢‚¨‚æ‚Ñ“d‹C‰j“®–@‚É‚æ‚é‰ðÍD‘æ25‰ñ“ú–{—Õ°‰»Šw“ŒŠC–k—¤Žx•”‘‰ï ‘æ33‰ñ“ú–{—Õ°ŒŸ¸ˆãŠw‰ï“ŒŠC–k—¤Žx•”—á‰ï˜A‡‘å‰ï;2014 Aug 2;–¼ŒÃ‰®D
  25. mˆäŒ©‰pŽ÷, ã–ì’q_, X³”V, ™]˜a–Î, –k“‡ŒMDŠ´õÇ‹N‰Š‹Ûv‘¬“¯’è–@(Tm mapping–@)‚ÌŠw“àŽŽŒ±‰^—p‚É‚¨‚¯‚鳊m«‚Ì•]‰¿D‘æ54‰ñ“ú–{—Õ°‰»Šw‰ï”NŽŸŠwpW‰ï;2014 Sep 5;“Œ‹žD
  26. ŽR‰º•ô*, –k“‡ŒMDLC-MS/MS‚ð—p‚¢‚½ŒŒ´25-ƒqƒhƒƒLƒVƒrƒ^ƒ~ƒ“‚Ì‘ª’èD‘æ54‰ñ“ú–{—Õ°‰»Šw‰ï”NŽŸŠwpW‰ï;2014 Sep 5;“Œ‹žD
  27. “àŽRŒ«Žq, ’‡‰ª‰pK, ˆÉŒ\ˆê˜Y, ¬àVˆ»‰À, œA–ìŒbˆê, Žs“c•™Žq, –k“‡ŒMDS‘ŸÄ“¯Šú—Ö@‚Ì‘OŒã‚Ì•]‰¿‚ÉSƒGƒR[‚ª—L—p‚Å‚ ‚Á‚½¬Ž™‚Ì1—áD‘æ22‰ñ–k—¤—Õ°•a—W’c‰ïƒZƒ~ƒi[;2014 Sep 20;•xŽRD
  28. ŽR‰º•ô*, ‘å’ÎW–ç, ‘½‰ê—R‹IŽq, 쓇–ÒŽu, –ìŽè—Ç„, –k“‡ŒMDCK-MB ’`”’—Ê‘ª’莎–òuL ƒ^ƒCƒvƒƒR[CK-MB massv‚Ì‹@”\•]‰¿‚¨‚æ‚Ñ“d‹C‰j“®–@‚É‚æ‚é‰ðÍD‘æ22‰ñ–k—¤—Õ°•a—W’c‰ïƒZƒ~ƒi[;2014 Sep 20;•xŽRD
  29. ã–ì’q_, mˆäŒ©‰pŽ÷, âV“¡Ž , –k“‡ŒMDTm mapping –@iŠ´õÇ‹N‰Š‹Ûv‘¬“¯’è–@j‚̉@“àŽŽŒ±‰^—pŒ‹‰Ê‚Æ‚»‚Ì•]‰¿D‘æ22‰ñ–k—¤—Õ°•a—W’c‰ïƒZƒ~ƒi[;2014 Sep 20;•xŽRD
  30. ŠÖŒûŒh•¶, X“c–¢, â–{ƒŽq, –ìŽè—Ç„, –k“‡ŒMDˆÓŽ¯áŠQ‚ðŒ_‹@‚É”­Œ©‚³‚ꂽ”dŽí«ƒmƒJƒ‹ƒWƒAÇ‚Ì1—áD‘æ53‰ñ“ú—Õ‹Z’†•”Œ—Žx•”ˆãŠwŒŸ¸Šw‰ï;2014 Sep 27;•xŽRD
  31. ‘å’ÎW–ç*, ŽR‰º•ô, –ìŽè—Ç„, –k“‡ŒM. ”Ä—pŽ©“®•ªÍ‘•’u‚ð—p‚¢‚½ƒCƒ“ƒXƒŠƒ“‘ª’莎–òuƒmƒ‹ƒfƒCƒAƒCƒ“ƒXƒŠƒ“v‚ÌŠî‘b“IŒŸ“¢. “ú–{—Õ°ŒŸ¸Ž©“®‰»Šw‰ï‘æ46‰ñ‘å‰ï;2014 Oct 11;_ŒË.
  32. ŽR‰º•ô*, ‘å’ÎW–ç, –ìŽè—Ç„, –k“‡ŒMDV‹KCK-MB ’`”’—Ê‘ª’莎–òuL ƒ^ƒCƒvƒƒR[CK-MBmass ‚ÌŠî‘b“IŒŸ“¢v“ú–{—Õ°ŒŸ¸Ž©“®‰»Šw‰ï‘æ46‰ñ‘å‰ï;2014 Oct 11;_ŒË.
  33. ‰¡“cˆ», –k“‡ŒM. ’¼Úƒgƒƒ“ƒrƒ“‘jŠQ–òƒ_ƒrƒKƒgƒ‰ƒ“‚̃‚ƒjƒ^ƒŠƒ“ƒOŒŸ¸‚ÉŠÖ‚·‚錟“¢. “ú–{—Õ°ŒŸ¸Ž©“®‰»Šw‰ï‘æ46‰ñ‘å‰ï;2014 Oct 11;_ŒË.
  34. ™XOŽq, ‘匴–ƒˆßŽq, •ú±GŽq, ‹Ÿ“c•¶G, ¬’r‹Î, ˆä㔎, Œ´“cŒ’‰E, –k“‡ŒMDŒ’í‚ȋΘJŽÒ‚É‚¨‚¯‚é—LŽ_‘f‰^“®‚Ì“]ŽÊˆöŽqNF-κB Šˆ«‰»‚É‹y‚Ú‚·‰e‹¿D‘æ37‰ñ“ú–{‚ŒŒˆ³Šw‰ï‘‰ï;2014 Oct 17;‰¡•lD
  35. mˆäŒ©‰pŽ÷Dv‘¬ŠÈ•Ö‚ÈŠ´õÇ‹N‰Š‹Û“¯’è‹Zp‚ÌŠJ”­D“ú—§’†‰›Œ¤‹†Šu‰‰;2014 Nov 13D
  36. mˆäŒ©‰pŽ÷, ã–ì’q_, X³”V, ‘½—t“c—_, “ì—m, ™]˜a–Î, âV“¡Ž , –k“‡ŒMDTm mapping –@iŠ´õÇ‹N‰Š‹Ûv‘¬“¯’è–@j‚̉@“àŽŽŒ±‰^—p‚Æ‚»‚Ì•]‰¿D‘æ61‰ñ“ú–{—Õ°ŒŸ¸ˆãŠw‰ïŠwpW‰ï;2014 Nov 23;•Ÿ‰ªD

‚»‚Ì‘¼

  1. “Á‹–Žæ“¾:–k“‡ŒMD“Á‹–‘æ5504477†D”­–¾–¼ÌuŽwë–¬”g‰ðÍ‘•’u‹y‚Ñ‚±‚ê‚ð—p‚¢‚½ŒŒŠÇ“à”ç‹@”\•]‰¿ƒVƒXƒeƒ€voŠè”Ô†;“ÁŠè2010-059907DoŠè“ú:•½¬22 ”N3 ŒŽ16 “ú, “o˜^“ú:•½¬26”N3ŒŽ28“ú
  2. “Á‹–Žæ“¾: ‘½—t“c—_, “ì—m, mˆäŒ©‰pŽ÷, –k“‡ŒM, ã–ì’q_, —ÑŽj˜Y, X³”VD“Á‹–‘æ5583602†D”­–¾–¼Ìu‘Ï«DNAƒ|ƒŠƒƒ‰[ƒ[‚ðŠÜ‚Þy‘f’²®•¨‚¨‚æ‚Ñ‚»‚Ì»‘¢•û–@, •À‚Ñ‚ÉŒŸo‘ÎÛ¶•¨‚ÌŒŸo•û–@vDoŠè”Ô†:“ÁŠè2010|546663DoŠè“ú:•½¬22”N1ŒŽ15“ú, “o˜^“ú:•½¬26”N7ŒŽ25“ú, ŒöŠJ“ú:•½¬26”N9ŒŽ3“ú
  3. –k“‡ŒM:•xŽRŒ§—Õ°ŒŸ¸ŠÇ—‹¦‹c‰ï‚̉ʂ½‚·–ðŠ„D•½¬16”N“x—Õ°ŒŸ¸¸“xŠÇ—’²¸•ñ‘2014;26:1D
  4. ‚‘qˆêŒb, ¼ˆäËŽq, –ìŒûŽõ”ü, “‡–Ø‹M‹vŽq, ²–ì—²Žq, ŽðˆäÂ, –k“‡ŒM.•—]R‘̉¿‚Ì“®Œü. Šw‰€‚Ì—Õ°Œ¤‹† 2014;13:11-5.

ƒy[ƒW‚Ì擪‚Ö–ß‚é

2013”N

’˜‘

  1. –k“‡ŒM. •W€—Õ°ŒŸ¸ˆãŠw. ‘æ4”Å. ‚–ØN, ŽR“crK•Ò. “Œ‹ž:ˆãŠw‘‰@;2013. d‹à‘®‚È‚ç‚Ñ‚ÉŠÖ˜A’`”’;p.232-40.
  2. –k“‡ŒM. V‹KR‹ÃŒÅ–ò‚Ì‘I‚Ñ•ûEŽg‚¢•û. –L“cˆê‘¥•Ò. ‘åã:ƒtƒWƒƒfƒBƒJƒ‹o”Å;2013. V‹KR‹ÃŒÅ–ò‚̃‚ƒjƒ^ƒŠƒ“ƒO;p. 88-99.
  3. –k“‡ŒM. —Õ°ŒŸ¸ƒf[ƒ^ƒuƒbƒNLAB DATA2013-2014. •ì´, t“ú³‰ë, –k‘º¹•Ò. “Œ‹ž:ˆãŠw‘‰@;2013. ƒvƒƒgƒƒ“ƒrƒ“ŽžŠÔiPTj, ƒgƒƒ“ƒ{ƒeƒXƒgiTTj, ƒwƒpƒvƒ‰ƒXƒ`ƒ“ƒeƒXƒgiHPTj, Šˆ«‰»•”•ªƒgƒƒ“ƒ{ƒvƒ‰ƒXƒ`ƒ“ŽžŠÔiAPTTj;p.375-9.
  4. –k“‡ŒM. —Õ°ŒŸ¸ƒf[ƒ^ƒuƒbƒNLAB DATA2013-2014. •ì´, t“ú³‰ë, –k‘º¹•Ò. “Œ‹ž:ˆãŠw‘‰@;2013. ƒtƒBƒuƒŠƒmƒQƒ“, ‰Â—n«ƒtƒBƒuƒŠƒ“ƒ‚ƒmƒ}[•¡‡‘ÌiFMCj, ƒtƒBƒuƒŠƒ“^ƒtƒBƒuƒŠƒmƒQƒ“•ª‰ðŽY•¨[FDP], Dƒ_ƒCƒ}[;p.375-87, 388-93, 394-9, 401-4, 404-12.
  5. –k“‡ŒM. —Õ°ŒŸ¸ƒf[ƒ^ƒuƒbƒNLAB DATA2013-2014. •ì´, t“ú³‰ë, –k‘º¹•Ò. “Œ‹ž:ˆãŠw‘‰@;2013. ƒvƒƒgƒƒ“ƒrƒ“, ƒvƒƒgƒƒ“ƒrƒ“ƒtƒ‰ƒOƒƒ“ƒgiPF1+2j, ‘æVˆöŽq, ‘æVIIˆöŽq, ‘æVIIIˆöŽq, von Willebrand ˆöŽq, von WillenrandˆöŽqƒ}ƒ‹ƒ`ƒ}[‰ðÍ, vWFØ’fy‘fiADAMTS13j, ‘æIXˆöŽq, ‘æXˆöŽq, ‘æXIˆöŽq, ‘æXIIˆöŽq, ‘æXIIIˆöŽq;p.387-98.
  6. –k“‡ŒM. —Õ°ŒŸ¸ƒf[ƒ^ƒuƒbƒNLAB DATA2013-2014. •ì´, t“ú³‰ë, –k‘º¹•Ò. “Œ‹ž:ˆãŠw‘‰@;2013. ‹ÃŒÅˆöŽqƒCƒ“ƒqƒrƒ^[’è«iƒNƒƒXƒ~ƒLƒVƒ“ƒOŽŽŒ±j, ‘æ‡[ˆöŽqƒCƒ“ƒqƒrƒ^[, ‘æIXˆöŽqƒCƒ“ƒqƒrƒ^[, ‘gDˆöŽqi‘gDƒgƒƒ“ƒ{ƒvƒ‰ƒXƒ`ƒ“j, ‘‘gDˆöŽqŒo˜HƒCƒ“ƒqƒrƒ^[i‘TFPIj. ƒAƒ“ƒ`ƒgƒƒ“ƒrƒ“iATj, ƒgƒƒ“ƒrƒ“EƒAƒ“ƒ` ƒgƒƒ“ƒrƒ“•¡‡‘ÌiTATj;p.396-404.
  7. –k“‡ŒM. —Õ°ŒŸ¸ƒf[ƒ^ƒuƒbƒNLAB DATA2013-2014. •ì´, t“ú³‰ë, –k‘º¹•Ò. “Œ‹ž:ˆãŠw‘‰@;2013. ƒgƒƒ“ƒ{ƒ‚ƒWƒ…ƒŠƒ“, ƒvƒƒeƒCƒ“C, ƒvƒƒeƒCƒ“S, ‘gDƒvƒ‰ƒXƒ~ƒmƒQƒ“ƒAƒNƒ`ƒx[ƒ^it-PAj, ƒvƒ‰ƒXƒ~ƒmƒQƒ“ƒAƒNƒ`ƒx[ƒ^ƒCƒ“ƒqƒrƒ^[1iPAI-1j, t-PAEPAI-1 •¡‡‘Ì, ƒvƒ‰ƒXƒ~ƒmƒQƒ“, α2-ƒvƒ‰ƒXƒ~ƒ“ƒCƒ“ƒqƒrƒ^[, ƒvƒ‰ƒXƒ~ƒ“Eα2-ƒvƒ‰ƒXƒ~ƒ“ƒCƒ“ƒqƒrƒ^[•¡‡‘ÌiPICƒeƒXƒgj;p.2013-4.

Œ´’˜

  1. Harada K, Mikuni S, Beppu H, Niimi H, Abe S, Hano N, Yamagata K, Kinjo M, Kitajima I. A rapid and high-throughput quantitation assay of the neclear factor κB activity using fluorescence correlation spectroscopy in the setting of clinical laboratories. PLoS One.2013 Oct;8:e75579. PMID:24124497
  2. Mimuro J, Takahashi H, Kitajima I, Tsuji H, Eguchi Y, Matsushita T, Kuroda T, Sakata Y. Impact of recombinant sokuble thrombomodulin (thrombomodulin alfa) on disseminated intravascular coagulation.Throm Res. 2013 May;131(5):436-43. PMID:23566534
  3. Madoiwa S, Kitajima I, Ohmori T, Sakata Y, Mimuro J. Distinct reactivity of the commercially available monoclonal antibodies of D-dimer and plasma FDP testing to the molecular variants of fibrin degradation products. Thromb Res. 2013 Oct;132(4):457-64. PMID:24011388

‘à

  1. –k“‡ŒM. yƒƒ“ƒ‰ƒ“ƒNã‚̬Ž™‚Ì—Õ°ŒŸ¸|¶—‚ÉŠî‚­‘I‚Ñ•ûEl‚¦•û|z¬Ž™‚Ì—Õ°ŒŸ¸‚ÌŠî‘b’mŽ¯ —Õ°ŒŸ¸‘˜_. ¬Ž™‰ÈŠwƒŒƒNƒ`ƒƒ[. 2013;3(2):281-8.
  2. –k“‡ŒM. Ö¬ŒŒðÇðÇiVTEj. ŒŸ¸‚Æ‹Zp. 2013;41(9):752-8.
  3. –k“‡ŒM. V‹KŒoŒûƒgƒƒ“ƒrƒ“‘jŠQ–ò‚É‚¨‚¯‚é‹ÃŒÅŒŸ¸‚Ìd—v«‚Æ–â‘è“_. •ºŒÉŒ§ˆãŽt‰ïˆãŠwŽGŽ. 2013;56(1):2-3.
  4. ŽR‰º•ô, –k“‡ŒM. ƒrƒ^ƒ~ƒ“D‚ÌRŽîᇌø‰Ê‚ɑ΂·‚éƒGƒrƒfƒ“ƒX. —Õ°‰»Šw. 2013;42(2):356-8.
  5. mˆäŒ©‰pŽ÷. ƒƒ^ƒQƒmƒ€‰ðÍ‚ª‘ñ‚­ƒ}ƒCƒNƒƒoƒCƒI[ƒ€ŒŸ¸‚̉”\«. —Õ°‰»Šw. 2013;42(1):83-4.
  6. mˆäŒ©‰pŽ÷. Tm mapping –@:ŒŸ‘ÌÌŽæŒã3ŽžŠÔˆÈ“à‚Å‚Ì‹Nˆö‹Û“¯’è‚ð‰Â”\‚Æ‚·‚éV‚½‚ÈŒŸ¸–@. —Õ°‰»Šw. 2013;42(2):124-30.
  7. mˆäŒ©‰pŽ÷. Š´õÇv‘¬ŒŸ¸‹Zp‚ÌUp To Date|ŠjŽ_ŒŸ¸–@‚Ì‹tP|. —Õ°‰»Šw. 2013;42(2):104.

Šw‰ï•ñ

  1. Niimi H, Ueno T, Hayashi S, Mori M, Tabata H, Minami H, Saito S, Kitajima I. A New rapid, easyand cost-effective method that identifies unknown pathogenic microorganisms within 3 hours from sample collection. 20th European Congress of Clinical Chemistry and Laboratory Medicine; 2013 May 19-23; Milano. (Invited lecture)
  2. Kitajima I, Hirano K, Tani M, Tanaka K. Novel haemostatic biomarkers in acute cardioembolic stroke. 20th European Congress of Clinical Chemistry and Laboratory Medicine; 2013 May 19-23; Milano.
  3. Kitajima I, Hirano K, Tani M, Tanaka K. Novel haemostatic biomarkers in acute cardioembolic stroke. 2013 American Association for Clinical Chemistry Annaul Meetin; 2013 Jul 28-Augst 1; Houston.
  4. Matsushita T, Watanabe J, Goichi Honda, Mimuro J, Takahashi H, Tsuji H, Eguchi Y, Kitajima I, Sakata Y. Thrombomodulin Alfa Treatment For Disseminated Intravascular Coagulation In Acute Promyelocytic Leukemia: A Retrospective Analysis Of The Open-Label, Multicenter Study Cohort. 55th American Society of Hematology Annual Meeting and Exposition; 2013 Dec 10-14; New Orleans.
  5. –k“‡ŒM. V‹KŒoŒûƒgƒƒ“ƒrƒ“‘jŠQ–òÜ‚É‚¨‚¯‚é‹ÃŒÅŒŸ¸‚Ìd—v«‚Æ–â‘è“_. “ú–{ˆãŽt‰ï¶ŠU‹³ˆç‹¦—ÍuÀ;2013 Jan 26;‹ž“s. iµ‘Òu‰‰j
  6. –k“‡ŒM. V‹KŒoŒû‹ÃŒÅ–ò‚Æ‹ÃŒÅEü—nŒŸ¸. “ú–{ˆãŽt‰ï•ŸˆäŒ§Žx•”¶ŠU‹³ˆç‹¦—ÍuÀ;2013 Feb 17;•Ÿˆä. iµ‘Òu‰‰j
  7. –k“‡ŒM. Šî‘b‚ÌŠÏ“_‚©‚çƒgƒƒ“ƒrƒ“‘jŠQ–ò‚Ì—L—p«‚ðl‚¦‚é. ‘æ38‰ñ“ú–{”]‘²’†Šw‰ï‘‰ïSTROKE2013;2013 Mar 23;“Œ‹ž. iµ‘Òu‰‰j
  8. –k“‡ŒM. Novel clinical laboratory markers of blood coagulation and fibrinolysis. ‘æ38‰ñ”]‘²’†Šw‰ï‘‰ïŒŒðŽ~ŒŒŠw‰ï‡“¯ƒVƒ“ƒ|ƒWƒEƒ€;2013 Mar 23;“Œ‹ž. iµ‘Òu‰‰j
  9. –k“‡ŒM. ŒŒðŽ~ŒŒŠw‚©‚ç‚Ý‚½ƒgƒƒ“ƒrƒ“‘jŠQ–ò‚Ì—L—p«. S‘ŸŒŒŠÇƒtƒH[ƒ‰ƒ€2013;2013 Apr 18;‘åã. iµ‘Òu‰‰j
  10. –k“‡ŒM. S–[ד®‚Æ”][Ç. “ú–{ˆãŽt‰ï¶ŠU‹³ˆç‹¦—ÍuÀ;2013 May 11;_ŒË. iµ‘Òu‰‰j
  11. –k“‡ŒM. V‹KŒoŒûR‹ÃŒÅ–òˆÀ‘S«ƒ`ƒFƒbƒN‚Ì‚½‚߂̋ÌŌŸ¸–ò’Tõ. ‘æ35‰ñ“ú–{ŒŒðŽ~ŒŒŠw‰ïŠwpW‰ï‰ï’·—v¿‹¤ÃƒVƒ“ƒ|ƒWƒEƒ€;2013 May31;ŽRŒ`. iµ‘Òu‰‰j
  12. –k“‡ŒM. ‹ÃŒÅŠw‚ÌŽ‹“_‚©‚çƒgƒƒ“ƒrƒ“‘jŠQ–ò‚Ì—L—p«‚ðl‚¦‚é. ‘æ35‰ñ“ú–{ŒŒðŽ~ŒŒŠw‰ïŠwpW‰ï‰ï’·ƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[;2013 May31;ŽRŒ`. iµ‘Òu‰‰j
  13. –k“‡ŒM. ƒgƒƒ“ƒrƒ“‘jŠQ–ò‚Ì“Á’¥‚ð—‰ð‚·‚é. ‘æ4‰ñNational Stroke Summit;2013 Jun 29;“Œ‹ž. iµ‘Òu‰‰j
  14. –k“‡ŒM. S–[ד®‚É‚¨‚¯‚é‹ÃŒÅ˜´i‚ƃgƒƒ“ƒrƒ“‘jŠQ–ò‚Ì—L—p«. ‘æ28‰ñŒ¢ŽR•s®–¬ƒJƒ“ƒtƒ@ƒŒƒ“ƒX;2013 Aug 24;–¼ŒÃ‰®. iµ‘Òu‰‰j
  15. –k“‡ŒM. zŠÂŠíŽ¾Š³‚̃oƒCƒIƒ}[ƒJ[ŒŸ¸‚Ìi•à ‹ÃŒÅEü—nƒ}[ƒJ[. “ú–{—Õ°ŒŸ¸Ž©“®‰»Šw‰ï‘æ45‰ñ‘å‰ï;2013 Oct 11;‰¡•l. iµ‘Òu‰‰j
  16. –k“‡ŒM. ŒŒðEŽ~ŒŒ•ªŽqƒ}[ƒJ[‚ÌÅ‘O. ‘æ60‰ñ“ú–{—Õ°ŒŸ¸ˆãŠw‰ïŠwpW‰ï;2013 Oct 31;_ŒË. iµ‘Òu‰‰j
  17. –k“‡ŒM. SŒ´«”]ÇðÇ‚Ì—\–h‚ÆÅVŽ¡—ÃE’·–ì“ú–{ˆãŽt‰ï¶ŠU‹³ˆç‹¦—ÍuÀ;2013 Oct 13;’·–ì. iµ‘Òu‰‰j
  18. mˆäŒ©‰pŽ÷. eukaryote-made Taq DNA polymerase ‚¨‚æ‚ÑTm mapping –@‚É‚æ‚銴õÇv‘¬ŒŸ¸ƒVƒXƒeƒ€‚Ì\’z. ‘æ22‰ñM‘å—Õ°ŒŸ¸ƒZƒ~ƒi[;2013 Sep 15;¼–{. iµ‘Òu‰‰j
  19. mˆäŒ©‰pŽ÷. ˆê”Ê׋ۂɂ¨‚¯‚éˆâ“`ŽqŒŸ¸. ŽR—œŒ§—Õ°‰q¶ŒŸ¸‹ZŽt‰ï”÷¶•¨Eˆâ“`ŽqŒŸ¸Œ¤‹†”LJ“¯Œ¤C‰ï;2013 Feb 15;’†‰›. iµ‘Òu‰‰j
  20. –ìŽè—Ç„, —Ñ—´“ñ, ŽO‘º‘וF, –kì—mŽq, –؉ëŽq, ŽR–{‘P—T, “c‘ã«l. “–‰@‚É‚¨‚¯‚éƒAƒ“ƒ`ƒoƒCƒIƒOƒ‰ƒ€‚Æ–òÜ‘Ï«‹Û‚Ì•ª—£ó‹µ. ‘æ28‰ñ“ú–{ŠÂ‹«Š´õŠw‰ï‘‰ï;2013 Mar 2;‰¡•l.
  21. ‘ê˜e³‹M, ŽR‰º•ô, ‰FŽ¡‹`‘¥, ‹Ÿ“c•¶G, ¬’r‹Î, ˆä㔎, –k“‡ŒM. –{‘Ô«‚ŒŒˆ³Ç‚É‚¨‚¯‚錌’†Ž‰Ž¿‚ÆŒŒ‰t”S«‚ÌŠÖŒW. ‘æ52‰ñ“ú–{—Õ°ŒŸ¸ˆãŠw‰ï“ŒŠC–k—¤Žx•”‘‰ïE‘æ326‰ñ“ú–{—Õ°‰»Šw‰ï“ŒŠC–k—¤Žx•”—á‰ï˜A‡‘å‰ï;2013 Mar 10;’Ã.
  22. ŽR‰º•ô, ‘ê˜e³‹M, ‰FŽ¡‹`‘¥, ‹Ÿ“c•¶G, ˆä㔎, –k“‡ŒM. –{‘Ô«‚ŒŒˆ³Š³ŽÒ‚É‚¨‚¯‚錌´25-ƒqƒhƒƒLƒVƒrƒ^ƒ~ƒ“D3”Z“x‚ÆCa, P ‘ãŽÓŽw•W‚ÌŠÖŒW. ‘æ52‰ñ“ú–{—Õ°ŒŸ¸ˆãŠw‰ï“ŒŠC–k—¤Žx•”‘‰ïE‘æ326‰ñ“ú–{—Õ°‰»Šw‰ï“ŒŠC–k—¤Žx•”—á‰ï˜A‡‘å‰ï;2013 Mar 10;’Ã.
  23. ŽR‰º•ô, ‘ê˜e³‹M, ‰FŽ¡‹`‘¥, –k“‡ŒM, ‹Ÿ“c•¶G, ˆä㔎. –{‘Ô«‚ŒŒˆ³ÇŠ³ŽÒ‚É‚¨‚¯‚錌´25-OHƒrƒ^ƒ~ƒ“D3”Z“x‘ª’è‚Ì•]‰¿. ‘æ24‰ñ¶•¨ŽŽ—¿•ªÍ‰ÈŠw‰ï”NŽŸŠwpW‰ï;2013 Mar 13;”Ž‘½.
  24. ‘ê˜e³‹M, ŽR‰º•ô, ‰FŽ¡‹`‘¥, ‹Ÿ“c•¶G, ˆäã ”Ž, –k“‡ŒM. –{‘Ô«‚ŒŒˆ³Ç‚É‚¨‚¯‚錌’†Ž‰Ž¿‚ÆŒŒ‰t”S«. ‘æ24‰ñ¶•¨ŽŽ—¿•ªÍ‰ÈŠw‰ï”NŽŸŠwpW‰ï;2013 Mar 13:”Ž‘½.
  25. ŠÖŒûŒh•¶, ‘ê˜e³‹M, ‰FŽ¡‹`‘¥, “c•”ˆä—m‰î, ó–ì‘׋v, –k“‡ŒM. y‘f–@‚É‚æ‚錌Ÿ÷Threonine’è—Ê–@‚ÌŠm—§. ‘æ24‰ñ¶•¨ŽŽ—¿•ªÍ‰ÈŠw‰ï”NŽŸŠwpW‰ï;2013 Mar 13:”Ž‘½.
  26. ‰–è^‹|, ŽRŠÝ“ÞX, ¬£—¢Œb, ‹g“cç», ‰FŽ¡‹`‘¥, •½ˆä’‰˜a, Žs“c•™Žq, ˆä㔎, –F‘º’¼Ž÷, –k“‡ŒM. zŠÂŠí“à‰ÈŠO—ˆ‚̬læ“V«SŽ¾Š³‚É‚¨‚¯‚éSƒGƒR[}ŠŒ©‚Ì“Á’¥. ‘æ77‰ñ“ú–{zŠÂŠíŠw‰ïŠwpW‰ï;2013 Mar 16;‰¡•l.
  27. ì“Y—F‹I, ‹g“c‘, •Ê•{GK, –k“‡ŒM. ŠÌ‚ª‚ñ×–E‚É‚¨‚¯‚éƒgƒƒ“ƒrƒ“‚É‚æ‚éTF‚ÆPAI-1”­Œ»‚ƌÓT“INF-κBƒVƒOƒiƒ‹’ᔽ‰ž«‚Æ‚ÌŠÖ˜A. ‘æ35‰ñ“ú–{ŒŒðŽ~ŒŒŠw‰ïŠwpW‰ï;2013 Jun 1;ŽRŒ`.
  28. “c슰Žq, mˆäŒ©‰pŽ÷, ã–ì’q_, –k“‡ŒM. ‰t‘ŠCell Counting–@, v‘¬‚ÅŠÈ•Ö‚È–òÜŠ´Žó«ŽŽŒ±–@‚ÌŠJ”­‚ÌŽŽ‚Ý. ‘æ24‰ñ“ú–{—Õ°‰»Šw“ŒŠCE–k—¤Žx•”‘‰ï^‘æ32‰ñ“ú–{—Õ°ŒŸ¸ˆãŠw‰ï“ŒŠCE–k—¤Žx•”—á‰ï;2013 Jul 20;•l¼.
  29. ã–ì’q—T, mˆäŒ©‰pŽ÷, X³”V, ‘½—t“c—_, “ì—m, âV“¡Ž , –k“‡ŒM. eukaryote-made Taq polymerase‚ð—p‚¢‚½v‘¬‚ÈŽq‹{“àŠ´õÇE‘Š‘ΓI’è—ÊŒŸo–@‚Ì\’z. ‘æ24‰ñ“ú–{—Õ°‰»Šw“ŒŠCE–k—¤Žx•”‘‰ï^‘æ32‰ñ“ú–{—Õ°ŒŸ¸ˆãŠw‰ï“ŒŠCE–k—¤Žx•”—á‰ï;2013 Jul 20;•l¼.
  30. ŽRŠÝ“ÞX, –k“‡ŒM. œŒ`¬ˆöŽqiBMPjŽó—e‘̕ψقƃVƒOƒiƒ‹ˆÙí‚Íã”ç×–EŽîᇉ»‚ɉe‹¿‚ð—^‚¦‚é. ‘æ53‰ñ“ú–{—Õ°‰»Šw‰ï”NŽŸŠwpW‰ï;2013 Aug 30;“¿“‡.
  31. mˆäŒ©‰pŽ÷, ã–ì’q_, X³”V, ‘½—t“c—_, “ì—m, –k“‡ŒM. Tm mappng–@:ŒŸ‘ÌÌŽæ3ŽžŠÔˆÈ“à‚Å•s“Á’è‚Ì‹Nˆö‹Û‚𓯒肷‚év‘¬ŒŸ¸–@. ‘æ53‰ñ“ú–{—Õ°‰»Šw‰ï”NŽŸŠwpW‰ï;2013 Aug 31;“¿“‡.
  32. ŽRŠÝ“ÞX, ‰–è^‹|, ¬£—Œb, ˆä㔎, –k“‡ŒM. S‘Ÿ“àŽîᎂ̌Ÿo‚É‚¨‚¯‚éŒo‹¹SƒGƒR[‚Ì—L—p«. ‘æ38‰ñ–k—¤—Õ°•a—W’k‰ï;2013 Sep14;‹à‘ò.
  33. ã–ì’q_, mˆäŒ©‰pŽ÷, X³”V, ‘½—t“c—_, “ì—m, âV“¡Ž , –k“‡ŒM. eukatyote-made Taq polymerase‚ð—p‚¢‚½v‘¬‚ÈŽq‹{“àŠ´õÇE‹ÛŒŸo–@‚Ì\’z. ‘æ38‰ñ–k—¤—Õ°•a—W’k‰ï;2013 Sep 14;‹à‘ò.
  34. ŽR‰º•ô, ‘ê˜e³‹M, –ìŽè—Ç„, ‰FŽ¡‹`‘¥, –k“‡ŒM. AQT90FLEX–Ɖu‘ª’è‘•’u‚É‚æ‚éCK-MB’`”’—Ê‘ª’è‚ÌŠî‘b“IŒŸ“¢. “ú–{—Õ°ŒŸ¸Ž©“®‰»Šw‰ï‘æ45‰ñ‘å‰ï;2013 Oct 11;‰¡•l.
  35. ŠÖŒûŒh•¶, ‘ê˜e³‹M, ã–ì’q_, ‰FŽ¡‹`‘¥, –k“‡ŒM. ‘SŽ©“®¶‰»Šw•ªÍ‘•’u‚É‚æ‚錌Ÿ÷Threonin, Tryptophan, Glycine•ªÍ–@\’z‚Æ—Õ°‚ւ̉ž—p. “ú–{—Õ°ŒŸ¸Ž©“®‰»Šw‰ï‘æ45‰ñ‘å‰ï;2013 Oct 11;‰¡•l.
  36. ‹g“c‘, ‹g“ciŽq, ŒÃŽsŒb’ÃŽq, ‹g“c‰Á“Þ”ü, ‰ª•”‘f“T, –k“‡ŒM. Image J ‚ð—p‰æ‘œ‰ðÍ‚Ì“K‰ž«. “ú–{‰ð–UŠw‰ï’†•”’n‹æ’n•û‰ï;2013 Oct 5;ŽR—œ.
  37. mˆäŒ©‰pŽ÷, ã–ì’q_, X³”V, ‘½—t“c—_, “ì—m, âV“¡Ž , –k“‡ŒM. Tm mapping–@:Š³ŽÒŒŸ‘ÌÌŽæŒã3ŽžŠÔˆÈ“à‚Å‚Ìv‘¬‹Nˆö‹Û“¯’è–@. ‘æ60‰ñ“ú–{—Õ°ŒŸ¸ˆãŠw‰ïŠwpW‰ï;2013 Oct 31;_ŒË.
  38. ã–ì’q_, mˆäŒ©‰pŽ÷, X³”V, ‘½—t“c—_, “ì—m, âV“¡Ž , –k“‡ŒM. eukaryote-made Taq polymerase‚ð—p‚¢‚½Žq‹{“àŠ´õÇ‚Ì‘Š‘ΓI’è—ÊŒŸo–@. ‘æ60‰ñ“ú–{—Õ°ŒŸ¸ˆãŠw‰ïŠwpW‰ï;2013 Oct 31;_ŒË.
  39. “c슰Žq, mˆäŒ©‰pŽ÷, –k“‡ŒM. ‰t‘ŠCell Counting–@:v‘¬‚©‚ŠȕւȖòÜŠ´Žó«ŽŽŒ±–@ŠJ”­‚ÌŽŽ‚Ý. ‘æ60‰ñ“ú–{—Õ°ŒŸ¸ˆãŠw‰ïŠwpW‰ï;2013 Oct 31;_ŒË.
  40. ‘ê˜e³‹M, ŠÖŒûŒh•¶, ‰FŽ¡‹`‘¥, “c•”ˆä—z‰î, ó–ì‘׋v, –k“‡ŒM. y‘f–@‚É‚æ‚錌Ÿ÷Threinine’è—Ê–@‚ÌŠm—§. ‘æ60‰ñ“ú–{—Õ°ŒŸ¸ˆãŠw‰ïŠwpW‰ï;2013 Oct 31;_ŒË.
  41. ŽR‰º•ô, ‘ê˜e³‹M, –k“‡ŒM, ‹Ÿ“c•¶G, ¬’r‹Î, ˆä㔎, ‰FŽ¡‹`‘¥. –{‘Ô«‚ŒŒˆ³Ç‚É‚¨‚¯‚éŒðŠ´_ŒoE•›t‘Ž¿Œn‚ÆŒŒ’†FGF-23‚Æ‚ÌŠÖŒW. ‘æ60‰ñ“ú–{—Õ°ŒŸ¸ˆãŠw‰ïŠwpW‰ï;2013 Oct 31;_ŒË.

‚»‚Ì‘¼

  1. ‰¢B“Á‹–ð–ñ‹–‰Â:Miimi H, Kitajima I. Method for identifying pathogenic microorganisms responsible for infection by extracting the DNA of a microorganism. oŠè”Ô†i07714581. 1jiPTC-TU4-33j
  2. –{“cFs, ¼”öŽû“ñ, ³–Ø[, Œ´“cŒ’‰E, ‚苧, ’†‘º•¶•F. —Õ°‚Å—˜—p‚µ‚â‚·‚¢ŒŸ¸Œ‹‰Ê‚ð’ñ‹Ÿ‚µ‚悤. ‘æ59‰ñŠwpW‰ïReversed Clinicopathological ConferenceiR-CPCj. —Õ°•a—. 2013;6(3):271-82.
  3. ¼ˆäËŽq, ‚‘qˆêŒb, “‡–Ø‹M‹vŽq, –ìŒûŽõ”ü, ²–ì—²Žq, ŽðˆäÂ, –k“‡ŒM. –ƒ]ƒAƒEƒgƒuƒŒ[ƒN‚»‚ÌŒã. Šw‰€‚Ì—Õ°Œ¤‹†i•xŽR‘åŠw•ÛŒ’ŠÇ—ƒZƒ“ƒ^[‹I—vj. 2013;12:1-4.
  4. ŽðˆäÂ, ¼ˆäËŽq, ‚‘qˆêŒb, “‡–Ø‹M‹vŽq, —§£„Žu, ‹g‰i’Žj, …–ì ŒO, Œ´àV‚³‚ä‚Ý, £”ö—F“¿, “ú‰º•”‚Žj, “‡–Ø‹M‹vŽq, ²–ì—²Žq, ŽlŠÔ’šçŽ}, “‡“c®‰À, ‹{‘ºŒ’‘s, M“c‹v, œAìTˆê˜Y, ‹{˜e—˜’j, –k“‡ŒM. ˆã–òƒLƒƒƒ“ƒpƒX‚É‚¨‚¯‚éŠw¶Žx‰‡‚ÌŒ»ó‚Ɖۑè|ˆÀ‘S”z—¶‹`–±‚Æ‚ÌŠÖ˜A‚©‚ç|. Šw‰€‚Ì—Õ°Œ¤‹†i•xŽR‘åŠw•ÛŒ’ŠÇ—ƒZƒ“ƒ^[‹I—vj. 2013;12:77-82.

ƒy[ƒW‚Ì擪‚Ö–ß‚é

2012”N

’˜‘

  1. –k“‡ŒM, N“Œ“V, ŒKŽ•F, ˆÀ“Œ—RŠì—Y:u—Õଉ»Šw Š©–@‘W•Ò2012”N“x”Åv“ú–{—Õ°‰»Šw‰ï•Ò, “ú–{—Õ°‰»Šw‰ï, “Œ‹ž, 2012.

Œ´’˜

  1. Uji Y., Motomiya Y., and Ando Y.:Effect of heparin on conformation of the β2-microglobulin molecule. Ther Apher Dial. Apr;16(2):159-62.2012. PMID:22458395
  2. Motomiya Y., Uji Y., and Ando Y. :Capillary electrophoretic profile of β2-microglobulin intermediate associated with hemodialysis. Ther Apher Dial. Aug;16(4):350-4.2012. PMID:22817123
  3. Hirano K., Takashima S., Dougu N., Taguchi Y., Nukui T., Konishi H., Toyoda S., Kitajima I., and Tanaka K. :Study of hemostatic biomarkers in acute ischemic stroke by clinical subtype. J Stroke Cerebrovasc Dis. Jul;21(5):404-10.2012. PMID:22516429
  4. ‘ê˜e³‹M–, ‰FŽ¡‹`‘¥, –k“‡ŒM:‰»Šw”­Œõy‘f–Ɖu–@‚ð—p‚¢‚½HBsRŒ´‘ª’è‚ÌBŒ^–«ŠÌ‰ŠŠ³ŽÒ‚Å‚Ì•]‰¿. ¶•¨ŽŽ—¿•ªÍ, 35:127-132, 2012.
  5. ‹v•Û“c’q”ü–, —ÑŽj˜N, mˆäŒ©‰pŽ÷, –k“‡ŒM:“–‰@6”NŠÔ‚Ì‚¨‚¯‚é׋۫ŠáŠ´õÇ‚ÌŒŸo‹Û“®Œü’²¸|ŒŸ¸Žº‚ÌŽ‹“_‚©‚ç|. —Õ°•a—, 60(7):605-11.2012. PMID:22973718

‘à

  1. –k“‡ŒM, mˆäŒ©‰pŽ÷:‹ÛŒŒÇ^‘Sg‰ŠÇ”½‰žÇŒóŒQ‚ɑ΂·‚év‘¬E‚Š´“xŒŸ¸ƒVƒXƒeƒ€‚Ì\’z. —Õ°•a—, 60:46-51, 2012.
  2. –k“‡ŒM, ‰¡“c_[:ƒ`[ƒ€ˆã—ÂðŽx‚¦‚é—Õ°ŒŸ¸. —Õ°‰»Šw, 41(suppl. 1): 149, 2012.
  3. ‰FŽ¡‹`‘¥, ‘ê˜e³‹M–, –k“‡ŒM:V‚µ‚¢CK-MB Šˆ«‘ª’è–@. —Õ°‰»Šw, 41: 86-87, 2012.
  4. ‰FŽ¡‹`‘¥: ‘Û•W€‰»‹@\iISOj.u“ìŽR“°ˆãŠw‘厫“T 2012v,“ìŽR“°, “Œ‹ž, 2012.
  5. ‰FŽ¡‹`‘¥: ŒŒ´ƒAƒ‹ƒuƒ~ƒ“, ‚»‚Ì‘¼‚Ì’`”’Ž¿.uƒƒfƒBƒJƒ‹ƒTƒCƒGƒ“ƒX•a‘Ô¶‰»Šw^—Õ°‰»ŠwŒŸ¸Šwv, ‹ß‘ão”Å, “Œ‹ž, 2012

Šw‰ï•ñ

  1. Niimi H., Ueno T.*, Hayashi S., Mori M., Tabata H., Minami H., and Kitajima I. :A novel rapid method enables identification of pathogenic micro-organisms within 3 hours after samples are collected. 22nd European Congress of Clinical Microbiology and Infectious Diseases, 2012, 4, 2, London.
  2. Uji Y., Yamashita M. *, Takiwaki M. *, and Kitajima I. :Evaluation of Sysmex new automated hematology analyzer XN-9000 in routine clinical laboratory. AACC Annual Meeting 2012 & Clinical Lab Expo, 2012, 7, 15-19, Los Angeles.
  3. Yamashita M. *, Takiwaki M. *, Uji Y., Kitajima I., Honda T., and Hidaka H. :Quantitative measurement of serum phosphatidylcholine and lysophosphatidylcholine using matrix-assisted laser desorption/ ionization time-of-flight mass spectrometry. AACC Annual Meeting 2012 & Clinical Lab Expo, 2012, 7, 15-19, Los Angeles.
  4. Harada K. *, Mikuni S., Tomoda F., S. Kagitani., Koike T., Kinjo M., Inoue H., and Kitajima I. :Nuclear factor-kappa B activity in the peripheral blood lymphocytes measured with the novel quantitative system using the fluorescent correlation spectroscopy correlates with intra-abdominal fat area in patients with essential hypertension. AACC Annual Meeting 2012 & Clinical Lab Expo, 2012, 7, 15-19, Los Angeles.
  5. Niimi H., Ueno T. *, Hayashi S., Mori M., Tabata H., Minami H., Saito S., and Kitajima I. :A novel TM-mapping methodthat enables identification of pathogenic microorganisms within 3 hours after samples are collected. 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy, 2012, 9, 11, San Francisco.
  6. Taki T., Tomoda F., Koike T., Ohara M., Hirose M., Kagitani S., Inoue H., Takiwaki M. *, Uji Y., and Kitajima I. :Relation of small dense low-density lipoprotein cholesterol to carotid atherosclerosis in essential hypertensives with normal renal function. The 24th Scientific Meeting of the International Society of Hypertension, 2012, 9, 30 -10, 3, Sydney.
  7. Miyamoto M., Yamazaki H., Tomoda F., Koike T., Kagitani S., Nakagawa T., Inoue H., Takiwaki M. *, Uji Y., and Kitajima I. :Small dense low-density lipoprotein cholesterol, and its clinical features in patients with nephrotic syndrome. The 45th Annual Meeting of American Society of Nephrology, 2012, 10, 30 -11, 4, San Diego.
  8. ì“Y—F‹I–, ‰FŽ¡‹`‘¥, –k“‡ŒM, ˆäã ”Ž:’¼Úƒgƒƒ“ƒrƒ“‘jŠQ–òƒ_ƒrƒKƒgƒ‰ƒ“ƒGƒeƒLƒVƒ‰[ƒg“Š—^‚É‚¨‚¯‚éPT, APTT ƒ‚ƒjƒ^[‚Ì•K—v«. ‘æ51‰ñ“ú–{—Õ°ŒŸ¸ˆãŠw‰ï“ŒŠC–k—¤Žx•”‘‰ïE‘æ32‰ñ“ú–{—Õ°‰»Šw‰ï“ŒŠC–k—¤Žx•”—á‰ï ˜A‡‘å‰ï, 2012, 3, 11, ¬“cŒ´.
  9. ‹v•Û“c’q”ü–, —Ñ Žj˜N, –ìŽè—Ç„, ‰FŽ¡‹`‘¥, mˆäŒ©‰pŽ÷, –k“‡ŒM:“–‰@‚É‚¨‚¯‚éŠá‰ÈŠ´õÇ‚Ì‹ÛŒŸo‚ÉŠÖ‚·‚镪Í. ‘æ51‰ñ“ú–{—Õ°ŒŸ¸ˆãŠw‰ï“ŒŠC–k—¤Žx•”‘‰ïE‘æ32‰ñ“ú–{—Õ°‰»Šw‰ï“ŒŠC–k—¤Žx•”—á‰ï ˜A‡‘å‰ï, 2012, 3, 11, ¬“cŒ´.
  10. ‘ê˜e³‹M–, ‰FŽ¡‹`‘¥, ‹g“cç», mˆäŒ©‰pŽ÷, ‹Ÿ“c•¶G, –{‹{‘P‰ø:“§Í‚É‚æ‚éβ2-ƒ~ƒNƒƒOƒƒuƒŠƒ“’†ŠÔ‘Ìœ‹Ž”\‚Ì•]‰¿. ‘æ22‰ñ¶•¨ŽŽ—¿•ªÍ‰ÈŠw‰ïŠwpW‰ï, 2012, 3, 10-11, •Ÿ‰ª.
  11. Œ´“cŒ’‰E–, •Ê•{GK, mˆäŒ©‰pŽ÷, ˆ¢•”Ž Ž÷, ‰H–ì—zŽq, ŽRŒ`_ˆê, –k“‡ŒM:ŒuŒõ‘ŠŠÖ•ªŒõ–@(FCS)‚É‚æ‚é“]ŽÊˆöŽqNF-κB Šˆ«‚̃nƒCƒXƒ‹[ƒvƒbƒg’è—Ê–@ŠJ”­. ‘æ51‰ñ“ú–{—Õ°ŒŸ¸ˆãŠw‰ï“ŒŠC–k—¤Žx•”‘‰ïE‘æ32‰ñ“ú–{—Õ°‰»Šw‰ï“ŒŠC–k—¤Žx•”—á‰ï ˜A‡‘å‰ï, 2012, 3, 11, ¬“cŒ´.
  12. Œ´“cŒ’‰E–, •Ê•{GK, mˆäŒ©‰pŽ÷, ‹Ÿ“c•¶G, Œ®’J‘, ¬’r‹Î, ˆä㔎, –k“‡ŒM:“]ŽÊˆöŽqNF-κB Šˆ«‚ª‚ŒŒˆ³‚É‹y‚Ú‚·‰e‹¿‚Æ‚»‚Ì‹K’èˆöŽq‚Ì—Õ°“IˆÓ‹`. ‘æ51‰ñ“ú–{—Õ°ŒŸ¸ˆãŠw‰ï“ŒŠC–k—¤Žx•”‘‰ïE‘æ32‰ñ“ú–{—Õ°‰»Šw‰ï“ŒŠC–k—¤Žx•”—á‰ï˜A‡‘å‰ï, 2012, 3, 11, ¬“cŒ´.
  13. ŽR‰º•ô–, ‘ê˜e³‹M–, ‰FŽ¡‹`‘¥, –k“‡ŒM:MtCKŠˆ«‘jŠQR‘Ì‚ð—p‚¢‚½V‹KCK-MB ‘ª’è–@‚Ì—Õ°•]‰¿. ‘æ52‰ñ“ú–{—Õ°‰»Šw‰ï”N‰ï, 2012, 9, 6-7, ·‰ª.
  14. ŽR‰º•ô–, ‘ê˜e³‹M–, “ú‚GÆ, ‰FŽ¡‹`‘¥, –k“‡ŒM:MALSI-TOF MS‚ð—p‚¢‚½ƒzƒXƒtƒ@ƒ`ƒWƒ‹ƒRƒŠƒ“‚¨‚æ‚уŠƒ]ƒzƒXƒtƒ@ƒ`ƒWƒ‹ƒRƒŠƒ“‚Ì’è—Ê•ªÍ. ‘æ23‰ñ“ú–{—Õ°‰»Šw‰ï“ŒŠC–k—¤Žx•”‘‰ïE‘æ31‰ñ“ú–{—Õ°ŒŸ¸ˆãŠw‰ï“ŒŠC–k—¤Žx•”—á‰ï˜A‡‘å‰ï, 2012, 8, 4, •xŽR.
  15. ã–ì’q_–, mˆäŒ©‰pŽ÷, —Ñ Žj˜N, –ìŽè—Ç„, –k“‡ŒM:Tm mapping –@‚ð—p‚¢‚½Š´õÇ‹N‰Š‹Ûv‘¬“¯’èƒVƒXƒeƒ€‚ÌŠJ”­. ‘æ23‰ñ“ú–{—Õ°‰»Šw“ŒŠC–k—¤Žx•”‘‰ïE‘æ31‰ñ“ú–{—Õ°ŒŸ¸ˆãŠw‰ï“ŒŠC–k—¤Žx•”—á‰ï ˜A‡‘å‰ï, 2012, 8, 4, •xŽR.
  16. ‹v•Û“c’q”ü–, —ÑŽj˜N, ã–ì’q_, –ìŽè—Ç„, mˆäŒ©‰pŽ÷, –k“‡ŒM:“–‰@6”NŠÔ‚É‚¨‚¯‚é׋۫ŠáŠ´õÇ‚ÌŒŸo‹Û“®Œü’²¸|ŒŸ¸Žº‚ÌŽ‹“_‚©‚ç|. ‘æ23‰ñ“ú–{—Õ°‰»Šw‰ï“ŒŠC–k—¤Žx•”‘‰ïE‘æ31‰ñ“ú–{—Õ°ŒŸ¸ˆãŠw‰ï“ŒŠC–k—¤Žx•”—á‰ï˜A‡‘å‰ï, 2012, 8, 4, •xŽR.
  17. ‘ê˜e³‹M–, ŽR‰º•ô–, ‰FŽ¡‹`‘¥, –k“‡ŒM:MtCKŠˆ«‚̉e‹¿‚ð‰ñ”ð‚µ‚½V‹KCK-MB‘ª’è–@‚Ì—Õ°•]‰¿. ‘æ23‰ñ“ú–{—Õ°‰»Šw‰ï“ŒŠC–k—¤Žx•”‘‰ïE‘æ31‰ñ“ú–{—Õ°ŒŸ¸ˆãŠw‰ï“ŒŠC–k—¤Žx•”—á‰ï ˜A‡‘å‰ï, 2012, 8, 4, •xŽR.
  18. ‘ê’m•F, ‹Ÿ“c•¶G, ¬’r‹Î, ‘匴–ƒˆßŽq, œA£‰ë‘ã, ˆä㔎, ‘ê˜e³‹M–, ‰FŽ¡‹`‘¥, –k“‡ŒM:–{‘Ô«‚ŒŒˆ³Ç‚É‚¨‚¯‚鎉Ž¿ˆÙíǂƑ匌ŠÇ‚Ì\‘¢ˆÙí‚Æ‚ÌŠÖŒW:¬Œ^‚–§“xLDL ‚Ìd—v«. ‘æ35‰ñ“ú–{‚ŒŒˆ³Šw‰ï‘‰ï, 2012, 9, 20-22, –¼ŒÃ‰®.
  19. ‘ê˜e³‹M–, ŽR‰º•ô–, ‰FŽ¡‹`‘¥, ‹Ÿ“c•¶G, ¬’r‹Î, ˆä㔎, –k“‡ŒM:–{‘Ô«‚ŒŒˆ³‚É‚¨‚¯‚ésmall dense LDL‚ÆŒŒ‰t”S«‚Æ‚ÌŠÖŒW. ‘æ59‰ñ“ú–{—Õ°ŒŸ¸ˆãŠw‰ïŠwpW‰ï, 2012, 11, 29-12, 2, ‹ž“s.
  20. mˆäŒ©‰pŽ÷, ã–ì’q_–, —ÑŽj˜N, X³”V, ‘½—t“c—_, “ì—m, –ìŽè—Ç„, Ö“¡Ž , –k“‡ŒM:Tm mapping–@‚ð—p‚¢‚½Š´õÇ‹N‰Š‹Ûv‘¬“¯’èƒVƒXƒeƒ€‚ÌŠJ”­. ‘æ59‰ñ“ú–{—Õ°ŒŸ¸ˆãŠw‰ïŠwpW‰ï, 2012, 11, 29 -12, 2, ‹ž“s.
  21. ã–ì’q_– , mˆäŒ©‰pŽ÷, —ÑŽj˜N, X³”V, ‘½—t“c—_, “ì—m, –ìŽè—Ç„, Ö“¡Ž , –k“‡ŒM :eukaryote-made Taq polymerase ‚ð—p‚¢‚½v‘¬‚ÈŽq‹{“àŠ´õÇŒŸ¸–@‚Ì\’z. ‘æ59‰ñ“ú–{—Õ°ŒŸ¸ˆãŠw‰ïŠwpW‰ï, 2012, 11, 29 -12, 2, ‹ž“s.
  22. ŽR‰º•ô–, ‘ê˜e³‹M–, ‰FŽ¡‹`‘¥, ‹Ÿ“c•¶G, ˆä㔎, –k“‡ŒM:–{‘Ô«‚ŒŒˆ³Ç‚É‚¨‚¯‚錌’†25-ƒqƒhƒƒLƒVƒrƒ^ƒ~ƒ“D3‚Ì•]‰¿. ‘æ59‰ñ“ú–{—Õ°ŒŸ¸ˆãŠw‰ïŠwpW‰ï, 2012, 11, 29 -12, 2, ‹ž“s.
  23. ‹v•Û“c’q”ü–, —ÑŽj˜N, ã–ì’q_–, –ìŽè—Ç„, mˆäŒ©‰pŽ÷, –k“‡ŒM:“–‰@6”NŠÔ‚É‚¨‚¯‚é׋۫ŠáŠ´õÇ‚ÌŒŸo‹Û“®Œü’²¸|ŒŸ¸Žº‚ÌŽ‹“_‚©‚ç|. ‘æ59‰ñ“ú–{—Õ°ŒŸ¸ˆãŠw‰ïŠwpW‰ï, 2012, 11, 29 -12, 2, ‹ž“s.
  24. Œ´“cŒ’‰E–, ã–ì’q_–, mˆäŒ©‰pŽ÷, ŽRé´“ñ, –k“‡ŒM:V‹KHMBSˆâ“`Žq•ÏˆÙ‚ð”F‚ß‚½‹}«ŠÔŒ‡«ƒ|ƒ‹ƒtƒBƒŠƒ“ǂ̈ê—á. ‘æ59‰ñ“ú–{—Õ°ŒŸ¸ˆãŠw‰ïŠwpW‰ï, 2012, 11, 29 -12, 2, ‹ž“s.
  25. ‘ê˜e³‹M–, ŽR‰º•ô–, ŒKŒ´‘ì”ü, ‰FŽ¡‹`‘¥, –k“‡ŒM:‘½€–ÚŽ©“®ŒŒ‹…•ªÍ‘•’uXN-9000 ‚ÌŠî–{«”\‚Æ‹Æ–±Œø—¦‚Ì•]‰¿. “ú–{—Õ°ŒŸ¸Ž©“®‰»Šw‰ï‘æ44‰ñ‘å‰ï, 2012, 10, 11-13, ‰¡•l.
  26. ì“Y—F‹I–, ‹g“c‘, ã–ì‹œ•q, •Ê•{GK, –k“‡ŒM:ƒgƒƒ“ƒrƒ“‚É‚æ‚é‘gDˆöŽq‚¨‚æ‚уvƒ‰ƒXƒ~ƒm[ƒQƒ“ƒAƒNƒ`ƒx[ƒ^ƒCƒ“ƒqƒrƒ^[1 ‚Ì”­Œ»‹@\‚̉ðÍ|NF-κB ‚ÆTGF-βƒVƒOƒiƒ‹‚Ì–ðŠ„. ‘æ85‰ñ“ú–{¶‰»Šw‰ï‘å‰ï, 2012, 12, 15-16, •Ÿ‰ª.
  27. ŽRŠÝ“ÞX–, Έä², •Ê•{GK, –k“‡ŒM:BMPR2 •ÏˆÙŠÔŽ¿×–E‚É‚¨‚¯‚éNF-κB Šˆ«‰»˜´i‚ÆCD34”­Œ»—U“±. ‘æ85‰ñ“ú–{¶‰»Šw‰ï‘å‰ï, 2012, 12, 15-16, •Ÿ‰ª.

‚»‚Ì‘¼

  1. –k“‡ŒM, •½–ìPŽ¡, ’J‚Ý‚ËŽq, “c’†k‘¾˜Y:”][Ç‹}«Šú‚É‚¨‚¯‚é‹ÃŒÅ•ªŽqƒ}[ƒJ[‚Ì•aŒ^•Ê‰ðÍ. ‘æ11‰ñTTMƒtƒH[ƒ‰ƒ€‹L˜^, 103-110, 2012.
  2. –k“‡ŒM, –îâ³O, ¼–{’¼Ž÷:ƒvƒ‰ƒUƒLƒT‚ð“K³‚ÉŽg—p‚·‚邽‚ß‚É•K—v‚È‚±‚Æ‚ðl‚¦‚é. Medical Tribune, 2012”N7ŒŽ26“ú†.
  3. ‰FŽ¡‹`‘¥:‘ª’è‚Ì•sŠm‚©‚³‚ƃgƒŒ[ƒTƒrƒŠƒeƒB. (à)VŠƒŒ§—\–hˆãŠw‹¦‰ïƒZƒ~ƒi[, 2012, 1, 6, VŠƒ. iµãÙu‰‰j
  4. ‰FŽ¡‹`‘¥:ISO15189 ”F’èŽæ“¾‚ÌŽÀÛ. “Œ‹žŽœŒb‰ïˆã‰È‘åŠwE—Õ°ŒŸ¸ˆãŠwƒZƒ~ƒi[, 2012, 9, 25, “Œ‹ž. iµãÙu‰‰j
  5. Niimi H., and Kitajima I. :Method for identifying pathogenic microorganisms responsible for infection by extracting the DNA of a microorganism. United States Patent, Patent NO. US8, 323, 898 B2, Date of patent:12, 4, 2012.
  6. ‰FŽ¡‹`‘¥, –k“‡ŒMi•Òj:‘æ23‰ñ“ú–{—Õ°‰»Šw‰ï“ŒŠC–k—¤Žx•”E‘æ31‰ñ“ú–{—Õ°ŒŸ¸ˆãŠw‰ï“ŒŠC–k—¤Žx•”—á‰ï˜A‡‘å‰ï ´˜^W, •xŽR, 2012.

ƒy[ƒW‚Ì擪‚Ö–ß‚é

2011”N

Œ´’˜

  1. Niimi H., Mori M., Tabata H., Minami H., Ueno T*., Hayashi S.and Kitajima I.: A novel geukaryote-madeh thermo stable DNA polymerase which is free from bacterial DNA contamination. Journal of Clinical Microbiology,49(9): 3316-3320, 2011. PMID:21775543
  2. ‘ê˜e³‹M*, ‰FŽ¡‹`‘¥, –k“‡ŒM:¬Ž™S•s‘SŠ³ŽÒ‚É‚¨‚¯‚錌´BNP, ŒŒŸ÷NT-ProBNP ‚Ì•]‰¿. ¶•¨ŽŽ—¿•ªÍ, 34i4j:287-292, 2011.

Ç—á•ñ

  1. Takano A., Niimi H., Atarashi Y., Sawasaki T., Terasaki T., Nakabayashi T., Kitajima I., Tobe K., and Takahara T. :A novel Y231del mutation of HFE in hereditary hemochromatosis provides in vivo evidence that the Huh-7 is a human haemochromatotic cell line. Liver International, 31(10): 1593-1594, 2011.

Šw‰ï•ñ

  1. Kitajima I., Yoshioka K., Kabata T., Tani M., Tomita K., and Uji Y. :Rapid change of the finbrin monomer complex level during the perioperative period for early diagnosis of venous thrombolism. 21st Internatinal Congress of Clinical Chemistry and Laboratory Medicine. 2011, 5, 15-19, Berlin, Germany.
  2. Kitajima I., Harada K. *, Tomoda F., Kagitani S., Koike T., and Inoue H. :NF-κB activity in the peripheral blood lymphocytes correlates with metabolic syndrome-related biomarkers in patients with essential hypertension. 2011 American Society for Clinical Pathology Annual Meeting/WASPaLM XXVI Wordld Cobgress, 2011, 10, 19-23, Las Vegas, USA.
  3. Kitajima I., Beppu H., Nogami T., Shoda N., and Fukunaga K. :Reduced expression of the ATRX gene, A chromatin-remodeling factor, causes abnormal behaviors and learning impairment. XXth World Congress of Neurology, 2011, 11, 12-17, Marrakesh, Morocco.
  4. Uji Y., Takiwaki M. *, Yoshida C. *, Niimi H., Motomiya Y., Ando Y., and Kitajima I. :Beta-2 microglobulin intermediate in serum by capillary electrophoresis. 21st International Congress of Clinical Chemistry and Laboratory Medicine. 2011, 5, 15-19, Berlin, Germany.
  5. Takiwaki M*., Uji Y., Yoshida C*., Niimi H., and Kitajima I. :Plasma B-trype natriuremic peptide (BNP) and serum N-terminal pro-BNP (NTP-BNP) and LVEF levels with heart failure children. 21st International Congress of Clinical Chemistry and Laboratory Medicine. 2011, 5, 15-19, Berlin, Germany.
  6. Niimi H., Mori M., Minami H., Ueno T. *, Hayashi S., and Kitajima I. :Highly sensitive detection of bacteria using novel geukaryote-madeh Taq polymerase. 21st International Congress of Clinical Chemistry and Laboratory Medicine. 2011, 5, 15-19, Berlin, Germany.
  7. Sakata Y., Mimuro J., Takahashi H., Tshuji H., Eguchi Y., Kitajima I., Matsushita T., and Kuroda T. :Post-marketing surveillance of the safety and effectiveness of thrombomodulin alfa in Japanease patients with DIC. XXIII Congress of the International Society of Thrombosis and Haemostasis. 2011, 7, 26, Kyoto, Japan.
  8. Takiwaki M*., Uji Y., Ueno T. *, Niimi H., and Kitajima I. :Evaluation of HBs antigen enzyme immunoassay for chronic hepatitis B patients, 2011 Annual meeting of American Association for Clinical Chemistry, 2011, 7, 24-28, Atlanta, USA.
  9. Œ´“cŒ’‰E*, •Ê•{GK, mˆäŒ©‰pŽ÷, ˆ¢•”Ž Ž÷, ‰H–ì—zŽq, ŽRŒ`_ˆê, –k“‡ŒM:ŒuŒõ‘ŠŠÖ•ªŒõ–@‚ð—p‚¢‚½¶‘ÌŽŽ—¿’†‚Ì“]ŽÊˆöŽqNF-κB ‘ª’è–@‚ÌŠJ”­. ‘æ21‰ñ¶•¨ŽŽ—¿•ªÍ‰»Šw”NŽŸŠwpW‰ï, 2011, 2, 19, ¼ŽR.
  10. ‘ê˜e³‹M*, ‰FŽ¡‹`‘¥, mˆäŒ©‰pŽ÷, –k“‡ŒM:BNP, NT-proBNP, ¬Ž™S•s‘SŠ³ŽÒ‚ɂ‚¢‚Ä‚Ì•]‰¿. ‘æ21‰ñ¶•¨ŽŽ—¿•ªÍ‰»Šw”NŽŸŠwpW‰ï, 2011, 2, 19, ¼ŽR.
  11. –k“‡ŒM, ’J‚Ý‚ËŽq, •½–ìPŽ¡, “c’†k‘¾˜Y:”][Ç‹}«Šú‚É‚¨‚¯‚é•aŒ^•Ê‰ðÍ. ‘æ11‰ñTTM ƒtƒH[ƒ‰ƒ€, 2011, 3, 5, “Œ‹ž.
  12. ‘ê˜e³‹M*, ã–ì’q_*, ‰FŽ¡‹`‘¥, mˆäŒ©‰pŽ÷, –k“‡ŒM:‰»Šw”­Œõ–Ɖu‘ª’è–@‚É‚æ‚éHBsRŒ´‘ª’è‚ÌŠî‘b“IŒŸ“¢. ‘æ50‰ñ“ú–{—Õ°ŒŸ¸Šw‰ï“ŒŠCE–k—¤Žx•”‘‰ï ‘æ322‰ñ“ú–{—Õ°‰»Šw‰ï“ŒŠCE–k—¤Žx•”—á‰ï˜A‡‘å‰ï, 2011, 3, 13, ‹à‘ò.
  13. mˆäŒ©‰pŽ÷, X³”V, ‘½—t“c—_, “ì—m, ã–ì’q_*, —ÑŽj˜N, –k“‡ŒM:eukaryote-made Taq polymerase ‚ÌŠJ”­‚É‚æ‚é‚Š´“x‚ȃoƒNƒeƒŠƒAŒŸo–@. ‘æ322‰ñ“ú–{—Õ°‰»Šw‰ï“ŒŠCE–k—¤Žx•”—á‰ï˜A‡‘å‰ï, 2011, 3, 13, ‹à‘ò.
  14. Žsì‹v”ü, ‹Ÿ“c•¶G, œA£‰ë‘ã, —«˜aK, ‘匴–ƒˆßŽq, ŽRèGŒ›, ’†ì‘׎O, ¬’r‹Î, Œ®’J‘Žu, ˆä㔎, –k“‡ŒM, ‰FŽ¡‹`‘¥, ›Œ´G•ä, ‰¡“c—Í:β2-ƒ~ƒNƒƒOƒƒuƒŠƒ“•ª‰æ‚Ì“§Íœ‹Ž”\:ƒ|ƒŠƒXƒ‹ƒtƒHƒ“iPSj–Œ‚ƃ|ƒŠƒG[ƒeƒ‹–Œ(PES)–Œ‚Æ‚Ì·ˆÙ. ‘æ56‰ñ“ú–{“§ÍˆãŠw‰ïŠwpW‰ï, 2011, 6, 18, ‰¡•l.
  15. ‹g“cç»*, Œ´“cŒ’‰E*, •ÐÀ»Žq, 쓇–ÒŽu, œA£‰ë‘ã, ‹Ÿ“c•¶G, ‰FŽ¡‹`‘¥, –k“‡ŒM:Endo-PAT2000 ‚¨‚æ‚щü—ÇŒ^ŒŒŠÇ‰ð̓VƒXƒeƒ€PRAS‚Ì•]‰¿. ‘æ22‰ñ“ú–{—Õ°‰»Šw‰ï“ŒŠC–k—¤Žx•”‘‰ï, ‘æ30‰ñ“ú–{—Õ°ŒŸ¸ˆãŠw‰ï“ŒŠC–k—¤Žx•”—á‰ï, 2011, 8, 6, –¼ŒÃ‰®.
  16. ‘ê˜e³‹M*, ã–ì’q_*, ‰FŽ¡‹`‘¥, mˆäŒ©‰pŽ÷, –k“‡ŒM:HBsRŒ´’è—Ê‘ª’è‚ÌŠî‘b“IŒŸ“¢‚Æ—Õ°•]‰¿, ‘æ51‰ñ“ú–{—Õ°‰»Šw‰ï”NŽŸŠwpW‰ï, 2011, 8, 26, ŽD–y.
  17. mˆäŒ©‰pŽ÷, ã–ì’q_*, —ÑŽj˜N, X³”V, ‘½—t“c—_, “ì—m, ‰FŽ¡‹`‘¥, –k“‡ŒM:"eukaryote-made" Taq polymerase ‚ð—p‚¢‚½‚Š´“xEv‘¬‚ÈŠ´õÇ‹Nˆö‹Û“¯’èƒVƒXƒeƒ€‚Ì\’z. ‘æ51‰ñ“ú–{—Õ°‰»Šw‰ï”NŽŸŠwpW‰ï, 2011, 8, 26, ŽD–y.
  18. ˆÀ–{—R‰À, X‰º‰p—Žq, ŠÖ’J‹ÅŽq, ŠÛŽRŒbŽq, ’‡—ёבã, mˆäŒ©‰pŽ÷, –k“‡ŒM, ’©‘q‰pô, ‘å’|–ÎŽ÷, ’†”öáÁ“ñ:[•”Ö¬ŒŒðÇ‚ð”­Ç‚µ‚½æ“V«‘æ‡XˆöŽqiFVjŒ‡–Rǂ̈ê—á. ‘æ36‰ñ–k—¤—Õ°•a—W’k‰ï, 2011, 9, 10, ‹à‘ò.
  19. ‘ê˜e³‹M*, ‰FŽ¡‹`‘¥, ‹g“cç», ‹Ÿ“c•¶G, –{‹{‘P‰ø, mˆäŒ©‰pŽ÷, –k“‡ŒM:β2-ƒ~ƒNƒƒOƒƒuƒŠƒ“’†ŠÔ‘Ì‚Ì“§Í‚É‚æ‚霋Ž”\‚ɂ‚¢‚Ä. ‘æ36‰ñ–k—¤—Õ°•a—W’k‰ï, 2011, 9, 10, ‹à‘ò.
  20. ã–ì’q_*, mˆäŒ©‰pŽ÷, —ÑŽj˜N, –ìŽè—Ç„, ‰FŽ¡‹`‘¥, –k“‡ŒM:v‘¬‚È”sŒŒÇ‹Nˆö‹Û“¯’èƒVƒXƒeƒ€‚Ì\’z‚ƳŠm«‚Ì•]‰¿. ‘æ36‰ñ–k—¤—Õ°•a—W’k‰ï, 2011, 9, 10, ‹à‘ò.
  21. ‘ê˜e³‹M*, ã–ì’q_*, ‰FŽ¡‹`‘¥, mˆäŒ©‰pŽ÷, –k“‡ŒM:–«BŒ^ŠÌ‰ŠŠ³ŽÒ‚É‚¨‚¯‚éHBsRŒ´’è—Ê‚Ì•]‰¿. “ú–{—ÕଌŸ¸Ž©“®‰»Šw‰ï‘æ43‰ñ‘å‰ï, 2011, 10, 8, ‰¡•l.
  22. ‰FŽ¡‹`‘¥:ˆã—ÃŒ»ê‚̃j[ƒY‚ɉž‚¦‚錤‹†‚Æ’mŽ¯‚ðŠˆ—p‚Å‚«‚鋳ˆçhV‚µ‚¢—Õ°ŒŸ¸–@‚ÌŠJ”­‚ƈã—ÂւÌvŒ£h. ‹ãB‘åŠw •ÛŒ’ŠwŒ¤‹†‰@ƒZƒ~ƒi[ 2011, 10, 24, •Ÿ‰ª.
  23. mˆäŒ©‰pŽ÷, ã–ì’q_*, —ÑŽj˜N, –ìŽè—Ç„, ‰FŽ¡‹`‘¥, –k“‡ŒM:eukaryote-made Taq polymerase ‚ð—p‚¢‚½³Šm‚Åv‘¬‚ÈŠ´õÇ‹Nˆö‹Û“¯’èƒVƒXƒeƒ€‚Ì\’z. ‘æ58‰ñ“ú–{—Õ°ŒŸ¸ˆãŠw‰ïŠwpW‰ï, 2011,11,18, ‰ªŽR.
  24. ã–ì’q_*, mˆäŒ©‰pŽ÷, —ÑŽj˜N, –ìŽè—Ç„, ‰FŽ¡‹`‘¥, –k“‡ŒM:v‘¬‚È”sŒŒÇ‹Nˆö‹Û“¯’èƒVƒXƒeƒ€‚Ì\’z‚ƳŠm«‚Ì•]‰¿. ‘æ58‰ñ“ú–{—Õ°ŒŸ¸ˆãŠw‰ïŠwpW‰ï, 2011, 11, 18, ‰ªŽR.
  25. ‘ê˜e³‹M*, ‰FŽ¡‹`‘¥, ‹g“cç», ‹Ÿ“c•¶G, –{‹{‘P‰ø, mˆäŒ©‰pŽ÷, –k“‡ŒM:β2-ƒ~ƒNƒƒuƒƒOƒŠƒ“•ª‰æ‚Ì“§Í‚É‚æ‚霋Ž”\‚ɂ‚¢‚Ä‚ÌŒŸ“¢. ‘æ58‰ñ“ú–{—Õ°ŒŸ¸ˆãŠw‰ïŠwpW‰ï, 2011,11,18, ‰ªŽR.
  26. ‹ß“¡ , mˆäŒ©‰pŽ÷, –k“‡ŒM:Huh-7‚ð—p‚¢‚½ƒwƒ‚ƒNƒƒ}ƒg[ƒVƒX•a‘ÔƒƒJƒjƒYƒ€‚̉ðÍ\Hepcidin ”­Œ»ˆÙí‚ÉŠÖ‚·‚ékey mediator ‚Ì’Tõ\. ‘æ58‰ñ“ú–{—Õ°ŒŸ¸ˆãŠw‰ïŠwpW‰ï, 2011,11,18, ‰ªŽR.
  27. ŒKŒ´‘ì”ü, ŽÄ‘¥Žq, ×’JFŽq, ‰FŽ¡‹`‘¥, –k“‡ŒM:XN-9000Šî‘bŒŸ“¢, ‰^—p—á. •xŽRŒ§—Õ°ŒŸ¸‹ZŽt‰ïŒŒ‰tŒŸ¸Œ¤‹†”ǃZƒ~ƒi[, 2011, 12, 12, •xŽR.

‚»‚Ì‘¼

  1. ‰FŽ¡‹`‘¥:ÅVˆã—Ã’T–K\¢ŠEÅ‚…€‚ÌŒŸ¸‚ð–ÚŽw‚·\. •xŽR‘åŠw•‘®•a‰@‚¾‚æ‚è ‚©‚í‚ç”Å, 116:8-9, 2011.
  2. –ìŽè—Ç„, ‹v•Û“c’q”ü*, ŠÖŒûŒh•¶*:ƒCƒ“ƒXƒgƒ‰ƒNƒ^[, ‘æ2‰ñ“h–•‹¾ŒŸƒXƒLƒ‹ƒgƒ‰ƒ“ƒXƒtƒ@[ in •xŽR, 2011, 12, 11, •xŽR.

ƒy[ƒW‚Ì擪‚Ö–ß‚é

2010”N

’˜‘

  1. Œ´“cŒ’‰E, –k“‡ŒM:ƒoƒCƒ^ƒ‹ˆÙíE‹}•ÏEME‹@Ší‚ł̃Aƒ‰[ƒ€ƒTƒCƒ“‚̃Aƒvƒ[ƒ`. ‹Ù‹}Ž¡—Âð—v‚·‚鎾Š³‚Ì•a‘Ô¶—‚Æ–ò•¨Ž¡—Ã. i¬–쎛Œ›Ž¡•Òj, –òŽ–“ú•ñŽÐi“Œ‹žjp1-186, 2010.

Œ´’˜

  1. Nogami T., Beppu H., Tokoro T., Moriguchi S., Shioda N., Fukunaga K., Ohtsuka T., Ishii Y., Sasahara M., Shimada Y., Nishijo H., Li E., Kitajima I.:Reduced expression of the ATRX gene, a chromatin-remodeling factor, causes hippocampal dysfunction in mice. Hippocampus; 21(6):678-87, 2011.PMID:20865721
  2. Yoshioka K., Kitajima I., Kabata T., Tani M., Kawahara N., Murakami H., Demura S., Tsubokawa T., Tomita K.:Venous thromboembolism after spinal surgery: Changes of the fibrin monomer complex and D-dimer level during the perioperative period. Journal of Neurosurgery. Spine, 13(5):594-599, 2010.PMID:21039150
  3. Shioda N., Beppu H., Fukuda T., Li E., Kitajima I., Fukunaga K.:Aberrant Calcium/Calmodulin-Dependent Protein Kinase II (CaMKII) Activity Is Associated with Abnormal Dendritic Spine Morphology in the ATRX Mutant Mouse Brain. J Neurosci., 31(1): 346-58, 2011.PMID:21209221
  4. mˆäŒ©‰pŽ÷, ”öì’q”ü, –ìŽè—Ç„, —ÑŽj˜N, ã–ì’q_, Œ´“cŒ’‰E, ‰FŽ¡‹`‘¥, –k“‡ŒM:ˆâ“`ŽqŒŸ¸Žº‚É‚¨‚¯‚éƒXƒvƒ‰ƒCƒVƒ“ƒOˆÙí‚̈â“`Žqf’f|ƒsƒbƒgƒtƒH[ƒ‹‚ƃAƒvƒ[ƒ`•û–@|. —Õ°•a—58:1162-1168, 2010.PMID:21348235

‘à

  1. –k“‡ŒM:DICf’f‚Ì‚½‚ß‚ÌV‹Kƒ}[ƒJ[‚Æ‚»‚Ì•]‰¿. ŒŒð‚ÆzŠÂ17 (4):30-35, 2009.
  2. –k“‡ŒM:IŒ^ƒvƒƒRƒ‰[ƒQƒ“C––’[ƒvƒƒyƒvƒ`ƒhiPICPj, IŒ^ƒRƒ‰[ƒQƒ“C––’[ƒeƒƒyƒvƒ`ƒhiICTPj. “ú–{—Õà¬. L”͈͌Œ‰tE”A‰»ŠwŒŸ¸–ƉuŠw“IŒŸ¸2: 252-255, 2010.
  3. –k“‡ŒM:“®‚«Žn‚ß‚½‚킪‘‚̃tƒ@[ƒ}ƒRƒQƒmƒ~ƒNƒX. —Õ°ŒŸ¸54i10j: 1105-1106, 2010.
  4. •Ê•{GK:BMPƒVƒOƒiƒ‹“`’BˆÙí‚ÆŽ¾Š³. ŽÀŒ±ˆãŠw28i4j:888-893, 2010.

Šw‰ï•ñ

  1. Kitajima I.:Anti-inflammatory effect of pitavastatin on NF-κB activated by TNF-alfa through Rho kinase pathway in breast cancer cells. Keystone Symposia 2010 NF-kappa B in inflammation and Disease, 2010, 1, 5-10, Santa Fe, USA.
  2. Kitajima I., Tani M., Uji Y., Yoshioka K., Kabara T.:Elevated levels of the fibrin monomer compex and D-dimer indicate high risk of venous thromboembolism after spinal surgery. 2010 AACC (American Association for Clinical Chemistry) Annual Meetin, 2010, 7, 25-29, Anaheim, CA, USA.
  3. Uji Y., Takiwaki M., Ueno T., Taga Y., Shiba N., Yoshida C., Kuwabara T., Niimi H., Kitajima I.:Plasma B-type natiuremic peptide (BNP) and serum N-terminal-proBNP (NTpBNP) levels with heart faifure children. 2010 AACC (American Association for Clinical Chemistry) Annual Meetin, 2010, 7, 25-29, Anaheim, CA, USA.
  4. Harada K., Kitajima I.:Nuclear factor-kappa B activity correlates with metabolic syndrome-related biomerkers in patients with essential hypertension. 2010 AACC (American Association for Clinical Chemistry) Annual Meetin, 2010, 7, 25-29, Anaheim, CA, USA.
  5. Niimi H., Takano A., Takahara T., Kitajima I.:A HEF-mutated hemochoromatotic cell line, which suggests the mechanism hepcidine expression rehulated by HEF-BMP-6-Samd pathway. Annual TGF-β meeting, 2010, 9, 3 Leiden, The Netherland.
  6. Beppu H., Leyton P., Liu R., and Bloch K. D.:BMP7 induces enhanced Smad1/5/8 phosphorylationin BMPR2 tail domain-deficient cells. TGF-β meeting, 2010, 9, 1-3, Leiden.
  7. Beppu H.:BMPR2-deficiency causes abnormal cell proliferation in cardiovascular and intestinal tracts. The 59th Fujihara Seminar, Molecular Mechanisms of TGF-beta signaling and disease, 2010, 7, 14-17, Hokkaido.(Invited lecture)
  8. –k“‡ŒM:V‚µ‚¢“®–¬d‰»ŒŸ¸–@‚ÌŠJ”­. •½¬21”N“x‘—§‘åŠw–@l•‘®•a‰@‹ZŽt‰ïŒ¤C‰ï, 2010, 2, 5, •xŽR
  9. –k“‡ŒM:“®–¬d‰»ŒŸ¸‚Ìup to date. ‘æ23‰ñ’†•”’n‹æ¶—ŒŸ¸Œ¤C‰ï, 2010, 2, 27, •xŽR
  10. –k“‡ŒM, •Ê•{GK, –ìã’B–ç, Έä—zŽq, ùŒ´³´, XŒû–ÎŽ÷, ‰–“c—ÏŽj, •Ÿ‰i_Ži, ¼ðŽõ•v:ƒNƒƒ}ƒ`ƒ“ƒŠƒ‚ƒfƒŠƒ“ƒOˆöŽqATRX’`”’”­Œ»’ቺƒ}ƒEƒX‚ÌŠC”nEG“‘Ì‹@”\ˆÙí‚Æ‚»‚Ì•ªŽq‹@\. í—ª“I‘n‘¢Œ¤‹†Ž–‹Æ„iŽ–‹ÆiCRESTju”]‚Ì‹@”\”­’B‚ÆŠwKƒƒJƒjƒYƒ€‚̉ð–¾v‘æ7‰ñ—̈æ“àŒ¤‹†‰ï, 2010, 3, 1, ‘åã.
  11. –k“‡ŒM:V‹KŒŒŠÇ‹@”\ŒŸ¸–@ŠJ”­‚É‚æ‚錌ŠÇƒGƒCƒWƒ“ƒO‚̉Ȋw“I•]‰¿‚Æ—Õ°‰ž—p. ‘æ4‰ñ–¢•a—\–hƒVƒXƒeƒ€Œ¤‹†‰ï, •½¬21”N“x’m“IƒNƒ‰ƒXƒ^[’nˆæƒvƒƒWƒFƒNƒgŽ–‹Æ, 2010, 3, 4, •xŽR.
  12. Œ´“cŒ’‰E, ‹Ÿ“c•¶G, Œ®’J‘Žu, ¬’r‹Î, ˆä㔎, –k“‡ŒM:“]ŽÊˆöŽqNF-κBŠˆ«‰»‚ª‚ŒŒˆ³‚É‹y‚Ô‚·‰e‹¿‚Æ‚»‚Ì‹K’èˆöŽq‚Ì—Õ°“IˆÓ‹`. ‘æ49‰ñ“ú–{—Õ°ŒŸ¸Šw‰ï“ŒŠC–k—¤Žx•”‘‰ïE‘æ320‰ñ“ú–{—Õ°‰»Šw‰ï“ŒŠC–k—¤Žx•”—á‰ï, 2010, 3, 14, –¼ŒÃ‰®.
  13. ã–ì’q_, –ìŽè—Ç„, mˆäŒ©‰pŽ÷, ‰FŽ¡‹`‘¥, –k“‡ŒM:Staphylococcus aureus‚Ì‹Û‘ÌŠO“Å‘f‚ÉŠÖ‚·‚錟“¢. ‘æ49‰ñ“ú–{—Õ°ŒŸ¸Šw‰ï“ŒŠC–k—¤Žx•”‘‰ïE‘æ320‰ñ“ú–{—Õ°‰»Šw‰ï“ŒŠC–k—¤Žx•”—á‰ï, 2010, 3, 14, –¼ŒÃ‰®.
  14. Œ´“cŒ’‰E, ‹Ÿ“c•¶G, Œ®’J‘Žu, ¬’r ‹Î, ˆä㔎, –k“‡ŒM:–¢Ž¡—Ö{‘Ô«‚ŒŒˆ³Š³ŽÒ‚É‚¨‚¯‚é“]ŽÊˆöŽqNF-κB‚ÌŠˆ«‰»‚Æ‚»‚Ì‹@˜. ‘æ107‰ñ“à‰ÈŠw‰ï‘‰ï, 2010, 4, 10, “Œ‹ž.
  15. Œ´“cŒ’‰E, mˆäŒ©‰pŽ÷, î’J»Žq, ‰FŽ¡‹`‘¥, –k“‡ŒM:æ“V«‘æVˆöŽqŒ‡‘¹ÇiPhe160Serj‚É‚¨‚¯‚镪Žq•a‘Ô‰ðÍ. ‘æ33‰ñ“ú–{ŒŒðŽ~ŒŒŠw‰ïŠwpW‰ï, 2010, 4, 22, Ž­Ž™“‡.
  16. mˆäŒ©‰pŽ÷, –k“‡ŒM:æ“V«ƒAƒ“ƒ`ƒgƒƒ“ƒrƒ“Œ‡–Rǂ̈â“`Žq‰ðÍ. ‘æ33‰ñ“ú–{ŒŒðŽ~ŒŒŠw‰ïŠwpW‰ï, 2010, 4, 22, Ž­Ž™“‡.
  17. –k“‡ŒM:αƒTƒ‰ƒZƒ~ƒAE¸_’x‘ØÇŒóŒQƒ‚ƒfƒ‹ƒ}ƒEƒX‚Í, •¶–¬‹L‰¯”\—͂̒ቺ‚ðŽ¦‚·. ‘æ51‰ñ“ú–{_ŒoŠw‰ï‘‰ï, 2010, 5, 20, “Œ‹ž.
  18. mˆäŒ©‰pŽ÷, –ìŽè—Ç„, ã–ì’q_, ‰FŽ¡‹`‘¥, –k“‡ŒM:Staphylococcus aureus‚Ì‹Û‘ÌŠO“Å‘fŽY¶‚ÉŠÖ‚·‚錟“¢. ‘æ17‰ñ“ú–{ˆâ“`Žqf—Êw‰ï‘å‰ï, 2010, 8, 7, ŽOd.
  19. ‘ê˜e³‹M, “ú‚GÆ, ‰FŽ¡‹`‘¥, –k“‡ŒM:Ž¿—Ê•ªÍ‚ð—p‚¢‚½ƒRƒŒƒXƒeƒ[ƒ‹ƒGƒXƒeƒ‰[ƒ[‚̃Šƒ“Ž‰Ž¿•ª‰æ‚ÉŠÖ‚·‚锽‰ž«‚ÌŒŸ“¢. ‘æ21‰ñ“ú–{—Õ°‰»Šw‰ï“ŒŠC–k—¤Žx•”‘‰ïE‘æ29‰ñ“ú–{—Õ°ŒŸ¸ˆãŠw‰ï“ŒŠC–k—¤Žx•”—á‰ï˜A‡‘å‰ï, 2010, 8, 28, •Ÿˆä.
  20. ‹g“cç», Œ´“cŒ’‰E, î’J»Žq, 쓇–ÒŽu, œA£‰ë‘ã, ‹Ÿ“c•¶G, ‰FŽ¡‹`‘¥, –k“‡ŒM:¶‘ÌŒŒŠÇ‹@”\‚𔽉f‚·‚éEndo-PAT2000‚Ì«”\•]‰¿‚ÆŒŸ¸¸“xŒüã‚ÉŒü‚¯‚½ŒŸ“¢. ‘æ21‰ñ“ú–{—Õ°‰»Šw‰ï“ŒŠC–k—¤Žx•”‘‰ïE‘æ29‰ñ“ú–{—Õ°ŒŸ¸ˆãŠw‰ï“ŒŠC–k—¤Žx•”—á‰ï˜A‡‘å‰ï, 2010, 8, 28, •Ÿˆä.
  21. –k“‡ŒM:POCT‚Ìl‚¦•û‚Æ‚»‚ÌŠˆ—p–@‚𓱓ü‚µ‚½ŒŸ¸•”ŽÀK‚ÌŽæ‚è‘g‚Ý. ‘æ57‰ñ“ú–{—Õ°ŒŸ¸ˆãŠw‰ïŠwpW‰ï, 2010, 9, 10, “Œ‹ž.
  22. –k“‡ŒM:X˜A½αƒTƒ‰ƒZƒ~ƒAE¸_’x‘ØÇŒóŒQ‚ð—‰ð‚·‚邽‚߂ɃlƒYƒ~‚ðŽg‚Á‚½Œ¤‹†. ‘æ2‰ñX˜A½αƒTƒ‰ƒZƒ~ƒAE¸_’x‘ØÇŒóŒQiATR-XÇŒóŒQjŠ³ŽÒ•×‹­‰ï, 2010, 9, 18, ‰¡•l.
  23. –k“‡ŒM:NF-κB‚©‚çŽa‚éŠàE‰ŠÇ«Ž¾Š³E¶ŠˆKŠµ•a‚Ì•ªŽq•a‘Ô‰ðÍ. ‘æ50‰ñ“ú–{—Õ°‰»Šw”NŽŸŠwpW‰ï, 2010, 9, 25, ŽR—œ.
  24. –k“‡ŒM:ŒŒðÇ‘Šú”­Œ©‚ÖŒü‚¯‚½ƒ‚ƒjƒ^ƒŠƒ“ƒO. “ú–{—Õ°ŒŸ¸Ž©“®‰»Šw‰ï‘æ42‰ñ‘å‰ï, 2010, 10, 9, _ŒË.
  25. –k“‡ŒM:DIC‚Ì•a‘ÔEf’fEŽ¡—Ã\•ªŽqƒ}[ƒJ[‚©‚ç‚Ì’ñŒ¾\. “ú–{—Õ°ŒŸ¸Ž©“®‰»Šw‰ï‘æ42‰ñ‘å‰ï, 2010, 10, 9, _ŒË.
  26. mˆäŒ©‰pŽ÷, ‰FŽ¡‹`‘¥, –k“‡ŒM:ŠÖ߃ŠƒEƒ}ƒ`‚Ì•a‘ÔƒƒJƒjƒYƒ€‚É‚¨‚¯‚éE1AF‚Ì‹@”\‰ðÍ. ‘æ57‰ñ“ú–{—Õ°ŒŸ¸ˆãŠw‰ïŠwpW‰ï, 2010, 9, 11, “Œ‹ž.
  27. mˆäŒ©‰pŽ÷, –ìŽè—Ç„, ‰FŽ¡‹`‘¥:HFEˆâ“`Žq‚ɕψقð”F‚ß‚½ˆâ“`«ƒwƒ‚ƒNƒƒ}ƒg[ƒVƒXÇ—á‚É‚¨‚¯‚é•a‘ÔƒƒJƒjƒYƒ€‚̉ðÍ. ‘æ57‰ñ“ú–{—Õ°ŒŸ¸ˆãŠw‰ïŠwpW‰ï, 2010, 9, 11, “Œ‹ž.
  28. Œ´“cŒ’‰E, ‹Ÿ“c•¶G, Œ®’J‘Žu, ¬’r‹Î, ˆä㔎, –k“‡ŒM:ŒuŒõ‘ŠŠÖ•ªŒõ–@‚ð—p‚¢‚½“]ŽÊˆöŽqNF-κB‚ÌV‚½‚È‘ª’è–@‚ÌŠm—§‚Æ‚»‚Ì—Õ°‰ž—p. ‘æ57‰ñ“ú–{—Õ°ŒŸ¸ˆãŠw‰ïŠwpW‰ï, 2010, 9, 10, “Œ‹ž.
  29. ‘ê˜e³‹M, ã–ì’q_, ‘½‰ê—R‹IŽq, ŽÄ‘¥Žq, ‹g“cç», ŒKŒ´‘ì”ü, ‰FŽ¡‹`‘¥, mˆäŒ©‰pŽ÷, –k“‡ŒM:¬Ž™S•s‘SŠ³ŽÒ‚É‚¨‚¯‚錌Ÿ÷BNP’l, ŒŒ´NT-ProBNP’l‚Ì•]‰¿. ‘æ57‰ñ“ú–{—Õ°ŒŸ¸ˆãŠw‰ïŠwpW‰ï, 2010, 9, 12, “Œ‹ž.
  30. —ÑŽj˜N, mˆäŒ©‰pŽ÷, ã–ì’q_, â–{ƒŽq, ‹g“cˆèŽq, X“c–¢, ‰FŽ¡‹`‘¥, –k“‡ŒM:Žq‹{“àŠ´õÇ‚É‚¨‚¯‚év‘¬‚ÈŒŸ¸. f—ÃVƒXƒeƒ€‚Ì\’z. ‘æ57‰ñ“ú–{—Õ°ŒŸ¸ˆãŠw‰ïŠwpW‰ï, 2010, 9, 12, “Œ‹ž.
  31. ã–ì’q_, mˆäŒ©‰pŽ÷, —ÑŽj˜N, ‰FŽ¡‹`‘¥, –k“‡ŒM:masked primer dimer–@‚ÆŠ´õNJȈՒè—ʃVƒXƒeƒ€‚ÌŠJ”­. ‘æ57‰ñ“ú–{—Õ°ŒŸ¸ˆãŠw‰ïŠwpW‰ï, 2010, 9, 12, “Œ‹ž.
  32. —ÑŽj˜N, mˆäŒ©‰pŽ÷, ã–ì’q_, â–{ƒŽq, ‹g“cˆèŽq, X“c–¢, ‰FŽ¡‹`‘¥, –k“‡ŒM:v‘¬‚ÈR¶ÜŠ´Žó«ŒŸ¸–@‚ÌŠJ”­. ‘æ57‰ñ“ú–{—Õ°ŒŸ¸ˆãŠw‰ïŠwpW‰ï, 2010, 9, 12, “Œ‹ž.
  33. ‘ê˜e³‹M, ‰FŽ¡‹`‘¥, –k“‡ŒM, ŽR‰º•ô, ì茒Ž¡, ›–ìŒõr, “ú‚ŒbˆÈŽq, –{“cFs, “ú‚GÆ:ƒRƒŒƒXƒeƒ[ƒXƒGƒXƒeƒ‰[ƒ[ˆ—‚É‚¨‚¯‚錌´HDLŽ‰Ž¿‚Ì•ªÍ. ‘æ50‰ñ“ú–{—Õ°‰»Šw‰ï”NŽŸŠwpW‰ï, 2010, 9, 24, ŽR—œ.
  34. ‘ê˜e³‹M, ã–ì’q_, ‘½‰ê—R‹IŽq, ŽÄ‘¥Žq, ‹g“cç», ŒKŒ´‘ì”ü, ‰FŽ¡‹`‘¥, –k“‡ŒM:‘SŒŒ’†, ŒŒŸ÷’†BNP‚¨‚æ‚ÑŒŒ´’†NT-ProBNP‚Ì•]‰¿. “ú–{—Õ°ŒŸ¸Ž©“®‰»Šw‰ï‘æ42‰ñ‘å‰ï, 2010, 10, 9, _ŒË.
  35. ‹g“cç», Œ´“cŒ’‰E, î’J»Žq, 쓇–ÒŽu, œA£‰ë‘ã, ‹Ÿ“c•¶G, ‰FŽ¡‹`‘¥, –k“‡ŒM:¶‘ÌŒŒŠÇ‹@”\‚𔽉f‚·‚éEndo-PAT2000‚Ì•]‰¿‚Ƹ“xŒüã‚ð–ÚŽw‚µ‚½Ž©“®‰»‚Ö‚ÌŽæ‚è‘g‚Ý. “ú–{—Õ°ŒŸ¸Ž©“®‰»Šw‰ï‘æ42‰ñ‘å‰ï, 2010, 10, 9, _ŒË.
  36. Œ´“cŒ’‰E, •Ê•{GK, mˆäŒ©‰pŽ÷, ˆ¢•”Ž Ž÷, ‰H–ì—zŽq, ŽRŒ`_ˆê, –k“‡ŒM:ŒuŒõ‘ŠŠÖ•ªŒõ–@‚ð—p‚¢‚½¶‘ÌŽŽ—¿’†‚Ì“]ŽÊˆöŽqNF-κB‘ª’è–@‚ÌŠJ”­. “ú–{—Õ°ŒŸ¸Ž©“®‰»Šw‰ï‘æ42‰ñ‘å‰ï, 2010, 10, 9, _ŒË.
  37. ã–ì’q_, mˆäŒ©‰pŽ÷, —ÑŽj˜N, ‰FŽ¡‹`‘¥, –k“‡ŒM:masked primer dimer–@ & one step nested PCR–@‚É‚æ‚é‚Š´“xE‚“ÁˆÙ“x‚ÈŠ´õ‹ÛŠÈˆÕ’è—ʃVƒXƒeƒ€‚ÌŠJ”­. “ú–{—Õ°ŒŸ¸Ž©“®‰»Šw‰ï‘æ42‰ñ‘å‰ï, 2010, 10, 9, _ŒË.
  38. —ÑŽj˜N, mˆäŒ©‰pŽ÷, ã–ì’q_, ‰FŽ¡‹`‘¥, –k“‡ŒM:v‘¬‚ÈR¶ÜŠ´Žó«ŽŽŒ±–@‚ÌŠJ”­‚ÆŽq‹{“àŠ´õÇ‚É‚¨‚¯‚év‘¬ŒŸ¸ƒVƒXƒeƒ€‚ւ̉ž—p. “ú–{—Õ°ŒŸ¸Ž©“®‰»Šw‰ï‘æ42‰ñ‘å‰ï, 2010, 10, 9, _ŒË.
  39. mˆäŒ©‰pŽ÷, —ÑŽj˜N, ã–ì’q_, Œ´“cŒ’‰E, ‰FŽ¡‹`‘¥, –k“‡ŒM:ˆâ“`ŽqŒŸ¸Žº‚É‚¨‚¯‚éƒXƒvƒ‰ƒCƒVƒ“ƒOˆÙí‚̈â“`Žqf’f\ƒsƒbƒgƒtƒH[ƒ‹‚ƃAƒvƒ[ƒ`–@\. “ú–{—Õ°ŒŸ¸Ž©“®‰»Šw‰ï‘æ42‰ñ‘å‰ï, 2010, 10, 9, _ŒË.
  40. ¼–ìŽåáÁ, “¹–ì~Žq, ’†oË‘ã, ²’|ˆÉ’ÃŽq, “‡‹žŽq, ˆÀ‘º•q, –k“‡ŒM:“–‰@‚É‚¨‚¯‚鎞ŠÔŠO—AŒŒŒŸ¸‹Æ–±‚ÌŒ»ó‚ɂ‚¢‚Ä. “ú–{—AŒŒE×–EŽ¡—Êw‰ï‘æ28‰ñ–k—¤Žx•”—á‰ï, 2010, 10, 9, •Ÿˆä.
  41. ’†oË‘ã, ²’|ˆÉ’ÃŽq, “¹–ì~Žq, ¼–ìŽåáÁ, “‡‹žŽq, ˆÀ‘º•q, –k“‡ŒM:PBSCT‚É‚æ‚é‰@“à‚ÌCD34+×–E”‚Ì‘ª’è‚Ì•K—v«. “ú–{—AŒŒE×–EŽ¡—Êw‰ï‘æ28‰ñ–k—¤Žx•”—á‰ï, 2010, 10, 9, •Ÿˆä.
  42. ‘ê˜e³‹M, ã–ì’q_, ‘½‰ê—R‹IŽq, ŽÄ‘¥Žq, ‹g“cç», ŒKŒ´‘ì”ü, ‰FŽ¡‹`‘¥, –k“‡ŒM:¬Ž™‚É‚¨‚¯‚éBNP, NT-ProBNP‚Ì•]‰¿. ‘æ35‰ñ–k—¤—Õ°•a—W’k‰ï, 2010, 10, 16, •xŽR.
  43. mˆäŒ©‰pŽ÷, –ìŽè—Ç„, ‰FŽ¡‹`‘¥, –k“‡ŒM:HFE•ÏˆÙ‚ð”F‚ß‚½ˆâ“`«ƒwƒ‚ƒNƒƒ}ƒg[ƒVƒXÇ—á‚É‚¨‚¯‚é•a‘ÔƒƒJƒjƒYƒ€‚̉ðÍ. ‘æ35‰ñ–k—¤—Õ°•a—W’k‰ï, 2010, 10, 16, •xŽR.
  44. ”ò“c–ë”nl, [’J¹O, •U“c^‹I, ‹g‰ªŽõ—Ï, –k“‡ŒM, ˆäã‰p“ñ, “n•Ó‰ë•F, ‘å’Ë–«‹v:•½–Ê“à×–E‹É«§Œä•ªŽqPrickle‚ÍŒãƒVƒiƒvƒX”ìŒú•”‚É‹ÇÝ‚µPSD-95‚¨‚æ‚ÑNMDAŽó—e‘Ì‚Æ•¡‡‘Ì‚ðŒ`¬‚·‚é. ‘æ33‰ñ“ú–{•ªŽq¶•¨Šw‰ï”N‰ï, 2010, 12, 9, _ŒË.

‚»‚Ì‘¼

  1. ‘Û“Á‹–oŠè:k”­–¾ŽÒl‘½—t“c—_, “ì—m, mˆäŒ©‰pŽ÷, –k“‡ŒM, ã–ì’q_, —ÑŽj˜N, X³”V k”­–¾–¼Ìl‘Ï”M«DNAƒ|ƒŠƒƒ‰[ƒ[‚ðŠÜ‚Þy‘f’²®•¨‚¨‚æ‚Ñ‚»‚Ì»‘¢•û–@, •À‚Ñ‚ÉŒŸo‘ÎÛ•¨‚ÌŒŸo•û–@ k‘Û“Á‹–oŠè”Ô†lPTC/JP2010/050443 k‘ÛoŠè“úl2010”N1ŒŽ15“ú.
  2. ‘“à“Á‹–oŠè:k”­–¾ŽÒl–k“‡ŒMk”­–¾–¼ÌlŽwë–¬”g‰ðÍ‘•’u‹y‚Ñ‚±‚ê‚ð—p‚¢‚½ŒŒŠÇ“à”ç‹@”\•]‰¿ƒVƒXƒeƒ€ koŠè”Ô†l“ÁŠè2010-59907† koŠè“úl2010”N3ŒŽ16“ú.
  3. ‘“à“Á‹–Žæ“¾:k”­–¾ŽÒlmˆäŒ©‰pŽ÷, –k“‡ŒM k“Á‹–Œ ŽÒl‘—§‘åŠw–@l•xŽR‘åŠw k”­–¾–¼ÌlŠ´õÇ‹Nˆö‹Û‚Ìv‘¬“¯’è•û–@ k“Á‹–”Ô†l“Á‹–4590573†.
  4. ‘Û“Á‹–oŠè:k”­–¾ŽÒlmˆäŒ©‰pŽ÷, –k“‡ŒM k“Á‹–oŠèll•xŽR‘åŠw k”­–¾–¼ÌlŠ´õÇ‹Nˆö‹Û‚Ìv‘¬“¯’è•û–@ k”Ô†l“ÁŠè2008-501721 k”F’è“úl•½¬22”N8ŒŽ10“ú.
  5. ’J‚Ý‚ËŽq, ‹g‰ªŽl, ‰Á”¨‘½•¶, ‰FŽ¡‹`‘¥, –k“‡ŒM:Ò’ÅŽèp‚É‚¨‚¯‚éVTE”­Ç‚Æp’†, pŒã‚Ì‹ÃŒÅEü—nŒn•ªŽqƒ}[ƒJ[‚Ì•Ï“®‚̈Ӌ`. ‘æ9‰ñTTMƒtƒH[ƒ‰ƒ€‹L˜^:69-76, 2010.
  6. –k“‡ŒM:ƒvƒƒtƒFƒVƒ‡ƒiƒ‹ƒŠƒYƒ€‚Ì‹³ˆç‚ð–ÚŽw‚µ‚Ä. •xŽR‘åŠwˆãŠw•”Œã‰‡‰ï‰ï•ñ37:3, 2010.
  7. –k“‡ŒM:•½¬22”N“xˆãŠw‹³ˆçƒtƒ@ƒJƒ‹ƒeƒCEƒfƒxƒƒvƒƒ“ƒg‚Ì‚²•ñ. •xŽR‘åŠwˆãŠw•”Œã‰‡‰ï‰ï•ñ38:3-4, 2010.
  8. –k“‡ŒM:•½¬22”N“x•xŽR‘åŠwˆãŠw•”ˆãŠw‰ÈFD‚Ì‘Š‡. •½¬22”N“x•xŽR‘æŠzˆãŠw•”ˆãŠw‰ÈFD•ñ‘:1-2, 2010.

ƒy[ƒW‚Ì擪‚Ö–ß‚é

2009”N

’˜‘

  1. –k“‡ŒM:EDTA•‰‰×ŽŽŒ±. ˆãŠw‘厫“Ti‘æ2”Åj, 258, ˆãŠw‘‰@, “Œ‹ž, 2009.
  2. –k“‡ŒM:ƒJƒ‹ƒVƒEƒ€‹zŽûŽŽŒ±. ˆãŠw‘厫“Ti‘æ2”Åj, 471, ˆãŠw‘‰@, “Œ‹ž, 2009.
  3. –k“‡ŒM:tŒ´«ƒTƒCƒNƒŠƒbƒNAMP. ˆãŠw‘厫“Ti‘æ2”Åj, 1406-7, ˆãŠw‘‰@, “Œ‹ž, 2009.
  4. –k“‡ŒM:ƒrƒ^ƒ~ƒ“D ‘ª’è–@. ˆãŠw‘厫“Ti‘æ2”Åj, 2335, ˆãŠw‘‰@, “Œ‹ž, 2009.
  5. –k“‡ŒM:•›bó‘B‹@”\ŒŸ¸. ˆãŠw‘厫“Ti‘æ2”Åj, 2429, ˆãŠw‘‰@, “Œ‹ž, 2009.
  6. –k“‡ŒM:•›bó‘Bƒzƒ‹ƒ‚ƒ“ŠÖ˜A’`”’Ž¿. ˆãŠw‘厫“Ti‘æ2”Åj, 2430, ˆãŠw‘‰@, “Œ‹ž, 2009.
  7. –k“‡ŒM:•›bó‘Bƒzƒ‹ƒ‚ƒ“•‰‰×ŽŽŒ±. ˆãŠw‘厫“Ti‘æ2”Åj, 2340-1, ˆãŠw‘‰@, “Œ‹ž, 2009.
  8. –k“‡ŒM:ƒCƒ“ƒ^ƒNƒg•›bó‘Bƒzƒ‹ƒ‚ƒ“. ˆãŠw‘厫“Ti‘æ2”Åj, 180, ˆãŠw‘‰@, “Œ‹ž, 2009.
  9. –k“‡ŒM:IŒ^ƒRƒ‰[ƒQƒ“‰Ë‹´N-ƒeƒƒyƒvƒ`ƒh. ˆãŠw‘厫“Ti‘æ2”Åj, 133, ˆãŠw‘‰@, “Œ‹ž, 2009.
  10. –k“‡ŒM:β-ƒNƒƒXƒ‰ƒvƒX. ˆãŠw‘厫“Ti‘æ2”Åj, 2535, ˆãŠw‘‰@, “Œ‹ž, 2009.
  11. –k“‡ŒM:—Õ°ŒŸ¸‚ÌŒ´“_‚ÍfŽ@Žº‚É‚ ‚è. ˆã—Âð•Ï‚¦‚éŠ÷‚Ìã‚ÌŒŸ¸Žº, 14-29, •ûˆãŠw‰»ŠwŒ¤‹†Š, “Œ‹ž, 2009.

Œ´’˜

  1. Tsuboi Y, Kurimoto M, Nagai S, Hayakawa Y, Kamiyama H, Hayashi N, Kitajima I, Endo S. Induction of autophagic cell death and radiosensitization by the pharmacological inhibition of nuclear factor-kappa B actication in human glioma cell lines. J Neurosurg. 2009;110(3):594-604.
  2. Tamura N, Kitajima I, Kawamura Y, Toda E, Eguchi Y, Ishida H, Goto S. Important regulatory role of activated platelet-derived procoagulant activity in the propagation of thrombi formed under arterial blood flow conditions. Circ J. 2009;73(3):540-8.
  3. Yamamoto M, Beppu H, Takaoka K, Meno C, Li E, Miyazono K, Hamada H. Antagonism between Smad1 and Smad2 signaling determines the site of distal visceral endoderm formation in the mouse embryo. J Cell Biol. 2009;184(2):323-34.
  4. Beppu H, Malhotra R, Beppu Y, Lepore JJ, Parmacek MS, Bloch KD. BMP type II receptor regulates positioning of outflow tract and remodeling of atrioventricular cushion during cardiogenesis. Dev Biol. 2009;331(2):167-178.

Ç—á•ñ

  1. Katayama Y, Kitajima I, Niimi H, Kitahara H, Kawai H. Diagnosis of cerebral cortical vein thrombosis with T2*-weighted magnetic resonance imaging. BMJ Case Reports published online 6 Sep 2009, doi:10.1136/bcr.03.2009.1651.

‘à

  1. –k“‡ŒM, Œ´“cŒ’‰E:‹³ˆç‚ÆŒ[–ÖŠˆ“®‚ª•a‰@ŒŸ¸•”‚ðŠˆ‚©‚·. Laboratory and Clinical Practice, 2008;26(29):78-89.
  2. –k“‡ŒM:ALP‚ª‚‚¢I —Õ°Œ¤Cƒvƒ‰ƒNƒeƒBƒX. 2009;6(3):60-5.
  3. –k“‡ŒM:—Õ°ŒŸ¸ˆãŠw‹³ˆç‚Ì‚ ‚é‚ׂ«Žp, ˆãŠw•”1”N¶‚̉Ȋw“I‹»–¡‚Æi˜HŠó–]i—Õ°ŒŸ¸‚ð’S‚¤ˆãŽtˆç¬‚ÉŒü‚¯‚Äj. Laboratory and Clinical Practice. 2009;27(1):8-12.
  4. –k“‡ŒM:ƒ`[ƒ€ˆã—ј_:ˆã—Ã]Ž–EŽí‚ð’m‚é. –òÜŽt. ƒ`[ƒ€ˆã—ÂƗհŒŸ¸. ƒ`[ƒ€ˆã—Ãlƒbƒgƒ[ƒNE—Õ°ŒŸ¸ŠÖ˜AŠé‹Æ‚ÌŽx‰‡. —Õ°•a—ƒŒƒrƒ…[. 2009;144:15-7.
  5. –k“‡ŒM:ŒŒ¬”ÂE’P‹…EŒŒŠÇ“à”ç×–E—R—ˆ‚̃}ƒCƒNƒƒp[ƒeƒBƒNƒ‹. —Õ°ŒŸ¸. 2009;53(10):1133-8.
  6. –k“‡ŒM:ƒŠƒsƒbƒhƒp[ƒIƒLƒVƒh(LPO). “ú–{—ÕଠL”͈͌Œ‰tE”A‰»ŠwŒŸ¸–ƉuŠw“IŒŸ¸. 2009;1:581-4.
  7. Œ´“cŒ’‰E, –k“‡ŒM:Š³ŽÒŒü‚¯ŒŸ¸‘Š’k. —Õ°ŒŸ¸. 2009;53(3):275-9.
  8. Œ´“cŒ’‰E, –k“‡ŒM:ŒŸ¸‘Š’k‚ÌŽÀÛ, •xŽR‘åŠw. —Õ°ŒŸ¸. 2009;53(3):333-4.
  9. ‰FŽ¡‹`‘¥, 쓇–ÒŽu, ŒKŒ´‘ì”ü, ‹g“cç», mˆäŒ©‰pŽ÷, –k“‡ŒM:•xŽR‘åŠw•‘®•a‰@ŒŸ¸•”‚É‚¨‚¯‚éISO15189”F’è‚ÌŒø‰Ê. —Õ°•a—. 2009;57:752-60.

Šw‰ï•ñ

  1. Niimi H, Kitajima I. Fastest ID system for detecting septic bacteris. 2009 Bio International Convention. The Global event for Biotechnology., 2009, 5, 18-21, Atlanta, USA.
  2. Uji Y, Miura M, Motomiyta Y, Ando Y, Yoshida C, Kitajima I. Meagerment of beta-2 microblobulin intermediate in serum by capillary electrophoresis. 2009 AACC Annual Meeting, 2009, 7, 21, Chicago, USA.
  3. –k“‡ŒM:‘Sg«‰ŠÇ”½‰žÇŒóŒQŠ³ŽÒ‹~–½—¦Œüã‚ð–ÚŽw‚µ‚½“Š‡“IŒŸ¸ƒVƒXƒeƒ€‚Ì\’z. 2009 ”NƒVƒXƒƒbƒNƒX’†‰›Œ¤‹†ŠƒZƒ~ƒi[, 2009, 4, 21, _ŒË.
  4. –k“‡ŒM:“à‰Èˆã‚ª’m‚Á‚Ä‚¨‚­‚ׂ«—Õ°ŒŸ¸‚Ìi•à. “à‰ÈŠw‰ï–k—¤Žx•”‘æ47‰ñ¶ŠU‹³ˆçu‰‰‰ï, 2009, 6, 7, •xŽR
  5. mˆäŒ©‰pŽ÷, –k“‡ŒM:cDNAƒ}ƒCƒNƒƒAƒŒƒC”­Œ»ƒvƒƒtƒ@ƒCƒ‹‚Ì•]‰¿. ‘æ49‰ñ“ú–{—Õ°‰»Šw‰ï”NŽŸŠwpW‰ï, 2009, 9, 19, ’·è.
  6. –ìŽè—Ç„, mˆäŒ©‰pŽ÷, ‰FŽ¡‹`‘¥, –k“‡ŒM:Š´õLjâ“`ŽqŒŸ¸‚É‚¨‚¯‚銴“x‘ª’è‚Æ’è—Ê–@, ‚¨‚æ‚ÑDNA ’Šo–@‚É‚æ‚é•Ï“®‚ɂ‚¢‚Ä‚ÌŒŸ“¢. ‘æ19‰ñ¶•¨ŽŽ—¿•ªÍ‰ÈŠw‰ï‘å‰ï, 2009, 2, 21, –¼ŒÃ‰®.
  7. ‘½‰ê—R‹IŽq, ã–ì—R”ü, Šp“c”ü—é, ŽÄ‘¥Žq, ŒKŒ´‘ì”ü, ‰FŽ¡‹`‘¥, –k“‡ŒM:¬Ž™‚É‚¨‚¯‚éNT-proBNP‚ÆBNP‚Æ‚ÌŠÖŒW. ‘æ48‰ñ“ú–{—Õ°ŒŸ¸“ŒŠCE–k—¤Žx•”‘‰ï, 2009, 3, 8, Šò•Œ.
  8. ’J‚Ý‚ËŽq, ‹g‰ªŽl, ‰Á”¨‘½•¶, ‰FŽ¡‹`‘¥, –k“‡ŒM:Ò’ÅŽèp‚É‚¨‚¯‚ép’†, pŒã‚Ì‹ÃŒÅEü—nƒ}[ƒJ[‚Ì•Ï“®‚̈Ӌ`. ‘æ48‰ñ“ú–{—Õ°ŒŸ¸“ŒŠCE–k—¤Žx•”‘‰ï, 2009, 3, 8, Šò•Œ.
  9. ã–ì’q_, mˆäŒ©‰pŽ÷, —ÑŽj˜N, –ìŽè—Ç„, ‰FŽ¡‹`‘¥, –k“‡ŒM:v‘¬EŠÈ•ÖEˆÀ‰¿‚È”sŒŒÇ“¯’èITƒVƒXƒeƒ€‚Ì\’z. ‘æ48‰ñ“ú–{—Õ°ŒŸ¸“ŒŠCE–k—¤Žx•”‘‰ï, 2009, 3, 8, Šò•Œ.
  10. ’J‚Ý‚ËŽq, ‹g‰ªŽl, ‰Á”¨‘½•¶, ‰FŽ¡‹`‘¥, –k“‡ŒM:Ò’ÅŽèp‚É‚¨‚¯‚éVTE ”­Ç‚Æp’†, pŒã‚Ì‹ÃŒŒEü—n•ªŽqƒ}[ƒJ[‚Ì•Ï“®‚̈Ӌ`. ‘æ9‰ñTTMƒtƒH[ƒ‰ƒ€, 2009, 3, 7, “Œ‹ž.
  11. –ìã’B–ç, Š’, mˆäŒ©‰pŽ÷, ‰–“c—ÏŽj, •Ê•{GK, •Ÿ‰i_Ži, –k“‡ŒM:’jŽ™¸_’x‘ØATRX ÇŒóŒQƒ‚ƒfƒ‹ƒ}ƒEƒX‚É‚¨‚¯‚éŠC”n‘Ì‚ÆG“‘̂̈â“`Žq”­Œ»ƒvƒƒtƒ@ƒCƒ‹‰ðÍ. í—ª“I‘n‘¢Œ¤‹†Ž–‹Æ„iŽ–‹Æ(CREST)u”]‚Ì‹@”\”­’B‚ÆŠwKƒƒJƒjƒYƒ€‚̉ð–¾v‘æ6‰ñ—̈æ“àŒ¤‹†‰ï, 2009, 3, 11, ‘åã.
  12. ’J‚Ý‚ËŽq, –k“‡ŒM:Ò’ÅŽèp‚É‚¨‚¯‚ép’†, pŒã‚Ì‹ÃŒÅEü—n•ªŽqƒ}[ƒJ[•Ï“®‚ÆÖ¬ŒŒðÇðÇ”­Ç‚Æ‚ÌŠÖ˜A. ‘æ32‰ñ“ú–{ŒŒðŽ~ŒŒŠw‰ïŠwpW‰ï, 2009, 6, 6, ¬‘q.
  13. –k“‡ŒM:V‹KŒŒŠÇ‹@”\ŒŸ¸–@ŠJ”­‚É‚æ‚錌ŠÇƒGƒCƒWƒ“ƒO‚̉Ȋw“I•]‰¿‚Æ—Õ°‰ž—p. ’m“IƒNƒ‰ƒXƒ^[’nˆæƒvƒƒWƒFƒNƒgu‘æ1‰ñ–¢•a—\–hƒVƒXƒeƒ€Œ¤‹†‰ïv, 2009, 6, 16, •xŽR.
  14. ¼ˆä“Ä, ‘åˆä“cŒ›‘×, –k“‡ŒM, mˆäŒ©‰pŽ÷:v‘¬EŠÈ•Ö‚Ȉâ“`ŽqˆÙíƒXƒNƒŠ[ƒjƒ“ƒO–@‚ÌŠJ”­‚ƃLƒbƒg‚ÌŠJ”­. ‘æ2‰ñ‚Æ‚â‚܃rƒWƒlƒXƒvƒ‰ƒ“ƒRƒ“ƒeƒXƒg, 2009, 6, 24, •xŽR.
  15. ’J‚Ý‚ËŽq, ‹g‰ªŽl, ‰Á”¨‘½•¶, ‰FŽ¡‹`‘¥, –k“‡ŒM:3 Ží—ނ̉—n«ƒtƒBƒuƒŠƒ“^ƒtƒBƒuƒŠƒ“ƒ‚ƒmƒ}[•¡‡‘ÌŒoŽž‘ª’è‚É‚æ‚éÒ’ÅŽèp‚É‚¨‚¯‚éVTE”­Ç‚Ì•]‰¿. ‘æ10‰ñ“ú–{ŒŸ¸ŒŒ‰tŠw‰ïŠwpW‰ï, 2009, 7, 4, b•{.
  16. mˆäŒ©‰pŽ÷, –k“‡ŒM:æiˆã—ÂƂµ‚Ä‚Ìæ“V«ƒAƒ“ƒ`ƒgƒƒ“ƒrƒ“Œ‡–Rǂ̈â“`Žqf’f]‹ß”N‚Ì‹@”\‰ðÍÇ—á‚ð’†S‚É]. ‘æ10‰ñ“ú–{ŒŸ¸ŒŒ‰tŠw‰ïŠwpW‰ï, 2009, 7, 4, b•{.
  17. Œ´“cŒ’‰E, mˆäŒ©‰pŽ÷, î’J»Žq, ‰FŽ¡‹`‘¥, –k“‡ŒM:æ“V«‘æVˆöŽqŒ‡‘¹ÇiPhe190Serj‚É‚¨‚¯‚锭ǃƒJƒjƒYƒ€‚̉ð–¾. ‘æ56‰ñ“ú–{—Õ°ŒŸ¸ˆãŠw‰ïŠwpW‰ï, 2009, 8, 27, ŽD–y.
  18. ’J‚Ý‚ËŽq, ‰FŽ¡‹`‘¥, –k“‡ŒM:Ò’ÅŽèp‚É‚¨‚¯‚éVTE”­Ç‚Æp’†, pŒã‚Ì‹ÃŒÅEü—nŒn•ªŽqƒ}[ƒJ[‚Ì•Ï“®‚̈Ӌ`. ‘æ56‰ñ“ú–{—Õ°ŒŸ¸ˆãŠw‰ïŠwpW‰ï, 2009, 8, 27, ŽD–y.
  19. mˆäŒ©‰pŽ÷, ¼ˆä“Ä, ‘åˆä“cŒ›‘×, ‰FŽ¡‹`‘¥, –k“‡ŒM:’è—ÊPCR–@‚ð—p‚¢‚½V‹Kˆâ“`Žq•ÏˆÙƒXƒNƒŠ[ƒjƒ“ƒO–@‚ÌlˆÄ‚ÆŽÀ—p‰»‚Ö‚ÌŽŽ‚Ý. ‘æ56‰ñ“ú–{—Õ°ŒŸ¸ˆãŠw‰ïŠwpW‰ï, 2009, 8, 27, ŽD–y.
  20. mˆäŒ©‰pŽ÷, ‰FŽ¡‹`‘¥, –k“‡ŒM:’è—Ê“IPCR –@‚ð—p‚¢‚½v‘¬‚ÅŠÈ•Ö‚ÈV‹Kˆâ“`Žq•ÏˆÙƒXƒNƒŠ[ƒjƒ“ƒO–@‚ÌlˆÄ‚ÆŽÀ—p‰»‚Ö‚ÌŽŽ‚Ý. ‘æ41‰ñ“ú–{—Õ°ŒŸ¸Ž©“®‰»Šw‰ï‘å‰ï, 2009, 10, 9, ‰¡•l.
  21. –k“‡ŒM:1•ªŽqŒuŒõ‘ŠŠÖ–@‚ð—p‚¢‚½“]ŽÊˆöŽqNF-κBŒv‘ª–@ŠJ”­‚Æv‘¬‚ȉŠÇ•a‘Ô‰ðÍ. 2009, 10, 9, ‰¡•l.
  22. ’J‚Ý‚ËŽq, ‰FŽ¡‹`‘¥, –k“‡ŒM:3Ží—ނ̉—n«ƒtƒBƒuƒŠƒ“ƒ‚ƒmƒ}[•¡‡‘Ì“¯Žž‘ª’è‚É‚æ‚éŽüpŠú‹ÃŒÅ”\‚Ì•]‰¿. 2009,10,9, ‰¡•l.
  23. ã–ì’q_, ‹g“cç», ‰FŽ¡‹`‘¥, mˆäŒ©‰pŽ÷, –k“‡ŒM, ˆÀ“Œ—RŠì—Y:ƒLƒƒƒsƒ‰ƒŠ[“d‹C‰j“®(CE)‘•’u‚ð—p‚¢‚½β2mƒAƒ~ƒƒCƒh‘O‹ì’`”’‘ª’è–@‚ÌŠJ”­. 2009,10,9, ‰¡•l.
  24. mˆäŒ©‰pŽ÷, ã–ì’q_, —ÑŽj˜N, ‰FŽ¡‹`‘¥, –k“‡ŒM:æ“V«ƒAƒ“ƒ`ƒgƒƒ“ƒrƒ“Œ‡–RÇIIŒ^‚̈â“`Žq‰ðÍ. ‘æ34‰ñ–k—¤—Õ°•a—W’k‰ï, 2009,9,26, ‹à‘ò.

‚»‚Ì‘¼

  1. “ÁŠè2009-23707. ”­–¾ŽÒ:mˆäŒ©‰pŽ÷, ã–ì’q_, –k“‡ŒM, —ÑŽj˜N. ”­–¾–¼Ìuƒvƒ‰ƒCƒ}[ƒ_ƒCƒ}[”ñ•\Ž¦•û–@v. oŠè“ú:•½¬21”N2ŒŽ4“ú.
  2. “ÁŠè2009-40052. ”­–¾ŽÒ:‘½—t“c—_, “ì—m, mˆäŒ©‰pŽ÷, –k“‡ŒM, ã–ì’q_, —ÑŽj˜N. ”­–¾–¼ÌuŒŸo‘ÎÛ¶•¨‚Ì‚Š´“x’è—Ê•û–@v. oŠè“ú:•½¬21”N2ŒŽ23“ú.
  3. “ÁŠè2009-181755. ”­–¾ŽÒ:mˆäŒ©‰pŽ÷, ã–ì’q_, –k“‡ŒM, —ÑŽj˜N. ”­–¾–¼Ìu‚Š´“xE‚“ÁˆÙ“x‚ÈPCR•Ï–@voŠè“ú:•½¬21”N8ŒŽ4“ú.
  4. ‘Û“Á‹–oŠè:mˆäŒ©‰pŽ÷, –k“‡ŒM, ¼ˆä“Ä, ‘åˆä“cŒ›‘×. ”­–¾–¼Ìu’è—Ê–@‚ð—˜—p‚µ‚½ˆâ“`Žq•ÏˆÙƒXƒNƒŠ[ƒjƒ“ƒO–@v. oŠè“ú:•½¬21”N7ŒŽ17“ú.
  5. –k“‡ŒM:‘æ31‰ñ“ú–{ŒŒðŽ~ŒŒŠw‰ï•ñ, ŒŒðÇ‚Ì•]‰¿‚ª‰Â”\‚É. Medical Tribune, 42(9): 31, 2009.
  6. –k“‡ŒM:‘æ19‰ñ“ú–{—Õ°ŒŸ¸ê–åˆã‰ït‹G‘å‰ï‘Š‡. JACLap News, 105: 4, 2009.
  7. mˆäŒ©‰pŽ÷, –k“‡ŒM:real-time PCR –@‚ð—p‚¢‚½v‘¬‚È”sŒŒÇ‹Nˆö‹Û“¯’èƒVƒXƒeƒ€‚Ì\’z‚ÉŠÖ‚·‚錤‹†. ’†’J“dŽqŒv‘ª‹ZpU‹»à’cAnnual Report 2009, 42-56, 2009.

ƒy[ƒW‚Ì擪‚Ö–ß‚é

2008”N

’˜‘

  1. –k“‡ŒM:DIC ‚É‚¨‚¯‚錌Ÿ÷•ª‰æ»Ü‚ÌŽg‚¢•û. ŒŒ‰t»Ü‚Ìl‚¦•û, Žg‚¢•û. i‘å‹v•ÛŒõ•v•Òj, 229-232, ’†ŠOˆãŠwŽÐ, “Œ‹ž, 2008.
  2. –k“‡ŒM:‹ÃŒÅEü—nEŒŒ¬”‹@”\ŒŸ¸. ŒŒ‰tE‘¢ŒŒŠíŽ¾Š³Šwi¬àVŒh–ç, ’¼]’mŽ÷, â“c—mˆê•Òj, 94-99, Medical viewŽÐ, “Œ‹ž, 2008.
  3. Ohtsuka T and Takai Y. Roles of the ELKS/CAST family and SAD kinase in neurotransmitter release: Chapter 9, 157-170, molecular mechanisms of neurotransmitter release. 2008.

Œ´’˜

  1. Kwan E, Xie L, Sheu L, Ohtsuka T, Gaisano HY. Interaction between Munc13-1 and RIM is Critical for Glucagon-like Peptide-1-mediated Rescue of Exocytotic Defects in Munc13-1-deficient pancreatic β-cells. Diabetes. 2007;56:2579-88.
  2. Wang J, Xu Z, Kitajima I, Wang Z. Effects of different statins on endothelial nitric oxide synthase and AKT phosphorylation in endothelial cells. International Journal of Cardiology. 2008;127:33-9.
  3. Misaki T, Kitajima I, Kabata T, Tani M, Kabata C, Tsubokawa T, Asakura H, Tomita K. Changes of the soluble fibrin monomer complex level in the perioperative period of hip replacement surgery. J Orthop Sci. 2008;13:419-24.
  4. Œ´“cŒ’‰E, Žs–Ñ—RŠóŽq, Šp“c”ü—é, ‘½‰ê—R‹IŽq, ŽÄ‘¥Žq, –k“‡ŒM:ˆãŠw¶‚ɑ΂·‚鑲‘O¶‰»ŠwŒŸ¸ŽÀK‚̉ۑè‚ƉðŒˆ, ŒŸ¸‘ª’茴—‚ðŒø‰Ê“I‚ÉŽÀK‚Å‚«‚éƒc[ƒ‹‚Ö‚ÌPOCT ‘ΉžŒ^¬Œ^Ž©“®•ªÍŠí‚̉ü‘¢‚Æ‚»‚ÌŠwKŒø‰Ê. —Õ°•a—. 2008;56(9):753-760.

Ç—á•ñ

  1. ìl_”V, ’†Œ´Ë•¶, ¯–쉷, ‰|–{¹Žq, ‘q“c”Ž”V, ’†‘º—²Žu, –k“‡ŒM, mˆäŒ©‰pŽ÷. Catheter-directed Intrathrombus Thrombolysis ‚ª’˜Œø‚µ‚½[•”Ö¬ŒŒðLJ•¹ƒAƒ“ƒ`ƒgƒƒ“ƒrƒ“Œ‡‘¹”D•w‚Ì1—á. ŒÄ‹z‚ÆzŠÂ. 2008;56:219-23.

‘à

  1. –k“‡ŒM:ƒNƒŠƒjƒbƒN‚É‚¨‚¯‚é—Õ°ŒŸ¸‚ÌŒ»ó‚ÆV‚½‚ȉ”\«. ’nˆæˆã—Ã, ‚Ö‚«’nˆã—Ã, ‚»‚µ‚Ä“Á’茒fE“Á’è•ÛŒ’Žw“±‚ւ̑Ήž. •ÊûASAHI Medical. 2008;37(4):1-6.
  2. –k“‡ŒM:‹ÃŒÅEü—n‚Æ—Õ°ŒŸ¸. “ú–{ŒŒðŽ~ŒŒŠw‰ïŽGŽ. 2008;19(4):462-6.
  3. –k“‡ŒM:•xŽR‘åŠw•‘®•a‰@ŒŸ¸Žº‚ª‘Û‹KŠiISO18159 ”F’è‚ðŽæ“¾. •xŽRŽsˆãŽt‰ï•ñ. 2008;450:5-6.

Šw‰ï•ñ

  1. Kitajima I: Role of Nuclear factor-kappa B (NF-κB) in tumor progresion. The 1st International traditional chinese medicine (TCM) and Interative Medicine Oncology Formum. 2008, 10, 18-19, Shanghai, China. (invited lecture)
  2. Kitajima I, Note R, Ogawa T, Abe S, Kadowaki M, Yamagata K: A new assay for NF-κB activity in biological samples using fluorescence correlation spectroscopy and its application to perioperative cardiac monitoring. 2008 Keystone symposia NF-κB. 2008, 2, 12-17, Banff, Canada.
  3. Kitajima I, Motomura H, Niimi H.:mRNA and micro RNA expression profile in chondrogenic differentiation regulated by BMP. Annual TGF-β meeting Leiden, 2008, 9, 4-6, Leiden, The Netherland.
  4. Ohtsuka T.:Phosphorylation network at the presynaptic active zone. US-Japan Brain Research Collaborative Program - "Workshop on Receptor Trafficking and Cell Biology of Neurons: Physiology and Disease. 2008, 2, 24-27. Asilomer, CS, USA.
  5. Niimi H, Motomura H, Kitajima I.:Gas 6, a new regulator of chodrogenic diffetentiation promoted by BMP. Annual TGF-β meeting Leiden, 2008, 9, 4-6, Leiden, The Netherland.
  6. –k“‡ŒM:ƒNƒƒ}ƒ`ƒ“ƒŠƒ‚ƒfƒŠƒ“ƒO’`”’ATRX •ÏˆÙƒ}ƒEƒX‚Ìs“®EŠwKáŠQ‚ƃqƒg¸_’x‘Ø•a‚Æ‚ÌŠÖ˜A. ‘æ81‰ñ“ú–{–ò—Šw‰ï”N‰ï, 2008, 3, 19, ‰¡•l. iµ‘Òu‰‰j
  7. •Ÿ‰i_Ži, ‰–“c—ÏŽj, Š’, •Ê•{GK, Œ´‰p², –k“‡ŒM:¸_Ž¾Š³ƒ‚ƒfƒ‹ƒ}ƒEƒX‚̃XƒpƒCƒ“Œ`¬ˆÙí‚̃ƒJƒjƒYƒ€. ‘æ81‰ñ“ú–{–ò—Šw‰ï”N‰ï, 2008, 3, 19-21, ‰¡•l.
  8. ŒKŒ´‘ì”ü, 쓇–ÒŽu, ‰FŽ¡‹`‘¥, –k“‡ŒM:ISO15189 ”F’è\¿’¼‘OŽ{Ý]\¿‚Ü‚Å‚ÌŒ»ó]. ‘æ47‰ñ“ú–{—Õ°ŒŸ¸ˆãŠw‰ï“ŒŠCE–k—¤Žx•”‘‰ï, 2008, 3, 9, •xŽR.
  9. –k“‡ŒM:‰Â—n«ƒtƒBƒuƒŠƒ“ƒ‚ƒmƒ}[•¡‡‘Ì‘ª’è‚Ì—Õ°“IˆÓ‹`. ‘æ57‰ñ“ú–{ˆãŠwŒŸ¸Šw‰ï, 2008, 5, 29-31, ŽD–y. (µ‘Òu‰‰)
  10. –k“‡ŒM:ŒŒðÇ‘Šúf’f–@ŠJ”­‚Æ‚»‚Ì•‹y‚É‚æ‚é—Õ°‚Ö‚ÌvŒ£. ‘æ2‰ñ–k—¤ŒŒðŽ~ŒŒŒŸ¸§˜b‰ï, 2008, 7, 5, ‹à‘ò. (µ‘Òu‰‰)
  11. –k“‡ŒM:–Ô—…“Iˆâ“`Žq”­Œ»‰ðÍŽè–@‚ð—p‚¢‚½ŠÖ߃ŠƒEƒ}ƒ`‚ÌŠ¿•û•ûÜ–òŒø‰ðÍ. ‘æ11‰ñ“V‘R–ò•¨Œ¤‹†•û–@˜_ƒAƒJƒfƒ~[Œà‰HŽRƒVƒ“ƒ|ƒWƒEƒ€, 2008, 8, 1, •xŽR. (µ‘Òu‰‰)
  12. –k“‡ŒM:ƒtƒ@[ƒ}ƒRƒQƒmƒ~ƒNƒXiPGxjŽÀ—p‰»‚ÌŒ»ó. ‘æ2‰ñJMCoE ƒlƒbƒgƒ[ƒNŠwpƒtƒH[ƒ‰ƒ€, 2008, 8, 9, “Œ‹ž. iµ‘Òu‰‰j
  13. mˆäŒ©‰pŽ÷, –ìŽè—Ç„, ã–ì’q_, —ÑŽj˜N, ‰FŽ¡‹`‘¥, –k“‡ŒM:v‘¬, ŠÈ•Ö, ˆÀ‰¿‚È”sŒŒÇ‹Nˆö‹Û“¯’èIT ƒVƒXƒeƒ€‚ÌŠJ”­. ‘æ48‰ñ“ú–{—Õ°‰»Šw”NŽŸŠwpW‰ï, 2008, 8, 30, •l¼. iµ‘Òu‰‰j
  14. ‘å’Ë–«‹v:ƒvƒŒƒVƒiƒvƒX‹@”\§Œä‚Ì•ªŽq¶—Šw. ‘æ31‰ñ“ú–{_Œo‰ÈŠwŠw‰ï‘å‰ï, ‰¡•l, 2008, 7, 9. iµ‘Òu‰‰j
  15. –ìŽè—Ç„, ”öì’q”ü, î’J»Žq, ‰FŽ¡‹`‘¥, mˆäŒ©‰pŽ÷, –k“‡ŒM:æ“V«ƒAƒ“ƒ`ƒgƒƒ“ƒrƒ“Œ‡–Rǂ̈â“`Žq‰ðÍ‚ÉŠÖ‚·‚錟“¢. ‘æ18‰ñ¶•¨ŽŽ—¿•ªÍ‰ÈŠw‰ïŠwpW‰ï, 2008, 2, 10, ‘åã.
  16. Š’, ‰–“c—ÏŽj, •Ê•{GK, •Ÿ‰i_Ži, –k“‡ŒM:ATRX •ÏˆÙƒ}ƒEƒX‚ÌŠwK‹L‰¯áŠQ‚ƃXƒpƒCƒ“Œ`‘ÔˆÙí. í—ª“I‘n‘¢Œ¤‹†Ž–‹Æ„iŽ–‹ÆiCRESTju”]‚Ì‹@”\”­’B‚ÆŠwKƒƒJƒjƒYƒ€‚̉ð–¾v‘æ5‰ñ—̈æ“àŒ¤‹†‰ï, 2008, 3, 5, ‘åã.
  17. —ÑŽj˜N, ²’|ˆÉ’ÃŽq, ×’JFŽq, ‰„–ì^‹|, ¬£—¢Œb, ‰FŽ¡‹`‘¥, Žs“c•™Žq, –k“‡ŒM:ƒzƒ‹ƒ^[S“d}ŒŸ¸‚É‚¨‚¯‚鬎™‚ð‘ÎÛ‚Æ‚µ‚½QT ‰„’·Šî€ŽQl”͈͂̌Ÿ“¢. ‘æ47‰ñ“ú–{—Õ°ŒŸ¸ˆãŠw‰ï“ŒŠC–k—¤Žx•”‘‰ï, 2008, 3, 9, •xŽR.
  18. ¬£—¢Œb, ²’|ˆÉ’ÃŽq, —ÑŽj˜N, ‰FŽ¡‹`‘¥, •Ÿ“cM”V, –k“‡ŒM:’ˆÓ[‚­•]‰¿‚µ‚½‚¢S‘Ÿ’´‰¹”gŒŸ¸‚Ì1—áiSŽG‰¹¸¸j. ‘æ47‰ñ“ú–{—Õ°ŒŸ¸ˆãŠw‰ï“ŒŠC–k—¤Žx•”‘‰ï, 2008, 3, 9, •xŽR.
  19. ‰„–ì^‹|, —ÑŽj˜N, ¬£—¢Œb, ×’JFŽq, ²’|ˆÉ’ÃŽq, ‰FŽ¡‹`‘¥, –k“‡ŒM:Heart rate turbulence (HRT)‚Ì“ú“à•Ï“®‚Æ—Õ°“IˆÓ‹`. ‘æ47‰ñ“ú–{—Õ°ŒŸ¸ˆãŠw‰ï“ŒŠC–k—¤Žx•”‘‰ï, 2008, 3, 9, •xŽR.
  20. î’J»Žq, ‹´–{–ƒˆßŽq, ‹g“cŒd, 쓇–ÒŽu, ’J‚Ý‚ËŽq, ŒKŒ´‘ì”ü, ŽRŒû—R–¾, ]”¦˜a”ü, ‹{‰€‘ìé, ‘ºãƒ, ™ŽR•q˜Y, ÎàVL, ‚–ìN—Y, ‰FŽ¡‹`‘¥, –k“‡ŒM:Œ`Ž¿×–E‚Ì’˜–¾‚È‘‰Á‚ð”F‚ß‚½Angioimmunoblastic T-cell lymphoma(AILT)‚Ì1—á. ‘æ47‰ñ“ú–{—Õ°ŒŸ¸ˆãŠw‰ï“ŒŠC–k—¤Žx•”‘‰ï, 2008, 3, 9, •xŽR.
  21. X“c–¢, â–{ƒŽq, ‹g“cˆèŽq, ‰FŽ¡‹`‘¥, ¼“c—I, “¡âŽÀç˜Y, –k“‡ŒM:Mycobacterium fortuitum ‚ª•ª—£‚³‚ꂽ’†Ž¨‰Š‚̈êÇ—á. ‘æ47‰ñ“ú–{—Õ°ŒŸ¸ˆãŠw‰ï“ŒŠC–k—¤Žx•”‘‰ï, 2008, 3, 9, •xŽR.
  22. Œ´“cŒ’‰E, ”öì’q”ü, –ìŽè—Ç„, mˆäŒ©‰pŽ÷, –k“‡ŒM, ™–{^–ç, í“cFK, ‹TŽR’qŽ÷, ˆä㔎:Žá”N”­Ç‚Ì”xŒŒðÇðÇ‚Å“ü‰@‚Æ‚È‚Á‚½ƒvƒƒeƒCƒ“S Œ‡–R—á‚̈â“`‰ðÍ. ‘æ47‰ñ“ú–{—Õ°ŒŸ¸ˆãŠw‰ï“ŒŠC–k—¤Žx•”‘‰ï, 2008, 3, 9, •xŽR.
  23. ”öì’q”ü, –ìŽè—Ç„, ‰FŽ¡‹`‘¥, mˆäŒ©‰pŽ÷, –k“‡ŒM:æ“V«ƒAƒ“ƒ`ƒgƒƒ“ƒrƒ“Œ‡–Rǂ̈â“`Žq‰ðÍ‚Æ‹@”\ˆÙ팤‹†. ‘æ47‰ñ“ú–{—Õ°ŒŸ¸ˆãŠw‰ï“ŒŠC–k—¤Žx•”‘‰ï, 2008, 3, 9, •xŽR.
  24. –ìŽè—Ç„, ”öì’q”ü, ‰FŽ¡‹`‘¥, mˆäŒ©‰pŽ÷, –k“‡ŒM:ˆâ“`«ƒwƒ‚ƒNƒƒ}ƒg[ƒVƒX‚̈â“`Žq‰ðÍ. ‘æ47‰ñ“ú–{—Õ°ŒŸ¸ˆãŠw‰ï“ŒŠC–k—¤Žx•”‘‰ï, 2008, 3, 9, •xŽR.
  25. Š’, mˆäŒ©‰pŽ÷, ˆø–ÔG², –k“‡ŒM:ŠÖ߃ŠƒEƒ}ƒ`Š³ŽÒ‚ð‘ÎÛ‚Æ‚µ‚½ŒjŽ}‰ÁžQ•“’•ž—pŒø‰Ê‚̃}ƒCƒNƒƒAƒŒƒC‚ð—p‚¢‚½‰ðÍ. ‘æ47‰ñ“ú–{—Õ°ŒŸ¸ˆãŠw‰ï“ŒŠC–k—¤Žx•”‘‰ï, 2008, 3, 9, •xŽR.
  26. ã–ì’q_, ‰FŽ¡‹`‘¥, ŒKŒ´‘ì”ü, 쓇–ÒŽu, ŽÄ‘¥Žq, Šp“c”ü—é, ‘½‰ê—R‹IŽq, –k“‡ŒM, ˆÀ“Œ—RŠì—Y, ‹g“cç», ŽO‰Y‰ëˆê, –{‹{‘S‰ø:ŒŒ´’†β2m ƒAƒ~ƒƒCƒh‘O‹ì‘Ì’`”’Ž¿•ªÍ–@‚Ì•]‰¿. ‘æ47‰ñ“ú–{—Õ°ŒŸ¸ˆãŠw‰ï“ŒŠC–k—¤Žx•”‘‰ï, 2008, 3, 9, •xŽR.
  27. –k“‡ŒM:’jŽ™¸_‰^“®’x‘Ø‚ð’æ‚·‚éATR-X ÇŒóŒQ‚̃‚ƒfƒ‹ƒ}ƒEƒX컂Ƃ»‚Ì‚ŽŸ”]‹@”\‰ðÍ. ‘æ49‰ñ“ú–{_ŒoŠw‰ï‘‰ï, 2008, 5, 17, ‰¡•l.
  28. mˆäŒ©‰pŽ÷, ”öì’q”ü, –ìŽè—Ç„, ã–ì’q_, ‰FŽ¡‹`‘¥, –k“‡ŒM:æ“V«ƒAƒ“ƒ`ƒgƒƒ“ƒrƒ“Œ‡–Rǂ̈â“`Žq‰ðÍ‚Æ‹@”\ˆÙ팤‹†. ‘æ15‰ñ“ú–{ˆâ“`Žqf—Êw‰ï‘å‰ï, 2008, 8, 1, å‘ä.
  29. –k“‡ŒM, Š’, –ìã‘ñ–ç, mˆäŒ©‰pŽ÷:cDNA ƒ}ƒCƒNƒƒAƒŒƒC‚ð—p‚¢‚½ŠÖ߃ŠƒEƒ}ƒ`‚É‚¨‚¯‚銿•û–ò–òŒø‚ÌŒŸØ. ‘æ48‰ñ“ú–{—Õ°‰»Šw‰ï”NŽŸŠwpW‰ï, 2008, 8, 29-30, •l¼.
  30. ‘åˆä“cŒ›‘×, ¼ˆä“Ä, mˆäŒ©‰pŽ÷, –k“‡ŒM:real-time PCR ‚ð—p‚¢‚½v‘¬EŠÈ•Ö‚Ȉâ“`Žq•ÏˆÙƒXƒNƒŠ[ƒjƒ“ƒO–@. ‘æ48‰ñ“ú–{—Õ°‰»Šw‰ï”NŽŸŠwpW‰ï, 2008, 8, 29-30, •l¼.
  31. —ÑŽj˜N, ã–ì’q_, mˆäŒ©‰pŽ÷, –k“‡ŒM:æ“V«ƒAƒ“ƒ`ƒgƒƒ“ƒrƒ“Œ‡–Rǂ̈â“`Žqf’f‚Æ‹@”\‰ðÍ. ‘æ6‰ñ–k—¤ŒŒðŒ¤‹†‰ï, 2008, 10, 25, ‹à‘ò.
  32. ‘ºãƒ, ‹{‰€‘ì‹X, •ÄàV˜a”ü, ²’|ˆÉ’ÃŽq, ’†oË‘ã, “¹–ì~Žq, ¼–ìŽåáÁ, “‡‹žŽq, ˆÀ‘º•q, –k“‡ŒM:•p‰ñ‚ÉHLA“K‡ŒŒ¬”—AŒŒ‚ð—v‚µ‚½œ‘ˆÙŒ`¬ÇŒóŒQ‚Ì1—á. ‘æ26‰ñ“ú–{—AŒŒE×–EŽ¡—Êw‰ï–k—¤’n•û‰ï, 2008, 11, 15, •xŽR.
  33. “‡‹žŽq, ‹{—Ñç’ߎq, ˆÀ‘º•q, ²’|ˆÉ’ÃŽq, ’†oË‘ã, “¹–ì~Žq, ¼–ìŽåáÁ, •ÄàV˜a”ü, –k“‡ŒM:ƒnƒCƒŠƒXƒN”DŽY•w‚Ì’™ŒŒŽ®Ž©ŒÈŒŒ—AŒŒ‚ÌŒ»ó‚Ɖۑè. ‘æ26‰ñ“ú–{—AŒŒE×–EŽ¡—Êw‰ï–k—¤’n•û‰ï, 2008, 11, 15, •xŽR.
  34. mˆäŒ©‰pŽ÷, ‰FŽ¡‹`‘¥, –k“‡ŒM:’è—ÊPCR –@‚ð—p‚¢‚½v‘¬‚ÅŠÈ•Ö‚ÈV‹Kˆâ“`Žq•ÏˆÙƒXƒNƒŠ[ƒjƒ“ƒO•û–@‚ÌlˆÄ. ‘æ55‰ñ“ú–{—Õ°ŒŸ¸ˆãŠw‰ïŠwpW‰ï, 2008, 11, 27-30, –¼ŒÃ‰®.
  35. mˆäŒ©‰pŽ÷, ”öì’q”ü, –ìŽè—Ç„, ‰FŽ¡‹`‘¥, –k“‡ŒM:æiˆã—ÂƂµ‚Ä‚Ìæ“V«ƒAƒ“ƒ`ƒƒ“ƒrƒ“Œ‡–Rǂ̈â“`Žqf’f|‹ß”N‚Ì‹@”\‰ðÍÇ—á‚ð’†S‚É|‘æ55‰ñ“ú–{—Õ°ŒŸ¸ˆãŠw‰ïŠwpW‰ï, 2008, 11, 27-30, –¼ŒÃ‰®.
  36. mˆäŒ©‰pŽ÷, –ìŽè—Ç„, ã–ì’q_, —ÑŽj˜N, ‰FŽ¡‹`‘¥, –k“‡ŒM:v‘¬, ŠÈ•Ö, ˆÀ‰¿‚È”sŒŒÇ‹Nˆö‹Û“¯’èIT ƒVƒXƒeƒ€‚Ì\’z. ‘æ55‰ñ“ú–{—Õ°ŒŸ¸ˆãŠw‰ïŠwpW‰ï, 2008, 11, 27-30, –¼ŒÃ‰®.
  37. –k“‡ŒM, Œ³‘º‘ñ:“ª‰»‚ð’²ß‚·‚镪ŽqGas6 ‚Ì”­Œ©‚Æ‚»‚Ì‹@”\‰ðÍ. ‘æ55‰ñ“ú–{—Õ°ŒŸ¸ˆãŠw‰ïŠwpW‰ï, 2008, 11, 27-30, –¼ŒÃ‰®.
  38. –ìŽè—Ç„, ”öì’q”ü, ‹g“cç», ‰FŽ¡‹`‘¥, mˆäŒ©‰pŽ÷, –k“‡ŒM:HFE ˆâ“`Žq‚ÌV‹K•ÏˆÙ‚ð”F‚ß‚½ˆâ“`«ƒwƒ‚ƒNƒƒ}ƒg[ƒVƒX‚Ì1—á. ‘æ55‰ñ“ú–{—Õ°ŒŸ¸ˆãŠw‰ïŠwpW‰ï, 2008, 11, 27-30, –¼ŒÃ‰®.
  39. î’J»Žq, 쓇–ÒŽu, ’J‚Ý‚ËŽq, ŒKŒ´‘ì”ü, ‰FŽ¡‹`‘¥, ‹{‰€‘ì‹X, ‘ºãƒ, ÎàVL, –k“‡ŒM:––½ŒŒ‚¨‚æ‚Ñ‹¹…’†‚ÉŒ`Ž¿×–E‚ª‘½”oŒ»‚µ‚½ŒŒŠÇ–Ɖu‰è‹…«T×–EƒŠƒ“ƒpŽîiAILTj‚Ì1Ç—á. ‘æ55‰ñ“ú–{—Õ°ŒŸ¸ˆãŠw‰ïŠwpW‰ï, 2008, 11, 27-30, –¼ŒÃ‰®.

‚»‚Ì‘¼

  1. –k“‡ŒM:cDNA ƒ}ƒNƒƒAƒŒƒC‚ð—p‚¢‚½ŠÖ߃ŠƒEƒ}ƒ`‚É‚¨‚¯‚éuØv‚ÌŒŸØ. •xŽR‘åŠw21 ¢‹ICOE ƒvƒƒOƒ‰ƒ€u“Œ—m‚Ì’m‚É—§‹r‚µ‚½ŒÂ‚̈ã—Â̑n¶vŠˆ“®•ñ‘:43-46, 2008.
  2. –k“‡ŒM:•ÒWŒã‹L, —Õ°ŒŸ¸‚ÌŽ¿. —Õ°•a—56(9): 833, 2008.
  3. Œ´“cŒ’‰E, –k“‡ŒM:ŒŒ‰tŒŸ¸Œ‹‰Ê‚̂Ƃ炦‚©‚½`ƒƒ^ƒ{ŒŸf€–Ú‚ð’†S‚É`. •xŽR‘åŠw•t‘®•a‰@‚¾‚æ‚è‚©‚í‚ç”Å103†2008, 8, 1 ”­s.
  4. ‘Û“Á‹–Šè:Hideki N, Kitajima I: Rapid method for identifying causative microorganism for infectious disease. Priority JP/21. 02. 06/JPA20006043469, JP/12. 1006/JPA2006278371, Date 15. 10. 08 Date of filing 20. 02. 07.
  5. ‘“à“Á‹–Šè:mˆäŒ©‰pŽ÷, –k“‡ŒM, ¼ˆä“Ä, ‘åˆä“cŒ›‘×2008-18678 PS08HOIJP ‘Û“Á‹–•ª—ÞC12Q1/68 ”­–¾–¼Ì:ˆâ“`Žq•ÏˆÙ‚̃XƒN[ƒŠƒ“ƒO–@oŠè“ú:2008, 7, 18.

ƒy[ƒW‚Ì擪‚Ö–ß‚é

2007”N

’˜‘

  1. –k“‡ŒM, –Ø‘º—TŽO, œAìTˆê˜Y–ó:uƒƒ‹ƒ{ƒ‹ƒ“‘åŠwŽ®“‡Œ^PBL, ƒRƒA—Õ°Ç—á‚©‚çŠî‘b•a‘Ô¶—‚Öv. Core Clinical Cases in Basic Biomedical Science. A problem-based learning approach. Samy A. Azer’˜, ƒGƒ‹ƒZƒrƒAEƒWƒƒƒpƒ“, “Œ‹ž, 1-412, 2007
  2. –k“‡ŒM:_ŒoE‹ØŽ¾Š³. u’m‚Á‚Ä‚¨‚«‚½‚¢—Õ°ŒŸ¸’lv“ú–{–òŠw‰ï•Ò, “Œ‹ž‰»Šw“¯l, “Œ‹ž, 132-135, 2007

Œ´’˜

  1. Yao I, Takagi H, Ageta H, Kahyo T, Sato S, Hatanaka K, Fukuda Y, Chiba T, Morone N, Yuasa S, Inokuchi K, Ohtsuka T, MacGregor GR, Tanaka K, and Setou M. SCRAPPER-dependent ubiquitination of active zone protein RIM1 regulates synaptic vesicle release. Cell. 2007;130:943-57.
  2. Grigoriev I, Splinter D, Keijzer N, Wulf P, Demmers J, Ohtsuka T, Modesti M, Maly I, Grosveld F, Hoogenraad CC, Akhmanova A. Rab6A regulates transport and targeting of exocytotic carriers. Dev Cell. 2007;13:305-14.
  3. Niimi H, Pardali K, Vanlandewijck M, Heldin CH, Moustakas A. Notch signaling is necessary for epithelial growth arrest by TGF-β. J Cell Biol. 2007;176:695-707.
  4. Suzuki S, Singhirunnusorn P, Mori A, Yamaoka S, Kitajima I, Saiki I, Sakurai H. Constitutive activation of TAK1 by HTLV-I Tax-dependent overexpression of TAB2 induces activation of JNK-ATF2 but not IKK-NF-κB. J Biol Chem. 2007;282:25177-81.
  5. Siksou L, Rostaing P, Lechaire JP, Boudier T, Ohtsuka T, Fejtov A, Kao HT, Greengard P, Gundelfinger ED, Triller A, Marty S. Three-dimensional architecture of presynaptic terminal cytomatrix. J Neurosci. 2007;27:6868-77.
  6. Matsuda N, Hatakeyama N, Shakunaga K, Sugano M, Kitajima I, Yamazaki M, Hattori Y. Silencing of caspase-8 and caspase-3 by RNA interference prevents vascular endothelial cell injury in septic mice. Cardiovascular Res. 2007;76:132-40.
  7. Motomura H, Niimi H, Sugimori K, Otsuka T, Kimura T, and Kitajima I. Gas6, a new regulator of chondrogenic differentiation in mesenchymal cells. Biochem Biophys Res Commun. 2007;357:997-1003.
  8. Tokoro T, Higa S, Deguchi-Tawarada M, Inoue E, Kitajima I, and Ohtsuka T. Localization of the active zone protein CAST, ELKS, and Piccolo at neuromuscular junctions. Neuroreport. 2007;18:313-6.
  9. Wang J, Kitajima I. Pitavastatin inactivates NF-κB and decreases IL-6 production through Rho kinase pathway in MCF-7 cells. Oncology Report. 200715:1149-54.
  10. Moustakas A, Valcourt U, Kowanetz M, Pardali K, Niimi H, Thuault S. Tumor suppressor and tumor promoting pathways under the control of TGF-β. Eur J Clin Invest. 2007;37:49.
  11. –ìŽè—Ç„, î’J»Žq, ŽRŠÝ–GŽq, X“c–¢, ‘½‰ê—R‹IŽq, â–{ƒŽq, ‹g“cˆèŽq, ‘å–å—Ç’j, mˆäŒ©‰pŽ÷, –k“‡ŒM:–òÜ‘Ï«ˆâ“`Žq‚ÌŒŸo‚ƈâ“`ŽqŒ^•Ê–@‚Ì—Õ°‰ž—p. •xŽRŒ§‰q¶ŒŸ¸‹ZŽt‰ïŽ. 2007;32:35-44.

‘à

  1. –k“‡ŒM, ”öì’q”ü, ’J‚Ý‚ËŽq:‚킪‘‚ÅŠJ”­‚³‚ꂽŒŒðÇ‹}«Šú‚𑨂¦‚錌‰t‹ÃŒÅ•ªŽqƒ}[ƒJ[, ‰Â—n«ƒtƒBƒuƒŠƒ“(SF)/ƒtƒBƒuƒŠƒ“ƒ‚ƒmƒ}[•¡‡‘Ì(FMC). ˆã•ñ‚Æ‚â‚Ü. 2007;1422:8-10.
  2. –k“‡ŒM, ŽRŒûŒjŽi, ”öì’q”ü, ’J‚Ý‚ËŽq:‰Â—n«ƒtƒBƒuƒŠƒ“(SF)‚ƃtƒBƒuƒŠƒ“ƒ‚ƒmƒ}[•¡‡‘Ì(FMC)ŽŽ–òŠÔ‚É‚æ‚阨—£ŒŸ“¢‚ÆŠeŒŸ¸‚Ì—L—p«‚ɂ‚¢‚Ä. TTMƒtƒH[ƒ‰ƒ€. 2007;6:53-63.
  3. –k“‡ŒM:ŒŒð‚ÆzŠÂ‚ÌŒŸ¸–@. ƒgƒƒ“ƒrƒ“¶¬–ÚˆÀ‚Æ‚µ‚Ä‚ÌTAT‚Æfibrin monomer‘ª’è–@‚Æ‚»‚̈Ӌ`. ŒŒð‚ÆzŠÂ. 2007;15:126-33.
  4. –k“‡ŒM:•a‰@ŒŸ¸Žº‚ÅŽÀ‘H‚Å‚«‚镪Žq•a‘ÔŒŸ¸–@ŠJ”­, “]ŽÊˆöŽqŠˆ«‰»ŒŸ¸‚Ì—Õ°‰ž—p‚ÉŒü‚¯‚Ä. —Õ°•a—. 2007;55:262-71.
  5. –k“‡ŒM:NF-κBŒ¤‹†‚ÌV“WŠJ. —Õ°‰»Šw. 2007;36:249-50.
  6. –k“‡ŒM:‹³ˆç—Í. —Õ°•a—. 2007;55:596.
  7. –k“‡ŒM:—Õ°‰»Šw‚Ì¡Œã‚Ì•ûŒü‚Æu—Õ°‰»ŠwvŽ‚Ì–ðŠ„. —Õ°‰»Šw. 2007;36:236-48.
  8. YàV˜a•F, “y“cŒj‘ , –k“‡ŒM:VŠƒŒ§’†‰z’nk”íÐŽÒzŠÂŠíŠO—ˆŠ³ŽÒ‚ÌDVT‚ÆŒŒ‰t‹ÃŒÅƒ}[ƒJ[‚ɂ‚¢‚Ä. TTMƒtƒH[ƒ‰ƒ€. 2007;6:71-3.

Šw‰ï•ñ

  1. Kitajima I.:Molecular role of tumor angiogenesis in hepatoma cells through constitutive interleukin-8 expression. 12th World congress on Advantages in Oncology and 10th Internatinal Symposium on Molecular Medicine, 2007, 10, 11-13, Crete, Greece. (Invited lecture)
  2. Kitajima I., and Tokoro T.:In search of Chinese Medicine showing molecular pharmacology efficacy against rheumatoid arthritis. Innovantive Team Program in Peking University-21st Century COE program in University of Toyama Joint Symposium. 2007, 6, 25, Biejing, China.
  3. Ohtsuka T.:Biochemistry of the presynaptic active zone , Gordon Research Canferencers, 2007, 6, 10-15, New Hampshire, USA(Invited lecture)
  4. Niimi H, and Moustakas A.:Notch signaling is necessary for epithelial growth arrest by TGF-β. The 8th TGF-β meeting, 2007, 5, 21-23, Uppsala, Sweden.
  5. Niimi H., and Moustakas A.:Notch signaling is necessary for epithelial growth arrest by TGF-β. International Conference "Phosphorylation, Signaling and Disease", 2007, 5, 16-20, Cold Spring Harbor Laboratory, USA.
  6. Tokoro T, Beppu H, Moriguchi S, Shioda N, Fukunaga K, Nishijo H, Niimi H, Ohtsuka T, En Li, and Kitajima I.:The analysis of ATRX mutant mice as a model of mild mental retardation. 2007 Keystone Synposia Epigenetics. 2007, 4-15, Cororado, USA
  7. Tokoro T and Kitajima I.:Proof of "SHO" in Rheumatoid Arthritis by cDNA array analysis. Innovantive Team Program in Peking University-21st Century COE program in University of Toyama Joint Symposium. 2007, 6, 25 , Biejing, China
  8. Tokoro T, Beppu H, Moriguchi S, Shioda N, Fukunaga K, Hori E, Nishijo H, Kitajima I and Li E.:The chomatin-remodeling gene ATRX mutant mice related to ADHD. 37th Annual meeting of Neuroscience. 2007, 11, 5, 2007, San Diego, USA
  9. Motomura H, Sugimori K, Kimura T and Kitajima I.:GAS6, New regulator of chondrogenic diffrentiation in mesenchymal cells. 53rd Annual Meeting of the Orthopaedic Research Society, 2007, 2, 11-14, San Diego, USA
  10. Shioda N, Tokoro T, Kitajima I, Beppu H and Fukunaga K.:Actication of CaM kinase II is implicated in generation of abnormal dendritic spines via Tiam1/PAK signaling in ATRX mutant mouse brain. 37th Annual meeting of Neuroscience 2007, 11, 5, 2007, San Diego, USA
  11. –k“‡ŒM:ŒŒðÇ‹}«Šú‚𔽉f‚·‚é‹ÃŒŒ•ªŽqƒ}[ƒJ[’Tõ‚Æ‚»‚Ì—Õ°‰ž—p, ‘æ7‰ñ•ªŽqŒŒŠÇŒ¤‹†‰ï, 2007, 1, 5, ‘åã(µ‘Òu‰‰)
  12. –k“‡ŒM:—₦‚Æ’É‚Ý‚É—R—ˆ‚·‚éœEŠÖߎ¾Š³‚ɑ΂·‚銿•û–ò‚Ì’Tõ‚Æ‚»‚Ì–ò—‹@˜‚̉ð–¾, •xŽRŒ§Š¿•û–òu‰‰‰ï, 2007, 1, 23, •xŽR
  13. –k“‡ŒM, ”öì’q”ü, ’J‚Ý‚ËŽq, ŽOè’q”Í, ‰Á”¨‘½•¶:ŒÒŠÖߎèp‚Ìp’†EpŒã‚É‚¨‚¯‚é‹ÃŒŒ•ªŽqƒ}[ƒJ[•Ï“®‚ÆDVTEPE”­Ç‚ÌŠÖŒW\‘I‘ð“IXa‘jŠQÜ‚Ì”­Ç—\–hŒø‰Ê‚ÌŒŸ“¢\ ‘æ7‰ñTTMƒtƒH[ƒ‰ƒ€, 2007, 3, 10, “Œ‹ž
  14. –k“‡ŒM:ŒŒðÇ‹}«Šú‚𔽉f‚·‚é‹ÃŒŒ•ªŽqƒ}[ƒJ[‚ɂ‚¢‚Ä, ‘æ22‰ñ’†•”’n‹æŒŒ‰tŒŸ¸Œ¤C‰ï, 2007, 3, 11, •xŽRiµ‘Òu‰‰j
  15. –k“‡ŒM:“]ŽÊˆöŽqŠˆ«‰»‰ðÍ–@‚ÌV‚½‚ÈŠm—§‚Æ—Õ°ŒŸ¸‚ւ̉ž—p, ‘æ26‰ñ“ú–{—Õ°‰»Šw‰ï‰ÄŠúƒZƒ~ƒi[, 2007, 7, 6, ˆÉ¨Žu–€
  16. –k“‡ŒM:‹ÃŒÅü—n•ªŽqƒ}[ƒJ[‚Ì—Õ°‰ž—p\ƒtƒBƒuƒŠƒ“ƒ‚ƒmƒ}[•¡‡‘Ì‚ÆŠeŽíŒŒðǂɂ‚¢‚Ä|, ‘æ8‰ñ“ú–{ŒŸ¸ŒŒ‰tŠw‰ïŠwpW‰ïƒZƒ~ƒi[, 2007, 7, 21, •Ÿˆäiµ‘Òu‰‰j
  17. –k“‡ŒM:ˆâ“`Žq‚Ì•sŽv‹c, •xŽRŒ§–¯‚ÌŒ’N‚ðl‚¦‚é‰ïŽs–¯ŒöŠJuÀ, 2007, 8, 12, •xŽR
  18. –k“‡ŒM, Š’, mˆäŒ©‰pŽ÷, ˆø–ÔG²:cDNAƒ}ƒCƒNƒƒAƒŒƒC‚ð—p‚¢‚½ŠÖ߃ŠƒEƒ}ƒ`‚É‚¨‚¯‚éØ‚ÌŒŸØ‚ÆŠ¿•û–ò‚Ì•ªŽq–ò—‹@\‰ð–¾, •xŽR‘åŠw21¢‹ICOEƒvƒƒOƒ‰ƒ€ƒVƒ“ƒ|ƒWƒEƒ€, 2007, 11, 16, •xŽR
  19. –k“‡ŒM, mˆäŒ©‰pŽ÷, Š’, —ÑŽj˜N:‘ã•\“I–¬f‚ÆŽ¾Š³‚ÌŠÖ˜A. •½¬18”N“x‰ÈŠw‹ZpU‹»’²®”ï. ‰ÈŠw‹Zp‚É•K—v‚È’²¸Œ¤‹†, Š¿•ûu–¬fvf’f–@‚̃JƒIƒX‰ð͂ƉȊw‰»Œ¤‹†•ñ‰ï, 2007, 3, 16, Ž­Ž™“‡
  20. –k“‡ŒM, Œ´“cŒ’‰E, mˆäŒ©‰pŽ÷, Žs–Ñ—R‹IŽq:—Õ°ŒŸ¸ŽÀKŒø‰ÊŒüã‚ð–ÚŽw‚µ‚½‘ìãŒ^ŒŸ¸‹@ŠíŠˆ—p‚Æ‚»‚ÌŠwK•]‰¿, ‘æ39‰ñ“ú–{ˆãŠw‹³ˆçŠw‰ï‘å‰ï, 2007, 7, 27, ·‰ª
  21. –k“‡ŒM:ƒƒ^ƒ{ƒŠƒbƒNƒVƒ“ƒhƒ[ƒ€‚Æ‚Í, •½¬19”N“x‘OŠú•xŽR‘åŠwŒöŠJuÀ, 2007, 8, 4, •xŽR
  22. –k“‡ŒM, –ìŽè—Ç„, ”öì’q”ü, ‰FŽ¡‹`‘¥, mˆäŒ©‰pŽ÷, ˆ¢•”Ž Ž÷, –å˜e³˜a, ŽRŒ`_ˆê:1•ªŽqŒuŒõ‘ŠŠÖ–@‚ð—p‚¢‚½“]ŽÊˆöŽqNF-κB‘ª’è‚É‚æ‚éS‘ŸŽüpŠúƒ‚ƒjƒ^[‚ւ̉ž—p, ‘æ54‰ñ“ú–{—Õ°ŒŸ¸ˆãŠw‰ïŠwpW‰ï, 2007, 11, 23, ‘åã
  23. ‘å’Ë–«‹v:_ŒoƒVƒiƒvƒXƒAƒeƒBƒuEƒ][ƒ“‚̶‰»Šw, ‘æ30‰ñ“ú–{•ªŽq¶•¨‰ï”N‰ï, 2007, 12, 11-15, ‰¡•l
  24. mˆäŒ©‰pŽ÷:ˆâ“`ŽqŒŸ¸‚ÌŒ»ó‚Æ«—ˆ“W–], ‹³ˆçu‰‰, ‘æ22‰ñ’†•”’n‹æŒŒ‰tŒŸ¸Œ¤C‰ï, 2007, 3, 10, •xŽR
  25. mˆäŒ©‰pŽ÷:real-time PCR‚ð—p‚¢‚½v‘¬‚È”sŒŒÇ‹Nˆö‹Û“¯’èƒVƒXƒeƒ€‚Ì\’z, ‘æ46‰ñ“ú–{—Õ°ŒŸ¸ˆãŠw‰ï“ŒŠCE–k—¤Žx•”‘‰ï, 2007, 3, 4, ŽOd
  26. mˆäŒ©‰pŽ÷, –ìŽè—Ç„, –k“‡ŒM:real-time PCR–@‚ð—p‚¢‚½v‘¬‚È”sŒŒÇ‹Nˆö‹Û“¯’èƒVƒXƒeƒ€‚Ì\’z‚ÉŠÖ‚·‚錤‹†, ‘æ39‰ñ“ú–{—Õ°ŒŸ¸Ž©“®‰»Šw‰ï‘å‰ï, 2007, 9, 27, ‰¡•lŽs
  27. mˆäŒ©‰pŽ÷, –ìŽè—Ç„, –k“‡ŒM, :v‘¬‚È”sŒŒÇ‹Nˆö‹Û“¯’èƒVƒXƒeƒ€‚Ì\’z‚ÉŠÖ‚·‚錤‹†, ‚Æ‚â‚ÜŽYŠwŒð—¬‰ï2007, 2007, 11, 21, •xŽRŽs
  28. mˆäŒ©‰pŽ÷, ”öì’q”ü, î’J»Žq, –ìŽè—Ç„, ‰FŽ¡‹`‘¥, ¬àV“N•v, –k“‡ŒM:‚“xæiˆã—ÂƂµ‚Ä‚Ìæ“V«‘æVIIˆöŽqŒ‡–RLjâ“`Žqf’f‚ÌŽæ‚è‘g‚Ý, ‘æ54‰ñ“ú–{—Õ°ŒŸ¸ˆãŠw‰ïŠwpW‰ï, 2007, 11, 24, ‘åãŽs
  29. Œ´“cŒ’‰E, â–{ƒŽq, Šp“c”ü—é, –k“‡ŒM:NSTŠˆ“®‚̉h—{ŠÇ—‚É‚¨‚¯‚érefeeding syndrome‚ƒ჊ƒ“ŒŒÇ‚Ìd—v«. ‘æ46‰ñ“ú–{—Õ°ŒŸ¸ˆãŠw‰ï“ŒŠCE–k—¤Žx•”‘‰ï, 2007, 3, 4, ’Ã
  30. Œ´“cŒ’‰E:ƒƒ^ƒ{ƒŠƒbƒNƒVƒ“ƒhƒ[ƒ€‚ÉŠÖ‚·‚錌‰tŒŸ¸’l‚Ì“Ç‚Ý•û. •½¬19”N“x‘OŠú•xŽR‘åŠwŒöŠJuÀ, 2007, 8, 4, •xŽR
  31. Œ´“cŒ’‰E:’´‰¹”g‚ł݂郃^ƒ{ƒŠƒbƒNƒVƒ“ƒhƒ[ƒ€. •½¬19”N“x‘OŠú•xŽR‘åŠwŒöŠJuÀ, 2007, 8, 4, •xŽR
  32. Œ´“cŒ’‰E, –k“‡ŒM, Žs–Ñ—RŠóŽq:ŒŸ¸‘ª’茴—‚ðŒø‰Ê“I‚ÉŽÀK‚Å‚«‚éƒc[ƒ‹‚Ö‚ÌPOCT‘ΉžŒ^¬Œ^Ž©“®•ªÍŠí‚̉ü‘¢‚Æ‚»‚ÌŠwKŒø‰Ê. ‘æ54‰ñ“ú–{—Õ°ŒŸ¸ˆãŠw‰ïŠwpW‰ï. 2007, 11, 23, ‘åã
  33. ã–ì’q_, ‰FŽ¡‹`‘¥, ŒKŒ´‘ì”ü, 쓇–ÒŽu, î’J»Žq, ’J‚Ý‚ËŽq, ŽÄ‘¥Žq, ‰œ“c’‰s, –k“‡ŒM, –{‹{‘P‰ø, ŽO‰Y‰ëˆê, ‹g“cç», ˆÀ“Œ—RŠì•v. ‘æ54‰ñ“ú–{—Õ°ŒŸ¸ˆãŠw‰ïŠwpW‰ï. 2007, 11 , 24, ‘åã
  34. ˆ¢•”Ž Ž÷, –å˜e³˜a, ŽRŒ`_ˆê, –k“‡ŒM:ŒuŒõ‘ŠŠÖ•ªŒõ–@‚ð—p‚¢‚½“]ŽÊˆöŽqŠˆ«v‘¬‘ª’è–@‚ÌŠJ”­. ‘æ22‰ñ¶‘Ì‹@”\ŠÖ˜A‰»ŠwƒVƒ“ƒ|ƒWƒEƒ€, 2007, 9, 28, å‘ä
  35. ŽOè’q”Í, ‰Á”¨‘½•¶, ‘O“c‹œ, â‰z‘åŒå, “à“¡[Œ[, ˆÀ“¡’q¬, •x“cŸ˜Y, ’J‚Ý‚ËŽq, –k“‡ŒM:ŒÒŠÖߎèp‚É‚¨‚¯‚ép’†, pŒã‚Ì‹ÃŒÅEü—nŒnƒ}[ƒJ[‚Ì•Ï“®. ‰Â—n«ƒtƒBƒuƒŠƒ“ƒ‚ƒmƒ}[•¡‡‘Ì‚É’…–Ú‚µ‚Ä, ‘æ37‰ñ“ú–{lHŠÖߊw‰ï, 2007, 2, 3, “Œ‹ž
  36. ŽRŠÝ–GŽq, X“c–¢, ‘½‰ê—R‹IŽq, â–{ƒŽq, ‹g“cˆèŽq, ‘å–å—Ç’j, mˆäŒ©‰pŽ÷, –k“‡ŒM, L‰H‰Â“ÞŒÄ, ¬‹´eW, rˆäM‹M, ¬—ѳ:L. pneumophila‚É‚æ‚é”x‰Š‚ð‹N‚±‚µ‚½2Ç—á. ‘æ46‰ñ“ú–{—Õ°ŒŸ¸ˆãŠw‰ï“ŒŠCE–k—¤Žx•”‘‰ï, 2006, 3, 4, ’Ã
  37. ”ä‰Ã i, Š’, –k“‡ŒM, ‘å’Ë–«‹v: SAD kinase directly phosphorylates the active zone protein Bassoon. Œ¤‹†—̈æu”]‚Ì”­’B‚ÆŠwKƒƒJƒjƒYƒ€‚̉ð–¾v‘æ4‰ñ—̈æ“àŒ¤‹†•ñ‰ï. 2007, 3, 6, ‘åã
  38. Š’, •Ê•{GK, ¼ðŽõ•v, mˆäŒ©‰pŽ÷, ‘å’Ë–«‹v, En Li, –k“‡ŒM:Œy“x¸_’x‘؃‚ƒfƒ‹ATRX•ÏˆÙƒ}ƒEƒX‰ðÍ. Œ¤‹†—̈æu”]‚Ì”­’B‚ÆŠwKƒƒJƒjƒYƒ€‚̉ð–¾v‘æ4‰ñ—̈æ“àŒ¤‹†•ñ‰ï. 2007, 3, 6, ‘åã
  39. Š’, •Ê•{GK, XŒû–ÎŽ÷, ‰–“c—ÏŽj, •Ÿ‰i_Ži, ¼ðŽõ•v, mˆäŒ©‰pŽ÷, ‘å’Ë–«‹v, En Li, –k“‡ŒM:Œy“x¸_’x‘؃‚ƒfƒ‹ATRX•ÏˆÙƒ}ƒEƒX‚̉ðÍ. ‘æ127‰ñ“ú–{–òŠw‰ï. 2007, 3, 28, •xŽR
  40. ã–ì’q_, ‰FŽ¡‹`‘¥, ŒKŒ´‘ì”ü, 쓇–ÒŽu, ’J‚Ý‚ËŽq, ŽÄ‘¥Žq, –ìŽè—Ç„, ‰œ“c’‰s, –k“‡ŒM:ƒLƒƒƒsƒ‰ƒŠ[“d‹C‰j“®‘•’u‚ð—p‚¢‚½ƒŠƒ|’`”’•ªÍ–@‚Ì•]‰¿. ‘æ32‰ñ–k—¤—Õ°•a—W’c‰ïE‘æ15‰ñ“¯ƒZƒ~ƒi[, 2007, 9, 8, ‹à‘ò
  41. ã–ì’q_, ‰FŽ¡‹`‘¥, ŒKŒ´‘ì”ü, 쓇–ÒŽu, ’J‚Ý‚ËŽq, ŽÄ‘¥Žq, –ìŽè—Ç„, ‰œ“c’‰s, –k“‡ŒM:ŒŒ´’†β2mƒAƒ~ƒƒCƒh‘O‹ì‘Ì’`”’Ž¿‚Ì•ªÍ–@. ‘æ32‰ñ–k—¤—Õ°•a—W’c‰ïE‘æ15‰ñ“¯ƒZƒ~ƒi[, 2007, 9, 8, ‹à‘ò
  42. ”öì’q”ü, ’J‚Ý‚ËŽq, ‰FŽ¡‹`‘¥, –k“‡ŒM:ŒÒŠÖߎèp‚Ìp’†EpŒã‚É‚¨‚¯‚é‹ÃŒŒ•ªŽqƒ}[ƒJ[‚Ì•Ï“®‚Æ‘I‘ð«Xa‘jŠQÜ‚É‚æ‚éÖ¬ŒŒðÇ‚Ì—\–hŒø‰Ê”»’è. “ú–{—Õ°ŒŸ¸Ž©“®‰»Šw‰ï‘æ39‰ñ‘å‰ï, 2007, 9, 27, ‰¡•l
  43. –ìŽè—Ç„, ”öì’q”ü, ‰FŽ¡‹`‘¥, mˆäŒ©‰pŽ÷, –k“‡ŒM:ŒŸ¸•”‚É‚¨‚¯‚é‚“xæiˆã—ÂƂµ‚Ä‚Ìæ“V«ŒŒ‰t‹ÃŒÅˆÙíLjâ“`Žq‰ðÍ10”N‚ÌŽæ‚è‘g‚Ý‚Æ¡Œã‚Ì“W–]. “ú–{—Õ°ŒŸ¸Ž©“®‰»Šw‰ï‘æ39‰ñ‘å‰ï, 2007, 9, 27, ‰¡•l
  44. ŽOè’q”Í, ‰Á”¨‘½•¶, ‘O“c‹œ, “à“¡[Œ[, ‘½‰ê³, ˆÀ“¡’q¬, •x“cŸ˜Y, –k“‡ŒM, ’J‚Ý‚ËŽq, ‰Á”¨çt, ŽR–{ Œ’, ’©‘q‰pô:ŒÒŠÖߎèp‚É‚¨‚¯‚ép’†, pŒã‚Ì‹ÃŒÅEü—nŒnƒ}[ƒJ[‚Ì•Ï“®\‰Â—n«ƒtƒBƒuƒŠƒ“ƒ‚ƒmƒ}[•¡‡‘Ì‚É’…–Ú‚µ‚Ä[. ‘æ5‰ñ–k—¤ŒŒðŒ¤‹†‰ï. 2007, 10, 6, ‹à‘ò
  45. Žß‰i´Žu, a’JLŽq, “ì ‰ë”ü, ’J‚Ý‚ËŽq, –k“‡ŒM, ŽRèŒõÍ:lH•GŠÖß’uŠ·p‚É‚¨‚¯‚錌ðÇEŽ_‰»ƒXƒgƒŒƒXƒ}[ƒJ[‚̉ðÍ]–ƒŒ•û–@‚É‚æ‚é”äŠr]. ‘æ5‰ñ–k—¤ŒŒðŒ¤‹†‰ï, 2007, 10, 6, ‹à‘ò
  46. Š’, –k“‡ŒM:ŠÖ߃ŠƒEƒ}ƒ`‚Ì–òŒø‚ðŽ¦‚·Š¿•û•ûÜ‚Ì’Tõ‚Æ“]ŽÊˆöŽqŠˆ«’²ß‹@”\‚̉ð–¾. •xŽR‘åŠw21¢‹ICOEƒvƒƒOƒ‰ƒ€ƒVƒ“ƒ|ƒWƒEƒ€, 2007, 11, 16, •xŽR
  47. ˆ¢•”Ž Ž÷, –å˜e³˜a, ŽRŒ`_ˆê, –k“‡ŒM:ŒuŒõ‘ŠŠÖ•ªŒõ•û‚ð—p‚¢‚½¶‘ÌŽŽ—¿’†‚Ì“]ŽÊˆöŽqŠˆ«v‘¬‘ª’è–@‚ÌŠJ”­. ‘æ54‰ñ“ú–{—Õ°ŒŸ¸ˆãŠw‰ïŠwpW‰ï, 2007, 11, 24, ‘åã
  48. ”öì’q”ü, –ìŽè—Ç„, ‰FŽ¡‹`‘¥, mˆäŒ©‰pŽ÷, ‘Oì^l, –k“‡ŒM:”ñÇŒóŒQ«“ªŠWœ‘Šú–ü‡Ç‚ÌŒ´ˆöˆâ“`Žq’Tõ. ‘æ54‰ñ“ú–{—Õ°ŒŸ¸ˆãŠw‰ïŠwpW‰ï, 2007, 11, 24, ‘åã

‚»‚Ì‘¼

  1. H‹ÆŠ“¾Œ , mˆäŒ©‰pŽ÷, –k“‡ŒM:Š´õÇ‹Nˆö‹Û‚Ìv‘¬“¯’è•û–@, ‘ÛoŠè”Ô†:PCT/JP2007/053078, 2007
  2. H‹ÆŽæ“¾Œ , –k“‡ŒM, ŽRŒ`_ˆê, ˆ¢•”Ž Ž÷:ƒXƒeƒƒCƒhŠ´Žó«‚Ì”»’è•û–@‹y‚Ñ‘Sg«‰ŠÇ”½‰žÇŒóŒQ‚Ì”­Ç—\‘ª•û–@, “Á‹–Šè2007-177135, 2007

ƒy[ƒW‚Ì擪‚Ö–ß‚é

2006”N

’˜‘

  1. –k“‡ŒM:d‹à‘®‚È‚ç‚Ñ‚ÉŠÖ˜A’`”’. •W€—Õ°ŒŸ¸ˆãŠwi’–Žë~, ’†Œ´ˆê•F•ÒW, ˆãŠw‘‰@, “Œ‹ž, 233-238, 2006
  2. –k“‡ŒM:—¬‚ꂪ‚í‚©‚éŽÀ‘HŒŸ¸ƒ}ƒjƒ…ƒAƒ‹ãŠªiŒŸ¸‚ÌŠî‘b’mŽ¯, ŒŸ¸ŠT—vji–k“‡ŒMŠÄCj, ƒƒfƒBƒJƒ‹ƒŒƒrƒ…[ŽÐ, “Œ‹ž, 1-235, 2006
  3. –k“‡ŒM:—¬‚ꂪ‚í‚©‚éŽÀ‘HŒŸ¸ƒ}ƒjƒ…ƒAƒ‹‰ºŠªi‘ŸŠí•ÊŽ¾Š³‚ɑ΂·‚錟¸‚Ì—¬‚êji–k“‡ŒMŠÄCj, ƒƒfƒBƒJƒ‹ƒŒƒrƒ…[ŽÐ, “Œ‹ž, 10-495, 2006
  4. ¬àV“N•v, –k“‡ŒM:Šˆ«‰»ƒvƒƒeƒCƒ“C ƒŒƒWƒXƒ^ƒ“ƒX, ŒŒðǃiƒrƒQ[ƒ^[i’r“cN•v, “àŽRTˆê˜Y, Œã“¡MÆ, d¼G, ”¼“c½•Òj, ƒƒfƒCƒJƒ‹ƒŒƒrƒ…[ŽÐ, “Œ‹ž, 102-103, 2006.

Œ´’˜

  1. Deguchi-Tawarada M, Inoue E, Takao-Rikitsu E, Unoue M, Kitajima I, Ohtsuka, T, Takai Y. The active zone protein CAST is a component of conventional and ribbon synapses in mouse retina. J Comp Neurol. 2006;495:480-96.
  2. Wang J, Tokoro T, Higa S, Kitajima I. Anti-inflammatory Effect of Pitavastatin on NF-„{B Activated by TNF-α in Hepatocellular Carcinoma Cells. Biol Pharm Bull 2006;24:634-9.
  3. Matsui K, Sugimori K, Motomura H, Ejiri N, Tsukada K, Kitajima I. PEA3 cooperates with c-Jun in regulation of HER2/neu transcription. Oncology Reports. 2006;16:153-8.
  4. Inoue E, Mochida S, Takagi H, Higa S, Deguchi-Tawarada M, Unoue M, Yao I, Takeuchi K, Kitajima I, Setou M, Ohtsuka T, Takai Y. SAD: a novel presynaptic kinase associated with synaptic vesicles and the active zone cytomatrix that regulates neurotransmitter release. Neuron. 2006;50:261-75.
  5. Inoue E, Deguchi-Tawarada M, Takao-Rikitsu E, Inoue M, Ohtsuka T, Takai Y. ELKS, a protein structurally related to the active zone protein CAST, is involved in Ca-dependent exocytosis from PC12 cells. Gene Cells. 2006;11:659-72.
  6. Lansbergen G, Grigoriev I, Mimori-Kiyosue Y, Ohtsuka T, Higa S, Kitajima I, Demmers J, Galjart N, Houtsmuller AB, Grosveld F, Akhmanova A. CLASPs attach microtube plus ends to the cell cortex through a complex with LL5β. Dev Cell. 2006;11:21-32.
  7. Fujioka S, Hamazaki K, Itomura M, Huan M, Nishizawa H, Sawazaki S, Kitajima I, Hamazaki T. The effects of eicosapentaenoic acid-fortified food on inflammatory markers in healthy subjects-A randomized, placebo-controlled, double-blind study. J Nurtr Sci Vitaminol. 2006;52:261-5.
  8. Higa S, Tokoro T, Inoue E, Kitajima I, Ohtsuka T. The active zone protein CAST diretly associates with ligand of Numb protein X. Biochem Biophysic Res Commun. 2007;354:686-92.
  9. ”öì’q”ü, ’J‚Ý‚ËŽq, 쓇–ÒŽu, ‘å–å—Ç’j, –k“‡ŒM:Point of Care Testing(POCT)“±“ü‚ð–ÚŽw‚µ‚½‰Â—n«ƒtƒBƒuƒŠƒ“ƒ‚ƒmƒ}[•¡‡‘Ì(SFMC)‘SŒŒ‘ª’è–@‚ÌŒŸ“¢. “ú–{—Õ°ŒŸ¸Ž©“®‰»Šw‰ï‰ïŽ 2006;30:727-31.
  10. –k“‡ŒM:‰Â—n«ƒtƒBƒuƒŠƒ“(SF)‚ƃtƒBƒuƒŠƒ“ƒ‚ƒmƒ}[•¡‡‘Ì(FMC). “ú–{ŒŸ¸ŒŒ‰tŠw‰ïŽGŽ 2006;7:470-7.

‘à

  1. –k“‡ŒM:ŒŸ‘ÌŒŸ¸ƒsƒbƒgƒtƒH[ƒ‹. ˆã•ñ‚Æ‚â‚Ü. 2006;1409:10-1.
  2. –k“‡ŒM:‘ìã“dŽqŒ°”÷‹¾. •xŽRŽsˆãŽt‰ï‰ï•ñ. 2006;424:6-8.
  3. –k“‡ŒM:—Õ°‰»Šw‚ÌŽ‹“_‚É‚æ‚éƒAƒ‹ƒcƒnƒCƒ}[•aÅ‘Oü. —Õ°‰»Šw. 2006;35:320-1.
  4. ‘å’Ë–«‹v:Ž„‚ª–¼•t‚¯‚½ˆâ“`Žq, ƒAƒNƒeƒBƒuƒ][ƒ“‚̃ƒCƒ“ƒLƒƒƒXƒgCAST ŽÀŒ±ˆãŠw. 2006;24:875-7.
  5. ‘å’Ë–«‹v, ˆäã‰p“ñ:_Œo×–E‚Ì‹É«Œ`¬‚ðŽi‚éSAD ƒLƒi[ƒ[‚Í_Œo“`’B•¨Ž¿‚Ì•úo‚ð§Œä‚·‚é. ×–EHŠw. 2006;25:776-7.
  6. ‘å’Ë–«‹v:_ŒoƒVƒiƒvƒXƒAƒNƒeƒBƒuƒ][ƒ“‚Ì\‘¢‚Æ‹@”\ ¶‰»Šw. 2006;78:979-86.
  7. mˆäŒ©‰pŽ÷, –k“‡ŒM:×–E“àƒVƒOƒiƒ‹“`’B‰ðÍ‚Ì—Õ°ŒŸ¸Œ»ê‚Ö‚Ì“WŠJ. Medical Technology. 2006;34:122-3.
  8. ”öì’q”ü, –k“‡ŒM:‰Â—n«ƒtƒBƒuƒŠƒ“. V‚µ‚¢—Õ°ŒŸ¸E–¢—ˆ‚Ì—Õ°ŒŸ¸. ŒŸ¸‚Æ‹Zp. 2006;34:1099-100.

Šw‰ï•ñ

  1. Kitajima I, Sugimori K: Bone morphogenic protein-2 requires phosphorylation of NF-κB p65 and nuclear accumulation of IKK-α in chondrocyte differntiation and survival. 2006 Keystone Synposia Conference. NF-κB: 20 years on road from biochemistry to pathology. 2006, 3, Banff, Canada.
  2. Sugimori K, Motomura H, Kitajima I, Matsui K, Kimura T: The relationship between BMP-2 and PI3K/Akt-NF-κB activation pathway in chondrogenesis. 52nd Annual Meeting of the Orthopaedic Research Society, 2006, 3, Chicago, USA.
  3. Niimi H, Pardali K, Heldin C-H, Moustakas A: Notch signaling is necessary for epithelial growth arrest by TGF-β. 7th TGF-β meeting, 2006, 5, Uppsala, Sweden.
  4. Hanzawa K, Hayashi J-I, Nakajima T, Kitajima I, Tsuchida K: Economy class syndrome (venous thromboembolism) in midle Niigata prefecture earthquake 2004. 8th Asia Conference on Disaster Medicine (APCDM)-Global Collaboration for Disaster response-, 2006, 11, Tokyo, Japan
  5. –k“‡ŒM:ŒŸ¸•”‚̈ӎ¯‰üŠv. •xŽRŒ§—Õ°‰q¶ŒŸ¸‹ZŽt¶ŠU‹³ˆçƒZƒ~ƒi[. 2006, 1, •xŽR.
  6. –k“‡ŒM:ŒŒðÇ‚Ì‹}«Šú‚𑨂¦‚é‹ÃŒÅ•ªŽqƒ}[ƒJ[EƒtƒBƒuƒŠƒ“ƒ‚ƒmƒ}[•¡‡‘Ì. ƒtƒH[ƒ‰ƒ€•xŽRu‘n–òv‘æ18‰ñŒ¤‹†‰ï. 2006, 2, •xŽR.
  7. –k“‡ŒM:SF ‚ÆFMC. ‘æ7‰ñ“ú–{ŒŸ¸ŒŒ‰tŠw‰ïŠwpW‰ïƒeƒNƒjƒJƒ‹ƒZƒ~ƒi[. 2006, 7, “Œ‹ž.
  8. –k“‡ŒM:ŽŸ¢‘ã—Õ°‰»Šw‚Ì‚½‚ß‚É¡‚·‚ׂ«‚±‚Æ:lÞˆç¬, ˆãŽt‹³ˆç‚Ì—§ê‚©‚ç, ‘æ25‰ñ“ú–{—Õ°‰»Šw‰ÄŠúƒZƒ~ƒi[, 2006. 8, ŽD–y.
  9. –k“‡ŒM:ˆã—ÂɎ¿‚ÌŒüã‚ÆŠ³ŽÒ’†S‚̈ã—Âð–ÚŽw‚µ‚½ŒŸ¸•”‚̃}ƒlƒWƒƒ“ƒg. ‘æ25‰ñ“ú–{—Õ°ŒŸ¸ˆãŠw‰ï“ŒŠCE–k—¤Žx•”—á‰ï. 2006, 9, “à“å.
  10. –k“‡ŒM:ˆã—Â̎¿‚ÌŒüã‚ÆŒŸ¸•”‘¶Ý‰¿’l‚ð‚‚ß‚éV‚µ‚¢ŒŸ¸ƒVƒXƒeƒ€“±“üƒXƒgƒ‰ƒeƒW[. ‘æ45‰ñ’†•”ˆãŠwŒŸ¸Šw‰ïƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[, 2006, 9, ’Ã.
  11. –k“‡ŒM:“]ŽÊˆöŽqŒ¤‹†‚ÌŽ‹“_‚©‚猩‚½—Õ°ŒŸ¸ˆãŠw‚Ì–£—Í. ‘æ1‰ñ•a‘Ôî•ñ‰ðÍŠwƒZƒ~ƒi[. 2006, 10, ŒF–{.
  12. –k“‡ŒM:—Õ°ŒŸ¸‚Ì–¢—ˆ‚ðØ‚èŠJ‚­V‚µ‚¢ŒŸ¸ƒVƒ“ƒ|ƒEƒ€:•a‰@ŒŸ¸Žº‚ÅŽÀ‘H‚Å‚«‚镪Žq•a‘ÔŒŸ¸–@ŠJ”­i“]ŽÊˆöŽqŠˆ«‰»ŒŸ¸‚Ì•ªŽq•a‘ÔŒŸ¸–@ŠJ”­j. ‘æ53‰ñ“ú–{—Õ°ŒŸ¸ˆãŠw‰ïŠwpW‰ï. 2006, 11, O‘O.
  13. –k“‡ŒM:äPŒ´•a‚ÌÇó‚Æf’f. ‘æ1‰ñäPŒ´•aŽx‰‡ƒlƒbƒgƒ[ƒN‘‰ïˆã—Ãu‰‰‰ï. 2006, 11, ‹à‘ò.
  14. –k“‡ŒM. ‹{è—Ljê, ”~Œ´‹v”Í:Žá”NäPŒ´•a‚Æ”DPoŽY. ‘æ1‰ñäPŒ´•aƒlƒbƒgƒ[ƒN‘‰ïƒ[ƒNƒVƒ‡ƒbƒv, 2006, 11, ‹à‘ò.
  15. –k“‡ŒM:“]ŽÊˆöŽqNF-κB‚©‚çŽa‚镪Žq•a‘Ô. ‘æ3‰ñ•xŽR‘åŠw•a‰@•a—•”ƒZƒ~ƒi[. 2006, 2 •xŽR.
  16. ‘å’Ë–«‹v:_Œo×–E‚Ì‹É«Œ`¬‚ðŽi‚éSAD ƒLƒi[ƒ[‚Ì\‘¢‚Æ‹@”\. “ú–{•ªŽq¶•¨Šw‰ï2006 ƒtƒH[ƒ‰ƒ€, •ªŽq¶•¨Šw‚Ì–¢—ˆ. 2006, 12, –¼ŒÃ‰®.
  17. ‘å’Ë–«‹v _ŒoI––ƒAƒNƒeƒBƒuEƒ][ƒ“‚ÌŒ`¬‚Æ‹@”\‚É‚¨‚¯‚éSAD ƒLƒi[ƒ[‚Ì–ðŠ„. ‘æ29‰ñ“ú–{_Œo‰ÈŠwŠw‰ï‘å‰ï. 2006, 7, ‰¡•l.
  18. ‘å’Ë–«‹v:SAD ƒLƒi[ƒ[‚É‚æ‚é_Œo“`’B•¨Ž¿•úo‚Ì•ªŽq‹@\. ¶—ŠwŒ¤‹†‰ïƒVƒiƒvƒX‰Â‘Y«‚Ì•ªŽqŠî”Õ. 2006, 6, ‰ªè.
  19. ŽRŠÝ–GŽq, X“c–¢, ‘½‰ê—R‹IŽq, â–{ƒŽq, ‹g“cˆèŽq, ‘å–å—Ç’j, –k“‡ŒM:ƒ}ƒCƒNƒƒXƒLƒƒƒ“Rapid plus ƒpƒlƒ‹‚ð—p‚¢‚½‹ÛŒŒÇ‚Ìv‘¬f’f•ñ‚ÌŽŽ‚Ý. ‘æ45‰ñ“ú–{—Õ°ŒŸ¸ˆãŠw‰ïE“ŒŠC–k—¤Žx•”‘‰ï. 2006, 3, •l¼.
  20. –ìŽè—Ç„, î’J»Žq, X“c–¢, ‘½‰ê—R‹IŽq, â–{ƒŽq, ‹g“cˆèŽq, ‘å–å—Ç’j, mˆäŒ©‰pŽ÷, –k“‡ŒM:Real-time PCR–@‚ð—p‚¢‚½v‘¬‚È”sŒŒÇ‹Nˆö‹Û“¯’èƒVƒXƒeƒ€\’z‚ÌŒŸ“¢. ‘æ45‰ñ“ú–{—Õ°ŒŸ¸ˆãŠw‰ïE“ŒŠC–k—¤Žx•”‘‰ï. 2006, 3, •l¼.
  21. ”öì’q”ü, ’J‚Ý‚ËŽq, 쓇–ÒŽu, ‘å–å—Ç’j, –k“‡ŒM:ƒtƒBƒuƒŠƒ“ƒ‚ƒmƒ}[•¡‡‘ÌiFMCj‚Ɖ—n«ƒtƒBƒuƒŠƒ“iSFj‚̘¨—£ó‹µ‚Æ—Õ°“IˆÓ–¡. ‘æ45‰ñ“ú–{—Õ°ŒŸ¸ˆãŠw‰ïE“ŒŠC–k—¤Žx•”‘‰ï. 2006, 3, •l¼.
  22. Š’, •Ê•{GK, XŒû–ÎŽ÷, ‰–“c—ÏŽj, •Ÿ‰i_Ži, –x‰x˜Y, ã–ìÆŽq, ¬–ì•”N, ¼ðŽõ•v, ‘å’Ë–«‹v, En Li, –k“‡ŒM:ƒNƒƒ}ƒ`ƒ“ƒŠƒ‚ƒfƒŠƒ“ƒO•ªŽqATRX ”­Œ»’ቺƒ}ƒEƒX‚Ì‹L‰¯EŠwKáŠQ. CREST ‘æ3‰ñ”]‚Ì‹@”\”­’B‚ÆŠwKƒƒJƒjƒYƒ€‚̉𖾗̈æ“àŒ¤‹†•ñ‰ï. 2006, 3, ‘åã.
  23. –k“‡ŒM, ŽRŒûŒjŽi, ”öì’q”ü, ’J‚Ý‚ËŽq:SFEFMC ŽŽ–òŠÔ‚É‚¨‚¯‚阨—£ŒŸ“¢‚ÆŠeŒŸ¸‚Ì—L—p«‚ɂ‚¢‚Ä. ‘æ6‰ñTTM (Thrombosis & Thrombolysis Markers Forum). 2006, 3, “Œ‹ž
  24. Y‘ò˜a•F, “y“cŒj‘ , –k“‡ŒM:VŠƒŒ§’†‰z’nk”íÐŽÒŠ³ŽÒzŠÂŠíŠO—ˆŠ³ŽÒ‚ÌDVT ‚ÆŒŒ‰t‹ÃŒÅƒ}[ƒJ[‚ɂ‚¢‚Ä. ‘æ6‰ñTTM (Thrombosis & Thrombolysis Markers Forum). 2006. 3, “Œ‹ž.
  25. Œ³‘º‘ñ, mˆäŒ©‰pŽ÷, ™Xˆêm, ‘å’Ë–«‹v, –Ø‘º—FŒú, –k“‡ŒM:–¢•ª‰»ŠÔ—tŒn×–E‚ÌGrowth Arrest Specific 6 ‚ð‰î‚·‚é“ª‰»’²ß‹@\. ‘æ24‰ñ“ú–{œ‘ãŽÓŠw‰ïŠwpW‰ï. 2006, 7, “Œ‹ž.
  26. mˆäŒ©‰pŽ÷, –ìŽè—Ç„, î’J»Žq, –k“‡ŒM:•xŽR‘åŠw•‘®•a‰@ˆâ“`ŽqŒŸ¸ŽºŠJÝ‚É”º‚¤æ“V«ŒŒ‰t‹ÃŒÅˆÙíljðÍó‹µ. ‘æ2‰ñ–k—¤ŒŒðŽ~ŒŒƒZƒ~ƒi[. 2006, 7, ‹à‘ò.
  27. î’J»Žq, –ìŽè—Ç„, ŠÝ“c‚Ý‚©, ‘å–å—Ç’j, mˆäŒ©‰pŽ÷, –k“‡ŒM:ƒAƒ~ƒmŽ_‘¤½ƒtƒFƒjƒ‹Šî‚Ì—L–³‚ªFV ’`”’‹@”\‚ɉe‹¿‚ð—^‚¦‚邱‚Æ‚ª‰ð–¾‚Å‚«‚½V‹Kæ“V«‘æV ˆöŽqŒ‡–RÇiPhe190Serj. ‘æ7‰ñ“ú–{ŒŸ¸ŒŒ‰tŠw‰ïŠwpW‰ï. 2006, 7, “Œ‹ž.
  28. ‹g“cŒd, ‚‘q—Œb, ”öì’q”ü, î’J»Žq, 쓇–ÒŽu, ’J‚Ý‚ËŽq, ŒKŒ´‘ì”ü, ‘å–å—Ç’j, å‹v”T, –쑺ŒbŽq, ‹àŒ“O˜a, –k“‡ŒM:ԉ苅Œn×–E‚Ì‘‰Á‚𔺂Á‚½Žá”N«œ‘’P‹…«”’ŒŒ•aiJMMLj‚Ì1 Ç—á. ‘æ31‰ñ–k—¤—Õ°•a—W’k˜b‰ï. 2006, 8, •xŽR.
  29. ‹g“cˆèŽq, ŽRŠÝ–GŽq, X“c”ü, â–{ƒŽq, –ìŽè—Ç„, ‘å–å—Ç’j, •½“‡¬•S‡, –k“‡ŒM:“ú—§‘ìã“dŽqŒ°”÷‹¾TM-1000Miniscope ‚ÌŽg—pŒoŒ±. ‘æ31‰ñ–k—¤—Õ°•a—W’k˜b‰ï. 2006, 8, •xŽR.
  30. ×’JFŽq, ²’|ˆÉ’ÃŽq, ¬£—Œb, ‰„–ì^‹|, —ÑŽj˜Y, Œ´“cŒ’‰E, –k“‡ŒM, “¹‹ïL_:Œz“®–¬ƒGƒR[‚Åf’f‚É‹ê—¶‚·‚鋑匌ð—l\‘¢•¨‚ð”F‚ß‚½ˆêÇ—á. ‘æ31‰ñ–k—¤—Õ°•a—W’k˜b‰ï. 2006, 8, •xŽR.
  31. ²’|ˆÉ’ÃŽq, ×’JFŽq, ¬£—Œb, ‰„–ì^‹|, —ÑŽj˜Y, Œ´“cŒ’‰E, –k“‡ŒM:ˆÓŽ¯ÁŽ¸”­ì‚𔺂Á‚½”xÇðŒŒðÇ‚ÌŒo‰ß•ñ. ‘æ31‰ñ–k—¤—Õ°•a—W’k˜b‰ï. 2006, 8, •xŽR.
  32. ŽÄ‘¥Žq, Šp“c”ü—é, ‘½‰ê—R‹IŽq, ã–ì’q_, ‰¡“cˆ», ‘å–å—Ç’j, –k“‡ŒM:PhD ƒVƒXƒeƒ€IFA ƒ‚ƒWƒ…[ƒ‹‚ð—p‚¢‚½RŠjR‘ÌŒŸ¸iHep-2j‘ª’è‚ÌŠî‘b“IŒŸ“¢. ‘æ31‰ñ–k—¤—Õ°•a—W’k˜b‰ï. 2006, 8, •xŽR.
  33. –k“‡ŒM, Œ´“cŒ’‰E, Žs–Ñ—RŠóŽq, ŽðˆäçŽ÷:‘ì㎩“®ŒŸ¸‹@Ší‚ð—p‚¢‚½—Õ°‰»Šw‚ÉŠÖ‚·‚éˆãŠw•”Šw¶ŽÀK‚ւ̉ž—p. ‘æ46‰ñ“ú–{—Õ°‰»Šw”N‰ï. 2006, 9, “Œ‹ž.
  34. –k“‡ŒM, ‘ü–ìd‘¾˜Y:ƒe[ƒ}‚Íu—Õ°ŒŸ¸‚ÌŒ´“_‚ÍfŽ@Žº‚É—L‚è`‚ǂ̂悤‚ȈãŽt‚ðˆç‚Ä‚é‚©`v. “ú—§»ìŠƒp[ƒ\ƒiƒ‹Eƒwƒ‹ƒXƒPƒAƒxƒ“ƒ`ƒƒ[ƒJƒ“ƒpƒj[EƒZƒ~ƒi[. 2006, 9, “Œ‹ž.
  35. ‰œ“c’‰s, –k“‡ŒM, •Ÿ‰išæ’£°:Ž©“®ŒŒ‰tƒKƒX•ªÍ‘•’uRoche ŽÐOMNIS ‚¨‚æ‚у‰ƒWƒIƒ[ƒ^[ŽÐABL800 ‚É‚¨‚¯‚錟“¢. ‘æ38‰ñ“ú–{—Õ°ŒŸ¸Ž©“®‰»Šw‰ï‘å‰ï. 2006, 10, _ŒË.
  36. ŽÄ‘¥Žq, Šp“c”ü—é, ã–ì’q_, ‘å–å—Ç’j, –k“‡ŒM:EVOLIS ‚ðŽg—p‚µ‚½PIVKA-II ’ZŽžŠÔ‘ª’è‚ÌŠî‘b“IŒŸ“¢. ‘æ38‰ñ“ú–{—Õ°ŒŸ¸Ž©“®‰»Šw‰ï‘å‰ï. 2006, 10, _ŒË
  37. ŒKŒ´‘ì”ü, ’J‚Ý‚ËŽq, ”öì’q”ü, ‚‘q—Œb, î’J»Žq, ã–ì’q_, 쓇–ÒŽu, ‘å–å—Ç’j, –k“‡ŒM:‘½€–ÚŽ©“®ŒŒ‹…•ªÍ‘•’uXE-2100 ‚ð—p‚¢‚½”jÓÔŒŒ‹…‘ª’è‚Ì—L—p«‚ɂ‚¢‚Ä. ‘æ38‰ñ“ú–{—Õ°ŒŸ¸Ž©“®‰»Šw‰ï‘å‰ï. 2006, 10, _ŒË.
  38. mˆäŒ©‰pŽ÷, –k“‡ŒM, –ìŽè—Ç„:Real-time PCR ‚ð—p‚¢‚½v‘¬‚È”sŒŒÇ‹Nˆö‹Û“¯’èƒVƒXƒeƒ€‚Ì\’z. ‘æ38‰ñ“ú–{—Õ°ŒŸ¸Ž©“®‰»Šw‰ï‘å‰ï. 2006, 10, _ŒË.
  39. mˆäŒ©‰pŽ÷, —ÑŽj˜Y, ŽðˆäL–ç, “ìàVŒ‰, “ˆ“c–L, –k“‡ŒM:–¬fE؂ƃJƒIƒX‰ðÍ‚Ì‘ŠŠÖ‚ɂ‚¢‚Ä(‘æ2•ñ). •½¬18”N“x‘æˆê‰ñ‰ÈŠw‹ZpU‹»’²®”ïuŠ¿•ûu–¬fvf’f–@‚̃JƒIƒX‰ð͂ƉȊw‰»v¬‰ÊŒŸ“¢‰ï. 2006, 11, •xŽR.
  40. ‰œ“c’‰s, –k“‡ŒM, •Ÿ‰iŽõ°:•xŽRŒ§‚É‚¨‚¯‚錌‰tƒKƒX•ªÍƒRƒ“ƒgƒ[ƒ‹ƒT[ƒxƒCŠî€’l‚ðŠO‚ꂽŒ´ˆö‚ÌŒŸ“¢. ‘æ53‰ñ“ú–{—Õ°ŒŸ¸ˆãŠw‰ïŠwpW‰ï. 2006, 11, O‘O.
  41. ’J‚Ý‚ËŽq, •£ã‰fŽq, ŽRŒûŒjŽi, YàV˜a•F, —уˆê, “y“cŒj‘ , –k“‡ŒM:VŠƒ’†‰z’nk”íÐŽÒ‚É‚¨‚¯‚éŒoŽž“I‹ÃŒŒ•ªŽqƒ}[ƒJ[‚̕ω». ‘æ53‰ñ“ú–{—Õ°ŒŸ¸ˆãŠw‰ïŠwpW‰ï. 2006, 11, O‘O.
  42. mˆäŒ©‰pŽ÷, –ìŽè—Ç„, î’J»Žq, ”öì’q”ü, –k“‡ŒM:ˆâ“`ŽqŒŸ¸ŽºŠJÝ‚É”º‚¤ˆâ“`ŽqŒŸ¸f’fƒVƒXƒeƒ€\’z‚̈Ӌ`‚Æ‚»‚Ì‰ðŒˆ‚·‚ׂ«–â‘è“_. ‘æ53‰ñ“ú–{—Õ°ŒŸ¸ˆãŠw‰ïŠwpW‰ï. 2006, 11, O‘O.
  43. ŒKŒ´‘ì”ü, ã–ì’q_, 쓇–ÒŽu, ‹g“cŒd, ”öì’q”ü, ã–ì—R”ü, ‚‘q—Œb, ‰¡“cˆ», Šp“c”ü—é, ’J‚Ý‚ËŽq, ŽÄ‘¥Žq, ‘å–å—Ç’j, –k“‡ŒM:Œo”ï팸‚ð–Ú“I‚Æ‚µ‚½¶‰»Šw–Ɖu•ªÍƒVƒXƒeƒ€‚Ì\’z‚Æ‚»‚Ì“±“üŒø‰Ê‚ɂ‚¢‚Ä. ‘æ53‰ñ“ú–{—Õ°ŒŸ¸ˆãŠw‰ïŠwpW‰ï. 2006, 11, O‘O.
  44. ‹g“cˆèŽq, X“c”ü, ŽRŠÝ–GŽq, â–{ƒŽq, –ìŽè—Ç„, ‘å–å—Ç’j, •½“‡¬•S‡, –k“‡ŒM:“ú—§‘ì㌰”÷‹¾TM-100Miniscope ‚ð—p‚¢‚½×‹Û‰æ‘œ‚ɂ‚¢‚Ä. ‘æ53‰ñ“ú–{—Õ°ŒŸ¸ˆãŠw‰ïŠwpW‰ï. 2006, 11, O‘O.
  45. ‹{—Ñç’ߎq, ˆÀ‘º•q, ‘½—t“cËŽq, “¹–ì~Žq, ]”¦˜a”ü, ¼–ìŽåáÁ, –k“‡ŒM:V”CŠÅŒìŽm‚ւ̈À‘S‚È—AŒŒ‚ÌŽæ‚舵‚¢‚Ì‚½‚ß‚Ì‹³ˆç‚ɂ‚¢‚Ä. ‘æ24‰ñ“ú–{—AŒŒŠw‰ï–k—¤Žx•”‘‰ï. 2006, 11, •Ÿˆä.
  46. “¹–ì~Žq, ‘½—t“cËŽq, ¼–ìŽåáÁ, ‹{—Ñç’ߎq, ]”¦˜a”ü, ˆÀ‘º•q, –k“‡ŒM, ŽR’J–¾Žq:RDib ‚ð—L‚·‚é•s“K‡”DP‚̈ê—á. ‘æ24‰ñ“ú–{—AŒŒŠw‰ï–k—¤Žx•”‘‰ï. 2006, 11, •Ÿˆä.
  47. Œ´“cŒ’‰E, –k“‡ŒM, ‹g‘º’¼Ž÷, ŽOè‘ñ˜Y, “n粈»‰À, Žs“c•™Žq, ‹{˜e—˜’j:ƒ[ƒtƒ@ƒŠƒ“ƒRƒ“ƒgƒ[ƒ‹—ÇD‚àŒŒð•Ù‚ðŒJ‚è•Ô‚·’PSŽº‚ÌlH•Ù’uŠ·pŒã3ÎŽ™’jŽ™. ‘æ4‰ñ–k—¤DICŒ¤‹†‰ï. 2006, 11, ‹à‘ò.
  48. —é–Ør•ã, Singhirunnunsom Pattama, ŽR‰ª¸Ži, –k“‡ŒM, ϖ؈ç•v, ŸNˆäG–¾:HTLV-I Tax ‚Ì‚æ‚éPí“ITAK1Šˆ«‰»‚Æ‚»‚Ì×–E“àƒVƒOƒiƒ‹‹@\‚É‚¨‚¯‚é–ðŠ„. •ªŽq¶•¨Šw‰ï2006 ƒtƒH[ƒ‰ƒ€, •ªŽq¶•¨Šw‚Ì–¢—ˆ. 2006, 12, –¼ŒÃ‰®.
  49. Š’, ”ä‰Ãi, –k“‡ŒM, ‘å’Ë–«‹v:ƒ}ƒEƒX_Œo‹ØÚ‡•”‚É‚¨‚¯‚éƒAƒNƒeƒCƒuƒ][ƒ“’`”’Ž¿CAST/ELKS ‚Ì‹ÇÝ. •ªŽq¶•¨Šw‰ï2006 ƒtƒH[ƒ‰ƒ€, •ªŽq¶•¨Šw‚Ì–¢—ˆ. 2006, 12, –¼ŒÃ‰®.
  50. Higa S, Inoue E, Tokoro T, Kitajima I, Ohtsuka T: The active zone protein CAST directly associates with the ligand Numb. •ªŽq¶•¨Šw‰ï2006ƒtƒH[ƒ‰ƒ€, •ªŽq¶•¨Šw‚Ì–¢—ˆ. 2006, 12, –¼ŒÃ‰®.
  51. Œ´“cŒ’‰E:’`”’, ƒAƒ~ƒmŽ_‘ãŽÓ‚̈ê”ÊŒŸ¸. ‘æ28‰ñNST •×‹­‰ï. 2006, 7, •xŽR.
  52. Œ´“cŒ’‰E:’჊ƒ“ŒŒÇ‚ÆRefeeding Syndrome. ‘æ33‰ñNST •×‹­‰ï. 2006, 12, •xŽR.

‚»‚Ì‘¼

  1. –k“‡ŒM:•ªŽq•a‘Ô‰ðÍ–@‚ð—p‚¢‚½“Œ—mˆãŠwf’f–@‰ð–¾. ㌴‹L”O¶–½‰ÈŠwà’cŒ¤‹†•ñW19: 65-67, 2005.
  2. –k“‡ŒM:‘æ18‰ñŒ¤‹†‰ï•ñ. ƒtƒH[ƒ‰ƒ€•xŽRu‘n–òvNews No6: 6-7, 2006.
  3. ‘å’Ë–«‹v:_Œo‰ñ˜H‚̃ƒJƒjƒYƒ€‚𕪎qƒŒƒxƒ‹‚ʼnð–¾. ŽÀ‹Æ”V•xŽRNo8: 40-42, 2006.

ƒy[ƒW‚Ì擪‚Ö–ß‚é

2005”N

’˜‘

  1. –k“‡ŒM:ƒgƒƒ“ƒrƒ“AŽ_‰»ƒXƒgƒŒƒXƒiƒrƒQ[ƒ^[(‘q—ѳ•FAŽRŠÝ¹ˆê•Ò)AƒƒfƒCƒJƒ‹ƒŒƒrƒ…[ŽÐAp90-91A2005
  2. –k“‡ŒM:SIRS‚Ì—Õ°ŒŸ¸-“]ŽÊˆöŽq‚É‚æ‚é•a‘Ô‰ðÍBˆãŠw‚Ì‚ ‚ä‚Ý:ŒŒ‰tŽ¾Š³-state of arts (â“c—mˆêA¬àVŒ[–ç•Ò)@ˆãŽ•–òo”ÅŠ”Ž®‰ïŽÐAp272-273A2005
  3. –k“‡ŒM:ŒŒ‰tE‹ÃŒÅü—nŒŸ¸(“ú–{“œ”A•aŠw‰ï@•Ò)A“œ”A•aŠw‚Ìi•à2005Af’f‚ÆŽ¡—ÃŽÐAp50-52A2005
  4. –k“‡ŒM:50l‚Ìê–åˆã‚ª‹³‚¦‚é•a‹C‚ÆŒŸ¸‚Ì‚Í‚È‚µB(“ú–{—Õ°ŒŸ¸ˆã‰ï@ŠÄC)A(ŽÐ)“ú–{‰q¶ŒŸ¸Š‹³‰ïA(Š”)¯‰_ŽÐAp60-62A2005

Œ´’˜

  1. Wang J, Tokoro T, MatsuiK, Higa S, Kitajima I: Pitavastatin at low dose activates endothelial nitric oxide synthase through PI3K-Akt pathway in endothelial cells. Life Siences 76(19):2257-2268, 2005
  2. Sugimori K, Matsui K, Motomura H, Tokoro T, Wang J, Kimura T, Kitajima I: BMP2 prevents apoptosis of N1511 chodrocytic cells through PI3K/Akt-mediated NF-κB activation. J. Bone Miner. Metab. 23:411-419, 2005
  3. Terauchi R, Arai Y, Takahashi KA, Inoue A, Tonomura H, Asada H, Kishida T, Imanishi J, Mazda O, Kitajima I, Kubo T: The effect of apoptosis signal-regulating kinase 1 gene transfer on rat collagen induced arthritis. J Rheumatol 32(12):2373|2380, 2005
  4. Tanaka Y., Ueda K., Ozawa T., Kitajima I., Okamura S., Morita M., Yokota S., and Imanaka T. :Mutation study of antithrombin: the role of disulfide bonds in the intracellular accumulation and formation of Russell body-like structures. J. Biochem, 137(3):273-285, 2005
  5. Takayama K, Hashimoto N, Tanaka Y, Ozawa T, Emi Y, Ikeda T, Katayama M, Nomura S, Kitajima I, Nakano T, Imanaka T: Identification of a novel aminoacid deletion mutation and a very rare single nucleotide variant in a Japanese family with type 1 antithrombin deficiency. Thromb. Res 116:215-221, 2005
  6. Michino J, Hata Y, Matsui K, Takizawa H, Kominato Y, Tabata S, Nishino K, Yasumura S, Kitajima I: Demonstration of a antigen and a allele ofABOhisto-blood group in nail in a case with the absence of a antigen and anti-A antibody in blood. Legal Medicine 7:194-197, 2005
  7. Valcourt U, Kowanetz M, Niimi H, Heldin CH, Moustakas A: TGF-b and Smad signaling pathway support transcriptomic reprogramming during epithelial-mesenchymal cell transcription. Mol. Biol. Cell. 16(4):1987-2002, 2005
  8. Kakunaga S, Ikeda W, Ito S, Deguchi-Tawarada M, Ohtsuka T, Mizoguchi A, Takai Y: Nectin-like molecule-1/TSLL1/SynCAM3: a novel tissue-specific immunoglobulin-like cell-cell adhesion molecule localizing at non-junctional contactsites of presynaptic nerveterminals, axons and glia cell processes. J Cell Sci 118:1267-1277, 2005
  9. Inagaki M, Irie K, Ishizaki H, Tanaka-Okamoto M, Morimoto K, Inoue E, OhtsukaT, Miyoshi J, Takai Y: Roles of cell-adhesion molecules nectin 1and nectin 3 in ciliary body develoment. Development 132:1525-1537, 2005
  10. Hagiwara A, Fukagawa Y, Deguchi-Tawarada M, Ohtsuka T, Shigemoto R: Differentiatial distribution of release-relatedproteins in the hipocampal CA3 area as revealed by freeze-fracture replica labeling. J Comp. Neurol. 489:195-216, 2005
  11. Ohhara-Imaizumi M, Ohtsuka T, Matsushima S, Akimoto Y, Nishiwaki C, Nakamichi Y, Kikuta T, Nagai S, Kawakami H, Watanabe T, Nagamatsu S: ELKS, a protein structurally related to the active zone-associated protein CAST, is expressed in pancreatic β cells and functions in insulin exocytosis: Interaction of ELKS with exocytotic machinery analyzed by total internal reflection fluorescence microscopy. Mol. Biol. Cell. 16:3289-3300, 2005
  12. Deguchi-Tawarada M, @Inoue@E, Takao-Rikitsu E, Unoue M, Kitajima I, @Ohtsuka, T., and Takai Y: The active zone protein CAST is a component of conventional and ribbon synapses in mouse retina. J. Comp. Neurol. 495:480-96, 2006.
  13. â–{ƒŽqAŠp“c”ü—éA–k“‡ŒM:–«ŠÌŽ¾Š³‚É•¹”­‚µ‚½“œ”A•a‚É‚¨‚¯‚éƒOƒŠƒRƒAƒ‹ƒuƒ~ƒ“‚Ì—Õ°“I•]‰¿B“ú–{—Õ°ŒŸ¸Ž©“®‰»Šw‰ï‰ïŽ30(1):85-88A2005
  14. ŽÄ‘¥ŽqAX“c”üA‘å–å—Ç’jA–k“‡ŒM:“œ”A•a•a‘Ô”cˆ¬‚É‚¨‚¯‚éƒAƒfƒCƒ|ƒlƒNƒ`ƒ“‘ª’è‚̈Ӌ`\ƒAƒfƒCƒvƒlƒNƒ`ƒ“’lAƒgƒŠƒOƒŠƒZƒ‰ƒCƒh’lA‚Š´“xCRP’l‚¨‚æ‚ѶŠˆ—ð‚Æ‚Ì‘ŠŠÖ‰ðÍ\B“ú–{—Õ°ŒŸ¸Ž©“®‰»‰»Šw‰ï‰ïŽ@30(2):172-176A2005
  15. –ìŽè—Ç„AŠâé—L‰ÀAX“c–¢A‘½‰ê—R‹IŽqA‹g“cˆèŽqA‘å–å—Ç’jA¬àV“N•vA–k“‡ŒM:‰@“àŠ´õ‘Îô‚É‚¨‚¯‚éˆâ“`ŽqŒŸ¸‚Ì—L—p«B‘Ï«ˆâ“`Žq‚ÌŒŸo‚ƈâ“`ŽqŒ^•Ê‚ɂ‚¢‚ÄB“ú–{õF‘̈â“`ŽqŒŸ¸Šw‰ïŽ23(1):28-36A2005
  16. ‹àXŽu’ÃŽqA’†‰Í—³–çAŠâé—L‰ÀA‹g“cˆèŽqA•Ä“cˆèŽqA•Ä“c^ŠìŽqA’Ò“c—R‰Á—˜A—ÑŠì‘ãŽuA’†‘º­—YA²X–ØŽûˆêAù“ˆˆÀŠóŽqA΋´ŽjŽqA¬˜H‘”üA¼–ìˆê”üAˆê’J—SŽqAã–ìŸA”–Ø‘¼ŠìŽqA‘O“cŒb”ü:•xŽRŒ§“à‚É‚¨‚¯‚郃^ƒ-β-ƒ‰ƒNƒ^ƒ}[ƒ[ŽY¶‹Û’²¸(‘æ2•ñ)B•xŽRŒ§‹ZŽt‰ï•ñ165:A2004
  17. ‰œ“c’‰sAŒKŒ´‘ì”üA쓇–ÒŽuA–ìŽè—Ç„A‘å–å—Ç’jA–k“‡ŒM:S”•Ï“®ƒXƒyƒNƒgƒ‰ƒ€‰ðÍ‚É‚¨‚æ‚Ú‚·‰e‹¿(‚Æ‚­‚É“úís“®‚ɂ‚¢‚Ä)•xŽRŒ§—Õ°‰q¶ŒŸ¸‹ZŽt‰ï‰ï•ñ168:7-9A2005

‘à

  1. –k“‡ŒM:“]ŽÊˆöŽqNuclear Factor-kappa B (NF-κB)‚©‚çŽa‚鎾Š³•ªŽq•a‘Ô‰ðÍ\“]ŽÊˆöŽqŠˆ«‰»ŒŸ¸‚ÌŽ©“®‰»‚ÉŒü‚¯‚Ä|B“ú–{—Õ°ŒŸ¸Ž©“®‰»Šw‰ï‰ïŽ 2005;30(1):3-17.
  2. –k“‡ŒM:Ž_‰»ƒXƒgƒŒƒXƒ}[ƒJ[Œ¤‹†‚Æ—Õ°ŒŸ¸‚Ì”­“WB—Õ°ŒŸ¸. 2005;49(2):119-120.
  3. –k“‡ŒM:LPO‚Æ‚»‚ÌŒŸ¸–@B—Õ°ŒŸ¸. 2005;49(2):188-91.
  4. –k“‡ŒMAŽÄ‘¥Žq:ŒŒ’†ƒAƒfƒBƒ|ƒlƒNƒ`ƒ“‘ª’è‚É‚æ‚é2Œ^“œ”A•a‚Ì•a‘Ô”cˆ¬BMedical Practice. 2005;22(8):1428.
  5. –k“‡ŒMA•x‰i^‹ÕA‘Oì^l:ŒŸ¸Žº‚©‚çŒÂl‚Æ’nˆæBModern Media. 2005;51:1-21.
  6. “c’†—zŽqA–k“‡ŒM:ŒŒŠÇ“à”ç‹@”\AŒŒ¬”‚ƋÌÅü—nŒn:Ú’…•ªŽqBMedical Technology. 2004;32:1506-10.
  7. ¬àV“N•vA–k“‡ŒM:ƒAƒ“ƒ`ƒgƒƒ“ƒrƒ“Œ‡–RÇE‘æ‡ZˆöŽqŒ‡–RÇ(æ“V«ŒŒ‰t‹ÃŒÅˆÙíÇ)B“ú–{—Õ°. 2005;63(3):408-12.
  8. ŽRŒûŒjŽiA–k“‡ŒM:ŒŒðÇ‹}«Šú‚Ì•a‘Ô”cˆ¬‚É—L—p‚È‹ÃŒŒ•ªŽqƒ}[ƒJ[AƒtƒBƒuƒŠƒ“ƒ‚ƒmƒ}[•¡‡‘ÌBŒŸ¸‚Æ‹Zp 2005;33(8):785-8.
  9. î’J»ŽqA–k“‡ŒM:RƒKƒ‰ƒNƒgƒVƒ‹IgGR‘ÌB“ú–{—Õ°. 2005;63:469-71.
  10. ŽRŒûŒjŽiA“c’†—zŽqA‚X‰fŽqA–k“‡ŒM:•xŽRˆã‰È–ò‰È‘åŠw•‘®•a‰@ŒŸ¸‚æ‚낸‘Š’kŽºŠJÝ1”N‚ÌŒo‰ß‚Æ‚»‚Ì–ðŠ„B“ú–{—Õ°ŒŸ¸ˆãŠwŠw‰ïŽ. 2005;53(7):609-16.
  11. ‘å’Ë–«‹v:ƒvƒŒƒVƒiƒvƒXƒAƒNƒeƒBƒuƒ][ƒ“‚Ì\‘¢‚Æ‚»‚Ì•ªŽqŠî”ÕCAST‚ð‰î‚µ‚½‹‘啪Žq•¡‡‘̂̉ðÍB×–EHŠw. 2005;24(1):66-71.
  12. ˆÀ‘º•qA–k“‡ŒMA”óŒû´”Ž:—AŒŒŽ–‹Æ‚ÌŒ»ó‚Æ”½ÈBŠO‰È. 2004;66:931-6.

Šw‰ï•ñ

ŠCŠO”­•\

  1. Matsui K, Tsukada K, Sugimori K, Tokoro T, Higa S, Motomura H, Kitajima I: Ets gene PEA3 cooperates with c-Jun in regulation of HER2/neu transcription in breast cancer cell. Keystone Symposia Cancer and Development, Feb5-10, 2005, Banff, CANADA
  2. Ohtuka T: Molecular mechanisms of the presynaptic active zone atructure and function. Max-Plank Institute Dr Nils Brose’s Lab Invited seminar, May17, 2005, Gottingen, Germany
  3. Ohtuka T: Molecular mechanisms of the presynaptic active zone atructure and function. Max-Plank Institute Dr. Suzanne tom Dieck’s Invited seminar, May18, 2005, Frankfrut, Germany
  4. Ohtsuka T: The active zone protein CAST is component of conventional and ribbon synapses in mouse retina. Molecular Anatomy and Physiology of Ribbon Synapses Symposium. Sept. 23-24, 2005, Gottingen, Germany
  5. Tokoro T, Kitajima I: The bihabial abnormality of ATRX hypomorpholic mutant mice. Novartis Institute for Biomedical research, En Li lab meeting. Augst 26, 2005, Boston, USA

‘“àŠw‰ï

  1. –k“‡ŒM:ˆÕŒŒð«‚ð”cˆ¬‚Å‚«‚é‹ÃŒŒ•ªŽqƒ}[ƒJ[B‘æ39‰ñ“œ”A•aŠw‚Ìi•àB•½¬17”N2ŒŽ19“ú(å‘ä)
  2. –k“‡ŒM:dÇŠ´õÇ‚É‚¨‚¯‚é“]ŽÊˆöŽqNF-κBŠˆ«‰»‚̈Ӌ`‚Æv‘¬f’f–@ŠJ”­A‚»‚µ‚Ä‚»‚̧Œä‚É‚æ‚鎡—Ãí—ªB‘æ32‰ñ“ú–{W’†Ž¡—ÈãŠw‰ïŠwpW‰ïA•½¬17”N2ŒŽ24“ú(“Œ‹ž)
  3. –k“‡ŒM:—Õ°ŒŸ¸‚Ì“Ç‚Ý•ûA—Õ°ŒŸ¸‚̃sƒbƒgƒtƒH[ƒ‹B‘æ1‰ñ“¯—F‰ït“úƒNƒŠƒjƒbƒNŒŸfƒZƒ~ƒi[B•½¬17”N6ŒŽ10“ú(“Œ‹ž)
  4. –k“‡ŒM:ŒŒðÇ‹}«Šú‚𑨂¦‚é‹ÃŒŒ•ªŽqƒ}[ƒJ[A‰Â—n«ƒtƒBƒuƒŠƒ“ƒ‚ƒmƒ}[•¡‡‘̂̈Ӌ`‚Æ—Õ°‰ž—pBVŠƒŒŒ—\–hŒ¤‹†‰ïB•½¬17”N6ŒŽ17“ú(VŠƒ)
  5. –k“‡ŒM:ŒŸ¸’l‚̳‚µ‚¢‰ðŽß‚̃gƒŒ[ƒjƒ“ƒOAƒŠƒo[ƒXCPC‚ÌŽÀ‘HA–k—¤’n‹æˆãŠw¶‡“¯•×‹­‰ïƒZƒ~ƒi[B•½¬17”N7ŒŽ3“ú(•xŽR)
  6. –k“‡ŒM:•xŽRˆã‰È–ò‰È‘åŠwŒŸ¸‚æ‚낸‘Š’kŽºŠJÝ1”N”¼‚É‚¨‚¯‚錟¸‘Š’kŠˆ“®‚Æ‚»‚̈Ӌ`B‘æ30‰ñ–k—¤—Õ°•a—W’k‰ïA‘æ13‰ñ“¯ƒZƒ~ƒi[B•½¬17”N9ŒŽ10“ú(‹à‘ò)
  7. –k“‡ŒM:SNPs‚ð—p‚¢‚½ŒÂ‚ÌŒŸ¸‚ƃI[ƒ_[ƒƒCƒhˆã—ÃB•½¬17”N“x’m“IƒNƒ‰ƒXƒ^[‘n¬Ž–‹Æu‚Æ‚â‚܈ã–òƒoƒCƒIƒNƒ‰ƒXƒ^[v‘æˆê‰ñBMEŒ¤‹†‰ïE‘æ1‰ñŽ–‹Æ‰»ŒŸ“¢ˆÏˆõ‰ïB•½¬17”N9ŒŽ26“ú(•xŽRŽs•xŽR‹ZpŒð—¬ƒZƒ“ƒ^[)
  8. –k“‡ŒM:“Æ—§s­–@l‰º‚É‚¨‚¯‚é‘åŠw•‘®•a‰@ŒŸ¸Žº‚̕ω»‚Æ¡Œã‚Ì“W–]B“ú—§ƒnƒCƒeƒNƒmƒƒW[ƒYƒZƒ~ƒi[A•½¬17”N10ŒŽ4“ú(“ú—§“߉ώs)
  9. ‘å’Ë–«‹v:Scaffolding proteins and the active zone funtion:ƒvƒŒƒVƒiƒvƒXŒ¤‹†‚ÌV“WŠJ\•ªŽq\‘¢‚Æ‚»‚Ì‹@”\\The Cutting Edge of Presynaptic Research:Molecular mechanisms of presynaptic structure and function. ‘æ28‰ñ“ú–{_Œo‰ÈŠwŠw‰ï‘å‰ïA•½¬17”N7ŒŽ26-28“ú@(‰¡•l)
  10. ‘å’Ë–«‹v:Scaffolding proteins and the active zone funtion. •xŽR‘åŠwEƒuƒŠƒeƒbƒVƒ…ƒRƒƒ“ƒrƒA‘åŠw_Œo‰ÈŠwƒWƒ‡ƒCƒ“ƒgƒ~[ƒeƒ“ƒO2005. •½¬17”N11ŒŽ24“ú(•xŽRŽs)
  11. Šp“c”ü—éAâ–{ƒŽqA“c’†—zŽqA–k“‡ŒM:“–‰@‚É‚¨‚¯‚éNSTŠˆ“®‚ɂ‚¢‚ÄB‘æ44‰ñ“ú–{—Õ°ŒŸ¸ˆãŠw‰ï“ŒŠCE–k—¤Žx•”‘‰ïA•½¬17”N3ŒŽ6“ú(•Ÿˆä)
  12. ŠÝ“c‚Ý‚©A‘½Šì”Ž•¶A•½–ìPŽiA“¡‰º—²AŠâ“cŽÀA²“¡Œ[AŽR蟖çA‰Y•—‰ëtA¬—ѳA¬àV“N•v:2Œ^“œ”A•a‚ÌŽ¡—Ã’†‚É”­Œ©‚³‚ꂽˆâ“`«‹…óÔŒŒ‹…Ç‚Ææ“V«‘æ5ˆöŽqŒ‡–Rǂ̇•¹—áB‘æ102‰ñ“ú–{“à‰ÈŠw‰ïu‰‰‰ïB•½¬17”N4ŒŽ9“ú(‘åã)
  13. ™XˆêmA–k“‡ŒMA¼ˆäPŽuAŒ³‘º‘ñAŠ’A‰¤‹e—EA”ä‰ÃiA–Ø‘º—FŒú:“îœ×–EŠ”‚É‚¨‚¯‚éBMP-2‚̃Aƒ|ƒg[ƒVƒX—}§‹@\B‘æ37‰ñ“ú–{Œ‹‡‘gDŠw‰ïŠwp‘å‰ïB•½¬17”N5ŒŽ26“úA•xŽR
  14. ¼–ìŽå^AˆÀ‘º•qA“¹–ì~ŽqA‘½—t“cË‘ãA‹{—Ñç’ߎqA‰„–ì^‹|A–k“‡ŒM:I&AŽóŒŸ‚É‚æ‚è‰ü‘P‚³‚ꂽ“–‰@‚Ì—AŒŒ‹Æ–±‚ɂ‚¢‚ÄB‘æ53‰ñ“ú–{—AŒŒŠw‰ï‘‰ïB•½¬17”N5ŒŽ27“úA“Œ‹ž
  15. ‰„–ì^‹|A“¹–ì~ŽqA‘½—t“cË‘ãA¼–ìŽå^AˆÀ‘º•qA–k“‡ŒM:PeGŽ©ŒÈR‘Ì‹zŽû–@‚ª“¯ŽíR‘Ì‚É‹y‚Ú‚·‰e‹¿B‘æ53‰ñ“ú–{—AŒŒŠw‰ï‘‰ïB•½¬17”N5ŒŽ27“úA“Œ‹ž
  16. –ìŽè—Ç„Aî’J»ŽqAX“c–¢A‘½‰ê—R‹IŽqAâ–{ƒŽqA‹g“cˆèŽqA‘å–å—Ç’jAmˆäŒ©‰pŽ÷A–k“‡ŒM:PCR–@‚ð—p‚¢‚½v‘¬‚È׋ۓ¯’èƒVƒXƒeƒ€\’zB‘æ30‰ñ–k—¤—Õ°•a—W’k‰ïA‘æ13‰ñ“¯ƒZƒ~ƒi[B•½¬17”N9ŒŽ10“ú(‹à‘ò)
  17. î’J»ŽqA–ìŽè—Ç„AmˆäŒ©‰pŽ÷AŠÝ“c‚Ý‚©A–k“‡ŒM:ˆâ“`«‹…óÔŒŒ‹…Ç‚Ææ“V«‘æVˆöŽqŒ‡–Rǂ̇•¹—áB‘æ30‰ñ–k—¤—Õ°•a—W’k‰ïA‘æ13‰ñ“¯ƒZƒ~ƒi[B•½¬17”N9ŒŽ10“ú(‹à‘ò)
  18. â–{ƒŽqA–k“‡ŒMA–쑺ŒbŽqA‹àŒ“O˜a:œ‘ˆÚAŒãBKƒEƒCƒ‹ƒXŠ´õ‚É‚æ‚è”A’†ƒEƒCƒ‹ƒXŠ´õ×–E‚ª”F‚ß‚ç‚ꂽˆêÇ—áB‘æ30‰ñ–k—¤—Õ°•a—W’k‰ïA‘æ13‰ñ“¯ƒZƒ~ƒi[B•½¬17”N9ŒŽ10“ú(‹à‘ò)
  19. ‰œ“c’‰sAã–ì’q_A‘å–å—Ç’jA–k“‡ŒMA‰Á“¡‹P—²:W‡Z‘î‚É‚¨‚¯‚é‘›‰¹B‘æ30‰ñ–k—¤—Õ°•a—W’k‰ïA‘æ13‰ñ“¯ƒZƒ~ƒi[B•½¬17”N9ŒŽ10“ú(‹à‘ò)
  20. ’J‚Ý‚ËŽqA”öì’q”üA쓇–ÒŽuA‘å–å—Ç’jA–k“‡ŒM:ƒGƒsƒg[ƒv‚̈قȂé“ñŽí—Þ‚ÌR‘Ì‚É‚æ‚éƒtƒBƒuƒŠƒ“ƒ‚ƒmƒ}[•¡‡‘Ì’l˜¨—£‚Ì–â‘è‚Æ‚»‚Ì—Õ°“IˆÓ‹`B“ú–{—Õ°ŒŸ¸Ž©“®‰»‰»Šw‰ï‘‰ïB•½¬17”N9ŒŽ29“ú(‰¡•l)
  21. ŽRŒûŒjŽiA–k“‡ŒM:‹Ù‹}ŒŸ¸‚̃sƒbƒgƒtƒH[ƒ‹B³‚µ‚¢‹Ù‹}ŒŸ¸‚ÌŽg‚¢•ûB‘æ8‰ñ•xŽR‘åŠw•‘®•a‰@Œ¤CˆãƒCƒuƒjƒ“ƒOƒZƒ~ƒi[B•½¬17”N10ŒŽ6“ú(•xŽR)
  22. Y‘ò˜a•FA—уˆêA“y“cŒj‘ :VŠƒ’†‰z’nk”íÐŽÒ‚É‚¨‚¯‚éÖ¬ŒŒðÇðÇ‚Æ‹ÃŒŒ•ªŽqƒ}[ƒJ[B‘æ12‰ñ”xÇðŒ¤‹†‰ïEŠwpW‰ïB•½¬17”N11ŒŽ5“ú(“Œ‹ž)
  23. Žß‰i´ŽuAa’JLŽqAŽRŒûŒjŽiA’J‚Ý‚ËŽqA–k“‡ŒMAŽRèŒõÍ:lH•GŠÖß’uŠ·p‚̋쌌‘ÑŠJ•ú‚É‚æ‚é‰Â—n«ƒtƒBƒuƒŠƒ“ƒ‚ƒmƒ}[•¡‡‘̂̕ω»B‘æ3‰ñ–k—¤DICŒ¤‹†‰ïB•½¬17”N11ŒŽ12“ú(‹à‘ò)
  24. ŽRŒûŒjŽiA“c’†—zŽqA‚X‰fŽqA–k“‡ŒM:—Õ°ŒŸ¸ˆã‚̃Rƒ“ƒTƒ‹ƒeƒBƒ“ƒO‹Æ–±Šˆ“®‚Ìê‚Æ‚µ‚Ä‚Ì‘åŠw•a‰@ŒŸ¸•”“à‚æ‚낸‘Š’kŽºŠJÝ1”N‚ÌlŽ@B‘æ52‰ñ“ú–{—Õ°ŒŸ¸ˆãŠw‰ï‘‰ïB•½¬17”N11ŒŽ18“ú(•Ÿ‰ª)
  25. ‚X‰fŽqA“c’†—zŽqAŽRŒû”ü—éAâ–{ƒŽqA–k“‡ŒMB‘æ52‰ñ“ú–{—Õ°ŒŸ¸ˆãŠw‰ï‘‰ïB•½¬17”N11ŒŽ19“ú(•Ÿ‰ª)
  26. ‰œ“c’‰sA‘å–å—Ç’jA²“¡Œ[A–k“‡ŒM:ŠeŽ¾Š³(“œ”A•aA‚ŒŒˆ³A‹N—§«’ጌˆ³‹^‚¢)‚É‚¨‚¯‚éS”EŒŒˆ³•Ï“®ƒXƒyƒNƒgƒ‹‰ðÍ‚ÌŒŸ“¢B‘æ52‰ñ“ú–{—Õ°ŒŸ¸ˆãŠw‰ï‘‰ïB•½¬17”N11ŒŽ20“ú(•Ÿ‰ª)
  27. ‘½—t“cË‘ãA“¹–ì~ŽqA¼–ìŽåáÁA‹{—Ñç’ߎqAˆÀ‘º•qA–k“‡ŒM:“–‰@‚ÅŽŽ‚Ý‚½—AŒŒ‚É‚æ‚éCŒ^ŠÌ‰ŠŠ³ŽÒ‚ÌŒ@‚è‹N‚±‚µ‚ɂ‚¢‚ÄB‘æ23‰ñ“ú–{—AŒŒŠw‰ï–k—¤Žx•”‘‰ïA•½¬17”N11ŒŽ19“ú(‹à‘ò)
  28. ¼–ìŽåáÁA‘½—t“cË‘ãA“¹–ì~ŽqA‹{—Ñç’ߎqAˆÀ‘º•qA–k“‡ŒM:I&A‚Ì”FØ‚ðŽó‚¯‚ÄB‘æ23‰ñ“ú–{—AŒŒŠw‰ï–k—¤Žx•”‘‰ïA•½¬17”N11ŒŽ19“ú(‹à‘ò)
  29. ‹{—Ñç’ߎqAˆÀ‘º•qA‘½—t“cË‘ãA“¹–ì~ŽqA]”¦˜a”üA¼–ìŽåáÁA–k“‡ŒM:“–‰@—AŒŒE×–EŽ¡—Õ”‚É‚¨‚¯‚éŠÅŒìŽt‚Ì–ðŠ„B‘æ23‰ñ“ú–{—AŒŒŠw‰ï–k—¤Žx•”‘‰ïA•½¬17”N11ŒŽ19“ú(‹à‘ò)
  30. ‘å’Ë–«‹v:ƒvƒŒƒVƒiƒvƒXƒAƒNƒeƒBƒuƒ][ƒ“‚É‚¨‚¯‚郊ƒ“Ž_‰»ƒvƒƒeƒI[ƒ€B•½¬17”N“x¶—ŠwŒ¤‹†ŠŒ¤‹†‰ï@ƒVƒiƒvƒX‚̈ê¶:’a¶EˆÛŽEœ‹Ž‰ß’ö‚Ì“‡“I—‰ð‚ÖŒü‚¯‚ÄB•½¬17”N12ŒŽ1|2“ú(‰ªè)
  31. –k“‡ŒM:—₦‚ƒɂ݂ɑ΂·‚é˜aŠ¿–ò‚Ì’TõB˜aŠ¿–òEƒoƒCƒIƒeƒNƒmƒƒW[Œ¤‹†¬‰Ê”­•\‰ïB•½¬17”N12ŒŽ6“ú(•xŽR)
  32. –k“‡ŒM:•xŽR‘åŠw‚Ì“Œ¼ˆãŠw—Z‡Œ¤‹†‚ƃJƒIƒX–¬”gŒv‚ð—p‚¢‚½–¬”g‰ðÍ‚ÌŽæ‚è‘g‚ÝB•½¬17”N“x‰ÈŠw‹ZpU‹»’²®”ïu‰ÈŠw‹Zp‚É•K—v‚È’²¸Œ¤‹†:Š¿•ûu–¬fvf’f–@‚̃JƒIƒX‰ð͂ƉȊw‰»Œ¤‹†•ñ‰ïB•½¬17”N12ŒŽ16“ú(Ž­Ž™“‡)

‚»‚Ì‘¼

  1. –k“‡ŒM:HTLV-TŠÖ˜AŽ¾Š³”­Ç‚É‚¨‚¯‚éƒvƒƒEƒCƒ‹ƒXŠ´õ—Ê‚ÆHTLV-I Taxˆâ“`Žq•ÏˆÙ‚ÌŠÖ˜A‚ÉŠÖ‚·‚錤‹†B•ZˆãŠwŒ¤‹†U‹»à’cŒ¤‹†‹ÆÑW:75A2005
  2. –k“‡ŒM:—₦‚ƒɂ݂ɑ΂·‚é˜aŠ¿–ò‚Ì’TõBŠÖ߃ŠƒEƒ}ƒ`‚É–òŒø‚ðŽ¦‚·“]ŽÊˆöŽqŠˆ«’²ß‹@\‰ð–¾B•½¬16”N“xŽó‘õŒ¤‹†˜aŠ¿–òEƒoƒCƒIƒeƒNƒmƒƒW[Œ¤‹†Œ¤‹†¬‰Ê•ñ‘:1-14A2005
  3. –k“‡ŒM:˜aŠ¿–ò‚É‚æ‚錌ŠÇV¶“]ŽÊˆöŽq‚ÌŠˆ«‰»§Œä-˜aŠ¿–ò‚ÌV‚µ‚¢Žg‚¢•û-@•½¬16”N“xŽó‘õŒ¤‹†˜aŠ¿–òEƒoƒCƒIƒeƒNƒmƒƒW[Œ¤‹†Œ¤‹†¬‰Ê•ñ‘:69-72A2005
  4. –k“‡ŒM:–{•¨‚ðŒ©‹É‚ß‚éŠáBModern Media 51(February 2):24, 2005
  5. –k“‡ŒM:•½¬17”N“x•ÒWŒã‹LB—Õ°•a—@53(12):1206, 2005

ƒy[ƒW‚Ì擪‚Ö–ß‚é

2004”N

’˜‘

  1. –k“‡ŒM:ƒŠƒsƒbƒhƒp[ƒIƒLƒVƒh(LPO)BL”͈͌Œ‰tE”A‰»ŠwŒŸ¸A–ƉuŠw“IŒŸ¸y‘æ6”Åz“ú–{—Õ°62Ap530-532A“ú–{—Õ°ŽÐ, “Œ‹žA2004
  2. “c’†—zŽqA–k“‡ŒM:IŒ^ƒRƒ‰[ƒQƒ“C––’[ƒeƒƒyƒvƒ`ƒh(ICTP)BL”͈͌Œ‰tE”A‰»ŠwŒŸ¸A–ƉuŠw“IŒŸ¸y‘æ6”Åz“ú–{—Õ°62Ap240-243A“ú–{—Õ°ŽÐ, “Œ‹žA2004
  3. “c’†—zŽqA–k“‡ŒM:IŒ^ƒvƒƒRƒ‰[ƒQƒ“C––’[ƒvƒƒyƒvƒ`ƒh(PICP)BL”͈͌Œ‰tE‰»ŠwŒŸ¸A–ƉuŠw“IŒŸ¸y‘æ6”Åz“ú–{—Õ°62Ap244-246A“ú–{—Õ°ŽÐ, “Œ‹žA2004
  4. ¬àV“N•vA–k“‡ŒM:ƒ‚ƒfƒ‹“®•¨Še˜_@ŒŒ¬”Â. uƒ‚ƒfƒ‹“®•¨‚Ì컂ƈێvX˜e˜a˜Y‘¼•Ò, 286-292, ƒGƒ‹EƒAƒCEƒV[,“Œ‹ž,2004

Œ´’˜

  1. Wang J, Tokoro T, MatsuiK, Higa S, Kitajima I. Pitavastatin at low dose activates endothelial nitric oxide synthase through PI3K-Akt pathway in endothelial cells. Life Siences 2005;76:2257-68.
  2. Kainuma M, Sakai S, Sekiya N, Mantani N, Ogata N, Shimada Y, Terasawa K. The effects of a harbal medicine (Mao-to) in patients with chronic hepatitis C after injection of IFN-β. Phytomedicine 2004;11:5-10.
  3. Tokoro T, Wang J, Kitajima I. The novel HMG-CoA reductase inhibitor, Pitavastatin, induces a protective action in vascular endothelial cells through the production of nitric oxide (NO). Yakugaku Zasshi. 2004;124:121-6.
  4. Katayama K, Hashimoto N, Tanaka Y, Ozawa T, Emi Y, Ikeda T, Katayama M, Nomura S, Kitajima I, Nakano T, Imanaka T. Identification of a novel amino acid deletion mutation and a very rare single nucleotide variant in a Japanese family with type I antithrombin deficiency. Thromb Res. 2005;116:215-21.
  5. Tanaka Y, Ueda K, Ozawa T, Kitajima I, Okamura S, Morita M, Yokota S, Imanaka T. Mutation study of antithrombin: the role of disulfide bonds in the intracellular accumulation and formation of Russell body-like structures. J Biochem. 2005;137:273-85.
  6. —ÑŽj˜NA“¡–Ø–¾A›¶¹‚A²’|ˆÉ’ÃŽqA×’JFŽqAˆä㔎:24ŽžŠÔƒzƒ‹ƒ^[S“d}‚ð—p‚¢‚½V‚µ‚¢QTŽžŠÔ‚Ì’è—Ê•]‰¿–@B“ú–{S“d}Šw‰ïŽ2004;24:199-207.
  7. ’†“ˆ»ŽqAŽÄ‘¥ŽqA‘å–å—Ç’jA–k“‡ŒM:ŒŒ’†”]«Na—˜”Aƒyƒvƒ`ƒh(BNP)‚Ì•a‰@ŒŸ¸Žº“±“ü‚É‚Þ‚¯‚Ä-RIA–@‚©‚çEIA–@‚Ö‚Ì“]Š·‚É‚æ‚郋[ƒ`ƒ“‰»\. “ú–{—Õ°ŒŸ¸Ž©“®‰»Šw‰ï‰ïŽ2004;29:617-20.
  8. Šp“c”ü—éA‘å–å—Ç’jA–k“‡ŒMA‘å–ì‰ëŒ›A–؉º—ÇŽ¡:‘’`”’EŽ‰Ž¿‰ñŽû—¦Œüã‚ð‚ß‚´‚µ‚½’†‹óŽ…–Œ—˜—pƒv[ƒ‹ŒŒ´ì»•û–@BˆãŠwŒŸ¸ 2004;53:43-6.
  9. ‘½‰ê—R‹IŽqAŠâé—L‰ÀAX“c”üA‹g“cˆèŽqA—ÑŠì‘ãŽuA’†‘º­—YA‹àXŽu’ÃŽqA–k“‡ŒM:•xŽRŒ§“à14Ž{Ý‚É‚¨‚¯‚郃^ƒ-β-ƒ‰ƒNƒ^ƒ}[ƒ[ŽY¶‹Û‚ÌŒŸoó‹µ. ˆãŠwŒŸ¸2004;53:882-5.
  10. Ôˆä‘ì–ç, ŽR–{Œª“ñ, ”Ñ’ËG–¾, ìãd•F, Š`ÀG–¾, ¬àV“N•v:“ªŠWœ‘Šú–ü‡Ç‚Æ”­’B’x‘Ø -FGFRˆâ“`ŽqˆÙí‚ÌŒŸ“¢-. ¬Ž™‚Ì”]_Œo, 2004;29:224-8.
  11. Sakai M, Kitagawa Y, Yoshida I, Nakagawa T, Mizushima Y, Ochiai H. Bacteriological study on the contamination of flow vase water. •xŽRˆã‰È–ò‰È‘åŠwŠÅŒìŠwŽGŽ. 2003;5:41-8.

‘à

  1. –k“‡ŒM:ˆãŠw•”‚ÌŠw¶‹³ˆç‰üŠvBLab. Clin. Pract., 22(1):68-76A2004
  2. –k“‡ŒM:•xŽR‚ÌŽYŠw‹¤“¯Œ¤‹†‚Í‚Ç‚±‚Ü‚Åi‚ñ‚Å‚¢‚é‚©B-‚à‚¤ˆê‚‚ÌuƒT[ƒYv\BŽÀ‹Æ”V•xŽR4ŒŽ†:38-40A2004
  3. –k“‡ŒM:“]ŽÊˆöŽq‚ƉŠÇB—Õ°ŒŸ¸48(3):315-325A2004
  4. –k“‡ŒM:ƒVƒOƒiƒ‹“`’BŒnˆÙí‚ÆŽ¾Š³B—Õ°‰»Šw33:163-176A2004
  5. –k“‡ŒM:ƒVƒOƒiƒ‹“`’B•a‚Æ‚µ‚Ä‚ÌŒŒðÇBŒŒŠÇˆãŠw5(2):19-28A2004
  6. –k“‡ŒM:‚Š´“xCRP‚É‚æ‚阒ŒŊԔƒwƒ‹ƒjƒA‚Ì•]‰¿BMedical Practice 21(11):1923, 2004
  7. Š’A–k“‡ŒM:ƒTƒCƒgƒJƒCƒ“B—Õ°ŒŸ¸47(13):1687-1692, 2003
  8. ŽRŒûŒjŽiA–k“‡ŒM:ƒgƒƒ“ƒrƒ“EƒAƒ“ƒ`ƒgƒƒ“ƒrƒ“•¡‡‘Ì(TAT)BŒŒðÇŒŸ¸ƒKƒCƒhƒuƒbƒNBŒŒð‚ÆzŠÂ12(4):76-79A2004
  9. ŽRŒûŒjŽiA–k“‡ŒM:FDPAFgDP, @FDP-EBŒŒðÇŒŸ¸ƒKƒCƒhƒuƒbƒNBŒŒð‚ÆzŠÂ12(4):101-104A2004
  10. ŽÄ‘¥Žq:ƒAƒfƒBƒ|ƒlƒNƒ`ƒ“‚ð‚²‘¶’m‚Å‚·‚©B•xŽRŒ§—Õ°‰q¶ŒŸ¸‹ZŽt‰ï‰ï•ñ:7-11, 2004
  11. ‘å–å—Ç’j:Šw‰ïˆóÛ‹L@ˆãŠwŒŸ¸ƒtƒH[ƒ‰ƒ€B@ƒƒfƒBƒJƒ‹ƒŠƒXƒNƒ}ƒlƒWƒƒ“ƒg@Medical Technology 32:868-869, 2004

Šw‰ï•ñ(“Á•Êu‰‰A‹³ˆçu‰‰AƒVƒ“ƒ|ƒWƒEƒ€‚Ì‚Ý)

  1. Isao Kitajima: Upregulation of Toll-like receptor 2 gene expression in macrophage response to high concentration of lipopolysaccharide is involved in NF-κB activation. Keystone symposia NF-κB: Biology and Pathology, 2004, Jan 19, Solt Lake City, USA
  2. Tokoro T, Kitajima I: Behavioral analyses and molecular pathogenesisi of ATRX mutant mice. Cardiovascular Research Center/MGH Kenneth D. Boch’s Lab Meeting, 2004, 10, 25
  3. –k“‡ŒM:‰F’ˆˆãŠwAŒ¤‹†‚Ìi‚ß•ûBƒX[ƒp[ƒTƒCƒGƒ“ƒXƒnƒCƒXƒN[ƒ‹(SSH)–k—¤’n‹æŒð—¬‰ïA•½¬16”N2ŒŽ15“úA(•xŽRŽsA•xŽRŒ§—§•xŽR‚Z)
  4. –k“‡ŒM:”xŒŒðÇðÇ‚Æ‹ÃŒŒƒ}[ƒJ[BONOƒXƒvƒŠƒ“ƒOƒtƒH[ƒ‰ƒ€inŽRŒ`B•½¬16”N6ŒŽ23“ú(ŽRŒ`)
  5. –k“‡ŒM:ƒiƒmƒeƒNƒmƒƒW[‚ðŠˆ—p‚µ‚½21¢‹IŒ^—Õ°ŒŸ¸\’zB•½¬15”NŒú¶˜J“­‰ÈŠwŒ¤‹†:ƒiƒmƒƒfƒVƒ“ƒtƒH[ƒ‰ƒ€NMF2003(III)Aƒiƒmƒ}ƒCƒNƒƒCƒ[ƒWƒ“ƒO‚̈ã—Éž—pB•½¬16”N3ŒŽ18“ú(“Œ‹žƒrƒbƒOƒTƒCƒg)
  6. –k“‡ŒM:“Æ—§s­–@l‰»‚É‚¨‚¯‚é‘åŠw•a‰@ŒŸ¸•”B•½¬16”N“x‘S‘ŒŸ¸‹ZŽt‰ï‘å‰ïB•½¬16”N5ŒŽ13“ú(•xŽRŽs)
  7. –k“‡ŒM:ˆâ“`Žqî•ñ‚ð‘g‚Ýž‚ñ‚¾21¢‹IŒ^—Õ°ŒŸ¸‚Ì\’zB‘æ53‰ñ“ú–{ˆãŠwŒŸ¸Šw‰ïB•½¬16”N5ŒŽ15“ú(•xŽRŽs)
  8. –k“‡ŒM:ƒƒRƒ‚[ƒVƒ‡ƒ“ƒTƒCƒGƒ“ƒX‚Æ‚Ì•à‚ÝB‹ß‹E’ߗˉïA•½¬16”N6ŒŽ12“ú(‘åã)
  9. –k“‡ŒM:“Æ—§s­–@l‰»‚ðŒ}‚¦‘ł‘åŠw•a‰@ŒŸ¸•”B‘æ23‰ñ“ú–{—Õ°‰»Šw‰ï‰ÄŠúƒZƒ~ƒi[B•½¬16”N7ŒŽ15“ú(Ž­Ž™“‡Žs)
  10. –k“‡ŒM:•a‰@ŒŸ¸•”‚ðŠˆ—p‚µ‚½‘²‘OE‘²ŒãŒŸ¸‹³ˆç‚Ì‚ ‚è•ûB‘æ23‰ñ“ú–{—Õ°‰»Šw‰ï‰ÄŠúƒZƒ~ƒi[B•½¬16”N7ŒŽ15“ú(Ž­Ž™“‡Žs)
  11. –k“‡ŒM:ŒŒð‹}«Šúf’f‚ɑΉž‚Å‚«‚éƒtƒBƒuƒŠƒ“ƒ‚ƒmƒ}[•¡‡‘Ì‚ÌPOCT“±“ü‚ÉŒü‚¯‚ÄB‘æ51‰ñ“ú–{—Õ°ŒŸ¸ˆãŠw‰ï‘‰ïƒCƒuƒjƒ“ƒOƒZƒ~ƒi[B•½¬16”N9ŒŽ4“ú(“Œ‹ž)
  12. –k“‡ŒM:“Æ—§s­–@l‰º‚É‚¨‚¯‚é21¢‹I‘ΉžŒ^ŒŸ¸•”‚É‚Þ‚¯‚ÄB–kŠC“¹‘åŠw•‘®•a‰@ŒŸ¸•”ƒZƒ~ƒi[B•½¬16”N11ŒŽ5“ú(ŽD–y)
  13. –k“‡ŒM:•xŽRˆã‰È–ò‰È‘åŠw•a‰@‚É‚¨‚¯‚éNST—§‚¿ã‚°‚Æ¡Œã‚Ì“W–]:•a‰@ŒŸ¸•”‚Ì—§ê‚©‚çB‘æ2‰ñ–kŠC“¹‘åŠwNSTu‰‰‰ïB•½¬16”N11ŒŽ5“ú(ŽD–y)
  14. –k“‡ŒM:ŒŒðŒ`¬‹}«Šú‚𔽉f‚·‚é‹ÃŒŒ•ªŽqƒ}[ƒJ[‚ð’T‚éB‘æ7‰ñ“ú–{ðŽqŒŸo‚ÆŽ¡—Êw‰ï‘å‰ïB•½¬16”N12ŒŽ5“ú(‰¡•l)

ƒy[ƒW‚Ì擪‚Ö–ß‚é

2003”N

’˜‘

  1. –k“‡ŒM:•›bó‘B‹@”\ŒŸ¸AˆãŠw‘‰@ˆãŠw‘厫“T(ˆÉ“¡³’jAˆä‘º—T•vA‚‹vŽj–›•Ò)A“Œ‹žAˆãŠw‘‰@pp2138A2003
  2. ¬•û‘¥•v:ƒfƒ‹ƒ^(DŒ^)ŠÌ‰ŠƒEƒCƒ‹ƒXƒQƒmƒ€:“ÁˆÙ“I‚ȃQƒmƒ€\‘¢E•¡»‚Æ•aŒ´«‚Æ‚ÌŠÖ˜ABV¢‹I‚ÌŠ´õÇŠw(‰ºŠª):ƒQƒmƒ€EƒOƒ[ƒoƒ‹Žž‘ã‚ÌŠ´õǃAƒbƒvƒf[ƒgB(ŽRŒûŒbŽOAŠâ–{ˆ¤‹g•Ò)A“ú–{—Õ°ŽÐA“Œ‹žApp634-639, 2003
  3. ¬•û‘¥•vA“‡–Ø‹M‹vŽqAŒKŽç”üç‘ãA‚“‡C‘¾˜YA“n•Ó–¾Ž¡:ƒEƒCƒ‹ƒXŠÌ‰Š‘Îô:ˆã—ÃŒnŠw¶‚ÌBŒ^ŠÌ‰ŠƒƒNƒ`ƒ“ÚŽí󋵂¨‚æ‚ÑŠl“¾HBsR‘Ì•]‰¿‚Ì–â‘èBCAMPUS HEALTH‘æ40ŠªA‘S‘‘åŠw•ÛŒ’ŠÇ—‹¦‰ïA‹ž“sApp252-253, 2003

Œ´’˜

  1. Shibakura M, Niiya K, Kibuchi K, Kitajima I, Niiya M, Asaumi N, Huh N-K, Nakata Y, Harada M, Tanimoto M. Induction of interleulin-8 and monocyte chemoattractant protein-1 by doxorubicin in human small-cell lung cartinoma cells. Int J Cancer. 2003;103:380-6.
  2. Sarker KP, Biswas KK, Yamakuchi M, Lee KY, Hashiguchi T, Kuracht M, Kitajima I, Maruyama I. ASK-1-p38 MAPK/JNK signaling cascade mediates anandamide-ondeced PC12 cell death. J Neurochem. 2003;85(1):50-61.
  3. Arisato T, Sarker KP, Kawahara K, Nakata M, Hashiguchi T, Osame M, Kitajima I, Maruyama I. The agonist of the protease-activated receptor1- (PAR) but not PAR3 mimics@thrombin-inducedvascular endothelial growth factor release in human smooth muscle cells. Cell Mol Life Sci. 2003;60(8):1716-24.
  4. Sugimori K, Kawaguchi Y, Morita M, Kitajima I, Kimura T. High-sensitive analysis of serum C-reactive protein in young patients with lumbar disc herniation. J Bone Joint Surg Br. 2003;85(8):1151-4.
  5. Ogata N, Ichida T, Aoyagi Y, Kitajima I. Development of peptide nucleic acid mediated polymerase chain reaction clamping (PMPC). Direct sequencing method for detecting lamivudene-resistant hepatitis B virus (HBV) variants with high sensitive and specificity. J Jpn Soc Lab Med. [Rinsho Byori] 2003;51:313-9.
  6. Ogata N, Takashima S, Shimaki K, Kuwamori M, Kitajima I, Watanabe A. Antibody to hepatitis B surface antigen (anti-HBs) induced by recombinant hepatisis B vaccine consisting of subtype adr antigen is underestimayed on the World Health Organization (WHO)-standardized assay. Inter Med. 2003;42(5):446-7.
  7. Okoshi S, Ogata N, Ichida T: The long-term clinical outcome of 1-year treatment of chronic hepatitis B with lamivudine-5 year observation. Hepatol Res. 2003;27:13-7.
  8. ˆÀ‘º•qA”óŒû´”ŽA‘½—t“cËŽqA“¹–ì~ŽqA¼–ìŽåáÁAŽOè‘ñ˜YA–k“‡ŒMA“nç²–¾Ž¡A‰–Œ´NŽiA•½ˆä”£A¼–쎡gA’bŽ¡—Fº:RIgAR‘Ì•Û—LŽÒ‚ÌR‘̉¿‘ª’è‚̈Ӌ`‚Æ—AŒŒã‚̑ΉžB“ú–{—AŒŒŠw‰ïŽGŽ49(5)646-652A2003
  9. Šâé—R‰ÀAX“c–¢A‘½‰ê—R‹IŽqA–ìŽè—Ç„A‹g“cˆèŽqA¬àV“N•vA–k“‡ŒM:Serratia marcescens‚Ìnuclease‚É‚æ‚éPCRŽY•¨‚Ì•ª‰ð. ŒŸ¸‚Æ‹Zp. 2003;13:468-9.
  10. ‰œ“c’‰sA¼ˆäËŽqAŽÄŒ´’¼—˜AŠÖª“¹˜aAã–ì’q_A‘å–å—Ç’jA–k“‡ŒM:ŒŒ‰tƒKƒX•ªÍ‹@Ší‚Ì‘Šˆá‚É‚æ‚éPaCO2’l˜¨—£‚ÌŒŸ“¢. —Õ°ŒŸ¸ 2003;47:553-8.
  11. ‰„–ì^‹|¤Šp“c”ü—餗юj˜N¤‘å–å—Ç’j¤–k“‡ŒM¤‘å–ì‰ë”ͤ–؉º—ÇŽ¡:‘Ca‘ª’è‚É‚¨‚¯‚é–â‘è“_‚Æ‚»‚̉ü—Ç–ò-uƒGƒXƒpECav-‚Ì—L—p«@ˆã—ÂƌŸ¸‹@ŠíEŽŽ–ò. 2003;26(3):235-9.
  12. ‰œ“c’‰s¤–ìŽè—Ç„AŒKŒ´‘ì”üA쓇–ÒŽuA‘å–å—Ç’jA”~–ìŽg:Žs–¯ƒ‰ƒ“ƒi[‚ð‘ÎÛ‚Æ‚µ‚½D‹C“IEŒ™‹C“IƒgƒŒ[ƒjƒ“ƒOŒø‰Ê‚Ì•]‰¿\Ž©Šo“IÅ‘åŽ_‘fÛŽæ—Ê(peakVO2)AŒ™‹C“I‘ãŽÓˆæ’l(AT)‚¨‚æ‚Ѷ‰»Šw•ªÍ‚æ‚è[•xŽRŒ§—Õ°ŒŸ‰q¶ŒŸ¸‹ZŽt‰ïŽ. 2003;29:9-11.
  13. ‘½‰ê—R‹IŽqAŠâé—R‰ÀA, X“c–¢A–ìŽè—Ç„A‹g“cˆèŽqA¬àV“N•vA–k“‡ŒM:ƒƒ^ƒ[β-ƒ‰ƒNƒ^ƒ}[ƒ[ŽY¶‹Û‚Ì•Û—L’²¸B•xŽRŒ§—Õ°‰q¶ŒŸ¸‹ZŽt‰ïŽ. 2003;29:16-9.
  14. ŒKŒ´‘ì”üAâ–{ƒŽqAî’J»ŽqA“c‘º‚È‚¨‚ÝA¬àV“N•vA–k“‡ŒM:ITP‚ªˆâ“`‚·‚éBæ“V«ŒŒ¬”ÂŒ¸­ÇBMedical Tecnology. 2003;31:893-6.

‘à

  1. –k“‡ŒM:œ‹zŽûƒ}[ƒJ[;ƒfƒIƒLƒVƒsƒŠƒWƒmƒŠƒ“AIŒ^ƒRƒ‰[ƒQƒ“‰Ë‹´N-ƒeƒƒyƒvƒ`ƒh(NTTx)AIŒ^ƒRƒ‰[ƒQƒ“Cƒeƒƒyƒvƒ`ƒh(ICTP). ‘‡—Õ°. 2003;52:101-7.
  2. –k“‡ŒM:ˆãŠw‹³ˆçŽÀ‘H‚Ìê‚Æ‚µ‚Ä‚Ì‘åŠwŒŸ¸•”‚Ì–ðŠ„. JACLaP News 2003;68:4-5.
  3. –k“‡ŒM:ƒVƒŠ[ƒYÅVˆãŠwuÀ¥II. ƒVƒOƒiƒ‹“`’BŠT—v. —Õ°ŒŸ¸ 2003;47(1):89-101.
  4. –k“‡ŒM¤“Þ—ÇM—YAaã‰ëŽjA‘Oì^l:V‚µ‚¢ŒŒ´ƒ}[ƒJ[. Medico. 2003;34(4):16-30.
  5. –k“‡ŒM:—Õ°ŒŸ¸ˆãŠw‚̃RƒAEƒJƒŠƒLƒ…ƒ‰ƒ€‚ւ̑Ήž(‘—§‘åŠw). —Õ°•a—. 2003;51:357-61.
  6. –k“‡ŒM:‘²‘O‚ÌŒŸ¸ˆãŠw‹³ˆç‚É‚¨‚¯‚éŽÀK‚Ì‚ ‚è•û. —Õ°•a—. 2003;51:983-94.
  7. –k“‡ŒM:‘å‘Úœ“ª‰óŽ€‚ƃAƒ|ƒg[ƒVƒX. ˆãŠw‚Ì‚ ‚ä‚Ý. 2003;205(10):824-8.
  8. –k“‡ŒM:ˆâ“`Žqî•ñ(SNPsAƒVƒOƒiƒ‹“`’B)‚ðŠˆ—p‚µ‚½Ž¾Š³•ªŽq•a‘Ô‰ðÍŒŸ¸. “ú–{—Õ°‰»Šw‰ï‹ãBŽx•”—á‰ïŽ. 2003;13:1-10.
  9. ¬•û‘¥•v:SIRS. sespsis‚Æ”sŒŒÇ:’è‹`‚̈Ӌ`‚Æ¡Œã. ‰»Šw—Ö@‚̗̈æ. 2003;19:941-6.
  10. ‰„–ì^‹|A–k“‡ŒM:‚MgŒŒÇ‚ð‚Ý‚½‚çCa‘ª’è–@‚É’ˆÓ. Medical Practice. 2003;20:695.
  11. î’J»Žq¤–k“‡ŒM:ŠÖ߃ŠƒEƒ}ƒ`f’f‚É‚¨‚¯‚郊ƒEƒ}ƒgƒCƒhˆöŽq‚ÆMMP3“¯Žž‘ª’è‚Ì—L—p«. Medical Practice. 2003;20(8):1417.
  12. â–{ƒŽqA–k“‡ŒM:–«ŠÌŽ¾Š³‚É•¹”­‚µ‚½“œ”A•a‚ÌŒŒ“œƒRƒ“ƒgƒ[ƒ‹Žw•W‚ɉ½‚ªÅ“K‚©. Medical Practice. 2003;20(11):1955.

Šw‰ï•ñ(“Á•Êu‰‰A‹³ˆçu‰‰AƒVƒ“ƒ|ƒWƒEƒ€‚Ì‚Ý)

  1. –k“‡ŒM:ŠÖ߃ŠƒEƒ}ƒ`‚Ìœ”j‰ó‚Æœ‘eé Ç”­ÇƒƒJƒjƒYƒ€. ‘æ1‰ñŒF–{œ‘eé ÇŒ¤‹†‰ï@2003”N2ŒŽ15“ú(ŒF–{)
  2. –k“‡ŒM: ˆâ“`î•ñ(SNPs, ƒVƒOƒiƒ‹“`’B)‚ðŠˆ—p‚µ‚½Ž¾Š³•ªŽq•a‘Ô‰ðÍ. ‘æ13‰ñ—Õ°‰»Šw‹ãBŽx•”‘‰ï@2003”N2ŒŽ22“ú(•Ÿ‰ª)
  3. –k“‡ŒM:¶ŠˆKŠµ•a‚É‚¨‚¯‚é“]ŽÊˆöŽq’²ßˆÙí‚Æ•ªŽq•a‘Ô‰ðÍ. ‘æ47‰ñ“ú–{—Õ°ŒŸ¸ˆãŠw‰ï‹ãB’n•û‰ï@2003”N2ŒŽ22“ú(•Ÿ‰ª)
  4. –k“‡ŒM:ˆâ“`î•ñ‚ð‚¢‚©‚Ɉã—ÃŒ»ê‚É“`‚¦‚é‚©. “ú—§ƒnƒCƒeƒNƒmƒƒW[ƒYEƒ‰ƒCƒtƒTƒCƒGƒ“ƒXƒZƒ~ƒi[@2003”N3ŒŽ6“ú(“ú—§“߉ώs)
  5. –k“‡ŒM::‚Ç‚¤‚·‚éE‚Ç‚¤‚È‚é—Õ°ŒŸ¸. ‘æ26‰ñ“ú–{ˆãŠw‰ï‘‰ï•ª‰È‰ï‘æ7‰ñ“ú–{—Õ°ŒŸ¸ˆãŠw‰ï“Á•Ê—á‰ï@2003”N4ŒŽ3“ú(•Ÿ‰ª)
  6. –k“‡ŒM:ƒ|ƒXƒgƒV[ƒPƒ“ƒXŽž‘ã‚Ì—Õ°ŒŸ¸ˆãŠw‚Æ“Æ—§s­–@l‰»Œã‚ÌŒŸ¸•”‚ðl‚¦‚é. MB‘åŠwŒŸ¸•”ƒZƒ~ƒi[@2003”N10ŒŽ14“ú(¼–{)
  7. –k“‡ŒM:ŒŒðÇ—\’mƒ}[ƒJ[‚Æ‚µ‚Ẳ—n«ƒtƒBƒtƒŠƒ“ƒ‚ƒmƒ}[‘ª’è‚Ì—L—p«B‘æ50‰ñ“ú–{—Õ°ŒŸ¸ˆãŠw‰ï‘‰ïƒ‰ƒ“ƒ`ƒZƒ~ƒi[@2003”N10ŒŽ30“ú(L“‡)
  8. –k“‡ŒM::œ‘ãŽÓˆÙí‚©‚ç‚Ý‚½ŠÖ߃ŠƒEƒ}ƒ`‚Ì•a‘ÔB‘æ12‰ñ‹ž“sœ‘ãŽÓŒ¤‹†‰ïB2003”N11ŒŽ6“ú
  9. –k“‡ŒM:œ‘ãŽÓˆÙí‚©‚ç‚Ý‚½ŠÖ߃ŠƒEƒ}ƒ`‚Ìœ”j‰ó‹@˜B‘æ76‰ñ“ú–{®Œ`ŠO‰ÈŠw‰ïŠwpW‰ïB2003”N5ŒŽ25“ú(‹à‘ò)
  10. –k“‡ŒM:Á‰»ŠíŽ¾Š³‚É‚¨‚¯‚éReversed CPCB•½¬15”N“x•xŽRˆã‰È–ò‰È‘åŠwŒöŠJuÀ@2003”N8ŒŽ3“ú(•xŽR)
  11. –k“‡ŒM:“®–¬d‰»Up to date. @‘æ17‰ñ’†•”’n‹æ¶—ŒŸ¸Œ¤C‰ïB2003”N11ŒŽ15“ú(‚‰ªŽs)
  12. ¬•û‘¥•v:nj󂩂ç‚Ý‚½• •”’´‰¹”gf’f‚Ì‚·‚·‚ß•ûB•½¬15”N“x•xŽRˆã‰È–ò‰È‘åŠwŒöŠJuÀ@2003”N8ŒŽ3“ú(•xŽR)
  13. Ozawa T., Tanaka Y., Imanaka T., Kitajima:Intracellular behavior of antithrombin Morioka (Cys95Arg), a mutant protein causing type I deficiency: escape from intracellular protein degradation systems and accumulation within newly formed Russell Body-like structures. The International Society on Thrombosis and haemostasis, XIX Congress, Oral Communication, July 2003, Birmingham, UK
  14. Kitajima I: Development of Laboratory testing systems and Research for new biomarker. Seminar of Pathology Core Lab and Biomarker Discovery Center, Johns Hopkins Medical Institutions. 2003, 12, 1
  15. Tokoro T, Kitajima I: The novel HMG-CoA reductase inhibitor, Pitavastatin. Induce a protective action in vascular endothelial cells through the production of nitric oxide. Cardiovascular Research Center/MGH Kenneth D. Boch’s Lab Meeting, 2003, 11, 24
  16. Tokoro T, Kitajima I: Behavioral analyses of ATRX mutant mice. Novaritis Institutes for BioMedical Research. En Li lab Meeting. 2003, 11, 25

ƒy[ƒW‚Ì擪‚Ö–ß‚é

2002”N

’˜‘

  1. –k“‡ŒMA—«•FAŠÛŽRª˜Y:ƒ}ƒNƒƒtƒ@[ƒW‚É‚¨‚¯‚éToll-like receptor 2. 4‚̈â“`Žq”­Œ»’²ß‹@\ ƒGƒ“ƒhƒgƒLƒVƒ“Œ¤‹†5(–]ŒŽ‰p—¤A¬–ì‘A¬‹Ê³’qA‰¡’n‚ŽuA’J“OA•Ò) ˆãŠw}‘o”ÅŠ”Ž®‰ïŽÐA“Œ‹žA2002Ap152-159
  2. ¬•û‘¥•v:Peptide nucleic acid mediated polymerase chain reaction clamping (PMPC)‚ÌŠJ”­E‰ž—p‚É‚¨‚¯‚éYMDDƒ‚ƒ`[ƒt‰–Šîƒ_ƒCƒiƒ~ƒNƒX‚̉ðÍ(’Jì‹vˆê, ‘¼)ŠÌŽ¾Š³Œ¤‹†‚ÌV‚µ‚¢“WŠJ‘æ‡WŠªAƒƒfƒBƒJƒ‹ƒŒƒrƒ…[ŽÐA‘åãA2002A8

Œ´’˜

  1. Shoji Y, Noguchi A, Shoji Y, Matsumori M, Takasago Y, Takayanagi M, Yoshida Y, Ihara K, hara T, Yamaguchi S, Yoshino M, Kaji M, Yamamoto S, Nakai A, Koizumi A, Hokezu Y, Nagamatsu K, Mikami H, Kitajima I, Takada G. Five novel SLC7A7 variants and y+L gene-expression pattern in cultured lymphoblasts from Japanese patients with lysinuric protein intolerance. Hum Mutat. 2002;20(5):375-81.
  2. Yamahata H, Takeshima H, Kuratsu J, Sarker KP, Tanioka K, Wakimaru N, Nakata M, Kitajima I, Maruyama I. The role of thrombin in the neo-vascularization of malignant gliomas: An intrinstic modulator for the up-regulation of vascular endothelial growth factor. Int J Oncol. 2002;20(5):921-8.
  3. Obara S, Nakata M, Takeshima H, Kuratsu J, Maruyama I, Kitajima I. Inhibition of migration of human cells by ceribastatin in association with focal adhesion kinase (FAK). Cancer Lett. 2002;185(2):153-61.
  4. Nishimura S , Nakata M, Matsuo K, Nakajima T, Kitajima I, Saito H, Maruyama I. Human lactiferous mammary gland cells produce vascular endothelial growth factor (VEGF) and express the VEGF receptors, Flt-1 and KDR/Flk-1. Cytokine. 2002;18(4):191-8.
  5. Tezono K, Sarker KP, Kikuchi H, Nasu M, Kitajima I, Maruyama I. Bioactivity of the vascular endothelial growth factor trapped in fibrin clots: production of IL-6 and IL-8 in monocytes by fibrin clots. Haemostasis. 2002;31(2):71-9.
  6. Kainuma M, Ogata N, Kogure T, Kohta K, Hattori N, Mitsuma T, Terasawa K. The efficacy of a herbal medicine (Mao-to) in combination with intavenous natural interferon-beta for patients with chronic hepatitis C genotype 1b and high viral load: a pilot study. Phytomedicine. 2002;9:365-72.
  7. Ohkoshi S, Igarashi M, Suda T, Ogata N. Remote development of hepatocellular cartinoma in patients with liver cirrhosis type B serologically cured for HBs antigenemia with long-standing normalization of ATL values. Dig Dis Sci. 2002;47:2002-6.
  8. Tanaka Y, Ueda K, Ozawa T, Sakuragawa N, Yokota S, Sato R, Okamura S, Morita M, Imanaka T. Intracellular Accumulation of Antithrombin Morioka (Cys95Arg), A Novel Mutation Causing Type I Antithrombin Deficiency. J Biol Chem. 2002;277, 51058-67.
  9. Akai T, Iizuka H, Kishibe M, Kawakami S, Kobayashi A, Ozawa T. A Case of Beare-Stevenson Cutis gyrata Syndrome Confirmed by Mutation Analysis of the Fibroblast Growth Factor Receptor 2 Gene. Pediatr Neurosurg. 2002;37:97-9.
  10. –k“‡ŒMA—«•FAŠÛŽRª˜Y. Toll like receptor (TLR)‚ð‰î‚·‚é“]ŽÊˆöŽqNF-κBŠˆ«‰»•ªŽq‹@\‚ƃAƒ“ƒ`ƒZƒ“ƒXNF-κB‚É‚æ‚éƒGƒ“ƒhƒgƒLƒVƒ“ŒŒÇŽ¡—Ö@ŠJ”­. ƒGƒ“ƒhƒgƒLƒVƒ“ŒŒÇ‹~–½Ž¡—ÃŒ¤‹†‰ïŽ. 2001;5:173-7.
  11. ¬àV“N•v. ŒŒð«Ž¾Š³‚Ì—\’mEf’f‚ɖ𗧂‹ÌÅEü—nŒŸ¸\ˆâ“`ŽqŒŸ¸‚ðŠÜ‚Þ-B“ú–{—Õ°ŒŸ¸Ž©“®‰»Šw‰ï‰ïŽ 2002;27:131-4.
  12. ‰œ“c’‰sA²“¡Œ[A‘åŠp½Ž¡AŠÖª“¹˜aA–k“‡ŒM. Œ’í¬l‚É‚¨‚¯‚é’j—•Ê‚ÌŒŒˆ³ES”•Ï“®ƒXƒyƒNƒgƒ‹‰ð͂̉Á—î‚ÌŒŸ“¢. —Õ°•a—. 2001;50:186-90.
  13. ‰œ“c’‰sA‹g“c–«Aì麑ãAŽO“úŽsœ¨ŽqA–k“‡ŒMA•Ÿ‰iŽõ°. •xŽRŒ§‚É‚¨‚¯‚é12”NŠÔ‚ÌŒŒ‰tƒKƒX•ªÍƒRƒ“ƒg[ƒ‹ƒT[ƒxƒC‚Ì•]‰¿. —Õ°ŒŸ¸. 2002;46:1051-7.
  14. ’J‚Ý‚ËŽqA쓇–ÒŽuA‘å–å—Ç’jA¬àV“N•vA•½ˆä’‰˜aA–k“‡ŒM. V‚µ‚¢‰Â—n«ƒtƒBƒuƒŠƒ“ƒ‚ƒmƒ}[ŽŽ–òƒI[ƒgLIA FM‚ÌŒŸ“¢:¶SŽ¨ŒŒðÇf’f‚Ì—L—p«. ˆãŠw‚Æ–òŠw. 2002;48(4):600-5.

‘à

  1. –k“‡ŒM:21¢‹I‚̃Gƒ“ƒhƒgƒLƒVƒ“ŒŒÇBƒGƒ“ƒhƒgƒLƒVƒ“ŒŒÇ‹~–½Ž¡—ÃŒ¤‹†‰ïŽ. 2001;5:184-194.
  2. –k“‡ŒM:ŒJ‚è•Ô‚·ˆÓŽ¯áŠQ”­ì‚Ƭl”­ÇŒ^ƒŠƒWƒ“”A«’`”’•s‘ÏÇBMedical Practice. 2002;19:505.
  3. –k“‡ŒM:ƒ|ƒXƒgƒV[ƒPƒ“ƒXŽž‘ã‚Ì—Õ°ŒŸ¸Å‘OüB•xŽRŒ§—Õ°‰q¶ŒŸ¸‹ZŽt‰ïŽ. 2002;28(1):2-11.
  4. –k“‡ŒM:One Point Meno No182: ŒŒ‰tA”A‚Å‚Ìœ‘eé Ç‚Ìf’f‚ÆdÇ“x‚Ì”»’è. @ƒ‚ƒ_ƒ“ƒƒfƒCƒA. 2002;48(4):20-6.
  5. –k“‡ŒM:ƒ|ƒXƒgƒQƒmƒ€Žž‘ã‚É‚¨‚¯‚éV‚µ‚¢ŒŸ¸•”E—Õ°ŒŸ¸ˆãŠw‚Ö‚Ì’§í. •xŽRˆã‰È–ò‰È‘åŠwˆãŠw‰ïŽ. 2002;14(1):27-31.
  6. –k“‡ŒM:“]ŽÊˆöŽq‰ðÍ‚ðŠî”Õ‚É‚µ‚½Ž¾Š³•ªŽq•a‘Ô‰ðÍŒŸ¸‚Ö‚Ì’§í. Laboratory and Clinical Practice. 2002;20:79-84.
  7. –k“‡ŒM:“îœ×–E‚ƃƒJƒjƒJƒ‹ƒXƒgƒŒƒXBRheumatology. Clinical Update. 2002;8:37-9.
  8. –k“‡ŒM:ˆâ“`ŽqŽ¡—ÃB—Õ°‚É—L—p‚Ȉâ“`ŽqŒŸ¸. —Õ°•a—ƒŒƒrƒ…[. @2002;123:207-13.
  9. ™XˆêmA–k“‡ŒM:yŠÖ߃ŠƒEƒ}ƒ`‚É”º‚¤œ‘eé Ç‚Ì•a‘Ô‚ÆŽ¡—ÃzƒXƒeƒƒCƒh—U”­«œ‘eé Ç. ƒŠƒEƒ}ƒ`‰È. 2002;28(1):24-30.
  10. ¬•û‘¥•v:˜aŠ¿–ò‚É‚æ‚é–ò•¨«ŠÌáŠQ\ŒŸ¸‘Of’f‚Ì–â‘è‚Æ«—ˆ. —Õ°ŒŸ¸. 2002;46:197-200.
  11. ¬•û‘¥•v:“à‰È100”N‚Ì‚ ‚ä‚Ý(Š´õÇ):”sŒŒÇ. “ú–{“à‰ÈŠw‰ïŽGŽ. 2002;91:2975-82.
  12. ¬àV“N•v@ŒŒð«Ž¾Š³‚Ì—\’mEf’f‚ɖ𗧂‹ÌÅEü—nŒŸ¸-ˆâ“`ŽqŒŸ¸‚ðŠÜ‚Þ-. “ú–{—Õ°ŒŸ¸Ž©“®‰»Šw‰ï‰ïŽ. 2002;27:131-4.
  13. –k“‡ŒM:V‚µ‚¢—Õ°ŒŸ¸ˆãŠw‚Ö‚Ì’§í. ’ߗˉï‰ï•ñ. 2001;30:18-9.
  14. –k“‡ŒM:EBM(Evidence based medicine)ŽÀŽ{‚É‚¨‚¯‚é—Õ°ŒŸ¸ˆã‚Ì–ðŠ„. ˆã•ñ‚Æ‚â‚Ü. 2002;1314:6-7.
  15. –k“‡ŒM:ŽÀŒ±Žº‚É‚¨‚¯‚鎊•Ÿ‚ÌuŠÔ. “à“¡‹L”Oà’cŽž•ñ. 2002;70:25.

Šw‰ï•ñ

  1. Isao Kitajima, Akihiro Iguchi, Ikuro Maruyama: Molecular role of angiogenesis in hepatocellular cartinoma cells through constitutive interleukin-8 gene expression. Angiogenesis in Cancer and Other Diseases: From Genes to Function to Therapy. Keystone Symposia, 2002, Feb8-13, Banff, Canada.
  2. Isao Kitajima: Topics of angiogenesis in cancer and other diseases. The 18th International Congress of Clinical Chemistry and Laboratory Medicene, 2002 Oct 20-25, Kyoto
  3. Tetsuo Ozawa, Yuki Tanaka, Tsuneo Imanaka, and Isao Kitajima. Antithrombin Morioka (Cys95Arg) Is Accumulated in the Newly Formed Intracytoplasmic Membrane Structures Without Degradation: An Experimental Study. The 29th World Congress of the International Society of Hematology, August 24 - 28, 2002, Seoul.
  4. Isao Kitajima: Molecular role of tumor angiogenesis through constitutivr interleukin-8 gene expression. 5 th Endothelome Conference. 2002, Feb 2, (Okayama)
  5. –k“‡ŒM:ŒŒ‰t‹ÃŒÅ‚Æ“®–¬d‰»i“W‚̃NƒƒXƒg[ƒNB‘æ26‰ñSŒŒŠÇŒn‚Ì’²ß‚ÉŠÖ‚·‚錤‹†‰ïB2002”N2ŒŽ15“úA“Œ‹ž
  6. –k“‡ŒM:“]ŽÊˆöŽqNF-κBŠˆ«‰»‘ª’èDNAƒ`ƒbƒvŠJ”­‚É‚æ‚éƒGƒ“ƒhƒgƒLƒVƒ“ƒVƒ‡ƒbƒNv‘¬f’fB‘æ18‰ñ’†’J“dŽqŒv‘ª‹ZpU‹»à’cŒ¤‹†•¬u‰‰‰ïB2002”N2ŒŽ22“ú
  7. –k“‡ŒM:ƒGƒ“ƒhƒgƒLƒVƒ“ƒVƒ‡ƒbƒNV‹Kf’f–@ŠJ”­BƒVƒXƒƒbƒNƒbƒXŽÐŒ¤‹†ŠŒ¤‹†ƒZƒ~ƒi[B2002”N3ŒŽ4“úA_ŒË
  8. –k“‡ŒM:“]ŽÊˆöŽq‰ðÍ‚ðŠî”Õ‚É‚µ‚½Ž¾Š³•ªŽq•a‘ÔŒŸ¸‚Ö‚Ì’§íB‘æ12‰ñ“ú–{—Õ°ŒŸ¸ˆã‰ït‹G‘å‰ïB2002”N4ŒŽ20“úA•Ÿ‰ª
  9. –k“‡ŒM:–«ŠÖ߃ŠƒEƒ}ƒ`‚ÌŠÖß”j‰ó‚Æ‚»‚ÌŒŸ¸ŽŽ–òŠJ”­B‘æ7‰ñƒtƒH[ƒ‰ƒ€•xŽRu‘n–òvB2002”N5ŒŽ23“úA•xŽR
  10. –k“‡ŒM:‘åŠw•a‰@ƒ}ƒl[ƒWƒƒ“ƒg‰üŠv‚Æ—Õ°ŒŸ¸ˆãŠwuÀEŒŸ¸‚Ì«—ˆBŽ­Ž™“‡‘åŠw—Õ°ŒŸ¸ˆãŠwuÀ10Žü”N‹L”O‰ïB2002”N6ŒŽ1“úAŽ­Ž™“‡
  11. –k“‡ŒM:–«ŠÖ߃ŠƒEƒ}ƒ`‚Ìœ”j‰ó‹@\B‘æ19‰ñ—§ŽRƒZƒ~ƒi[B2002”N7ŒŽ6“úA•xŽR
  12. –k“‡ŒM:‚±‚ê‚©‚ç‚Ì—Õ°ŒŸ¸‚ª‚ß‚´‚·‚à‚ÌBˆâ“`Žqî•ñ‚ð‚¢‚©‚É—Õ°ŒŸ¸‚ɉž—p‚µ‚Ä‚ä‚­‚©B‘æ41‰ñ’†•”ˆãŠwŒŸ¸Šw‰ïB2002”N10ŒŽ5“úA•xŽR
  13. –k“‡ŒM:—Õ°ŒŸ¸ˆãŠw‚̃RƒAEƒJƒŠƒLƒ…ƒ‰ƒ€‚ւ̑Ήž(‘—§‘åŠw)B‘æ49‰ñ“ú–{—Õ°ŒŸ¸ˆãŠw‰ï‘‰ïB2002”N11ŒŽ22“úA‘åã
  14. 쓇–ÒŽuAŒKŒ´‘ì”üA’J‚Ý‚ËŽqAâ–{ƒŽqA‘å–å—Ç’jA–k“‡ŒM:ŒŸ¸•]‰¿ƒVƒXƒeƒ€‚Ì\’zB•½¬13”N“x‘—§‘åŠw•‘®•a‰@ˆã—Ãî•ñˆ—•”–å˜A—‰ï‹cB2002”N1ŒŽO‘O
  15. –î–ìÊŽqA‰„–ì^‹|AX“c–¢AŠp“c”ü—éA‘å–å—Ç’jA–k“‡ŒM:ƒfƒ^ƒ~ƒi[LPO‚ð—p‚¢‚½‰ßŽ_‰»Ž‰Ž¿‚Ì—Õ°“I—L—p«‚ɂ‚¢‚Ä‚ÌŒŸ“¢B‘æ41‰ñ“ú–{—Õ°ŒŸ¸ˆãŠw‰ï“ŒŠCE–k—¤Žx•”‘‰ïB2002”N3ŒŽ10“úA‹à‘ò
  16. ‰„–ì^‹|AX“c–¢AŠp“c”ü—éA‘å–å—Ç’jA–k“‡ŒM:‚MgŒŒÇ‚É‚¨‚¯‚éƒAƒ‹ƒZƒiƒ]IIIF‘f‚ð—p‚¢‚½V‹KƒJƒ‹ƒVƒEƒ€ŽŽ–ò‚Ì—L—p«B‘æ41‰ñ“ú–{—Õ°ŒŸ¸ˆãŠw‰ï“ŒŠCE–k—¤Žx•”‘‰ïB2002”N3ŒŽ10“úA‹à‘ò
  17. ŠpŒû—ŒbAŽÄ‘¥ŽqA–ìŽè—Ç„A¬àV“N•vA–k“‡ŒM:“ñ•ô«ƒAƒ‹ƒuƒ~ƒ“‚ð’悵‚½1‰ÆŒn‚̈ÙíƒAƒ‹ƒuƒ~ƒ“’`”’‰ðÍB‘æ41‰ñ“ú–{—Õ°ŒŸ¸ˆãŠw‰ï“ŒŠCE–k—¤Žx•”‘‰ïB2002”N3ŒŽ10“úA‹à‘ò
  18. î’J»ŽqAŽÄ‘¥ŽqAŠpŒû—ŒbA‘å–å—Ç’jA¬àV“N•vA–k“‡ŒM:RA‚¨‚æ‚ÑäPŒ´•aŠ³ŽÒ‚É‚¨‚¯‚éƒKƒ‰ƒNƒg[ƒXŒ‡‘¹IgGR‘Ì‘ª’è‚Ì—Õ°“I—L—p«‚ÌŒŸ“¢B‘æ41‰ñ“ú–{—Õ°ŒŸ¸ˆãŠw‰ï“ŒŠCE–k—¤Žx•”‘‰ïB2002”N3ŒŽ10“úA‹à‘ò
  19. —ÑŽj˜NA²’|ˆÉ’ÃŽqA×’JFŽqA“c‘º‚È‚¨‚ÝA‘å–å—Ç’jA–k“‡ŒMA›¶–`‚A“¡–Ø–¾:ƒzƒ‹ƒ^[S“d}‚É‚¨‚¯‚éRR‚ÆQTŽžŠÔ‚Ì‘ŠŠÖ•ªÍ‚Ì•]‰¿B‘æ41‰ñ“ú–{—Õ°ŒŸ¸ˆãŠw‰ï“ŒŠCE–k—¤Žx•”‘‰ïB2002”N3ŒŽ10“úA‹à‘ò
  20. X“c–¢A‰„–ì^‹|AŠp“c”ü—éA—ÑŽj˜NA‘å–å—Ç’jA–k“‡ŒM:“œ”A•a‚É‚¨‚¯‚é‚Š´“xCRP‚Ì—L—p«B‘æ51‰ñˆãŠwŒŸ¸Šw‰ïB2002”N5ŒŽ16“úAå‘ä
  21. Šp“c”ü—éA‘å–å—Ç’jA–k“‡ŒMA‘å–ì‰ë”ÍA–؉º—ÇŽ¡:‘æ51‰ñˆãŠwŒŸ¸Šw‰ïB2002”N5ŒŽ16“úAå‘ä
  22. î’J»ŽqAŽÄ‘¥ŽqAŠpŒû—ŒbA‘å–å—Ç’jA¬àV“N•vA–k“‡ŒM:RƒKƒ‰ƒNƒg[ƒXŒ‡‘¹IgGR‘Ì‘ª’è‚É‚¨‚¯‚éRA‚ÆäPŒ´•a‚ÌŠÓ•ÊB‘æ33‰ñ•xŽRŒ§—Õ°‰q¶ŒŸ¸Šw‰ïB5ŒŽ22“úA•xŽR
  23. ‰„–ì^‹|AX“c–¢AŠp“c”ü—éA‘å–å—Ç’jA–k“‡ŒM:O-CPO–@‚Æ”äŠr‚µ‚½ƒAƒ‹ƒZƒiƒ]IIIF‘f‚ð—p‚¢‚½V‹KCaŽŽ–ò‚Ì—L—p«B‘æ33‰ñ•xŽRŒ§—Õ°‰q¶ŒŸ¸Šw‰ïB5ŒŽ22“úA•xŽR
  24. –k“‡ŒMA¬Œ´‘sˆêAŠÛŽRª˜Y:ƒXƒ^ƒ`ƒ“Œn–òÜ‚Í_ŒoäP‰èŽî×–E‚ÌZ‚ð—}§‚µAƒAƒ|ƒg[ƒVƒX‚ð—U“±‚·‚éB‘æ43‰ñ“ú–{_ŒoŠw‰ï‘‰ïB2002”N5ŒŽ30“úAŽD–y
  25. 쓇–ÒŽuAŒKŒ´‘ì”üA’J‚Ý‚ËŽqAâ–{ƒŽqAî’J»ŽqA‘å–å—Ç•vA–k“‡ŒMBŒŸ¸•]‰¿ƒVƒXƒeƒ€‚Ì‹@”\•]‰¿B“ú–{ŒŸ¸ŒŒ‰tŠw‰ï2002”N7ŒŽ6“úA“Œ‹ž
  26. ’J‚Ý‚ËŽqA쓇–ÒŽuAâ–{ƒŽqAî’J»ŽqAŒKŒ´‘ì”üA‘å–å—Ç•vA–k“‡ŒMA•½ˆä’‰˜a:@V‚µ‚¢‰Â—n«ƒtƒBƒuƒŠƒ“ƒ‚ƒmƒ}[ŽŽ–ò‚ÌŠî‘bŒŸ“¢B“ú–{ŒŸ¸ŒŒ‰tŠw‰ï2002”N7ŒŽ6“úA“Œ‹ž
  27. –k“‡ŒMAò³˜a:ŒŸ¸•”–å‚Ì“WŠJAŠe—̈æ‚É‚¨‚¯‚é“WŠJB‘æ21‰ñ“ú–{—Õ°ŒŸ¸ˆãŠw‰ïA“ŒŠCE–k—¤Žx•”—á‰ïB2002”N8ŒŽ31“úA–¼ŒÃ‰®
  28. –k“‡ŒM¤@–쓇F”V:—Õ°ŒŸ¸‚ƈã—ÉüŠv@?ˆã—Â̎¿‚ÌŒüã‚ÆŠ³ŽÒ’†S‚̈ã—Âð–ÚŽw‚µ‚ÄB‘æ10‰ñ–k—¤—Õ°•a—ƒZƒ~ƒi[B2002”N9ŒŽ8“úA•xŽR
  29. 쓇–ÒŽuAŒKŒ´‘ì”üA’J‚Ý‚ËŽqAâ–{ƒŽqAî’J»ŽqA‘å–å—Ç’jA–k“‡ŒM:ŒŸ¸•]‰¿ƒVƒVƒeƒ€‚ÌŠˆ—pB‘æ27‰ñ–k—¤—Õ°•a—W’k‰ïA2002”N9ŒŽ8“úA•xŽR
  30. â–{ƒŽqA‰œ“c’‰sA–k“‡ŒMAŽR蟖ç:–«ŠÌŽ¾Š³‚É•¹”­‚µ‚½“œ”A•a‚É‚¨‚¯‚éƒOƒŠƒRƒwƒ‚ƒOƒƒrƒ“‘ª’è‚Ì–â‘è“_‚ÆŒ»óB‘æ27‰ñ–k—¤—Õ°•a—W’k‰ïA2002”N9ŒŽ8“úA•xŽR
  31. ™XˆêmAìŒû‘PŽ¡A–k“‡ŒMAX“c–¢A‘åXˆê¶A‹àX¹•FAÎŒ´—T˜aA–Ø‘º—FŒú:®Œ`ŠO‰È—̈æ‚É‚¨‚¯‚é‚Š´“xCRPB‘æ27‰ñ–k—¤—Õ°•a—W’k‰ïA2002”N9ŒŽ8“úA•xŽR
  32. î’J»ŽqAŽÄ‘¥ŽqA‘å–å—Ç’jA¬àV“N•vA–k“‡ŒM:RA‚É‚¨‚¯‚éMMP-3ƒeƒXƒguBSv‚ƃpƒiƒNƒŠƒAMMP-3uƒvƒŒ[ƒgv‚Æ‚Ì—Õ°“I—L—p«‚Ì”äŠrŒŸ“¢B‘æ27‰ñ–k—¤—Õ°•a—W’k‰ïA2002”N9ŒŽ8“úA•xŽR
  33. ‹g“cˆèŽqAX“c–¢A‘½‰ê—R‹IŽqAŠâé—R‰ÀA–ìŽè—Ç„A‘å–å—Ç’jA¬àV“N•vA–k“‡ŒM:AŒQ—nƒŒƒ“‹Û‚É‚æ‚é‰óŽ€«‹Ø–Œ‰Š‚Ì‹N‚±‚µ‚½2Ç—áB‘æ27‰ñ–k—¤—Õ°•a—W’k‰ïA2002”N9ŒŽ8“úA•xŽR
  34. ŒKŒ´‘ì”üAâ–{ƒŽqAî’J»ŽqA쓇–ÒŽuA’J‚Ý‚ËŽqA‘å–å—Ç’jA¬àV“N•vA–k“‡ŒM:ŒŒ¬”ÂŒ¸­Ç‚ÌŠÓ•Êf’f‚Æ—Õ°ŒŸ¸B-æ“V«ŒŒ¬”ÂŒ¸­Ç‚Ì1‰ÆŒn‚ð—á‚É-B‘æ27‰ñ–k—¤—Õ°•a—W’k‰ïA2002”N9ŒŽ8“úA•xŽR
  35. –ìŽè—Ç„AŠâé—L‰ÀAX“c–¢‰ÀB‘½‰ê—R‹IŽqA‹g“cˆèŽqA‘å–å—Ç’jA¬àV“N•vA–k“‡ŒM. ‘æ41‰ñ’†•”ˆãŠwŒŸ¸Šw‰ïA2002”N10ŒŽ6“úA•xŽR
  36. –k“‡ŒM¤–Ø‘º—FŒú¤æ®’‰l:œŠÖߎ¾Š³‚É–òŒø‚ðŽ¦‚·Š¿•û–ò’Tõ‚Æ‚»‚Ì“]ŽÊˆöŽq’²ß‹@\‰ð–¾. •½¬13”N“x‹³ˆçŒ¤‹†Šw“à“Á•ÊŒo”ïŽÀŽ{•ñ‰ïA2002”N10ŒŽ15“úA•xŽR
  37. ¬•û‘¥•vA–k“‡ŒM:PMPC-DS–@‚É‚æ‚é‹t“]ŽÊy‘fYMDD‰–Šî‰ðÍŒn‚ÌŠJ”­‚Ɖž—p:HBVEHIV‚Ì‘Šˆá‚Æ–òÜ‘Ï«ƒeƒXƒg. ‘æ49‰ñ“ú–{—Õ°ŒŸ¸ˆãŠw‰ï‘‰ïB2002”N11ŒŽ22“úA‘åã
  38. î’J»ŽqAŽÄ‘¥ŽqA‘å–å—Ç’jA¬àV“N•vA–k“‡ŒM:RŠjR‘Ì—z«Š³ŽÒRA‹y‚ÑäPŒ´•aŠ³ŽÒ‚É‚¨‚¯‚éMMP-3ACA. RFŒŸ¸‚Ì—Õ°“IˆÓ‹`B‘æ49‰ñ“ú–{—Õ°ŒŸ¸ˆãŠw‰ï‘‰ïB2002”N11ŒŽ24“úA‘åã
  39. ¬àV“N•vAÔˆä‘ì–çA–k“‡ŒM:“ªŠWœ‘Šú–ü‡Ç‚É‚¨‚¯‚éFGFRˆâ“`Žq‰ðÍ‚Ì—Õ°“I—L—p«‚ɂ‚¢‚Ä. ‘æ49‰ñ“ú–{—Õ°ŒŸ¸ˆãŠw‰ï‘‰ïB2002”N11ŒŽ23“úA‘åã
  40. X“c–¢A‰„–ì^‹|AŠp“c”ü—éA‘å–å—Ç’jA¬àV“N•vA–k“‡ŒM:“œ”A•aŠ³ŽÒ‚É‚¨‚¯‚é‚Ž‰ŒŒÇ‚ÆCRP’l‚Æ‚ÌŠÖ˜AB‘æ49‰ñ“ú–{—Õ°ŒŸ¸ˆãŠw‰ï‘‰ïB2002”N11ŒŽ23“úA‘åã
  41. ‰„–ì^‹|AX“c–¢AŠp“c”ü—éA‘å–å—Ç’jA–k“‡ŒMA‘å–ì‰ë”ÍA–؉º—ÇŽ¡B‚”Z“xMgŒŸ‘Ì(ŒŒ´‹y‚Ñ”A)‚É‚¨‚¯‚éƒAƒ‹ƒZƒiƒ]III–@‚ð—p‚¢‚½Ca‘ª’è‚Ì—Õ°“I—L—p«B‘æ49‰ñ“ú–{—Õ°ŒŸ¸ˆãŠw‰ï‘‰ïB2002”N11ŒŽ23“úA‘åã
  42. ‰œ“c’‰sA¼ˆäËŽqAŽÄŒ´’¼—˜AŠÖª“¹˜aAŽÄ‘¥ŽqAã–ì’q_A‘å–å—Ç’jA–k“‡ŒM:ŒŒ‰tƒKƒX•ªÍ‚É‚¨‚¯‚é‚PCO2‚̃[ƒJ[ŠÔ·‚ÌŒŸ“¢(ƒ‰ƒWƒIƒ[ƒ^[ŽÐ vs BayerŽÐ)‘æ49‰ñ“ú–{—Õ°ŒŸ¸ˆãŠw‰ï‘‰ïB2002”N11ŒŽ24“úA‘åã
  43. ¬•û‘¥•vA–k“‡ŒMA’©‘q‹Ï:ˆâ“`ŽqŒ^CEHBVŠ´õǂɑ΂·‚郉ƒ~ƒuƒWƒ“Ž¡—ÃŒø‰Ê‚ÉŠÖ—^‚·‚é—vˆö:HBVƒJƒCƒlƒeƒBƒNƒXAYMDD—̈æ”ñ–춌^‰–ŠîA‹t“]ŽÊy‘fˆâ“`ŽqˆŸŒ^‚̉ðÍB‘æ38‰ñ“ú–{ŠÌ‘ŸŠw‰ï‘‰ïB2002”N6ŒŽA‘åã
  44. ¬•û‘¥•vA“‡–Ø‹M‹vŽqAŒKŽç”üç‘ãA‚“ˆC‘¾˜YA“n•Ó–¾Ž¡:ƒEƒCƒ‹ƒXŠÌ‰Š‘Îô:BŒ^ŠÌ‰ŠƒƒNƒ`ƒ“ÛŽæ󋵂¨‚æ‚ÑHBsR‘Ì•]‰¿‚Ì–â‘è“_B‘æ40‰ñ‘S‘‘åŠw•ÛŒ’ŠÇ—Œ¤‹†‘‰ïA2002”N10ŒŽA“Œ‹ž
  45. ‘å‰zÍŒáA‚‹´’BAŽs“c—²•¶A¬•û‘¥•v:BŒ^–«ŠÌ‰Š‚ɑ΂·‚郉ƒ~ƒuƒWƒ“1”NŠÔ“Š—^—á‚Ì’·Šú—\Œã:’·Šú“Š—^—á‚Æ‚Ì”äŠrB‘æ88‰ñ“ú–{Á‰»Ší•aŠw‰ï‘‰ïA2002”N4ŒŽAˆ®ì

ƒy[ƒW‚Ì擪‚Ö–ß‚é

2001”N

’˜‘

  1. –k“‡ŒM:Ž~ŒŒEŒŒðAŒŒŠÇ“à‰È(]“ªŒ’•ãA‹v•Ä“TºA‘q—ѳ•FAŒIŒ´—TŠîA–x“೎kAX‰º—³ˆê•Ò)AƒƒfƒBƒJƒ‹ƒŒƒrƒ…[ŽÐA“Œ‹žApp95-104A2001
  2. –k“‡ŒM:ŒŒŠÇ“à”ç×–EAÅVäPŒ´•aEƒŠƒEƒ}ƒ`Šw@(‹{âM”V•Ò)A’©‘q‘“XA“Œ‹žApp6-13, 2001
  3. ŽRŒû@ˆêA–k“‡ŒM:LPS, Vascular Biology ƒiƒrƒQ[ƒ^[. (ŠÛŽRª˜YAˆÀ“¡÷“ñA²“¡–õŽj•Ò)AƒƒfƒBƒJƒ‹ƒŒƒrƒ…[ŽÐA“Œ‹žApp362-363A2001
  4. ¬•û‘¥•v:㑺’©‹PA”©ŽRdH. DŒ^ŠÌ‰Š. Žs“c•¶OA‘¼A•ÒA—Õ°ŠÌ‘Ÿ•aApp 64-68, “ú–{ƒƒfƒBƒJƒ‹ƒZƒ“ƒ^[, “Œ‹ž, 2001.

Œ´’˜

  1. Kubo T, Kitajima I, Makinodan A, Nirastuka S, Inoue S, Otsuka G, Ohashi S, Ueshima K, Hirasawa Y. Fibrin Monomer would be useful predictor of pulmonary embolism following total hip arthropathy. -preliminary report- J Orthopaedic Sci. 2001;6:119-22.
  2. Yoneda T, Maruyama Y, Uji Y, Motomiya Y, Hashiguchi Y, Miura M, Kitajima I, Mariyama I. A possible role of leptin in the normo or hypoparathyroidism uremic bone in postmenopausal dialysis women. J Bone Miner Metab. 2001;19:119-24.
  3. Sarker KP. Nakata M, Kitajima I, Nakajima T, Maruyama I. Inhibition of caspase-3 activation by SB203580, p38 Mitogen-activated protein kinase inhibitor in nitric oxide induced apoptosis of PC12 cells. J Mol Neurosc. 2001;15:243-50.
  4. Saker KP, Uchimura T, Nakajima T, Sorimachi M, Kitajima I, Maruyama I. Epinephrine prevents oxide-/peroxynitrite induced apoptosis of neural cell death through b-adrenergic receptor activation. Neurosci Res Commun.
  5. Wang Y, Liu Y, Ito Y, Hashiguchi T, Kitajima I, Yamakuchi M, Shimizu H, Matsu S, Imaizumi H, Maruyama I. Simultaneous measurement of anandamide and 2-arachidonoylglycerol by polymyxin B-selective adsorption and subsequent high-performance liquid chromatography analysis: Increase in endogenous cannabinoids in the seraof patients with endotoxin shock. Anal Biochem. 2001;249:73-82.
  6. Liu Y, Wang Y, Yamakuchi M, Masuta S, Tokioka T, Yamaoka S, Maruyama I, Kitajima I. Phosphoinositide-3 kinase-PKB/Akt pathway activation is involved in fibroblast Rat-1 transformation by human T-cell leukemia virus type-1 tax. Oncogene. 2001;20:2514-26.
  7. Iguchi A, Kobayashi R, Yoshida M, Kobayashi K, Matsuo K, Kitajima I, Maruyma I. Vascular endothelial growth factor (VEGF) is one of the causative and predictive cytokines of hepatic veno-occlusive disease (VOD) in stem cell transplantation. Bone Marrow Transplantation. 2001;27:1173-80.
  8. Kishida A, Matsuyam T, Kitajima I, Maruyama I. Study of cell-material interaction by estimating NF-κB activation in HeLa S3 cells adhered on to hydrophilic substrates, Biomaterials. 2001;22:541-6.
  9. Liu Y, Wang Y, Yamakuchi M, Iwasaki S, Nagata E, Kanmura Y, Kitajima I, Maruyama I. Upregulation of toll-like receptor 2 gene expression in macrophage response to peptidoglycan and high concentration of lipopolysaccharide is involved in NF-κB activation. Infect Immun. 2001;69:2788-96.
  10. Kubo T, Arai Y, Takahashi K, Ikeda T, Ohashi S, Kitajima I, Mazda O, Takigawa M, Imanishi J, Hirasawa Y. Expression of transduced HSP70 gene protects chondrocytes from stress. J Rheum. 2001;28:330-5.
  11. ¬•û‘¥•vA–k“‡ŒMAŽs“c—²•¶A’©‘q‹ÏA‚‹´‘¥•FA–؉º·•q. ƒ‰ƒ~ƒuƒWƒ“‘Ï«BŒ^ŠÌ‰ŠƒEƒCƒ‹ƒX:peptide nucleic acid mediated PCR clamping (PMPC)–@‚É‚æ‚éƒ|ƒŠƒƒ‰[ƒ[YMDDƒ‚ƒ`[ƒt‰–Šî•ÏˆÙ‚Ì‚Š´“xŒŸo. ŠÌ‘Ÿ. 2001;42:223-4.

Ç—á•ñ

  1. Niimi H, Arimura K, Jonosono M, Hashiguchi T, Kawabata M, Osame M, Kitajima I: VEGF is causative for pulmonary hypertension in apatients with Crow-Fukase (POEMS) syndrome. Internal Medicine. 39:1101-1104, 2000.

‘à

  1. –k“‡ŒM:ŒŸ‘̃Tƒ“ƒvƒŠƒ“ƒOAŒŒ‰t•Û‘¶‚Æ‚KŒŒÇBMedical Practice 18: 317, 2001
  2. –k“‡ŒM:‘½”­«œ‘Žî‚ÆÔ’¾BMedical Practice 18:1028, 2001
  3. –k“‡ŒM:ƒ|ƒXƒgƒQƒmƒ€Žž‘ã‚É‚¨‚¯‚é‘åŠwf—Õ”‚̉ʂ½‚·‚ׂ«–ðŠ„Bˆâ“`Žqf—ÂÌd—v«BŽ­Ž™“‡‘åŠwˆãŠw•”ˆâ“`ŽqŽ¡—ÃŒ¤‹†‰ï”N‰ïŽB4-6A2001
  4. –k“‡ŒM:ˆâ“`Žqˆã–ò•iŠJ”­‚Æ‚»‚Ì—Õ°‰ž—p‚ð–ÚŽw‚µ‚Ä:HTLV-IŠ´õÇ‚ÌŽ¡—Éž—pAŒŒŠÇV¶—}§–@‚ւ̉ž—pBŽ­Ž™“‡‘åŠwˆãŠw•”ˆâ“`ŽqŽ¡—ÃŒ¤‹†‰ï”N‰ïŽB8-9A2001
  5. –k“‡ŒM:ƒXƒeƒƒCƒh—U”­«œ‘eé ÇBCLINICAL CALCIUM 11:34-40, 2001
  6. –k“‡ŒM:—Õ°ŒŸ¸ˆãŠw‚ÌV‚µ‚¢ƒ`[ƒY‚ðŠy‚µ‚à‚¤BJACLaP NEWS 60:5A2001
  7. –k“‡ŒM:ƒ|ƒXƒgƒQƒmƒ€Žž‘ã‚Ì—Õ°ŒŸ¸Å‘OüB‘æ8‰ñ’†•”’n‹æ—Õ°ŒŸ¸Œ¤C‰ïŽ:27-28, 2001
  8. –k“‡ŒM:ŒŒŠÇV¶‚É‚¨‚¯‚é“]ŽÊ’²ß‹@\BŒŒŠÇˆãŠw2:553-560, 2001
  9. –k“‡ŒM:comments for the paper of “Vascular endothelial growth factor enhances atherosclerotic plaque progression. Nature Medicine, 2001;7:425-429”. Chugai Selected Cardiovascular Evidence, Excerpta Media. 10:2, 2001
  10. –k“‡ŒM:Molecular pathomechanisms of human T-cell leikemia virus type I (HTLV-I) rax-mediated tumorgenesis. @ç—tH‹Æ‘åŠwƒnƒCƒeƒNƒŠƒT[ƒ`ƒZƒ“ƒ^[@•½¬12”N“xuƒAƒ“ƒ`ƒZƒ“ƒXŠjŽ_‚Ì•ªŽqÝŒvvŒ¤‹†¬‰Ê•ñ‘:26A2001
  11. ŽRŒû@ˆêA–k“‡ŒM:‰ŠÇ‚É‚¨‚¯‚錌ŠÇV¶‚ÉŠÖ‚·‚éÅ‹ß‚Ìi•àB—Õ°–Ɖu33:544-540, 2000
  12. ‹v•ÛrˆêA–k“‡ŒM:”xÇð—\‘ª‚ɃtƒBƒuƒŠƒ“ƒ‚ƒmƒ}[‘ª’èBMedical Practice 18:1727, 2001
  13. ¬•û‘¥•v:˜aŠ¿–ò‚É‚æ‚é–ò•¨«ŠÌáŠQ:ŒŸ¸Žºf’f‚Ì–â‘è‚Æ«—ˆ. —Õ°ŒŸ¸

Šw‰ïŠˆ“®

‘ÛŠw‰ï

  1. Kabata@T, @Kubo@T, @Matshumoto@T, @Nishino@M, @Horii@T, Kitajima@I, @Tomota@K:Apoptotic@cell death in steroid-induced osteonecrosis: an experimental study in rabbits. The 46th Annual Meeting of Orthopaedic Research Society. 2001, 3, SanFransico, USA
  2. Kabata@T, @Kubo@T, @Matshumoto@T, @Nishino@M, @Horii@T, Tomota@K, Kitajima I:Apoptotic@cell death in steroid-induced osteonecrosis in rabbits. The 4th Korea-Japan Combined Meeting of Rheumatology, 2001, 3, Tokyo

‘“àŠw‰ï

ƒVƒ“ƒ|ƒWƒEƒ€

  1. –k“‡ŒMA—«•FAŠÛŽRª˜Y:Toll like receptor (TLR)‚ð‰î‚·‚é“]ŽÊˆöŽqNF-κBŠˆ«‰»•ªŽq‹@\:ƒAƒ“ƒ`ƒZƒ“ƒXNF-κB‚É‚æ‚éƒGƒ“ƒhƒgƒLƒVƒ“ŒŒÇŽ¡—Ö@ŠJ”­B‘æ5‰ñƒGƒ“ƒhƒgƒLƒVƒ“ŒŒÇŽ¡—ÃŒ¤‹†‰ïA2001”N1ŒŽA‰¡•l
  2. –k“‡ŒM:21¢‹I‚̃Gƒ“ƒhƒgƒLƒVƒ“ŒŒÇŽ¡—ÃB‘æ5‰ñƒGƒ“ƒhƒgƒLƒVƒ“ŒŒÇŽ¡—ÃŒ¤‹†‰ïA2001”N1ŒŽA‰¡•l
  3. –k“‡ŒM: ŒŒŠÇV¶A‰ŠÇ‚ð•W“I‚É‚µ‚½ˆâ“`Žqˆã–ò•i‚ÌŠJ”­B‘æ44‰ñ“ú–{t‘Ÿ•aŠw‰ï2001”N5ŒŽA“Œ‹ž
  4. –k“‡ŒM:ƒEƒCƒ‹ƒXŠ´õÇŽ¡—ÂÌi•à‚Æ“W–]BŠ´õÇ•a‘ÔŒ`¬‰ß’ö‚ðl—¶‚µ‚½ˆâ“`Žqˆã–ò•i‚ÌŠJ”­B‘æ73‰ñ“ú–{¶‰»Šw‰ï‘å‰ï@2001”N10ŒŽA‹ž“s
  5. –k“‡ŒM:ƒGƒ“ƒhƒgƒLƒVƒ“ŒŒÇ‚ɑ΂·‚éV‚µ‚¢Ž¡—Ãí—ª:‚”Z“xLPSŽhŒƒó‘Ô‚Å‚ÍNF-κBŠˆ«‰»‚ð‰î‚µ‚ÄToll-like receptor 2‚Ì”­Œ»—U“±‚ª¶‚¶‚éB‘æ7‰ñ“ú–{ƒGƒ“ƒhƒgƒLƒVƒ“Œ¤‹†‰ïB2001”N11ŒŽ‘å‹{
  6. –k“‡ŒM:œ‘eé Ç‚Ìf’f‚ÆŽ¡—ÃB‘æ16‰ñ“ú–{—Õ°ƒŠƒEƒ}ƒ`Šw‰ï‘‰ïB2001”N11ŒŽA–¼ŒÃ‰®

µãÙu‰‰

  1. –k“‡ŒM:“®–¬d‰»i“W‚ƃvƒ‰[ƒNƒ‰ƒvƒ`ƒƒ[‚É‚¨‚¯‚錌ŠÇ“à”ç×–EŠˆ«‰»‚Ìd—v«A‘æ2‰ñS‹Ø‹•ŒŒŒ¤‹†‰ï2001”N5ŒŽA‘åã
  2. –k“‡ŒM:–«ŠÖ߃ŠƒEƒ}ƒ`‚Ìœ”j‰ó‚Æœ‘ãŽÓˆÙí‚ɂ‚¢‚ÄB‹à‘ò®Œ`ŠO‰È‰ÄŠúƒZƒ~ƒi[B2001”N7ŒŽA‹à‘ò
  3. –k“‡ŒM:ƒ|ƒXƒgƒQƒmƒ€Žž‘ã‚Ì—Õ°ŒŸ¸Å‘OüB‘æ8‰ñ’†•”’n‹æ—Õ°‰»ŠwŒŸ¸Œ¤C‰ïB2001”N9ŒŽA•xŽR
  4. ¬•û‘¥•v: HBVŠ´õǂɑ΂·‚郉ƒ~ƒuƒWƒ“Ž¡—ÂÆHBVƒ|ƒŠƒƒ‰[ƒ[•ÏˆÙ@‘æ87‰ñ“ú–{Á‰»Ší•aŠw‰ï‘‰ïƒ‰ƒ“ƒ`ƒ‡ƒ“ƒZƒ~ƒi[, 2001”N4ŒŽA“Œ‹ž(“úŒoƒƒfƒBƒJƒ‹ŽÐŽæÞ‹L˜^:Nikkei Medical 2001”N6ŒŽ†App 102-105. )
  5. ¬•û‘¥•v: HBV YMDDƒ‚ƒ`[ƒt‰–Šî•ÏˆÙ‚Ì‚Š´“xŒŸo
  6. ‘æ3‰ñƒ[ƒtƒBƒbƒNƒXŽ¡—ÃŒ¤‹†‰ï, 2001”N7ŒŽAVŠƒ
  7. ¬•û‘¥•v:‚aŒ^ŠÌ‰ŠƒEƒCƒ‹ƒXŠ´õǂɑ΂·‚郉ƒ~ƒuƒWƒ“Ž¡—Ã@‘æ1‰ñŠÌŽ¾Š³Ž¡—ÃJƒ“ƒtƒ@ƒŒƒ“ƒXA2001”N12ŒŽA•xŽR

ˆê”ʉ‰‘è

  1. ²“¡Œ[AΖ؊wAŽR蟖çA’†‘º“T—YA‰Y•—‰ëtA‘åŠp½Ž¡A¬—ѳA‰œ“c’‰s:ŒŒˆ³’·•Ï“®ƒXƒyƒNƒgƒ‹‚É‚æ‚é“œ”A•aŽ©—¥_ŒoáŠQ‚Ì•]‰¿B‘æ9‰ñ•xŽR“œ”A•a‡•¹ÇŒ¤‹†‰ïB2001”N2ŒŽ15“ú@•xŽRŽs
  2. ’·àV’qŽqA—ÑŽj˜NAŠp“c”ü—éAX“c–¢A‘å–å—Ç’jA–k“‡ŒM:‹}«S‹Ø[Ç‚Ì—Õ°Œo‰ß‚É‚¨‚¯‚éƒgƒƒ|ƒjƒ“T—L—p«‚ÌŒŸ“¢B‘æ40‰ñ“ú–{—Õ°ŒŸ¸ˆãŠw‰ïA“ŒŠC–k—¤Žx•”‘‰ïB2001”N3ŒŽ11“úAɪ
  3. ‰œ“c’‰sA–k“‡ŒMA²“¡Œ[A‘åŠp½Ž¡AŠÖª“¹˜a:S”EŒŒˆ³•Ï“®ƒXƒyƒNƒgƒ‹‰ðÍ‚É‚¨‚¯‚éŽQl³í’l‚ɂ‚¢‚ÄB‘æ40‰ñ“ú–{—Õ°ŒŸ¸ˆãŠw‰ïA“ŒŠC–k—¤Žx•”‘‰ïB2001”N3ŒŽ11“úAɪ
  4. –k“‡ŒMA‘å–å—Ç’j:‘åŠw¶‚̈ùŽðKŠµ‚Æaldehyde dehydrogenese 2 ˆâ“`Žq‘½Œ^‚Æ‚ÌŠÖ˜AB‘æ12‰ñ“ú–{—Õ°‰»Šw‰ï“ŒŠC–k—¤Žx•”‘‰ïB2001”N6ŒŽ23“ú
  5. ŒKŒ´‘ì”üA쓇–ÒŽuA’J‚Ý‚ËŽqAâ–{ƒŽqA‘å–å—Ç’jA–k“‡ŒMA‰Á“¡‹Î:ŒŒ‰t×–E‰æ‘œƒtƒ@ƒCƒŠƒ“ƒOƒVƒXƒeƒ€‚Ì\¬‚¨‚æ‚Ñ‚»‚ÌŠˆ—pB‘æ2‰ñ“ú–{ŒŸ¸ŒŒ‰tŠw‰ïŠwpW‰ïB2001”N6ŒŽA‘åã
  6. –k“‡ŒM:: –«ŠÖ߃ŠƒEƒ}ƒ`‚ÌŠÖß”j‰ó‹@˜(œ‰è×–E‚̃Aƒ|ƒg[ƒVƒX—U“±•ªŽq‹@\‚ɂ‚¢‚Ä)B‘æ31‰ñ•xŽRƒŠƒEƒ}ƒ`‚ƖƉuŒ¤‹†‰ïB2001”N8ŒŽA•xŽR
  7. –k“‡ŒMA‰Á”¨‘½•¶A‹v•Ûrˆê:ƒXƒeƒƒCƒh—U”­œ“ª‰óŽ€‚É‚¨‚¯‚éƒAƒ|ƒg[ƒVƒX‚ÌŠÖ—^B‘æ19‰ñ“ú–{œ‘ãŽÓŠw‰ïB2001”N8ŒŽA•xŽR
  8. ‰œ“c’‰sA‘å–å—Ç’jA–k“‡ŒMA²“¡Œ[A‘åŠp½Ž¡AŠÖª“¹˜a:ŒŒˆ³•Ï“®ES”•Ï“®ƒXƒyƒNƒgƒ‰ƒ€‰ðÍ‚É‚¨‚¯‚鎾Š³(“œ”A•aA‚ŒŒˆ³)‚Æ‚ÌŠÖŒWB‘æ48‰ñ“ú–{—Õ°ŒŸ¸ˆãŠw‰ï‘‰ïB2001”N8ŒŽA‰¡•l
  9. ’·àV’qŽqA‘½‰ê—R‹IŽqA¬–ì—TŽqA–ìŽè—Ç„A‹g“c“sŽqA‘å–å—Ç’jA–k“‡ŒM:Haemophilus—Þ‚Ì–òÜŠ´Žó«ŽŽŒ±‚ɂ‚¢‚ÄBƒfƒCƒXƒN–@‚ÆMIC–@‚Ì”äŠrB‘æ26‰ñ–k—¤—Õ°•a—W’c‰ïB2001”N9ŒŽA‹à‘ò
  10. ‘å–å—Ç’jA‰œ“c’‰sAŒKŒ´‘ì”üA–k“‡ŒM:Š³ŽÒƒT[ƒrƒXŒüã‚ð–ÚŽw‚µ‚½‘åŠw•a‰@ŒŸ¸•”“à‰üŠv‚ÌŽæ‚è‘g‚Ý:ŒŸ¸•”“àŠˆ«‰»‚ÆŽžŠÔŠO‹Ù‹}ŒŸ¸®”õB‘æ26‰ñ–k—¤—Õ°•a—W’c‰ïB2001”N9ŒŽA‹à‘ò
  11. ŽÄ‘¥ŽqA—ÑŽj˜NA–ìŽè—Ç„A‘å–å—Ç’jA¬àV“N•vA–k“‡ŒMB¬Ž™RŠjR‘̂ɂ‚¢‚Ä‚ÌŒŸ“¢B‘æ26‰ñ–k—¤—Õ°•a—W’c‰ïB2001”N9ŒŽA‹à‘ò
  12. ’J‚Ý‚ËŽqAî’J»ŽqAâ–{ƒŽqA쓇–ÒŽuAŒKŒ´‘ì”üA‘å–å—Ç’jA–k“‡ŒMA“n•Óˆ»‰ÀAŒIŒ´^‹IŽqA–쑺œ¨ŽqA‹àŒ“O˜aA–{‹½˜a‹vA”ª–ØMˆêA‹{˜e—˜’j:––½ŒŒƒŠƒ“ƒp‹…‚Ì‹ó–EŒ`¬‚ÆDŽ_‹…‚̈Ùí‰Ê—±oŒ»‚ðŒ_‹@‚Éf’f‚³‚ꂽGM1ƒKƒ“ƒOƒŠƒIƒVƒh[ƒVƒX‚Ì1—áB‘æ26‰ñ–k—¤—Õ°•a—W’c‰ïB2001”N9ŒŽA‹à‘ò
  13. •Ÿ‰iŽõ°A’†‘º³lA‰œ“c’‰sAŠâ²ˆê˜YA’JÂA”~–{‰ë•vAŒKŽ•F:ŒŒ‰tƒKƒX‘ª’è—p•W€•¨Ž¿‚É‚æ‚é•W€‰»‚ÌŽŽ‚Ý(‘æ3•ñ)B‘æ33‰ñ“ú–{—Õ°ŒŸ¸ŒŸ¸Ž©“®‰»Šw‰ïB2001”N9ŒŽA‰¡•l
  14. ²“¡Œ[AΖ؊wAŽR蟖çAŠâ“cŽÀA‘é“c”ü’qŽqA‰Y•—‰ëtAŠÝ“c‚Ý‚©AŒÜ\—’•ÛŽjAù‰ª—˜ˆÀA‘åŠp½Ž¡A‰œ“c’‰sA–k“‡ŒMA¬—ѳ:ŒŒˆ³•Ï“®ƒXƒyƒNƒgƒ‰ƒ€‰ðÍ‚É‚æ‚é“œ”A•a«SŒŒŠÇŒnŽ©—¥_ŒoÇŠO‚Ì•]‰¿B‘æ16‰ñ“ú–{“œ”A•a‡•¹ÇŠw‰ïB2001”N10ŒŽA‘åã
  15. ŠLÀ–ÎŽO˜YA¬•û‘¥•vAäÝ’J’¼Ž÷A‘¼. “«CŒ^–«ŠÌ‰Š‚ɑ΂·‚éƒCƒ“ƒ^[ƒtƒFƒƒ“‚Æ–ƒ‰©“’‚Ì•¹—p—Ö@‚ɂ‚¢‚Ä. ‘æ34‰ñ“ú–{ŠÌ‘ŸŠw‰ï¼•”‰ïA2001”N12ŒŽA‚’m

‚»‚Ì‘¼(u‰‰AŒ¤‹†‰ïA•×‹­‰ï“™)

  1. –k“‡ŒM:‰F’ˆ—·s‚©‚眂̌’N‚ðl‚¦‚éB@•½¬13”N“x•xŽRˆã‰È–ò‰È‘åŠwŒöŠJuÀB6ŒŽ16“úA•xŽR
  2. ¬•û‘¥•v: u‚aŒ^ŠÌ‰Š‚ÌŽ¡—Ãv MutationŒŸoŒn@‘æ6‰ñ Otsuka Liver Symposium, 2001”N11ŒŽA‘åã

Œ¤‹†”ï

  1. ‰ÈŠwŒ¤‹†”ï•â•‹à(Šî”ÕŒ¤‹†C2):uŠài“W‚É‚¨‚¯‚éƒCƒ“ƒ^[ƒƒCƒLƒ“8Pí”­Œ»‹@\‰ð–¾‚Æ”­Œ»—}§‚É‚æ‚錌ŠÇV¶—}§—Ö@vŒ¤‹†‘ã•\ŽÒ(–k“‡ŒM)
  2. •¶•”È‘åŠw‰@“Á•ÊŒo”ï:•ª’SŽÒ@(–k“‡ŒM)
  3. “ú–{Š¿•ûˆãŠwŒ¤‹†ŠŒ¤‹†•¬:u–«ŠÖ߃ŠƒEƒ}ƒ`‚É–òŒø‚ðŽ¦‚·˜aŠ¿–ò‚Ì“]ŽÊˆöŽqNF-κB)Šˆ«’²ß‹@\‰ð–¾BŒ¤‹†‘ã•\ŽÒ(–k“‡ŒM)
  4. “à“¡‹L”O‰ÈŠwU‹»à’c:uŒŒŠÇˆâ“`Žq‚Ì“]ŽÊ’²ß‹@\‰ð–¾‚ÆŒŒŠÇV¶•a‚ÌV‹Kˆâ“`Žqˆã–ò•iŠJ”­BŒ¤‹†‘ã•\ŽÒ(–k“‡ŒM)
  5. •½¬13”N“x‹³ˆçŒ¤‹†Šw“à“Á•ÊŒo”ï:uœEŠÖߎ¾Š³‚É–òŒø‚ðŽ¦‚·Š¿•û–ò’Tõ‚Æ‚»‚Ì“]ŽÊˆöŽq’²ß‹@\‰ð–¾vŒ¤‹†‘ã•\ŽÒ(–k“‡ŒM)

ŽÐ‰ï“IŠˆ“®

  1. –k“‡ŒM:—Õ°ŒŸ¸¸“xŠÇ—‹¦‹c‰ïŒÚ–â
  2. –k“‡ŒM:Ž­Ž™“‡‘åŠwˆãŠw•””ñí‹ÎuŽt
  3. –k“‡ŒM:ˆã—Ê֘AƒT[ƒrƒX’²¸Žw“±ˆõ
  4. –k“‡ŒM:—Õ°•a—¸“Ljψõ
  5. –k“‡ŒM:“ú–{œ‘ãŽÓŠw‰ï•]‹cˆõA“ú–{—Õ°ŒŸ¸Šw‰ï•]‹cˆõ
  6. Isao Kitajima: membership of New York Academy of Science
  7. ¬•û‘¥•v:‘Š’kˆõ. ŠÌ‚ª‚ñ–o–ŃtƒH[ƒ‰ƒ€2001 uŠÌ‰Š110”Ôv|ŠÌ‘Ÿ•a“d˜b‘Š’kŽºA2001”N5ŒŽ, •xŽR@(–k“ú–{V•·ŽÐŽæÞ‹LŽ–:•½¬13”N5ŒŽ21“ú)

ƒy[ƒW‚Ì擪‚Ö–ß‚é

2000”N

Šw‰ïŠˆ“®

‘ÛŠw‰ï

symposium

  1. Isao Kitajima:Molecular pathomechanisms of human T cell leukemia virus type I (HTLV-I) Tax mediated tumorigenesis. Antisense, ribozyme development for HTLV-I related diseases 1st symposium of Chiba High Technology Research Center. Drug Discovery for Virus. (September 6-7, 2000) (Chiba, JAPAN)

‘“àŠw‰ï

ƒVƒ“ƒ|ƒWƒEƒ€

  1. –k“‡ŒM:ˆâ“`Žqˆã–ò•i‚É‚æ‚鎾Š³Ž¡—ÂւÌV‚½‚ÈŒ¤‹†“WŠJ:ˆâ“`Žqˆã–ò•i‚̈قȂéì—p“_‚ð—˜—p‚µ‚½ŒŒŠÇV¶‚ւ̉ž—p, ‘æ73‰ñ“ú–{¶‰»Šw‘å‰ï@10ŒŽ23“ú2000”N(‰¡•l)

µãÙu‰‰

  1. –k“‡ŒM:ƒ|ƒXƒgƒV[ƒNƒGƒ“ƒXŽž‘ã‚É‚¨‚¯‚é—Õ°ŒŸ¸ˆãŠw‚Ì“W–], ‘æ6‰ñƒvƒƒWƒFƒNƒgƒtƒH[ƒ‰ƒ€ƒCƒ“”ò’¹ 12ŒŽ2“ú2000”N(•xŽR)
  2. –k“‡ŒM:ŒŒŽî‚Ì–ðŠ„‚ÆŒŒŠÇV¶‚̧Œä‚ÉŠÖ‚·‚éÅ‹ß‚ÌŒ¤‹†
    ‘æ3‰ñ Cardiovascular Research Forum 12ŒŽ9“ú2000”N(“Œ‹ž)

ˆê”ʉ‰‘è

  1. –k“‡ŒMAˆäŒû»—TAŒü“c’¼ŽjAŠÛŽRª˜Y:ŠÌ‘ŸŠà‚É‚¨‚¯‚éƒCƒ“ƒ^[ƒƒCƒLƒ“8‚ÌPí“I”­Œ»•ªŽq‹@\‚Æ‚»‚̧Œä‚É‚æ‚錌ŠÇV¶—}§—Ö@ŠJ”­, ‘æ47‰ñ“ú–{—Õ°•a—Šw‰ï‘‰ï@11ŒŽ3“ú2000”N(ŒSŽR)
  2. ˆäŒû»—TA–k“‡ŒMAŽRŒû@ˆêAã–ì^ˆêAˆ¤bFA¼“‡jŽ¡AŒü“c’¼ŽjAŠÛŽRª˜Y:The transcription factor, PEA3 and AP-1 are required for constitutive Il-8 gene expression in human hepatoma cells. ‘æ23‰ñ“ú–{•ªŽq¶•¨Šw‰ï”N‰ï@12ŒŽ13“ú2000”N(_ŒË)

Œ´’˜

  1. Yamakuchi M, Higuchi I, Masuda S, Ohira Y, Kubo T, Kato Y, Maruyama I:Type I muscle atrophy caused by microgravity-induced decrease of myocyte enhancer factor 2C (MEF2C) protein expression. FEBS Lett. 2000;477:135-140.
  2. Saker KP, Obara S, Nakata M, Kitajima I, Maruyama I:Anandamide induced apoptosis of PC12 cells. Involvement of superoxide and caspase-3. , FEBS Lett. 2000;472:39-44.
  3. Wang Y, Liu Y, Sarker KP, Nakashima M, Serizawa T, Kishida A, Akashi M, Nakata M, Kitajima I, Maruyama I. :Polymyxin B binds to anandamide and inhibits its cytotoxic effect., FEBS Lett. 2000;470:151-5.
  4. Kabata T, Kubo T, Matsumoto T, Nishino M, Tomita K, Katsuda S, Horii T, Nuto N, Kitajima I. :Apoptotic cell death in steroid-induced osteonecrosis: An experimental study in rabbits., J. Rheumatol. 2000;27:2166-71.
  5. Kabata T, Matsumoto T, Nishio M, Horii T, Kubo T, Kitajima I, Tomita K. :Histopathological and immunohistochemical study of femoral bone and bone marrow tissue in steroid treated rabbit. J., Neurol Orthop Med Surg. 2000;20:41-6.
  6. Ogata N:J. Gastroenteol Hepatol. 2000;15:100.
  7. Hayakawa Y, Hayashi T, Jung-Bum Lee, Ozawa T, Sakuragawa N.:Activation of heparin cofactor II by calcium spirulan. J., Biol. Chem. 2000;275:11379-82.
  8. Ozawa T, Sakuragawa N.:A thymine base is missed out of the published nucleotide sequence data of the antithrombin gene.,Br J Haematol. 2000;110:493.
  9. Ohta S, Ozawa T, Izumino K, Sakuragawa N, Fuse H.:A novel missense mutation of the WT1 gene causing Denys-Drash syndrome with exceptionally mild renal manifestations., J. Urology 2000;163:1857-8.
  10. Ohta S, Ozawa T, Shirage H, Fuse H. Genetic analysis of two female patients with incomplete Denys-Drash syndrome., Endocrine J. 2000;47:683-7.

‘à

  1. –k“‡ŒM:ƒŠƒ{ƒUƒCƒ€‚̈â“`ŽqŽ¡—Âւ̉ž—pBˆãŠw‚Ì‚ ‚ä‚Ý. 2000;129:240-1.
  2. –k“‡ŒM:ŒŒðÇB21¢‹I‚Ì•ªŽqˆãŠwBSŒŒŠÇ•a‚ÌŽ•ž‚ð‚ß‚´‚µ‚ÄB•ªŽqŒŒŠÇ•a. 2000;1:63-71.
  3. —«•FA–k“‡ŒM:ƒGƒ“ƒhƒgƒLƒVƒ“‚ÌŽó—e‘̂ƃVƒOƒiƒ‹“`’BBŒŒ‰tƒtƒƒ“ƒeƒA. 2000;10:27-32.
  4. X‰º—³ˆêA΋´•qKA–k“‡ŒM:‹}«Š¥ÇŒóŒQ‚Æ‚»‚̃ŠƒXƒNƒtƒ@ƒNƒ^[. Pharma Medica. 2000;18:155-164.
  5. ¬àV“N•v:æ“V«ƒAƒ“ƒ`ƒgƒƒ“ƒrƒ“IIIŒ‡–RÇ‚¨‚æ‚шÙíÇBŒŒ‰tƒtƒƒ“ƒeƒCƒA. 2000;10:13-9.
  6. ¬àV“N•v:ŸNìM’j:DICŽ¡—Öò‚Ì–ò—|ƒwƒpƒŠƒ“‚ƃvƒƒeƒA[ƒ[ƒCƒ“ƒqƒrƒ^[‚Í‚È‚ºŒø‚­‚Ì‚©|.Medical Practice. 2000;17:237-9.

ƒy[ƒW‚Ì擪‚Ö–ß‚é